Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/005596

International filing date: 24 February 2005 (24.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US

Number: 60/579,342


Filing date: 15 June 2004 (15.06.2004)

Date of receipt at the International Bureau: 23 March 2005 (23.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in

compliance with Rule 17.1(a) or (b)





AND AND IND WINDOWS THRUSH, PROCESSINAS; SHAND, COMBU;

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

March 14, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/579,342

FILING DATE: June 15, 2004

RELATED PCT APPLICATION NUMBER: PCT/US05/05596

Certified by

Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office



This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 C.F.R. §1.53(b)(2)

Atty. Docket: KOPCHICK15.1			
INVENTOR(S)/APPLICANT(S)			
LAST NAME	FIRST NAME	М	RESIDENCE (CITY AND EITHER STATE OR FOREIGN COUNTRY)
KOPCHICK	John	J.	Athens, Ohio
COSCHIGANO	Karen	T.	The Plains, Ohio
BOYCE	Keith	S.	Wexford, Pennsylvania
KRIETE	Andres		Pittsburgh, Pennsylvania
Additional inventors are being named on separately numbered sheets attached hereto			
TITLE OF THE INVENTION (280 characters max)			
DIAGNOSIS OF HYPERINSULINEMIA AND TYPE II DIABETES AND PROTECTION AGAINST SAME BASED ON GENES DIFFERENTIALLY EXPRESSED IN MUSCLE CELLS (15.1)			
CORRESPONDENCE ADDRESS			
Direct all correspondence to the address associated with Customer Number 001444, which is presently:			
BROWDY AND NEIMARK, P.L.L.C. 624 Ninth Street, N.W., Suite 300			
Washington, D.C. 20001-5303			
ENCLOSED APPLICATION PARTS (check all that apply)			
[X] Specification	Number of Pages	293	[X] Applicant claims small entity status. See 37 C.F.R. §1.27
[X] Drawing(s)	Number of Sheets	6	Other (specify)
·	Figures 1A-3B		
METHOD OF PAYMENT (check one)			
[X] Credit Card Payment Form PTO-2038 is enclosed to cover the Provisional filing fee of			
[]\$160 large entity [X] \$80 small entity			
[X] The Commissioner is hereby authorized to charge filing fees and credit Deposit Account Number 02-4035			

The invention was made by an agency of the United Stated Government or under a contract with an agency of the United States Government.

] Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted,

BROWDY AND NEIMARK, P.L

Date: June 15, 2004

Registration No.: 28,005

IPC:jlu



10

15

20

25

30

35

DIAGNOSIS OF HYPERINSULINEMIA AND TYPE II DIABETES AND PROTECTION AGAINST SAME BASED ON GENES DIFFERENTIALLY EXPRESSED IN MUSCLE CELLS (15.1)

Cross-Reference to Related Applications

Anti-Aging Applications. Mice with a disrupted growth hormone receptor/binding protein gene enjoy an increased lifespan. In U.S. Prov. Appl. 60/485,222, filed July 8, 2003 (Kopchick8) mouse genes differentially expressed in comparisons of gene expression in growth hormone receptor/binding protein gene-disrupted mouse livers and normal mouse livers were identified, as were corresponding human genes and proteins. It was suggested that the human molecules, or antagonists thereof, could be used for protection against faster-than-normal biological aging, or to achieve slower-than-normal biological aging. It was also taught that the human molecules may also be used as markers of biological aging.

In provisional application Ser. No. 60/474,606, filed June 2, 2003 (our docket Kopchick7-USA) , our research group used a gene chip to study the genetic changes in the liver of C57Bl/6J mice that occur at frequent intervals of the aging process. Differential hybridization techniques were used to identify mouse genes that are differentially expressed in mice, depending upon their age. The level of gene expression of approximately 10,000 mouse genes (from the Amersham Codelink UniSet Mouse I Bioarray, product code: 300013) in the liver of mice with average ages of 35, 49, 56, 77, 118, 133; 207, 403, 558 and 725 days was determined. In essence, complementary RNA derived from mice of different ages was screened for hybridization with oligonucleotide probes each specific to a particular mouse gene, each gene in turn representative of a particular mouse gene cluster (Unigene). Mouse genes which were differentially expressed (younger vs. older), as measured by different levels of hybridization of the respective cRNA samples with the particular probe corresponding to that mouse gene, were identified. Related human genes and proteins were identified by sequence comparisons to the

mouse gene or protein. In the international appl.

Kopchick7A-PCT, filed June 2, 2004, we added some additional studies of CIDE-A (see below).

In a like manner, the effect of aging on the expression of genes in mouse skeletal muscle was studied, see provisional application Ser. No. 60/566,068, filed April 29, 2004 (our docket Kopchick14-USA).

5

20

25

30

35

Anti-Diabetes Applications. In U.S. Provisional Appl.

Ser. No. 60/458,398 (our docket Kelder1-USA), filed March
31, 2003, members of our research group describe the
identification of genes differentially expressed in normal
vs. hyperinsulinemic, hyperinsulinemic vs. type II diabetic,
or normal vs. type II diabetic mouse liver. Forward- and
reverse-substracted cDNA libraries were prepared, clones
were isolated, and differentially expressed cDNA inserts
were sequenced and compared with sequences in publicly
available sequence databases. The corresponding mouse and
human genes and proteins were identified.

The purpose of our research group's provisional application Ser. No. 60/460,415 (our docket: Kopchick6-USA), filed April 7, 2003, was similar, but complementary RNA, derived from RNA of mouse liver, was screened against a mouse gene chip. See also 60/506,716, filed Sept. 30, 2003 (Kopchick6.1).

Gene chip analyses have also been used to identify genes differentially expressed in normal vs. hyperinsulinemic, hyperinsulinemic vs. type II diabetic, or normal vs. type II diabetic mouse pancreas, see U.S. Provisional Appl. 60/517,376, filed Nov. 6, 2003 (Kopchick12) and muscle, see U.S Provisional Appl.

(Kopchick12) and muscle, see U.S Provisional Appl. 60/547,512, filed Feb. 26, 2004 (Kopchick15).

Other differential hybridization applications. The use of differential hybridization to identify genes and proteins is also described in our research group's Ser. No. PCT/US00/12145 (Kopchick 3A-PCT), Ser. No. PCT/US00/12366 (Kopchick4A-PCT), and Ser. No. 60/400,052 (Kopchick5).

All of the foregoing applications are hereby incorporated by reference in their entirety.

5 BACKGROUND OF THE INVENTION

Field of the Invention

The invention relates to various nucleic acid molecules and proteins, and their use in (1) diagnosing hyperinsulinemia and type II diabetes, or conditions associated with their development, and (2) protecting mammals (including humans) against them.

Description of the Background Art

15

20

25

30

10

Diabetes

A deficiency of insulin in the body results in diabetes mellitus, which affects about 18 million individuals in the United States. It is characterized by a high blood glucose (sugar) level and glucose spilling into the urine due to a deficiency of insulin. As more glucose concentrates in the urine, more water is excreted, resulting in extreme thirst, rapid weight loss, drowsiness, fatigue, and possibly dehydration. Because the cells of the diabetic cannot use glucose for fuel, the body uses stored protein and fat for energy, which leads to a buildup of acid (acidosis) in the blood. If this condition is prolonged, the person can fall into a diabetic coma, characterized by deep labored breathing and fruity-odored breath.

There are two types of diabetes mellitus, Type I and Type II. Type II diabetes is the predominant form found in the Western world; fewer than 8% of diabetic Americans have the type I disease.

35 Type I diabetes. In Type I diabetes, formerly called juvenile-onset or insulin-dependent diabetes mellitus, the pancreas cannot produce insulin. People with Type I diabetes must have daily insulin injections. But they need to avoid taking too much insulin because that can lead to insulin

shock, which begins with a mild hunger. This is quickly followed by sweating, shallow breathing, dizziness, palpitations, trembling, and mental confusion. As the blood sugar falls, the body tries to compensate by breaking down 5 fat and protein to make more sugar. Eventually, low blood sugar leads to a decrease in the sugar supply to the brain, resulting in a loss of consciousness. Eating a sugary food can prevent insulin shock until appropriate medical measures can be taken. 10 Type I diabetics are often characterized by their low or absent levels of circulating endogenous insulin, i.e., hypoinsulinemia (1). Islet cell antibodies causing damage to the pancreas are frequently present at diagnosis. Injection of exogenous insulin is required to prevent 15 ketosis and sustain life. Type II diabetes. Type II diabetes, formerly called adult-onset or non-insulin-dependent diabetes mellitus (NIDDM), can occur at any age. The pancreas can produce 20 insulin, but the cells do not respond to it. Type II diabetes is a metabolic disorder that affects approximately 17 million Americans. It is estimated that another 10 million individuals are "prone" to becoming diabetic. These vulnerable individuals can become resistant 25 to insulin, a pancreatic hormone that signals glucose (blood sugar) uptake by fat and muscle. In order to maintain normal glucose levels, the islet cells of the pancreas produce more insulin, resulting in a condition called hyperinsulinemia. When the pancreas can no longer produce 30 enough insulin to compensate for the insulin resistance, and thereby maintain normal glucose levels, hyperglycemia (elevated blood glucose) results, and type II diabetes is diagnosed. Early Type II diabetics are often characterized by 35 hyperinsulinemia and resistance to insulin. Late Type II diabetics may be normoinsulinemic or hypoinsulinemic. Type II diabetics are usually not insulin dependent or prone to ketosis under normal circumstances. Little is known about the disease progression from the

normoinsulinemic state to the hyperinsulinemic state, and from the hyperinsulinemic state to the Type II diabetic state.

As stated above, type II diabetes is a metabolic 5 disorder that is characterized by insulin resistance and impaired glucose-stimulated insulin secretion (2,3,4). However, Type II diabetes and atherosclerotic disease are viewed as consequences of having the insulin resistance syndrome (IRS) for many years (5). The current theory of 10 the pathogenesis of Type II diabetes is often referred to as the "insulin resistance/islet cell exhaustion" theory. According to this theory, a condition causing insulin resistance compels the pancreatic islet cells to hypersecrete insulin in order to maintain glucose 15 homeostasis. However, after many years of hypersecretion, the islet cells eventually fail and the symptoms of clinical diabetes are manifested. Therefore, this theory implies that, at some point, peripheral hyperinsulinemia will be an antecedent of Type II diabetes. Peripheral hyperinsulinemia 20 can be viewed as the difference between what is produced by the β cell minus that which is taken up by the liver. Therefore, peripheral hyperinsulinemia can be caused by increased β cell production, decreased hepatic uptake or some combination of both. It is also important to note that 25 it is not possible to determine the origin of insulin resistance once it is established since the onset of peripheral hyperinsulinemia leads to a condition of global insulin resistance.

Multiple environmental and genetic factors are involved in the development of insulin resistance, hyperinsulinemia and type II diabetes. An important risk factor for the development of insulin resistance, hyperinsulinemia and type II diabetes is obesity, particularly visceral obesity (6,7,8). Type II diabetes exists world-wide, but in developed societies, the prevalence has risen as the average age of the population increases and the average individual becomes more obese.

30

35

Obesity and Diabetes. Obesity is a serious and growing

problem in the United States. Obesity-related health risks include high blood pressure, hardening of the arteries, cardiovascular disease, and Type II diabetes (also known as non-insulin-dependent diabetes mellitus, Type II diabetes) (9,10,11). Recent studies show that 85% of the individuals with Type II diabetes are obese (12).

Treatment of Diabetes. For many years, treatment was insulin therapy for Type I and oral sulfonylureas and/or insulin therapy for Type II. Metformin (glucophage) was the

5

10

15

20

25

30

35

Treatment of Diabetes. For many years, treatment was insulin therapy for Type I and oral sulfonylureas and/or insulin therapy for Type II. Metformin (glucophage) was the first antidiabetic drug approved by FDA (May 1995) for the treatment of Type II diabetes since the oral sulfonylureas were introduced in 1984. Metformin promotes the use of insulin already in the blood. This May 1995 approval was followed by the September 1995 approval of another antidiabetic drug, Acarbose (precose). It slows down the digestion and absorption of complex sugars, which reduces blood sugar levels after meals.

Before 1982, insulin was purified from beef or pork pancreas. This was a problem for those diabetics allergic to animal insulin. Researchers produced a synthetic insulin called humulin. Approved by FDA in 1982, it was the first genetically engineered consumer health product manufactured for diabetics. Synthetic insulins can be produced in unlimited quantities.

Another possible treatment for diabetes includes surgically replacing the pancreas' endocrine tissues (islets of Langerhans) with healthy islet of Langerhans tissue grafts. Since 1988, 45 patients worldwide have undergone successful transplantation.

Complications. Complications of diabetes (end organ damage) include retinopathy, neuropathy, and nephropathy (traditionally designated as microvascular complications) as well as atherosclerosis (a macrovascular complication). Early stages of hyperglycemia can usually be controlled by an alteration in diet and increasing the amount of exercise, but drug treatment, including insulin, may be required. It has been shown that meticulous blood glucose control can

often slow down or halt the progression of diabetic complications if caught early enough (1). However, tight metabolic control is extremely difficult to achieve.

5

10

15

Animal Models

Transgenic Mouse Models of Diabetes or Diabetes
Resistance. McGrane, et al., J. Biol. Chem. 263:11443-51
(1988) and Chen, et al., J. Biol. Chem., 269:15892-7 (1994)
describe the genetic engineering of mice to express bovine
growth hormone (bGH) or human growth hormone (hGH),
respectively. These mice exhibited an enhanced growth
phenotype. They also developed kidney lesions similar to
those seen in diabetic glomerulosclerosis, see Yang, et al.,
Lab. Invest., 68:62-70 (1993). Ogueta, et al., J.
Endocrinol., 165: 321-8 (2000) reported that transgenic mice
expressing bovine GH develop arthritic disorder and selfantibodies.

Growth hormone has many roles, ranging from regulation of protein, fat and carbohydrate metabolism to growth 20 promotion. GH is produced in the somatrophic cells of the anterior pituitary and exerts its effects either through the GH-induced action of IGF-I, in the case of growth promotion, or by direct interaction with the GHR on target cells including liver, muscle, adipose, and kidney cells. 25 Hyposecretion of GH during development leads to dwarfism, and hypersecretion before puberty leads to gigantism. adults, hypersecretion of GH results in acromegaly, a clinical condition characterized by enlarged facial bones, 30 hands, feet, fatigue and an increase in weight. Of those individuals with acromegaly, 25% develop type II diabetes. This may be due to insulin resistance caused by the high circulating levels of GH leading to high circulating levels of insulin (Kopchick et al., Annual Rev. Nutrition 1999. 35 19:437-61).

A further mode of GH action may be through the transcriptional regulation of a number of genes contributing to the physiological effects of GH.

Growth hormone genes and the proteins encoded by them can be converted into growth hormone antagonists by mutation, see Kopchick USP 5,350,836. Transgenic mice have been made that express the GH antagonists bGH-G119R or hGH G120R, and which exhibit a dwarf phenotype. Chen, et al., J. Biol. Chem., 263:15892-7 (1994); Chen, et al., Mol. Endocrinol, 5:1845-52 (1991); Chen, et al., Proc. Nat. Acad. Sci. USA 87:5061-5 (1990). These mice did not develop kidney lesions. See Yang (1993), supra.

5

10

15

20

25

30

35

Chen, et al., Endocrinol, 136:660-7 (1995) compared the effect of streptozotocin treatment in normal nontransgenic mice, and in mice transgenic for (1) a GH receptor antagonist, the G119R mutant of bovine growth hormone or (2) the E117L-mutant of bGH. (According to Chen's ref. 24, these large GH transgenic streptozotocin-treated mice constitute an animal model for diabetes.) Glomerulosclerosis was seen in diabetic (STZ-treated) nontransgenic mice and in diabetic bGH-E117L mice, but not in diabetic bGH-G119R (GH antagonist) mice.

Two of the proteins which mediate growth hormone activity are the growth hormone receptor and the growth hormone binding protein, encoded by the same gene in mice(GHR/BP). It is possible to genetically engineer mice so that the gene encoding these proteins is disrupted ("knocked-out"; inactivated), see Zhou, et al., Proc. Nat. Acad. Sci. (USA), 94:13215-20 (1997). Zhou, et al. inactivated the GHR/BP gene by replacing the 3' portion of exon 4 (which encodes a portion of the GH binding domains) and the 5' region of intron 4 with a neomycin gene cassette. The modified gene was introduced into the target mice by homologous recombination. Like mice expressing a GH antagonist, homozygous GHR/BP-KO mice exhibit a dwarf phenotype. GHR/BP-KO mice, made diabetic by streptozotocin treatment, are protected from the development of diabetesassociated nephropathy. Bellush, et al., Endocrinol., 141:163-8 (2000).

High-Fat Diets. High-fat diets have been shown to induce both obesity and Type II diabetes in laboratory

a

animals (13). Surwit and colleagues demonstrated that male C57BL/6J mice are extremely sensitive to the diabetogenic effects of a high-fat diet when initiated at weaning. At six months of age, high-fat fed animals had significantly elevated fasting blood-glucose and insulin levels and also demonstrated a decrease in insulin sensitivity (14). Ahren and colleagues (15) reported evidence of insulin resistance as well as diminished glucose-stimulated insulin release, after feeding with a high-fat diet for 12 weeks. These mice also showed elevated levels of total cholesterol, triglycerides, and free fatty acids, another hallmark of Type II diabetes.

15 Anatomy and Physiology of Muscle

5

10

20

25

30

35

Muscle tissue constitutes about 40% of the body mass.

Muscles may be classified by location, i.e., skeletal if attached to bone, cardiac if forming the wall of the heart, and visceral if associated with another body organ. Muscles may also be classified as voluntary or involuntary, depending on how their contractions and relaxations are controlled. Skeletal muscles are voluntary, while cardiac and visceral muscles are involuntary. It is also possible to classify muscles morphologically; skeletal and cardiac muscle cells are striated, whereas visceral muscle cells are not.

Each skeletal muscle is composed of many individual muscle cells called muscle fibers. The fibers are held together by fibrous connective-tissue membranes called fascia. The fascium which envelops the entire muscle is the epimysium, and the fascia which penetrate the muscle, separating the fibers into bundles (fasciculi) are called perimysium. Very thin fascia (endomysium) sheath each muscle fiber. Skeletal muscles are attached either directly to a bone, or indirectly through a tendon.

The individual muscle fibers (cells) comprise threadlike protein structures called myofibrils.

There are over 600 muscles in the human body. We will have occasion later to refer to the gastrocnemius. It is a superficial muscle in the posterior compartment of the lower leg, which together with the underlying soleus forms the characteristic bulge of the calf.

Role of Muscle in Development of Type II Diabetes

Muscle, fat and liver tissues are the major contributors to the development of insulin resistance, hyperinsulinemia, and, ultimately, type II diabetes.

Muscle cells respond to insulin by increasing glucose uptake from the bloodstream. Muscle tissue can become resistant to insulin, causing the beta cells to initially increase insulin secretion. Eventually, though, the beta cells become unable to compensate for this increasing insulin resistance from muscle and other cells, and they fail to respond to elevated blood glucose levels. Thus, clinical type 2 diabetes results from the combination of insulin resistance and impaired beta cell function.

Defects in muscle glycogen synthesis are known to play a role in the development of insulin resistance. At least three steps-those mediated by glycogen synthase, hexokinase, and GLUT4-have been reported to be defective in patients with type 2 diabetes.

Fatty acids can induce insulin resistance, and it has been suggested that this was a consequence of altered insulin signaling through PI3-kinase. PKC-theata has also been implicated.

See generally Petersen, et al., "Pathogenesis of Skeletal muscle insulin resistance in type 2 diabetes mellitus", in "A Symposium: Evolution of type 2 diabetes mellitus management", at Amer. J. Cardiol., 90(5A): 11G-18G, (Sept. 5, 2002).

5

10

15

20

25

30

35

Adverse Effects of Type II Diabetes on Muscle

"Myopathy is a general term used to describe any disease of muscles, such as the muscular dystrophies and myopathies associated with thyroid disease. It can be caused

by endocrine disorders, including diabetes, metabolic disorders, infection or inflammation of the muscle, certain drugs and mutations in genes. In diabetes, myopathy is thought to be caused by neuropathy, a complication of diabetes. General symptoms of myopathies include muscle weakness of limbs sometimes occurring during exercise although in some cases the symptoms diminish as exercise increases. Depending on the type of myopathy, one muscle group may be more affected than others." See "Joint and Muscle Problems Associated with Diabetes", www.iddtinternational.org/jointandmuscleproblems.html [Last modified June 12, 2003].

Diabetic muscle infarction can spontaneously affect 15 patients with a long history of poorly controlled diabetes. "Most affected patients have multiple microvascular complications (neuropathy, nephropathy, and retinopathy). The clinical presentation is an acute onset of pain and swelling over days to weeks in the affected muscle groups 20 (usually the thigh or calf), along with varying degrees of tenderness.... Therapy consists of rest and analgesia. Routine daily activities are not deleterious to the condition, but physical therapy may cause exacerbation. Spontaneous diabetic muscle infarction tends to resolve over 25 a period of weeks to months in most cases." "Musculoskeletal Complications of Diabetes - Part 2", www.diabetic-lifestyle.com/articles/jan02 whats 1.htm [last modified Feb. 9, 2004]. See also Trujillo-Santos, et al., "Diabetes muscle infarction: an underdiagnosed complication 30 of long-standing diabetes," Diabetes Care, 26(1):211-5 (2003).

5

Identification of genes involved in hyperinsulinemia and type II diabetes, generally

Our attention recently has focused on the generation of muscle mRNA expression profiles and the identification of genes involved in the genesis of the obesity-induced hyperinsulinemia and type-II diabetes. To date, no one has attempted to study the actual progression from the normal condition to that of hyperinsulinemia or from hyperinsulinemia to Type II diabetes in an attempt to identify genes that are up-regulated or down-regulated in muscle as the disease progresses.

In previous studies aimed at identifying genes involved in diabetes-induced glomerulosclerosis, differential display and traditional subtractive hybridization techniques were used (16-20). While effective for the identification of a few genes (e.g. hmunc13, PED/PEA-15, lactate dehydrogenase, amiloride sensitive sodium channel, ubiquitin-like protein, mdr 1, and a-amyloid protein precursor as well as a few novel genes), these techniques can be quite labor intensive. The PCR-based method of subtractive hybridization requires less starting material, and allows the simultaneous isolation of all differentially expressed cDNAs into two groups (up-regulated and down-regulated).

However, the PCR-based method of subtractive hybridization is also quite labor-intensive, produced large numbers of false positive candidates and ultimately resulted in the identification of a relatively limited number of differentially expressed genes. (see Kelderl-USA application).

In order to expand the number of genes that can be analyzed simultaneously, several groups have begun to utilize DNA microarray analysis to measure differences in gene expression between normal and diseased states.

However, these experiments have been limited in regards to the number of experimental conditions analyzed. DNA microarray analysis has been performed on normal, obese and diabetic mice (21). Also, the obesity and diabetes in the

mouse models examined were caused by a specific endogenous genetic mutation (22). The differentially expressed genes in the above models may be very different from genes differentially expressed due to diet-induced obesity and Type-II diabetes.

1.3

The use of differential expression and related techniques to identify genes useful in the treatment of diabetes has been reviewed by Perfetti, et al., Diabetes Technol. & Therapeut., 5(3): 421-3 (2003). Bernal-Mizrachi, et al., Diabetes Metab. Res. Rev. 19: 32-42 (2003).

Other papers of interest include:

5

10

15

20

25

30

35

Wada, et al., "Gene expression profile in streptozotocin-induced diabetic mice kidneys undergoing glomerulosclerosis", Kidney Int, 59:1363-73 (2001);

Song, et al., "Cloning of a novel gene in the human kidney homologous to rat muncl3S: its potential role in diabetic nephropathy", Kidney Int., 53:1689-95 (1998);

Page, et al., "Isolation of diabetes-associated kidney genes using differential display", Biochem. Biophys. Res. Comm., 232:49-53 (1997).

Peradi, "Subtractive hybridization claims: An efficient technique to detect overexpressed mRNAs in diabetic nephropathy," Kidney Int. 53:926-31 (1998).

Condorelli, EMBO J., 17:3858-66 (1998).

Diabetes-Specific Differential Expression in Muscle

Sreekumar, et al., "Gene expression profile in skeletal msucle of type 2 diabetes and the effect of insulin treatment," Diabetes 51: 1913 (June 2002) surveyed 6,451 genesw, and identified 85 genes for which there was an alteration in skeletal muscle transcription in diabetic patients after withdrawal of insulin treatment. Subsequent insulin treatment resulted in further changes in transcription of 74 of the 85 genes (15 increased, 59 decreased), and also resulted in alteration of 29 additional gene transcripts.

10

15

20

Mootha, et al., "PCG-1 α responsive genes involved in oxidative phosphorylation are coordinatively downregulated in human diabetes," Nature Genetics 34(3); 267 (July 2003), used DNA microarrays to detect changes in the expression of sets of related genes, rather than of individual genes. They classified over 22,000 genes into 149 data sets; some of these data sets overlapped. They looked for a statistical correlation between the overall rank order of the genes in differential expression, and the groups to which the genes Expression was compared pairwise among three groups: males with normal glucose tolerance; males with impaired glucose tolerance; and males with type 2 diabetes. The set with the highest enrichment score (the one whose members ranked highly most often relative to chance expectation) was an internally curated set of 106 genes involved in oxidative phosphorylation. While the average decrease for the individual genes was modest (~20%), it was also consistent, being observed in 89% (94/106) of the genes in question. This paper is reviewed by Toye and Gauguier, "Genetics and functional genomics of type 2 diabetes mellitus", Genome Biology, 4: 241 (2003).

Patti, et al., "Coordinated reduction of genes of oxidative 25 metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1", Proc. Nat. Acad. SCi. (USA), 100(14): 8466 (July 8, 2003) used microarrays to analyze skeletal muscle expression of genes in nondiabetic insulin-resistant subjects at high risk for diabetes (based 30 on family hisotry of diabetes and Mexican-American ethnicity) and diabetic Mexican-American subjects. Of 7,129 sequences represented on the microarray, 187 were differentially expressed between control and diabetic subjects. However, no single gene remained significantly 35 differentially expressed after controlling for multiple comparison false discovery by using the Benjamini-Hochberg method, see Benjamini, et al., J. R. Stat. Soc. Sert. B. 57:289-300 (1995); Dudait, et al., Stat. Sin. 12: 111-139 (2002). Consequently, Patti et al. sought to identify

groups of related genes with similar patterns of differential expression using MAPP FINDER and ONTOEXPRESS.

According to MAPP FINDER, the top-ranked cellular component terms were mitochondrion, mitochondrial membrane,

mitochondrial inner membrane, and ribosome, and the top-ranked process term was ATP biosynthesis. According to ONTOEXPRESS, the over-represented groups were energy generation, protein biosynthesis/ribosomal proteins, RNA binding, ribosomal structural protein, and ATP synthase complex.

Huang, Xudong, "Identification of abnormally expressed genes in skeletal muscle contributing to insulin resistance and type 2 diabetes", Thesis, document id: 9576 Lunds University 2002, reported differential expression of the mitochondrially-encoded ND1 gene in human diabetic patients and of the nuclear-encoded cathepsin L gene in mice.

15

30

35

Standaert, et al., ":Skeletal muscle insulin resistance in obesity-associated type 2 diabetes in monkeys is linked to a defect in insulin activation of protein kinase C-zeta/lambda/iota Diabetes 51: 2936 (Oct. 2002). the authors concluded that defective activation of atypical PKCs played an important role in the patehogenesis of peripheral insulin resistance in both obese prediabetic and diabetic monkeys. They attributed this linkage to the apparent requirement for aPKCs during insulin-stimulated glucose transport.

Srommer, et al., Am. J. Physiol., "Skeletal muscle insulin resistance after trauma: insulin signaling and glucose transport", 275(2 Pt. 1): E3518(Aug. 1998) concluded that insulin resistance in skeletal muscle after surgical trauma is associated with reduced glucose transport but not with impaired glucose signaling to PI 3-kinase or its downstream target, Akt.

Aging-Specific Differential Expression in Muscle

16 Gene Chip-Based Identification of genes involved in aging of skeletal muscle Several groups have used DNA microarrays to measure differences in gene expression caused by the aging process. However, these experiments are extremely limited in regards 5 to the number of aging time points or experimental conditions. Weindruch, et al., "Microarray profiling of gene expression in aging and its alteration by caloric restriction in mice" in Symposium: Calorie Restriction: 10 effects on Body Composition, Insulin Signaling and Aging 918S-923S (2001)(21) compared expression in gastrocnemius muscle from 5- and 30-month old C57BL/6 mice, with and without caloric restriction. In this analysis, the expression of 113 genes was found to be changed by at least 15 two-fold in 5-month old mice compared to 30-month old mice. Caloric restriction of comparable mice caused a reversal of the altered gene expression of 33 genes. Of the 6347 genes surveyed in the oligonucleotide 20 microarray, only 58 (0.9%) displayed a greater than 2 fold increase in gene expression as a function of aging, whereas 55(0.9%) displayed a greater than 2 fold decrease. Of the genes positively correlated with aging, 16% could be assigned to stress responses. The largest 25 differential expression between young and aged animals (3.8 fold) was the mitochondrial sarcomeric creatine kinase. Of the genes negatively correlated with aging, 13% were involved in energy metabolism. A noteworthy number were genes encoding biosynthetic enzymes (cytochrome P450 IIC12, 30 squaelene synthase, stearoyl-CoA desaturase, EF-1-gamma. Another down regulator was a CpG binding protein, MeCP2. Weindruch further reported that age-related changes in gene expression profile were "remarkably attenuated" by caloric restriction. 35 What appears to be the same experiment is discussed in Lee, et al., "Gene expression profile of aging and its retardation by caloric restriction," Science, 285: 1390 (Aug. 27, 1999). This papers lists the individual genes which

Welle, et al., "Skeletal muscle gene expression profiles in 20-29 year old and 65-71 year old women," Exper. Gerontol., 39: 369-77 (2004) and available electronically as doi:10.1016/j.exger.2003.11.011 studied gene expression and physical condition in seven young and eight older women. With respect to physical condition, the measured or calculated parameters were total body mass, lean body mass, left leg lean mass (by biopsy), maximum isometric left knee extension force, left knee extension force/left keg lean mass, Peak VO₂/lean body mass, and Peak VO₂/left leg lean mass.

There were 1178 "probe sets" (representing 1053 different Unigene clusters) for which differential expression was detected; 550 for which expression was higher in older women, and 628 the inverse effect. The differences ranged from 1.2 to 4 fold; most (78A%) were less than 1.5 fold. The complete list of differentially expressed genes is given in the Rochester Muscle database website, www.urmc.rochester.edu/smd/crc/swindex (".html" omitted, in accordance with USPTO requirements, so that the publication of this application will not create an active hyperlink).

The gene most highly overexpressed in older muscle was p21 (cyclin-dependent kinase inhibitor 1A) (4.01 fold). This one of several genes (see Welle Table 2) which are potentially related to DNA damage and repair. Welle also thought it noteworthy how many of the differentially expressed genes were ones that encode proteins which bind to pre-mRNAs or mRNAs (see Welle Table 3).

Other Differential/Subtractive Hybridization Studies of Interest

Zhang, et al., Kidney International, 56:549-558 (1999) identified genes up-regulated in 5/6 nephrectomized

5

15

10

20

25

30

(subtotal renal ablation) mouse kidney by a PCR-based subtraction method. Ten known and nine novel genes were identified. The ultimate goal was to identify genes involved in glomerular hyperfiltration and hypertrophy. Melia, et al., Endocrinol., 139:688-95 (1998) applied subtractive hybridization methods for the identification of androgen-regulated genes in mouse kidney. The treatment mice were dosed with dihydrotestosterone, an androgen. Kidney androgen-regulated protein gene was used as a positive control, as it is known to be up-regulated by DHT.

See also Holland, et al., Abstract 607, "Identification of Genes Possibly Involved in Nephropathy of Bovine Growth Hormone Transgenic Mice" (Endocrine Society Meeting, June 22, 2000) and Coschigano, et al., Abstract 333, "Identification of Genes Potentially Involved in Kidney Protection During Diabetes" (Endocrine Society Meeting, June 22, 2000).

The following differential hybridization articles may also be of interest: Wada, et al., "Gene expression profile in streptozotocin-induced diabetic mice kidneys undergoing glomerulosclerosis", Kidney Int, 59:1363-73 (2001); Song, et al., "Cloning of a novel gene in the human kidney homologous to rat muncl3S: its potential role in diabetic nephropathy", Kidney Int., 53:1689-95 (1998); Page, et al., "Isolation of diabetes-associated kidney genes using differential display", Biochem. Biophys. Res. Comm., 232:49-53 (1997); Peradi, "Subtractive hybridization claims: An efficient technique to detect overexpressed mRNAs in diabetic nephropathy," Kidney Int. 53:926-31 (1998); Condorelli, EMBO J., 17:3858-66 (1998).

Apoptosis and CIDE-A

Apoptosis is a form of programmed cell death that occurs in an active and controlled manner to eliminate unwanted cells. Apoptotic cells undergo an orchestrated cascade of morphological changes such as membrane blebbing,

19 nuclear shrinkage, chromatin condensation, and formation of apoptotic bodies which then undergo phagocytosis by neighboring cells. One of the hallmarks of cellular apoptosis is the cleavage of chromosomal DNA into discrete 5 oligonucleosomal size fragments. This orderly removal of unwanted cells minimizes the release of cellular components that may affect neighboring tissue. In contrast, membrane rupture and release of cellular components during necrosis often leads to tissue inflammation. 10 The process of apoptosis is highly conserved and involves the activation of the caspase cascade. Cohen, GM. Caspases: the executioners of apoptosis. J. 326:1-16; Budihardjo, I., Oliver, H., Lutter, M., Luo, Biochemical pathways of caspase X., Wang, X. (1999) 15 activation during apoptosis. Annnu. Rev. Cell. Dev. Biol.15:269-290; Jacobson, M.D., Weil, M., Raff, M.C. Programmed cell death in animal development. Cell 88:347-354. Caspases are a family of serine proteases that 20 ~ apoptotic signals such as CD95 (Fas) death receptor of specific target proteins and execution of the apoptotic program.

are synthesized as inactive proenzymes. Their activation by activation or tumor necrosis factor results in the cleavage Apoptosis may occur by either an extrinsic pathway involving the activation of cell surface death receptors 25 (DR) or by an intrinsic mitochondrial pathway. Yoon, J-H. Gores G.J. (2002)Death receptor-mediated apoptosis and the liver. J. Hepatology 37:400-410.

These pathways are not mutually exclusive and some cell types require the activation of both pathways for 30 maximal apoptotic signaling. In type-I cells, death receptor activation leads to the recruitment and activation of caspases-8/10 and the rapid cleavage and activation of caspase-3 in a mitochondrial-independent manner. Hepatocytes are members of the Type-II cells in which 35 mitochondria are essential for DR-mediated apoptosis Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K.J., Debatin, K.M., Krammer, P.H., Peter, M.E. (1998)Two CD95 (APO-1/Fas) signaling pathways. 17:1675-1687. In this pathway, the pro-apoptotic protein

Bid is truncated by activated caspases-8/10 and translocates to the mitochondria. Luo, X., Budihardjo, I., Zou, H., Slaughter, C., Wang, X. (1998) Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94:481-490; Li, H., Zhu, H., Xu, C.J., Yuan, J. (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94:491-501. This translocation leads to mitochondrial cytochrome c release and eventual activation of caspases-3 and 7 via cleavage by activated caspase-9.

One of the substrates for activated caspase-3 is the DNA fragmentation factor (DFF). DFF is composed of a 45 kDa regulatory subunit (DFF45) and a 40 kDA catalytic subunit (DFF40). Liu, X., Zou, H., Slaughter, C., Wang, DFF, a heterodimeric protein that downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 89:175-184. DFF45 cleavage by activated caspase-3 results in its dissociation from DFF40 and allows the caspase-activated DNAse (CAD) activity of DFF40 to cleave chromosomal DNA into oligonucleosomal size fragments. Liu, X., Li, P., Widlak, P., Zou, H., Luo, X., Garrard, W.T., Wang, X. (1998) The 40-kDa subunit of DNA fragmentation factor induces DNA fragmentation and chromatin condensation during apoptosis. Proc. Natl. Acad. Sci. USA. 95:8461-8466; Halenbeck, R., MacDonald, H., Roulston, A., Chen, T.T., Conroy, L., Williams, L.T. (1998) CPAN, a human nuclease regulated by the caspase-sensitive inhibitor DFF45. Curr Biol. 8:537-540; Nagata, S. (2000) Apoptotic DNA fragmentation. Exp. Cell Res. 256:12-8.

Recently, a novel family of cell-death-inducing DFF45-like effectors (CIDEs) have been identified that includes CIDE-A, CIDE-B and CIDE-3/FSP2. Inohara, N., Koseki, T., Chen, S., Wu, X., Nunez, G. (1998) CIDE, a novel family of cell death activators with homology to the 45 kDa subunit of the DNA fragmentation factor. EMBO J. 17:2526-2533; Danesch, U., Hoeck, W., Ringold, G.M. (1992) Cloning and transcriptional regulation of a novel adipocyte-specific gene, FSP27. CAAT-enhancer-binding protein (C/EBP)

25

30

35

5

10

15

fragmentation-factor (DFF45)-like effector family. Biochem. J. 370:195-203. The CIDEs contain an N-terminal domain that shares homology with the N-terminal region of DFF45 and may

represent a regulatory region via protein interaction. See Inohara, supra; Lugovskoy, A.A., Zhou, P., Chou, J.J., McCarty, J.S., Li, P., Wagner, G. (1999) structure of the CIDE-N domain of CIDE-B and a model for CIDE-N/CIDE-N interactions in the DNA fragmentation pathway of apoptosis. Cell 9:747-755. The family members also

share a C-terminal domain that is necessary and sufficient for inducing cell death and DNA fragmentation; see Inohara The overexpression of CIDE-A induces cell death that can be inhibited by DFF45. However, CIDE-A-induced apoptosis is not inhibited by caspase-8 inhibitors thereby

suggesting the presence of additional, caspase-independent, pathway(s) for the induction of apoptosis, see Inohara supra. Previous reports have indicated that human and mouse CIDE-A are expressed in several tissues such as brown adipose tissue (BAT) and heart and are localized to the

mitochondria, Zhou, Z., Yon Toh, S., Chen, Z., Guo, K., Ng, C.P., Ponniah, S., Lin, S.C., Hong, W., Li, P. Cidea-deficient mice have lean phenotype and are resistant to obesity. Nat. Genet. 35:49-56. . In addition to the ability to induce apoptosis, CIDE-A can interact and inhibit UCP1 in BAT and may therefore play a role in regulating energy balance, see Zhou supra.

Previous reports have indicated that CIDE-A is not expressed in either adult human or mouse liver tissue, see Inohara supra, Zhou supra.

The human protein cell death activator CIDE-A is of particular interest because of its highly dramatic change in liver expression with age, first demonstrated in our

5

10

15

20

25

30

Kopchick7 application, supra. CIDE-A expression is elevated in older normal mice. CIDE-A expression was studied for normal C57BI/6J mouse ages 35, 49, 77, 133, 207, 403 and 558 days. Expression is low at the first five data points, then rises sharply at 403 days, and again at 558 days.

CIDE-A was therefore classified as an "unfavorable protein", i.e., it was taught that an antagonist to CIDE-A could retard biological aging.

In Kopchick7A-PCT we reported that CIDE-A is also prematurely expressed in hyperinsulinemic and type-II diabetic mouse liver tissue. CIDE-A expression also correlates with liver steatosis in diet-induced obesity, hyperinsulinemia and type-II diabetes. These observations suggest an additional pathway of apoptotic cell death in Non-Alcoholic Fatty Liver Disease (NAFLD) and that CIDE-A may play a role in this serious disease and potentially in liver dysfunction associated with type-II diabetes.

SUMMARY OF THE INVENTION

Differential hybridization techniques have been used to identify mouse genes that are differentially expressed in the **muscle** (gastrocnemius) of mice, depending upon their development of hyperinsulinemia or type II diabetes.

In essence, complementary RNA derived from normal mice, or mouse models of hyperinsulinemia or type II diabetes, was screened for hybridization with oligonucleotide probes each specific to a particular mouse database DNA, the latter being identified, by database accession number, by the gene manufacturer. Each database DNA in turn was also identified by the gene chip manufacturer as representative of a particular mouse gene cluster (Unigene).

In most cases, this database DNA sequence is a full length genomic DNA or cDNA sequence, and is therefore either identical to, or otherwise encodes the same protein as does, a natural full-length genomic DNA protein coding sequence. Those which don't present at least a partial sequence of a natural gene or its cDNA equivalent.

For the sake of simplicity, all of these mouse database DNA sequences, whether full-length or partial, and whether cDNA or genomic DNA, are referred to herein as "mouse genes". When only the genomic sequence is intended, we will refer specifically to "genomic DNA" or "gDNA".

The sequences in the protein databases are determined either by directly sequencing the protein or, more commonly, by sequencing a DNA, and then determining the translated amino acid sequence in accordance with the Genetic Code. All of the mouse sequences in the mouse polypeptide database are referred to herein as "mouse proteins" regardless of whether they are in fact full length sequences.

Mouse genes which were differentially expressed (normal vs. hyperinsulinemic, hyperinsulinemic vs. diabetic, or normal vs. diabetic), as measured by different levels of hybridization of the respective cRNA samples with the particular probe corresponding to that mouse gene) were identified.

20

5

10

15

25

30

24 Since the progression is from normal to hyperinsulinemic, and thence from hyperinsulinemic to type II diabetic, one may define mammalian subjects as being more favored or less favored, with normal subjects being more 5 favored than hyperinsulinemic subjects, and hyperinsulinemic subjects being more favored than type II diabetic subjects. The subjects' state may then be correlated with their gene expression activity. The terms "normal" and "control" are used 10 interchangeably in this specification, unless expressly stated otherwise. The control or normal subject is a mouse which is normal vis-a-vis fasting insulin and fasting glucose levels. The term "normal", as used herein, means normal relative to those parameters, and does not 15 necessitate that the mouse be normal in every respect. A mouse gene is said to have exhibited a favorable behavior if, for a particular mouse age of observation, its average level of expression in mice which are in a more favored state is higher than that in mice which are in a less favored state. A mouse gene is said to have exhibited 20 an unfavorable behavior if, for a particular mouse age of observation, its average level of expression in mice which are in a more favored state is lower than that in mice which are in a less favored state. 25 When we observe the mice at several different ages, it is possible for their expression behavior to vary from time point to time point. For a given comparison of subjects, e.g., normal vs. hyperinsulinemic, we classify the mouse gene as favorable or unfavorable on the basis of the 30 direction of the largest expression change, and it is the magnitude of this largest expression change, expressed as a ratio of greater to lesser, which is set forth in the Master Table 1 data for that mouse gene. Thus, if at 2 weeks, there was a 3-fold favorable behavior, and at 8 weeks, there was a 4-fold unfavorable behavior, and at all other observed time 35 points, the behavior was weaker than 3-fold, the mouse gene would be classified as an unfavorable gene with respect to the subject comparison in question.

25 It will be appreciated that it may be that if the mouse gene were observed at an age other than one of the ages noted in the Examples, we would have observed a still stronger differential expression behavior. Nonetheless, we 5 must classify the mouse genes on the basis of the behavior which we actually observed, not the behavior which might have been observed at some other age. We are particularly interested in mouse genes which exhibit strongly favorable or unfavorable differential 10 expression behaviors. A behavior is considered strong if the ratio of the higher level to the lower level is at least two-fold. However, a mouse gene may still be identified as 15 favorable or unfavorable even if none of its observed behaviors are strong as defined above. In general, we consider the consistency of its behaviors (that is, are all or most of the differential expression behaviors at different ages in the same direction, e.g., hyperinsulinemic 20 higher than control), the magnitude of the behaviors (higher the better), and the expression behavior of structurally or functionally related mouse genes (a mouse gene is more likely to be identified as favorable on the basis of a weakly favorable behavior if it is related to other mouse 25 genes which exhibited favorable, especially strongly favorable, behavior). If we considered a mouse gene with only weak differential expression behavior to be worthy of consideration on the basis of these criteria, then we listed it in Master Table 1 in the appropriate subtable. 30 Preferably, the differential behavior observed is both strong and consistent. Preferably, if related mouse genes were tested, they exhibit the same direction of differential expression behavior. 35 A mouse gene which was more strongly expressed in hyperinsulinemic tissue than in either normal or type II diabetic tissue (i.e., C<HI, HI>D) will be deemed both "unfavorable", by virtue of the control:hyperinsulinemic comparison, and "favorable", by virtue of the

26 hyperinsulinemic: diabetic comparison. This is one of several possible "mixed" expression patterns. Thus, we can subdivide the "favorables" into wholly and partially favorables. Likewise, we can subdivide the 5 unfavorables into wholly and partially unfavorables. The genes/proteins with "mixed" expression patterns are, by definition, both partially favorable and partially unfavorable. In general, use of the wholly favorable or wholly unfavorable genes/proteins is preferred to use of the 10 partially favorable or partially unfavorable ones. It is evident from the foregoing that mixed genes/proteins are those exhibiting a combination of favorable and unfavorable behavior. A mixed gene/protein can be used as would a favorable gene/protein if its 15 favorable behavior outweighs the unfavorable. It can be used as would an unfavorable gene/protein if its unfavorable behavior outweighs the favorable. Preferably, they are used in conjunction with other agents that affect their balance of favorable and unfavorable behavior. Use of mixed 20 genes/proteins is, in general, less desirable than use of purely favorable or purely unfavorable genes/proteins, but it is not excluded. It should be noted that a mouse gene is classified on the basis of the strongest C-HI behavior among the ages 25 tested, the strongest HI-D behavior among the ages tested, and the strongest C-D behavior among the ages tested. If at least one of these three behaviors is significantly favorable, and none of the others of these three behaviors is significantly unfavorable, the mouse gene will be 30 classified as wholly favorable and listed in subtable 1A of Master Table 1. However, that does not mean that it may not have exhibited a weaker but unfavorable expression behavior at some tested age. The "favorable", "unfavorable" and "mixed" mouse 35 proteins of the present invention include the mouse database proteins listed in the Master Table in the same row as a particular "favorable", "unfavorable" or "mixed" mouse gene, respectively. These proteins may be the exact translation product of the identified mouse gene (database DNA).

27 However, if they were sequenced directly, they could be shorter or longer than that translation product. They could also differ in sequence from the exact translation product as a result of post-translational modifications. 5 The mouse proteins of interest also include mouse proteins which, while not listed in the table, correspond to (i.e., homologous to, i.e., which could be aligned in a statistically significant manner to) such mouse proteins or genes, and mouse proteins which are at least substantially identical or conservatively identical to the listed mouse 10 proteins. Related human genes (database DNAs) and proteins were identified by searching a database comprising human DNAs or 15 proteins for sequences corresponding to (i.e., homologous to, i.e., which could be aliqued in a statistically significant manner to) the mouse gene or protein. More than one human protein may be identified as corresponding to a particular mouse chip probe and to a particular mouse gene. 20 Note that the terms "human genes" and "human proteins" are used in a manner analogous to that already discussed in the case of "mouse genes" and "mouse proteins". As used herein, the term "corresponding" does not mean identical, but rather implies the existence of a 25 statistically significant sequence similarity, such as one sufficient to qualify the human protein or gene as a homologus protein or DNA as defined below. The greater the degree of relationship as thus defined (i.e., by the statistical significance of each alignment used to connect 30 the mouse cDNA to the human protein or gene, measured by an E value), the more close the correspondence. The connection may be direct (mouse gene to human protein) or indirect (e.g., mouse gene to human gene, human gene to human protein). By "mouse gene", we mean the mouse gene from which 35 the gene chip DNA in question was derived. In general, the human genes/proteins which most closely correspond, directly or indirectly, to the mouse genes are preferred, such as the one(s) with the highest, top two

28 highest, top three highest, top four highest, top five highest, and top ten highest E values for the final alignment in the connection process. The human genes/proteins deemed to correspond to our mouse genes are identified in the Master Tables. 5 Note that it is possible to identify homologous fulllength human genes and proteins, if they are present in the database, even if the query mouse DNA or protein sequence is not a full-length sequence. 10 If there is no homologous full-length human gene or protein in the database, but there is a partial one, the latter may nonetheless be useful. For example, a partial protein may still have biological activity, and a molecule which binds the partial protein may also bind the fulllength protein so as to antagonize a biological activity of 15 Likewise, a partial human gene may the full-length protein. encode a partial protein which has biological activity, or the gene may be useful in the design of a hybridization probe or in the design of a therapeutic antisense DNA. 20 The partial genes and protein sequences may of course also be used in the design of probes intended to identify the full length gene or protein sequence. For the sake of convenience, we refer to a human 25 protein as favorable if (1) it is listed in Master Table 1 as corresponding to a favorable mouse gene, or (2) it is at least substantially identical or conservatively identical to a listed protein per (1), or (3) it is a member of a human protein class listed in Master Table 2 (if provided) as 30 corresponding to a favorable mouse gene. We define a human protein as unfavorable in an analogous manner. We may further identify a human protein as being wholly favorable (see mouse genes of subtable 1A, wholly unfavorable (see mouse genes of subtable 1B), or mixed, i.e., both partially 35 favorable and partially unfavorable (see mouse genes of subtable 1C). Likewise, a human gene which encodes a particular human protein may be classified in the same way as the human protein which it encodes.

However, it should be noted that this classification is not based on the direct study of the expression of the human gene/protein. of course, the human genes/proteins of ultimate interest will be the ones whose change in level of expression is, in fact, correlated, directly or inversely, with the change of state (normal, hyperinsulinemic, diabetic) of the subject.

5

10

15

20

25

30

35

After identifying related human genes and proteins, one may formulate agents useful in screening humans at risk for progression toward hyperinsulinemia or toward type II diabetes, or protecting humans at risk thereof from progression from a normoinsulinemic state to a hyperinsulinemic state, or from either to a type II diabetic state.

Agents which bind the "favorable" and "unfavorable" nucleic acids (e.g., the agent is a substantially complementary nucleic acid hybridization probe), or the corresponding proteins (e.g., an antibody vs. the protein) may be used to evaluate whether a human subject is at increased or decreased risk for progression toward type II diabetes. A subject with one or more elevated "unfavorable" and/or one or more depressed "favorable" genes/proteins is at increased risk, and one with one or more elevated "favorable" and/or one or more depressed "unfavorable" genes/proteins is at decreased risk. One may further take into account whether the subject is normoinsulinemic or hyperinsulinemic at the time of the assay. If the subject is non-diabetic and normoinsulinemic, we are especially interested in the "favorable" and "unfavorable" human genes/proteins corresponding to mouse genes differentially expressed in hyperinsulinemic vs. normal muscle. subject is already hyperinsulinemic, yet non-diabetic, we are especially interested in the "favorable" and "unfavorable" human genes/proteins corresponding to mouse genes differentially expressed in type II diabetic vs. hyperinsulinemic muscle.

30 The assay may be used as a preliminary screening assay to select subjects for further analysis, or as a formal diagnostic assay. 5 The identification of the related genes and proteins may also be useful in protecting humans against these disorders. Thus, Applicants contemplate: (1) use of the "favorable" mouse DNAs (or fragments thereof) of the Master Tables (below) to isolate or identify 10 related human DNAs; (2) use of human DNAs, related to favorable mouse DNAs, to express the corresponding human proteins; (3) use of the corresponding human proteins (and mouse 15 proteins, if biologically active in humans), to protect against the disorder(s); (4) use of the corresponding mouse or human proteins, or nucleic acid probes derived from the mouse or human genes, in diagnostic agents, in assays to measure 20 progression toward hyperinsulinemia or type II diabetes, or protection against the disorder(s), or to estimate related end organ damage such as kidney damage; and (5) use of the corresponding human or mouse genes therapeutically in gene therapy, to protect against the 25 disorder(s). Moreover Applicants contemplate: (1) use of the "unfavorable" mouse DNAs (or fragments thereof) of the Master Tables to isolate or identify related human DNAs: 30 (2) use of the complement to the "unfavorable" mouse DNAs or related human DNAs, as antisense molecules to inhibit expression of the related human DNAs; (3) use of the mouse or human DNAs to express the corresponding mouse or human proteins; 35 (4) use of the corresponding mouse or human proteins, in diagnostic agents, to measure progression toward hyperinsulinemia or type II diabetes, or protection against the disorder(s), or to estimate related end organ damage such as kidney damage;

31 (5) use of the corresponding mouse or human proteins in assays to determine whether a substance binds to (and hence may neutralize) the protein; and (6) use of the neutralizing substance to protect 5 against the disorder(s). Thus, DNAs of interest include those which specifically hybridize to the aforementioned mouse or human genes, and are thus of interest as hybridization assay reagents or for antisense therapy. They also include synthetic DNA sequences 10 which encode the same polypeptide as is encoded by the database DNA, and thus are useful for producing the polypeptide in cell culture or in situ (i.e., gene therapy). Moreover, they include DNA sequences which encode polypeptides which are substantially structurally identical 15 or conservatively identical in amino acid sequence to the mouse and human proteins identified in the Master Table 1, subtables 1A or 1C. Finally, they include DNA sequences which encode peptide (including antibody) antagonists of the 20 proteins of Master Table 1, subtables 1B or 1C. The related human DNAs may be identified by comparing the mouse sequence (or its AA translation product) to known human DNAs (and their AA translation products). 25 Related human DNAs also may be identified by screening human cDNA or genomic DNA libraries using the mouse gene of the Master Table, or a fragment thereof, as a probe. If the mouse gene of Master Table 1 is not full-length, and there is no closely corresponding full-length mouse gene in 30 the sequence databank, then the mouse DNA may first be used as a hybridization probe to screen a mouse cDNA library to isolate the corresponding full-length sequence. Alternatively, the mouse DNA may be used as a probe to screen a mouse genomic DNA library. 35 Our animal models of hyperinsulinemia and diabetes are It is possible that the genes found to be favorable act indirectly by inhibiting obesity. Likewise, it is possible that the genes found to be unfavorable act. indirectly by accentuating obesity. Consequently, it is

within the compass of the present invention to use the favorable genes and proteins, or to use antagonists of the unfavorable genes and proteins, to protect against obesity, as well as against sequelae of obesity such as hyperinsulinemia and diabetes.

5

10

Since type II diabetes is an age-related disease, the agents of the present invention may be used in conunction with known anti-aging or anti-age-related disease agents. It is of particular interest to use the agents of the present invention in conjunction with an agent disclosed in one of the related applications cited above, in particular, an antagonist to CIDE-A, the latter having been taught in Kopchick7 and Kopchick7A-PCT.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Body weight gain [Fig. 1a], fasting glucose [Fig. 1b] and fasting insulin [Fig. 1c] levels of mice on the HF or Std diets.

5

Figure 2. Expression levels of Actin, alpha, cardiac (Actc1, NM_009608) using RNA isolated from gastrocnemius muscle of individual diabetic HF mice and corresponding Std mice at different time points.

10

15

Figure 3. Data shown are expression levels for additional actin-related and actin-binding genes exhibiting a consistent decrease in expression in the HF mice in comparison to Std mice at all four time points (Fig. 3(a)) or at three of the four time points (Fig. 3(b)).

34

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION

Full-Length vs. Partial Length Genes/Proteins

A "full length" gene is here defined as (1) a naturally occurring DNA sequence which begins with an initiation codon (almost always the Met codon, ATG), and ends with a stop codon in phase with said initiation codon (when introns, if any, are ignored), and thereby encodes a naturally occurring polypeptide with biological activity, or a naturally occurring precursor thereof, or (2) a synthetic DNA sequence which encodes the same polypeptide as that which is encoded by (1). The gene may, but need not, include introns.

A "full-length" protein is here defined as a naturally occurring protein encoded by a full-length gene, or a protein derived naturally by post-translational modification of such a protein. Thus, it includes mature proteins, proproteins, preproteins and preproproteins. It also includes substitution and extension mutants of such naturally occurring proteins.

Subjects

5

10

15

20

A mouse is considered to be a diabetic subject if, regardless of its fasting plasma insulin level, it has a fasting plasma glucose level of at least 190 mg/dL. A mouse is considered to be a hyperinsulinemic subject if its fasting plasma insulin level is at least 0.67 ng/mL and it does not qualify as a diabetic subject. A mouse is considered to be "normal" if it is neither diabetic nor hyperinsulinemic. Thus, normality is defined in a very limited manner.

A mouse is considered "obese" if its weight is at least 15% in excess of the mean weight for mice of its age and sex. A mouse which does not satisfy this standard may be characterized as "non-obese", the term "normal" being reserved for use in reference to glucose and insulin levels as previously described.

35 A human is considered a diabetic subject if, regardless of his or her fasting plasma insulin level, the fasting plasma glucose level is at least 126 mg/dL. A human is considered a hyperinsulinemic subject if the fasting plasma insulin level is more than 26 micro International Units/mL 5 (it is believed that this is equivalent to 1.08 ng/mL), and does not qualify as a diabetic subject. A human is considered to be "normal" if it is neither diabetic nor hyperinsulinemic. Thus, normality is defined in a very limited manner. 10 A human is considered "obese" if the body mass index (BMI) (weight divided by height squared) is at least 30 kg/m^2 . A human who does not satisfy this standard may be characterized as "non-obese", the term "normal" being 15 reserved for use in reference to glucose and insulin levels as previously described. A human is considered overweight if the BMI is at least 25 kg/m2. Thus, we define overweight to include obese individuals, consistent with the recommendations of the 20 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). A human who does not satisfy this standard may be characterized as "non-overweight." According to the Report of the Expert Committe on the 25 Diagnosis and Classification of Diabetes Mellitus, Diabetes Care 20: 1183-97 (1997), the following are risk factors for diabetes type II: older (e.g., at least 45; see below) 30 excessive weight (see below) first-degree relative with diabetes mellitus 35 member of high risk ethnic group (black, Hispanic, Native American, Asian) history of gestational diabetes mellitus or delivering a baby weighing more than 9 pounds (4.032 kg)

36 hypertensive (>140/90 mm Hq)

HDL cholesterol level >35 mg/dL (0.90 mmol/L)

triglyceride level >=250 mg/dL (2.83 mmol/L)

Hence, in a preferred embodiment, the diagnostic and protective methods of the present invention are applied to human subjects exhibiting one or more of the aforementioned risk factors. Likewise, in a preferred embodiment, they are applied to human subjects who, while not diabetic, exhibit impaired glucose homeostasis (110 to <126 mg/dL).

The risk of diabetes increases with age. Hence, in successive preferred embodiments, the age of the subjects is at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, and at least 75.

With regard to excessive weight, NIDDK says that "The relative risk of diabetes increases by approximately 25 percent for each additional unit of BMI over 22." Hence, in successive preferred embodiments, the BMIs of the human subjects is at least 23, at least 24, at least 25 (i.e., overweight by our criterion), at least 26, at least 27, at least 28, at least 29, at least 30 (i.e., obese), at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, or over 40.

Age-Related Diseases

30

35

5

10

15

20

25

Age-related (senescent) diseases include certain cancers, atherosclerosis, diabetes (type 2), osteoporosis, hypertension, depression, Alzheimer's, Parkinson's, glaucoma, certain immune system defects, kidney failure, and liver steatosis. In general, they are diseases for which the relative risk (comparing a subpopulation over age 55 to a suitably matched population under age 55) is at least 1.1.

37

Preferably, the agents of the present invention protect against one or more age-related diseases for at least a subpopulation of mature (post-puberty) adult subjects.

5

10

15

20

25

30

35

Direct and Indirect Utility of Identified Nucleic Acid Sequences and Related Molecules

The mouse or human genes (or fragments thereof) may be used directly. For diagnostic or screening purposes, they (or specific binding fragments thereof) may be labeled and used as hybridization probes. For therapeutic purposes, they (or specific binding fragments thereof) may be used as antisense reagents to inhibit the expression of the corresponding gene, or of a sufficiently homologous gene of another species.

If the database DNA appears to be a full-length cDNA or gDNA, that is, it encodes an entire, functional, naturally occurring protein, then it may be used in the expression of that protein. Likewise, if the corresponding human gene is known in full-length, it may be used to express the human protein. Such expression may be in cell culture, with the protein subsequently isolated and administered exogenously to subjects who would benefit therefrom, or in vivo, i.e., administration by gene therapy. Naturally, any DNA encoding the same protein may be used for the same purpose, and a DNA encoding a protein which a fragment or a mutant of that naturally occurring protein which retains the desired activity, may be used for the purpose of producing the active fragment or mutant. The encoded protein of course has utility therapeutically and, in labeled or immobilized form, diagnostically.

The genes may also be used indirectly, that is, to identify other useful DNAs, proteins, or other molecules. We have attempted to determine whether the mouse genes disclosed herein have significant similarity to any known human DNA, and whether, in any of the six possible combinations of reference frame and strand, they encode a protein similar to a known human protein. If so, then it

38
the known human protein, and D
be used in a similar manner.
man protein is known to have ad

follows that the known human protein, and DNAs encoding that protein, may be used in a similar manner. In addition, if the known human protein is known to have additional homologues, then those homologous proteins, and DNAs encoding them, may be used in a similar manner.

There thus are several ways that a human protein homologue of interest can be identified by database searching, including but not limited to:

- 1) a DNA->DNA (BlastN) search for human database DNAs closely related to the mouse gene identifies a known human gene, and the sequence of the human protein is deduced by the Genetic Code;
- 2) a DNA->Protein (BlastX) search for humn database proteins closely related to the translated DNA of the mouse gene identifies a known human protein; and
- 3) the sequence of the mouse protein is known or is deduced by the Genetic Code, and a Protein->Protein (BlastP) search for closely related database proteins identifies a known human protein.

Once a known human gene is identified, it may be used in further BlastN or BlastX searches to identify other human genes or proteins. Once a known human protein is identified, it may be used in further BlastP searches to identify other human proteins.

Searches may also take cognizance, intermediately, of known genes and proteins other than mouse or human ones, e.g., use the mouse sequence to identify a known rat sequence and then the rat sequence to identify a human one.

If we have identified a mouse gene, and it encodes a mouse protein which appears similar to a human protein, then that human protein may be used (especially in humans) for

20

5

10

15

25

30

35

39 purposes analogous to the proposed use of the mouse protein in mice. Moreover, a specific binding fragment of an appropriate strand of the corresponding human gene (gDNA or cDNA) could be labeled and used as a hybridization probe 5 (especially against samples of human mRNA or cDNA). In determining whether the disclosed genes (gDNA or cDNA) have significant similarities to known DNAs (and their translated AA sequences to known proteins), one would generally use the disclosed gene as a query sequence in a 10 search of a sequence database. The results of several such searches are set forth in the Examples. Such results are dependent, to some degree, on the search parameters. Preferred parameters are set forth in Example 1. results are also dependent on the content of the database. 15 While the raw similarity score of a particular target (database) sequence will not vary with content (as long as it remains in the database), its informational value (in bits), expected value, and relative ranking can change. Generally speaking, the changes are small. 20 It will be appreciated that the nucleic acid and protein databases keep growing. Hence a later search may identify high scoring target sequences which were not 25 uncovered by an earlier search because the target sequences were not previously part of a database. Hence, in a preferred embodiment, the cognate DNAs and proteins include not only those set forth in the examples, but those which would have been highly ranked (top ten, more 30 preferably top three, even more preferably top two, most preferably the top one) in a search run with the same parameters on the date of filing of this application. If the known mouse or human database DNA appears to be 35 a partial sequence (that is, partial relative to a cDNA or gDNA encoding the whole naturally occurring protein), it may be used as a hybridization probe to isolate the full-length DNA. If the partial DNA encodes a biologically functional fragment of the cognate protein, it may be used in a manner

similar to the full length DNA, i.e., to produce the functional fragment. If we have indicated that an antagonist of a protein or 5 other molecule is useful, then such an antagonist may be obtained by preparing a combinatorial library, as described below, of potential antagonists, and screening the library members for binding to the protein or other molecule in The binding members may then be further screened 10 for the ability to antagonize the biological activity of the The antagonists may be used therapeutically, or, in suitably labeled or immobilized form, diagnostically. If the identified mouse or human database DNA is related to a known protein, then substances known to 15 interact with that protein (e.g., agonists, antagonists, substrates, receptors, second messengers, regulators, and so forth), and binding molecules which bind them, are also of utility. Such binding molecules can likewise be identified by screening a combinatorial library. 20 Isolation of Full Length DNAs Using Partial DNAs as probes If it is determined that a DNA of the present invention is a partial DNA, and the cognate full length DNA is not listed in a sequence database, the available DNA may be used 25 as a hybridization probe to isolate the full-length DNA from a suitable DNA library. Stringent hybridization conditions are appropriate, that is, conditions in which the hybridization temperature is 5-10 deg. C. below the Tm of the DNA as a perfect duplex. 30 Identification and Isolation of Homologous Genes Using a DNA Probe It may be that the sequence databases available do not include the sequence of any homologous gene (cDNA or gDNA), 35 or at least of the homologous gene for a species of interest. However, given the cDNAs set forth above, one may readily obtain the homologous gene. The possession of one DNA (the "starting DNA") facilitates the isolation of homologous DNAs. If only a

41 partial DNA is known, this partial DNA may first be used as a probe to isolate the corresponding full length DNA for the same species, and that the latter may be used as the starting DNA in the search for homologous genes. 5 The starting DNA, or a fragment thereof, is used as a hybridization probe to screen a cDNA or genomic DNA library for clones containing inserts which encode either the entire homologous protein, or a recognizable fragment thereof. minimum length of the hybridization probe is dictated by the 10 need for specificity. If the size of the library in bases is L, and the GC content is 50%, then the probe should have a length of at least 1, where $L = 4^1$. This will yield, on average, a single perfect match in random DNA of L bases. The human cDNA library is about 108 bases and the human genomic DNA library is about 1010 bases. 15 The library is preferably derived from an organism which is known, on biochemical evidence, to produce a homologous protein, and more preferably from the genomic DNA or mRNA of cells of that organism which are likely to be 20 relatively high producers of that protein. A cDNA library (which is derived from an mRNA library) is especially preferred. If the organism in question is known to have substantially different codon preferences from that of the 25 organism whose relevant cDNA or genomic DNA is known, a synthetic hybridization probe may be used which encodes the same amino acid sequence but whose codon utilization is more similar to that of the DNA of the target organism. Alternatively, the synthetic probe may employ inosine as a 30 substitute for those bases which are most likely to be divergent, or the probe may be a mixed probe which mixes the codons for the source DNA with the preferred codons (encoding the same amino acid) for the target organism. By routine methods, the Tm of a perfect duplex of 35 starting DNA is determined. One may then select a hybridization temperature which is sufficiently lower than the perfect duplex Tm to allow hybridization of the starting DNA (or other probe) to a target DNA which is divergent from the starting DNA. A 1% sequence divergence typically lowers

42

the Tm of a duplex by 1-2°C, and the DNAs encoding homologous proteins of different species typically have sequence identities of around 50-80%. Preferably, the library is screened under conditions where the temperature is at least 20°C., more preferably at least 50°C., below the perfect duplex Tm. Since salt reduces the Tm, one ordinarily would carry out the search for DNAs encoding highly homologous proteins under relatively <u>low</u> salt hybridization conditions, e.g., <1M NaCl. The higher the salt concentration, and/or the lower the temperature, the greater the sequence divergence which is tolerated.

5

10

15

20

25

For the use of probes to identify homologous genes in other species, see, e.g., Schwinn, et al., J. Biol. Chem., 265:8183-89 (1990) (hamster 67-bp cDNA probe vs. human leukocyte genomic library; human 0.32kb DNA probe vs. bovine brain cDNA library, both with hybridization at 42°C in 6xSSC); Jenkins et al., J. Biol. Chem., 265:19624-31 (1990) (Chicken 770-bp cDNA probe vs. human genomic libraries; hybridization at 40°C in 50% formamide and 5xSSC); Murata et al., J. Exp. Med., 175:341-51 (1992) (1.2-kb mouse cDNA probe v. human eosinophil cDNA library; hybridization at 65°C in 6xSSC); Guyer et al., J. Biol. Chem., 265:17307-17 (1990) (2.95-kb human genomic DNA probe vs. porcine genomic DNA library; hybridization at 42°C in 5xSSC). conditions set forth in these articles may each be considered suitable for the purpose of isolating homologous genes.

Corresponding (Homologous) Proteins and DNAs

In the case of a gene chip, the manufacturer of the gene chip determines which DNA to place at each position on the chip. This DNA may correspond in sequence to a genomic DNA, a cDNA, or a fragment of genomic or cDNA, and may be natural, synthetic or partially natural and partially synthetic in origin. The manufacturer of the gene chip will normally identify the DNA for a mouse gene chip as corresponding to a particular mouse gene, in which case it will be assumed that the alignments of chip DNA to mouse gene satisfies the homology criteria of the invention.

43 Usually, the gene chip manufacturer will provide a sequence database accession number for the mouse DNA. If so, to identify the corresponding mouse protein, we will first inspect the database record for that mouse DNA. Often, the 5 mouse protein accession number will appear in that record or in a linked record. If it doesn't, the corresponding mouse protein can be identified by performing a BlastX search on a mouse protein database with the mouse database DNA sequence as the query sequence. Even if the protein sequence is not 10 in the database, if the DNA sequence comprises a full-length coding sequence, the corresponding protein can be identified by translating the coding sequence in accordance with the Genetic Code. 15 A human protein can be said to be identifiable as corresponding (homologous) to a gene chip DNA if it is identified as corresponding (homologous) to the mouse gene (gDNA or cDNA, whole or partial) identified by the gene chip manufacturer as corresponding to that gene chip DNA. 20 In turn, it is identifiable as corresponding (homologous) to said identified mouse gene, if (1) it can be aligned by BlastX directly to that mouse gene, 25 and/or (2) it is encoded by a human gene, or can be aligned to a human gene by BlastX, which in turn can be aligned by BlastN to said mouse gene and/or 30 (3) it can be aligned by BlastP to a mouse protein, the latter being encoded by said mouse gene, or aligned to said mouse gene BlastX, 35 where any alignment by BlastN, BlastP or BlastX is in accordance with the default parameters set forth below, and the expected value (E) of each alignment (the probability that such an alignment would have occurred by chance alone)

44 is less than e-10. (Note that because this is a negative exponent, a value such as e-50 is less than e-10.) Desirably, two or all three of these conditions (1)-(3) are 5 satisfied for the corresponding (homologous) human genes and proteins. A human gene is corresponding (homologous) to a mouse gene chip DNA, and hence to said identified mouse gene (or 10 cDNA) and protein, if it encodes a corresponding (homologous) human protein as defined above, or it can be aligned by BlastN to said mouse gene. Preferably, for at least one of conditions (1)-(3), the E value is less than e-50, more preferably less than e-60, 15 still more preferably less than e-70, even more preferably less than e-80, considerably more preferably less than e-90, and most preferably less than e-100. Desirably, it is true for two or even all three of these conditions. 20 In constructing Master table 1, we generally used a BlastX (mouse gene vs. human protein) alignment E value cutoff of e-50. However, if there were no human proteins with that good an alignment to the mouse DNA in question, or if there were other reasons for including a particular human 25 protein (e.g., a known functionality supportive of the observed differential cognate mouse protein expression), then a human protein with a score worse (i.e., higher) than e-50 may appear in Master Table 1. 30 If the manufacturer of the gene chip identifies the gene chip DNA as corresponding to an EST, or other DNA which is not a full-length mouse gene or cDNA, a longer (possibly full length) mouse gene or cDNA may be identified by a BlastN search of the mouse DNA database. Alternatively, the 35 identified DNA may be used to conduct a BlastN search of a human DNA database, or a BlastX search of a mouse or human protein database. Thus, more generally, a human protein can be said to be identifiable as corresponding (homologous) to a gene chip

45 DNA, or to a DNA identified by the manufacturer as corresponding to that gene chip DNA, if (1') it can be aligned directly to the gene chip or corresponding manufacturer identified DNA by BlastX. and/or 5 (2') it can be aligned to a human gene/cDNA by BlastX, whose genomic DNA (gDNA) or cDNA (DNA complementary to messenger RNA) in turn can be aligned to the gene chip or corresponding manufacturer identified DNA by BlastN, and/or 10 (3') it can be aligned to a mouse gene/cDNA by BlastX, whose gDNA or cDNA in turn can be aliqued to the gene chip or corresponding manufacturer identified DNA by BlastN, and/or 15 (4') it can be aligned to a mouse protein by BlastP, which in turn can be aligned to the gene chip or corresponding manufacturer identified DNA by BlastX, and/or 20 (5') it can be aligned to a mouse protein by BlastP, which in turn can be aligned to a mouse gene/cDNA by BlastX, whose gDNA or cDNA can in turn be aligned to the gene chip or corresponding manufacturer identified DNA by BlastN; 25 where any alignment by BlastN, BlastP, or BlastX is in accordance with the default parameters set forth below, and the expected value (E) of each alignment (the probability that such an alignment would have occurred by chance alone) is less than e-10. (Note that because this is a negative 30 exponent, a value such as e-50 is less than e-10.) Preferably, two, three, four or all five of conditions (1')-(5') are satisfied. Preferably, for at least one of conditions (1')-(5'), 35 for at least the final alignment (i.e., vs. the human protein), the E value is less than e-50, more preferably less than e-60, , still more preferably less than e-70, even more preferably less than e-80, considerably more preferably less than e-90, and most preferably less than e-100.

.blv. one or more of these standa

Desirably, one or more of these standards of preference are met for two, three, four or all five of conditions (1')-(5'). In particular, for those conditions in which the gene chip or corresponding manufacturer identified DNA is indirectly connected to the human protein by virtue of two or more successive alignments, the E value is preferably, so limited for all of said alignments in the connecting chain.

A human gene corresponds (is homologous) to a gene chip DNA or manufacturer identified corresponding DNA if it encodes a homologous human protein as defined above, or if it can be aligned either directly to that DNA, or indirectly through a mouse gene which can be aligned to said DNA, according to the conditions set forth above.

15

5

10

Master table 1 assembles a list of human protein corresponding to each of the mouse DNAs/proteins identified as related to the chip DNA. These human proteins form a set and can be given a percentile rank, with respect to E value, within that set. The human proteins of the present invention preferably are those scorers with a percentile rank of at least 50%, more preferably at least 60%, still more preferably at least 70%, even more preferably at least 80%, and most preferably at least 90%.

25

30

35

20

For each mouse gene (gDNA or cDNA) in Master Table 1, there is a particular human protein which provides the best alignment match as measured by BlastX, i.e., the human protein with the best score (lowest e-value). These human proteins form a subset of the set above and can be given a percentile rank within that subset, e.g., the human proteins with scores in the top 10% of that subset have a percentile rank of 90% or higher.

The human proteins of the present invention preferably are those best scorer subset proteins with a percentile rank within the subset of at least 50%, more preferably at least 60%, still more preferably at least 70%, even more preferably at least 80%, and most preferably at least 90%.

BlastN and BlastX report very low expected values as "0.0". This does not truly mean that the expected value is exactly zero (since any alignment could occur by chance), but merely that it is so infinitesimal that it is not reported. The documentation does not state the cutoff value, but alignments with explicit E values as low as e-178 (624 bits) have been reported as nonzero values, while a score of 636 bits was reported as "0.0".

Functionally homologous human proteins are also of interest. A human protein may be said to be functionally homologous to the mouse gene if the human protein has at least one biological activity in common with the mouse protein encoded by said mouse gene.

The human proteins of interest also include those that are substantially and/or conservatively identical (as defined below) to the homologous and/or functionally homologous human proteins defined above.

Degree of Differential Expression

The degree of differential expression may be expressed as the ratio of the higher expression level to the lower expression level. Preferably, this is at least 2-fold, and more preferably, it is higher, such as at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, or at least 10-fold.

Most preferably, the human protein of interest corresponds to a mouse gene for which the degree of differential expression places it among the top 10% of the mouse genes in the appropriate subtable.

30

5

15

20

25

48 If a gene is down-regulated in more favored mammals, or up-regulated in less favored mammals, (i.e., an "unfavorable gene") then several utilities are apparent. First, the complementary strand of the gene, or a 5 portion thereof, may be used in labeled form as a hybridization probe to detect messenger RNA and thereby monitor the level of expression of the gene in a subject. Elevated levels are indicative of progression, or propensity to progression, to a less favored state, and clinicians may take appropriate preventative, curative or 10 ameliorative action. Secondly, the messenger RNA product (or equivalent cDNA), the protein product, or a binding molecule specific for that product (e.g., an antibody which binds the product), or a downstream product which mediates the 15 activity (e.q., a signaling intermediate) or a binding molecule (e.g., an antibody) therefor, may be used, preferably in labeled or immobilized form, as an assay reagent in an assay for said nucleic acid product, protein 20 product, or downstream product (e.g., a signaling intermediate). Again, elevated levels are indicative of a present or future problem. Thirdly, an agent which down-regulates expression of the gene may be used to reduce levels of the corresponding 25 protein and thereby inhibit further damage. This agent could inhibit transcription of the gene in the subject, or translation of the corresponding messenger RNA. inhibitors of transcription and translation include antisense molecules and repressor molecules. The agent 30 could also inhibit a post-translational modification (e.g., glycosylation, phosphorylation, cleavage, GPI attachment) required for activity, or post-translationally modify the protein so as to inactivate it. Or it could be an agent which down- or up-regulated a positive or negative 35 regulatory gene, respectively. Fourthly, an agent which is an antagonist of the messenger RNA product or protein product of the gene, or of a downstream product through which its activity is

manifested (e.g., a signaling intermediate), may be used to inhibit its activity. This antagonist could be an antibody, a peptide, a peptoid, a nucleic acid, a peptide nucleic acid (PNA) oligomer, a small organic molecule of a kind for which a 5 combinatorial library exists (e.g., a benzodiazepine), etc. An antagonist is simply a binding molecule which, by binding, reduces or abolishes the undesired activity of its target. The antagonist, if not an oligomeric molecule, is 10 preferably less than 1000 daltons, more preferably less than 500 daltons. Fifthly, an agent which degrades, or abets the degradation of, that messenger RNA, its protein product or a downstream product which mediates its activity (e.g., a 15 signaling intermediate), may be used to curb the effective period of activity of the protein. If a gene is <u>up</u>-regulated in more favored mammals, or down-regulated in less favored animals then the utilities are converse to those stated above. 20 First, the complementary strand of the gene, or a portion thereof, may be used in labeled form as a hybridization probe to detect messenger RNA and thereby monitor the level of expression of the gene in a subject. Depressed levels are indicative of damage, or possibly of a 25 propensity to damage, and clinicians may take appropriate preventative, curative or ameliorative action. Secondly, the messenger RNA product, the equivalent cDNA, protein product, or a binding molecule specific for those products, or a downstream product, or a signaling 30 intermediate, or a binding molecule therefor, may be used, preferably in labeled or immobilized form, as an assay reagent in an assay for said protein product or downstream product. Again, depressed levels are indicative of a present or future problem. 35 Thirdly, an agent which up-regulates expression of the gene may be used to increase levels of the corresponding protein and thereby inhibit further progression to a less favored state. By way of example, it could be a vector which carries a copy of the gene, but which expresses the

50 gene at higher levels than does the endogenous expression system. Or it could be an agent which up- or down-regulates a positive or negative regulatory gene. Fourthly, an agent which is an agonist of the protein 5 product of the gene, or of a downstream product through which its activity (of inhibition of progression to a less favored state) is manifested, or of a signaling intermediate may be used to foster its activity. Fifthly, an agent which inhibits the degradation of 10 that protein product or of a downstream product or of a signaling intermediate may be used to increase the effective period of activity of the protein. 15 Mutant Proteins The present invention also contemplates mutant proteins (peptides) which are substantially identical (as defined below) to the parental protein (peptide). In general, the fewer the mutations, the more likely the mutant protein is 20 to retain the activity of the parental protein. The effect of mutations is usually (but not always) additive. Certain individual mutations are more likely to be tolerated than others. A protein is more likely to tolerate a mutation which 25 is a substitution rather than an insertion or (a) deletion: is an insertion or deletion at the terminus, rather than internally, or, if internal, is at a domain boundary, or a loop or turn, rather than in 30 an alpha helix or beta strand; affects a surface residue rather than an interior residue: affects a part of the molecule distal to the binding site; 35 (e) is a substitution of one amino acid for another of similar size, charge, and/or hydrophobicity, and does not destroy a disulfide bond or other crosslink; and

Surface vs. Interior Residues

Charged amino acid residues almost always lie on the surface of the protein. For uncharged residues, there is less certainty, but in general, hydrophilic residues are partitioned to the surface and hydrophobic residues to the interior. Of course, for a membrane protein, the membranespanning segments are likely to be rich in hydrophobic residues.

Surface residues may be identified experimentally by various labeling techniques, or by 3-D structure mapping techniques like X-ray diffraction and NMR. A 3-D model of a homologous protein can be helpful.

Binding Site Residues 20

5

10

15

25

30

35

mutants.

Residues forming the binding site may be identified by (1) comparing the effects of labeling the surface residues before and after complexing the protein to its target, (2) labeling the binding site directly with affinity ligands,

(3) fragmenting the protein and testing the fragments for binding activity, and (4) systematic mutagenesis (e.g., alanine-scanning mutagenesis) to determine which mutants If the binding site of a homologous destroy binding. protein is known, the binding site may be postulated by analogy.

Protein libraries may be constructed and screened that a large family (e.g., 108) of related mutants may be evaluated simultaneously.

Hence, the mutations are preferably conservative modifications as defined below.

"Substantially Identical"

A mutant protein (peptide) is substantially identical to a reference protein (peptide) if (a) it has at least 10%

52 of a specific binding activity or a non-nutritional biological activity of the reference protein, and (b) is at least 50% identical in amino acid sequence to the reference protein (peptide). It is "substantially structurally 5 identical" if condition (b) applies, regardless of (a). Percentage amino acid identity is determined by aligning the mutant and reference sequences according to a rigorous dynamic programming algorithm which globally aligns their sequences to maximize their similarity, the similarity 10 being scored as the sum of scores for each aligned pair according to an unbiased PAM250 matrix, and a penalty for each internal gap of -12 for the first null of the gap and -4 for each additional null of the same gap. The percentage identity is the number of matches expressed as a percentage 15 of the adjusted (i.e., counting inserted nulls) length of the reference sequence. A mutant DNA sequence is substantially identical to a reference DNA sequence if they are structural sequences, and encoding mutant and reference proteins which are 20 substantially identical as described above. If instead they are regulatory sequences, they are substantially identical if the mutant sequence has at least 10% of the regulatory activity of the reference sequence, and is at least 50% identical in nucleotide sequence to the 25 reference sequence. Percentage identity is determined as for proteins except that matches are scored +5, mismatches -4, the gap open penalty is -12, and the gap extension penalty (per additional null) is -4. More preferably, the sequence is not merely 30 substantially identical but rather is at least 51%, at least 66%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical in sequence to the reference sequence. DNA sequences may also be considered "substantially 35 identical" if they hybridize to each other under stringent conditions, i.e., conditions at which the Tm of the heteroduplex of the one strand of the mutant DNA and the more complementary strand of the reference DNA is not in

53 excess of 10°C. less than the Tm of the reference DNA Typically this will correspond to a percentage homoduplex. identity of 85-90%. 5 "Conservative Modifications" "Conservative modifications" are defined as conservative substitutions of amino acids as hereafter defined; or single or multiple insertions (extension) or deletions (truncation) of amino acids at the 10 termini. Conservative modifications are preferred to other modifications. Conservative substitutions are preferred to other conservative modifications. "Semi-Conservative Modifications" are modifications 15 which are not conservative, but which are (a) semiconservative substitutions as hereafter defined; or (b) single or multiple insertions or deletions internally, but at interdomain boundaries, in loops or in other segments of relatively high mobility. Semi-conservative modifications 20 are preferred to nonconservative modifications. conservative substitutions are preferred to other semiconservative modifications. Non-conservative substitutions are preferred to other 25 non-conservative modifications. The term "conservative" is used here in an a priori sense, i.e., modifications which would be expected to preserve 3D structure and activity, based on analysis of the naturally occurring families of homologous proteins and of 30 past experience with the effects of deliberate mutagenesis, rather than post facto, a modification already known to conserve activity. Of course, a modification which is

Preferably, except at the termini, no more than about five amino acids are inserted or deleted at a particular locus, and the modifications are outside regions known to contain binding sites important to activity.

post facto.

conservative a priori may, and usually is, also conservative

54 Preferably, insertions or deletions are limited to the termini. A conservative substitution is a substitution of one amino acid for another of the same exchange group, the 5 exchange groups being defined as follows Gly, Pro, Ser, Ala (Cys) (and any nonbiogenic, neutral amino acid with a hydrophobicity not exceeding that of the aforementioned a.a.'s) ΙI Arg, Lys, His (and any nonbiogenic, positively-10 charged amino acids) Asp, Glu, Asn, Gln (and any nonbiogenic III negatively-charged amino acids) IV Leu, Ile, Met, Val (Cys) (and any nonbiogenic, aliphatic, neutral amino acid with a 15 hydrophobicity too high for I above) V Phe, Trp, Tyr (and any nonbiogenic, aromatic neutral amino acid with a hydrophobicity too high for I above). Note that Cys belongs to both I and IV. 20 Residues Pro, Gly and Cys have special conformational Cys participates in formation of disulfide bonds. Gly imparts flexibility to the chain. Pro imparts rigidity to the chain and disrupts α helices. These residues may be essential in certain regions of the polypeptide, but 25 substitutable elsewhere. One, two or three conservative substitutions are more likely to be tolerated than a larger number. "Semi-conservative substitutions" are defined herein as being substitutions within supergroup I/II/III or within 30 supergroup IV/V, but not within a single one of groups I-V. They also include replacement of any other amino acid with alanine. If a substitution is not conservative, it preferably is semi-conservative. "Non-conservative substitutions" are substitutions 35 which are not "conservative" or "semi-conservative". "Highly conservative substitutions" are a subset of conservative substitutions, and are exchanges of amino acids within the groups Phe/Tyr/Trp, Met/Leu/Ile/Val, His/Arg/Lys, Asp/Glu and Ser/Thr/Ala. They are more likely to be

55 tolerated than other conservative substitutions. smaller the number of substitutions, the more likely they are to be tolerated. 5 "Conservatively Identical" A protein (peptide) is conservatively identical to a reference protein (peptide) it differs from the latter, if at all, solely by conservative modifications, the protein (peptide remaining at least seven amino acids long if the 10 reference protein (peptide) was at least seven amino acids long. A protein is at least semi-conservatively identical to a reference protein (peptide) if it differs from the latter, if at all, solely by semi-conservative or conservative 15 modifications. A protein (peptide) is nearly conservatively identical to a reference protein (peptide) if it differs from the latter, if at all, solely by one or more conservative modifications and/or a single nonconservative substitution. 20 It is highly conservatively identical if it differs, if at all, solely by highly conservative substitutions. Highly conservatively identical proteins are preferred to those merely conservatively identical. An absolutely identical protein is even more preferred. 25 The core sequence of a reference protein (peptide) is the largest single fragment which retains at least 10% of a particular specific binding activity, if one is specified, 30 or otherwise of at least one specific binding activity of the referent. If the referent has more than one specific binding activity, it may have more than one core sequence, and these may overlap or not. If it is taught that a peptide of the present invention 35 may have a particular similarity relationship (e.g., markedly identical) to a reference protein (peptide), preferred peptides are those which comprise a sequence having that relationship to a core sequence of the reference protein (peptide), but with internal insertions or deletions

56

in either sequence excluded. Even more preferred peptides are those whose entire sequence has that relationship, with the same exclusion, to a core sequence of that reference protein (peptide).

5

10

15

20

25

30

35

Library

The term "library" generally refers to a collection of chemical or biological entities which are related in origin, structure, and/or function, and which can be screened simultaneously for a property of interest.

Libraries may be classified by how they are constructed (natural vs. artificial diversity; combinatorial vs. noncombinatorial), how they are screened (hybridization, expression, display), or by the nature of the screened library members (peptides, nucleic acids, etc.).

In a "natural diversity" library, essentially all of the diversity arose without human intervention. This would be true, for example, of messenger RNA extracted from a nonengineered cell.

In a "synthetic diversity" library, essentially all of the diversity arose deliberately as a result of human intervention. This would be true for example of a combinatorial library; note that a small level of natural diversity could still arise as a result of spontaneous mutation. It would also be true of a noncombinatorial library of compounds collected from diverse sources, even if they were all natural products.

In a "non-natural diversity" library, at least some of the diversity arose deliberately through human intervention.

In a "controlled origin" library, the source of the diversity is limited in some way. A limitation might be to cells of a particular individual, to a particular species, or to a particular genus, or, more complexly, to individuals of a particular species who are of a particular age, sex, physical condition, geographical location, occupation and/or familial relationship. Alternatively or additionally, it might be to cells of a particular tissue or organ. Or it could be cells exposed to particular pharmacological,

57 environmental, or pathogenic conditions. Or the library could be of chemicals, or a particular class of chemicals, produced by such cells. In a "controlled structure" library, the library members are deliberately limited by the production conditions to particular chemical structures. For example, if they are oligomers, they may be limited in length and monomer composition, e.g. hexapeptides composed of the twenty genetically encoded amino acids. Hybridization Library In a hybridization library, the library members are nucleic acids, and are screened using a nucleic acid hybridization probe. Bound nucleic acids may then be

amplified, cloned, and/or sequenced.

Expression Library

In an expression library, the screened library members are gene expression products, but one may also speak of an underlying library of genes encoding those products. library is made by subcloning DNA encoding the library members (or portions thereof) into expression vectors (or into cloning vectors which subsequently are used to construct expression vectors), each vector comprising an expressible gene encoding a particular library member, introducing the expression vectors into suitable cells, and expressing the genes so the expression products are produced.

In one embodiment, the expression products are secreted, so the library can be screened using an affinity reagent, such as an antibody or receptor. expression products may be sequenced directly, or their sequences inferred by, e.g., sequencing at least the variable portion of the encoding DNA.

In a second embodiment, the cells are lysed, thereby exposing the expression products, and the latter are screened with the affinity reagent.

In a third embodiment, the cells express the library members in such a manner that they are displayed on the

10

15

20

25

5

30

35

58 surface of the cells, or on the surface of viral particles produced by the cells. (See display libraries, below). In a fourth embodiment, the screening is not for the ability of the expression product to bind to an affinity 5 reagent, but rather for its ability to alter the phenotype of the host cell in a particular detectable manner. the screened library members are transformed cells, but there is a first underlying library of expression products which mediate the behavior of the cells, and a second 10 underlying library of genes which encode those products. Display Library In a display library, the library members are each conjugated to, and displayed upon, a support of some kind. 15 The support may be living (a cell or virus), or nonliving (e.g., a bead or plate). If the support is a cell or virus, display will normally be effectuated by expressing a fusion protein which comprises the library member, a carrier moiety allowing 20 integration of the fusion protein into the surface of the

If the support is a cell or virus, display will normally be effectuated by expressing a fusion protein which comprises the library member, a carrier moiety allowing integration of the fusion protein into the surface of the cell or virus, and optionally a lining moiety. In a variation on this theme, the cell coexpresses a first fusion comprising the library member and a linking moiety L1, and a second fusion comprising a linking moiety L2 and the carrier moiety. L1 and L2 interact to associate the first fusion with the second fusion and hence, indirectly, the library member with the surface of the cell or virus.

Soluble Library

In a soluble library, the library members are free in solution. A soluble library may be produced directly, or one may first make a display library and then release the library members from their supports.

35 <u>Encapsulated Library</u>

In an encapsulated library, the library members are inside cells or liposomes. Generally speaking, encapsulated libraries are used to store the library members for future use; the members are extracted in some way for screening

25

30

purposes. However, if they differentially affect the phenotype of the cells, they may be screened indirectly by screening the cells.

5 <u>cDNA Library</u>

10

15

20

25

30

35

A cDNA library is usually prepared by extracting RNA from cells of particular origin, fractionating the RNA to isolate the messenger RNA (mRNA has a poly(A) tail, so this is usually done by oligo-dT affinity chromatography), synthesizing complementary DNA (cDNA) using reverse transcriptase, DNA polymerase, and other enzymes, subcloning the cDNA into vectors, and introducing the vectors into cells. Often, only mRNAs or cDNAs of particular sizes will be used, to make it more likely that the cDNA encodes a functional polypeptide.

A cDNA library explores the natural diversity of the transcribed DNAs of cells from a particular source. It is not a combinatorial library.

A cDNA library may be used to make a hybridization library, or it may be used as an (or to make) expression library.

Genomic DNA Library

A genomic DNA library is made by extracting DNA from a particular source, fragmenting the DNA, isolating fragments of a particular size range, subcloning the DNA fragments into vectors, and introducing the vectors into cells.

Like a cDNA library, a genomic DNA library is a natural diversity library, and not a combinatorial library. A genomic DNA library may be used the same way as a cDNA library.

Synthetic DNA_library

A synthetic DNA library may be screened directly (as a hybridization library), or used in the creation of an expression or display library of peptides/proteins.

Combinatorial Libraries

The term "combinatorial library" refers to a library in which the individual members are either systematic or random combinations of a limited set of basic elements, the properties of each member being dependent on the choice and location of the elements incorporated into it. Typically, the members of the library are at least capable of being screened simultaneously. Randomization may be complete or partial; some positions may be randomized and others predetermined, and at random positions, the choices may be limited in a predetermined manner. The members of a combinatorial library may be oligomers or polymers of some kind, in which the variation occurs through the choice of monomeric building block at one or more positions of the oligomer or polymer, and possibly in terms of the connecting linkage, or the length of the oligomer or polymer, too. the members may be nonoligomeric molecules with a standard core structure, like the 1,4-benzodiazepine structure, with the variation being introduced by the choice of substituents at particular variable sites on the core structure. Or the members may be nonoligomeric molecules assembled like a jigsaw puzzle, but wherein each piece has both one or more variable moieties (contributing to library diversity) and one or more constant moieties (providing the functionalities for coupling the piece in question to other pieces).

60

Thus, in a typical combinatorial library, chemical building blocks are at least partially randomly combined into a large number (as high as 10¹⁵) of different compounds, which are then simultaneously screened for binding (or other) activity against one or more targets.

In a "simple combinatorial library", all of the members belong to the same class of compounds (e.g., peptides) and can be synthesized simultaneously. A "composite combinatorial library" is a mixture of two or more simple libraries, e.g., DNAs and peptides, or peptides, peptoids, and PNAs, or benzodiazepines and carbamates. The number of component simple libraries in a composite library will, of course, normally be smaller than the average number of members in each simple library, as otherwise the advantage of a library over individual synthesis is small.

25

30

35

5

10

15

20

61 Libraries of thousands, even millions, of random oligopeptides have been prepared by chemical synthesis (Houghten et al., Nature, 354:84-6(1991)), or gene expression (Marks et al., J Mol Biol, 222:581-97(1991)), displayed on chromatographic supports (Lam et al., Nature, 5 354:82-4(1991)), inside bacterial cells (Colas et al., Nature, 380:548-550(1996)), on bacterial pili (Lu, Bio/Technology, 13:366-372(1990)), or phage (Smith, Science, 228:1315-7(1985)), and screened for binding to a variety of 10 targets including antibodies (Valadon et al., J Mol Biol, 261:11-22(1996)), cellular proteins (Schmitz et al., J Mol Biol, 260:664-677(1996)), viral proteins (Hong and Boulanger, Embo J, 14:4714-4727(1995)), bacterial proteins (Jacobsson and Frykberg, Biotechniques, 18:878-885(1995)), 15 nucleic acids (Cheng et al., Gene, 171:1-8(1996)), and plastic (Siani et al., J Chem Inf Comput Sci, 34:588-593(1994)). Libraries of proteins (Ladner, USP 4,664,989), peptoids (Simon et al., Proc Natl Acad Sci U S A, 89:9367-71(1992)), 20 nucleic acids (Ellington and Szostak, Nature, 246:818(1990)), carbohydrates, and small organic molecules (Eichler et al., Med Res Rev, 15:481-96(1995)) have also been prepared or suggested for drug screening purposes. The first combinatorial libraries were composed of 25 peptides or proteins, in which all or selected amino acid positions were randomized. Peptides and proteins can exhibit high and specific binding activity, and can act as catalysts. In consequence, they are of great importance in biological systems. 30 Nucleic acids have also been used in combinatorial Their great advantage is the ease with which a nucleic acid with appropriate binding activity can be amplified. As a result, combinatorial libraries composed of nucleic acids can be of low redundancy and hence, of high 35 diversity. There has also been much interest in combinatorial libraries based on small molecules, which are more suited to pharmaceutical use, especially those which, like benzodiazepines, belong to a chemical class which has

already yielded useful pharmacological agents. The techniques of combinatorial chemistry have been recognized as the most efficient means for finding small molecules that act on these targets. At present, small molecule combinatorial chemistry involves the synthesis of either pooled or discrete molecules that present varying arrays of functionality on a common scaffold. These compounds are grouped in libraries that are then screened against the target of interest either for binding or for inhibition of biological activity.

The size of a library is the number of molecules in it. The simple diversity of a library is the number of unique structures in it. There is no formal minimum or maximum diversity. If the library has a very low diversity, the library has little advantage over just synthesizing and screening the members individually. If the library is of very high diversity, it may be inconvenient to handle, at least without automatizing the process. The simple diversity of a library is preferably at least 10, 10E2, 10E3, 10E4, 10E6, 10E7, 10E8 or 10E9, the higher the better under most circumstances. The simple diversity is usually not more than 10E15, and more usually not more than 10E10.

The average sampling level is the size divided by the simple diversity. The expected average sampling level must be high enough to provide a reasonable assurance that, if a given structure were expected, as a consequence of the library design, to be present, that the actual average sampling level will be high enough so that the structure, if satisfying the screening criteria, will yield a positive result when the library is screened. Thus, the preferred average sampling level is a function of the detection limit, which in turn is a function of the strength of the signal to be screened.

There are more complex measures of diversity than simple diversity. These attempt to take into account the degree of structural difference between the various unique sequences. These more complex measures are usually used in the context of small organic compound libraries, see below.

63 The library members may be presented as solutes in solution, or immobilized on some form of support. latter case, the support may be living (cell, virus) or nonliving (bead, plate, etc.). The supports may be separable 5 (cells, virus particles, beads) so that binding and nonbinding members can be separated, or nonseparable (plate). In the latter case, the members will normally be placed on addressable positions on the support. The advantage of a soluble library is that there is no carrier moiety that could interfere with the binding of the members 10 to the support. The advantage of an immobilized library is that it is easier to identify the structure of the members which were positive. When screening a soluble library, or one with a 15 separable support, the target is usually immobilized. screening a library on a nonseparable support, the target will usually be labeled. Oligonucleotide Libraries 20 An oligonucleotide library is a combinatorial library, at least some of whose members are single-stranded oligonucleotides having three or more nucleotides connected by phosphodiester or analogous bonds. The oligonucleotides may be linear, cyclic or branched, and may include non-25 nucleic acid moieties. The nucleotides are not limited to the nucleotides normally found in DNA or RNA. For examples of nucleotides modified to increase nuclease resistance and chemical stability of aptamers, see Chart 1 in Osborne and Ellington, Chem. Rev., 97: 349-70 (1997). For screening of 30 RNA, see Ellington and Szostak, Nature, 346: 818-22 (1990). There is no formal minimum or maximum size for these oligonucleotides. However, the number of conformations which an oligonucleotide can assume increases exponentially with its length in bases. Hence, a longer oligonucleotide is 35 more likely to be able to fold to adapt itself to a protein surface. On the other hand, while very long molecules can be synthesized and screened, unless they provide a much superior affinity to that of shorter molecules, they are not likely to be found in the selected population, for the

reasons explained by Osborne and Ellington (1997). Hence, the libraries of the present invention are preferably composed of oligonucleotides having a length of 3 to 100 bases, more preferably 15 to 35 bases. The oligonucleotides in a given library may be of the same or of different lengths.

64

Oligonucleotide libraries have the advantage that libraries of very high diversity (e.g., 10¹⁵) are feasible, and binding molecules are readily amplified in vitro by polymerase chain reaction (PCR). Moreover, nucleic acid molecules can have very high specificity and affinity to targets.

In a preferred embodiment, this invention prepares and screens oligonucleotide libraries by the SELEX method, as described in King and Famulok, Molec. Biol. Repts., 20: 97-107 (1994); L. Gold, C. Tuerk. Methods of producing nucleic acid ligands, US#5595877; Oliphant et al. Gene 44:177 (1986).

The term "aptamer" is conferred on those oligonucleotides which bind the target protein. Such aptamers may be used to characterize the target protein, both directly (through identification of the aptamer and the points of contact between the aptamer and the protein) and indirectly (by use of the aptamer as a ligand to modify the chemical reactivity of the protein).

In a classic oligonuclotide, each nucleotide (monomeric unit) is composed of a phosphate group, a sugar moiety, and either a purine or a pyrimidine base. In DNA, the sugar is deoxyribose and in RNA it is ribose. The nucleotides are linked by 5'-3' phosphodiester bonds.

The deoxyribose phosphate backbone of DNA can be modified to increase resistance to nuclease and to increase penetration of cell membranes. Derivatives such as mono- or dithiophosphates, methyl phosphonates, boranophosphates, formacetals, carbamates, siloxanes, and dimethylenethio- sulfoxideo- and-sulfono- linked species are known in the art.

5

10

15

20

25

30

35

A peptide is composed of a plurality of amino acid residues joined together by peptidyl (-NHCO-) bonds. biogenic peptide is a peptide in which the residues are all genetically encoded amino acid residues; it is not necessary 5 that the biogenic peptide actually be produced by gene expression. Amino acids are the basic building blocks with which peptides and proteins are constructed. Amino acids possess both an amino group (-NH2) and a carboxylic acid group (-10 COOH). Many amino acids, but not all, have the alpha amino acid structure NH2-CHR-COOH, where R is hydrogen, or any of a variety of functional groups. Twenty amino acids are genetically encoded: Alanine, Arginine, Asparagine, Aspartic Acid, Cysteine, Glutamic Acid, Glutamine, Glycine, Histidine, Isoleucine, Leucine, 15 Lysine, Methionine, Phenylalanine, Proline, Serine, Threonine, Tryptophan, Tyrosine, and Valine. Of these, all save Glycine are optically isomeric, however, only the Lform is found in humans. Nevertheless, the D-forms of these 20 amino acids do have biological significance; D-Phe, for example, is a known analgesic. Many other amino acids are also known, including: 2-Aminoadipic acid; 3-Aminoadipic acid; beta-Aminopropionic acid; 2-Aminobutyric acid; 4-Aminobutyric acid (Piperidinic 25 acid); 6-Aminocaproic acid; 2-Aminoheptanoic acid; 2-Aminoisobutyric acid, 3-Aminoisobutyric acid; 2-Aminopimelic acid; 2,4-Diaminobutyric acid; Desmosine; 2,2'-Diaminopimelic acid; 2,3-Diaminopropionic acid; N-Ethylglycine; N-Ethylasparagine; Hydroxylysine; allo-30 Hydroxylysine; 3-Hydroxyproline; 4-Hydroxyproline; Isodesmosine; allo-Isoleucine; N-Methylglycine (Sarcosine); N-Methylisoleucine; N-Methylvaline; Norvaline; Norleucine; and Ornithine. Peptides are constructed by condensation of amino acids 35 and/or smaller peptides. The amino group of one amino acid (or peptide) reacts with the carboxylic acid group of a second amino acid (or peptide) to form a peptide (-NHCO-) bond, releasing one molecule of water. Therefore, when an amino acid is incorporated into a peptide, it should,

66 technically speaking, be referred to as an amino acid residue. The core of that residue is the moiety which excludes the -NH and -CO linking functionalities which connect it to other residues. This moiety consists of one 5 or more main chain atoms (see below) and the attached side chains. The main chain moiety of each amino acid consists of the -NH and -CO linking functionalities and a core main chain moiety. Usually the latter is a single carbon atom. 10 However, the core main chain moiety may include additional carbon atoms, and may also include nitrogen, oxygen or sulfur atoms, which together form a single chain. preferred embodiment, the core main chain atoms consist solely of carbon atoms. 15 The side chains are attached to the core main chain atoms. For alpha amino acids, in which the side chain is attached to the alpha carbon, the C-1, C-2 and N-2 of each residue form the repeating unit of the main chain, and the word "side chain" refers to the C-3 and higher numbered 20 carbon atoms and their substituents. It also includes H atoms attached to the main chain atoms. Amino acids may be classified according to the number of carbon atoms which appear in the main chain between the carbonyl carbon and amino nitrogen atoms which participate in the peptide bonds. Among the 150 or so amino acids which 25 occur in nature, alpha, beta, gamma and delta amino acids These have 1-4 intermediary carbons. are known. amino acids occur in proteins. Proline is a special case of an alpha amino acid; its side chain also binds to the 30 peptide bond nitrogen. For beta and higher order amino acids, there is a choice as to which main chain core carbon a side chain other than H is attached to. The preferred attachment site is the C-2 (alpha) carbon, i.e., the one adjacent to the carboxyl 35 carbon of the -CO linking functionality. It is also possible for more than one main chain atom to carry a side chain other than H. However, in a preferred embodiment, only one main chain core atom carries a side chain other than H.

67 A main chain carbon atom may carry either one or two side chains; one is more common. A side chain may be attached to a main chain carbon atom by a single or a double bond; the former is more common. 5 A simple combinatorial peptide library is one whose members are peptides having three or more amino acids connected via peptide bonds. The peptides may be linear, branched, or cyclic, and may covalently or noncovalently include nonpeptidyl 10 The amino acids are not limited to the naturally occurring or to the genetically encoded amino acids. A biased peptide library is one in which one or more (but not all) residues of the peptides are constant residues. 15 Cyclic Peptides Many naturally occurring peptides are cyclic. Cyclization is a common mechanism for stabilization of peptide conformation thereby achieving improved association 20 of the peptide with its ligand and hence improved biological activity. Cyclization is usually achieved by intra-chain cystine formation, by formation of peptide bond between side. chains or between N- and C- terminals. Cyclization was usually achieved by peptides in solution, but several 25 publications have appeared that describe cyclization of peptides on beads. A peptide library may be an oligopeptide library or a protein library. 30 Oligopeptides Preferably, the oligopeptides are at least five, six, seven or eight amino acids in length. Preferably, they are composed of less than 50, more preferably less than 20 amino acids. 35 In the case of an oligopeptide library, all or just some of the residues may be variable. The oligopeptide may be unconstrained, or constrained to a particular conformation by, e.g., the participation of constant

68 cysteine residues in the formation of a constraining disulfide bond.

Proteins

Proteins, like oligopeptides, are composed of a plurality of amino acids, but the term protein is usually reserved for longer peptides, which are able to fold into a stable conformation. A protein may be composed of two or more polypeptide chains, held together by covalent or noncovalent crosslinks. These may occur in a homooligomeric or a heterooligomeric state.

A peptide is considered a protein if it (1) is at least 50 amino acids long, or (2) has at least two stabilizing covalent crosslinks (e.g., disulfide bonds). Thus, conotoxins are considered proteins.

Usually, the proteins of a protein library will be characterizable as having both constant residues (the same for all proteins in the library) and variable residues (which vary from member to member). This is simply because, for a given range of variation at each position, the sequence space (simple diversity) grows exponentially with the number of residue positions, so at some point it becomes inconvenient for all residues of a peptide to be variable positions. Since proteins are usually larger than oligopeptides, it is more common for protein libraries than oligopeptide libraries to feature variable positions.

In the case of a protein library, it is desirable to focus the mutations at those sites which are tolerant of mutation. These may be determined by alanine scanning mutagenesis or by comparison of the protein sequence to that of homologous proteins of similar activity. It is also more likely that mutation of surface residues will directly affect binding. Surface residues may be determined by inspecting a 3D structure of the protein, or by labeling the surface and then ascertaining which residues have received labels. They may also be inferred by identifying regions of high hydrophilicity within the protein.

15

5

10

20

25

30

35

69 Because proteins are often altered at some sites but not others, protein libraries can be considered a special case of the biased peptide library. There are several reasons that one might screen a 5 protein library instead of an oligopeptide library, including (1) a particular protein, mutated in the library, has the desired activity to some degree already, and (2) the oligopeptides are not expected to have a sufficiently high affinity or specificity since they do not have a stable conformation. 10 When the protein library is based on a parental protein which does not have the desired activity, the parental protein will usually be one which is of high stability (melting point >= 50 deg. C.) and/or possessed of 15 hypervariable regions. The variable domains of an antibody possess hypervariable regions and hence, in some embodiments, the protein library comprises members which comprise a mutant of VH or VL chain, or a mutant of an antigen-specific binding 20 fragment of such a chain. VH and VL chains are usually each about 110 amino acid residues, and are held in proximity by a disulfide bond between the adjoing CL and CH1 regions to form a variable domain. Together, the VH, VL, CL and CH1 form an Fab fragment. 25 In human heavy chains, the hypervariable regions are at 31-35, 49-65, 98-111 and 84-88, but only the first three are involved in antigen binding. There is variation among VH and VL chains at residues outside the hypervariable regions, but to a much lesser degree. 30 A sequence is considered a mutant of a VH or VL chain if it is at least 80% identical to a naturally occurring VH or VL chain at all residues outside the hypervariable region. In a preferred embodiment, such antibody library 35 members comprise both at least one VH chain and at least one VL chain, at least one of which is a mutant chain, and which chains may be derived from the same or different antibodies. The VH and VL chains may be covalently joined by a suitable linker moiety, as in a "single chain antibody", or they may

70 be noncovalently joined, as in a naturally occurring variable domain. If the joining is noncovalent, and the library is displayed on cells or virus, then either the VH or the VL chain may be fused to the carrier surface/coat protein. complementary chain may be co-expressed, or added exogenously to the library. The members may further comprise some or all of an antibody constant heavy and/or constant light chain, or a mutant thereof. Peptoid Library A peptoid is an analogue of a peptide in which one or more of the peptide bonds (-NH-CO-) are replaced by pseudopeptide bonds, which may be the same or different. It is not necessary that all of the peptide bonds be replaced, i.e., a peptoid may include one or more conventional amino acid residues, e.g., proline. A peptide bond has two small divalent linker elements, -NH- and -CO-. Thus, a preferred class of psuedopeptide bonds are those which consist of two small divalent linker elements. Each may be chosen independently from the group consisting of amine (-NH-), substituted amine (-NR-), carbonyl (-CO-), thiocarbonyl (-CS-), methylene (-CH2-), monosubstituted methylene (-CHR-), disubstituted methylene (-CR1R2-), ether (-O-) and thioether (-S-). The more preferred pseudopeptide bonds include: N-modified -NRCO-Carba Ψ -CH₂-CH₂-Depsi Ψ -CO-O-Hydroxyethylene Ψ -CHOH-CH₂-Ketomethylene Ψ -CO-CH₂-Methylene-Oxy -CH2-O-Reduced -CH2-NH-Thiomethylene -CH2-S-Thiopeptide -CS-NH-Retro-Inverso -CO-NH-

5

10

15

20

25

30

35

A single peptoid molecule may include more than one kind of pseudopeptide bond.

For the purposes of introducing diversity into a peptoid library, one may vary (1) the side chains attached to the core main chain atoms of the monomers linked by the pseudopeptide bonds, and/or (2) the side chains (e.g., the R of an -NRCO-) of the pseudopeptide bonds. Thus, in one embodiment, the monomeric units which are not amino acid residues are of the structure -NR1-CR2-CO-, where at least

one of R1 and R2 are not hydrogen. If there is variability in the pseudopeptide bond, this is most conveniently done by using an -NRCO- or other pseudopeptide bond with an R group, and varying the R group. In this event, the R group will usually be any of the side chains characterizing the amino acids of peptides, as previously discussed.

If the R group of the pseudopeptide bond is not variable, it will usually be small, e.g., not more than 10 atoms (e.g., hydroxyl, amino, carboxyl, methyl, ethyl, propyl).

If the conjugation chemistries are compatible, a simple combinatorial library may include both peptides and peptoids.

Peptide Nucleic Acid Library

5

10

15

20

30

A PNA oligomer is here defined as one comprising a plurality of units, at least one of which is a PNA monomer which comprises a side chain comprising a nucleobase. For nucleobases, see USP 6,077,835.

The classic PNA oligomer is composed of (2-aminoethyl)glycine units, with nucleobases attached by methylene carbonyl linkers. That is, it has the structure

$$H- (-HN-CH_2-CH_2-N (-CO-CH_2-B)-CH_2-CO-)_n -OH$$

where the outer parenthesized substructure is the PNA monomer.

In this structure, the nucleobase B is separated from the backbone N by three bonds, and the points of attachment

72 of the side chains are separated by six bonds. The nucleobase may be any of the bases included in the nucleotides discussed in connection with oligonucleotide libraries. The bases of nucleotides A, G, T, C and U are 5 preferred. A PNA oligomer may further comprise one or more amino acid residues, especially glycine and proline. One can readily envision related molecules in which (1) the -COCH2- linker is replaced by another linker, especially one composed of two small divalent linkers as defined 10 previously, (2) a side chain is attached to one of the three main chain carbons not participating in the peptide bond (either instead or in addition to the side chain attached to the N of the classic PNA); and/or (3) the peptide bonds are 15 replaced by pseudopeptide bonds as disclosed previously in the context of peptoids. PNA oligomer libraries have been made; see e.g. Cook, 6,204,326. Small Organic Compound Library 20 The small organic compound library ("compound library", for short) is a combinatorial library whose members are suitable for use as drugs if, indeed, they have the ability to mediate a biological activity of the target protein. 25 Peptides have certain disadvantages as drugs. include susceptibility to degradation by serum proteases, and difficulty in penetrating cell membranes. Preferably, all or most of the compounds of the compound library avoid, or at least do not suffer to the same degree, one or more of 30 the pharmaceutical disadvantages of peptides. In designing a compound library, it is helpful to bear in mind the methods of molecular modification typically used to obtain new drugs. Three basic kinds of modification may be identified: disjunction, in which a lead drug is 35 simplified to identify its component pharmacophoric moieties; conjunction, in which two or more known pharmacophoric moieties, which may be the same or different, are associated, covalently or noncovalently, to form a new drug; and <u>alteration</u>, in which one moiety is replaced by

73 another which may be similar or different, but which is not in effect a disjunction or conjunction. The use of the terms "disjunction", "conjunction" and "alteration" is intended only to connote the structural relationship of the 5 end product to the original leads, and not how the new drugs are actually synthesized, although it is possible that the two are the same. The process of disjunction is illustrated by the evolution of neostigmine (1931) and edrophonium (1952) from 10 physostigmine (1925). Subsequent conjunction is illustrated by demecarium (1956) and ambenonium (1956). Alterations may modify the size, polarity, or electron distribution of an original moiety. Alterations include ring closing or opening, formation of lower or higher 15 homologues, introduction or saturation of double bonds, introduction of optically active centers, introduction, removal or replacement of bulky groups, isosteric or bioisosteric substitution, changes in the position or orientation of a group, introduction of alkylating groups, 20 and introduction, removal or replacement of groups with a view toward inhibiting or promoting inductive (electrostatic) or conjugative (resonance) effects. Thus, the substituents may include electron acceptors and/or electron donors. Typical electron donors (+I) 25 include -CH₃, -CH₂R, -CHR₂, -CR₃ and -COO⁻. Typical electron acceptors (-I) include -NH3+, -NR3+, -NO2, -CN, -COOH, -COOR, -CHO, -COR, -COR, -F, -C1, -Br, -OH, -OR, -SH, -SR, -CH=CH₂, -CR=CR₂, and -C=CH. The substituents may also include those which increase 30 or decrease electronic density in conjugated systems. former (+R) groups include -CH₃, -CR₃, -F, -C1, -Br, -I, -OH, -OR, -OCOR, -SH, -SR, -NH₂, -NR₂, and -NHCOR. The later (-R) groups include -NO₂, -CN, -CHC, -COR, -COOH, -COOR, -CONH₂, -SO₂R and -CF₃. 35 Synthetically speaking, the modifications may be achieved by a variety of unit processes, including nucleophilic and electrophilic substitution, reduction and oxidation, addition elimination, double bond cleavage, and cyclization.

74 For the purpose of constructing a library, a compound, or a family of compounds, having one or more pharmacological activities (which need not be related to the known or suspected activities of the target protein), may be disjoined into two or more known or potential pharmacophoric 5 Analogues of each of these moieties may be moieties. identified, and mixtures of these analogues reacted so as to reassemble compounds which have some similarity to the original lead compound. It is not necessary that all 10 members of the library possess moieties analogous to all of the moieties of the lead compound. The design of a library may be illustrated by the example of the benzodiazepines. Several benzodiazepine drugs, including chlordiazepoxide, diazepam and oxazepam, 15 have been used as anti-anxiety drugs. Derivatives of benzodiazepines have widespread biological activities; derivatives have been reported to act not only as anxiolytics, but also as anticonvulsants; cholecystokinin (CCK) receptor subtype A or B, kappa opioid receptor, platelet activating factor, and HIV transactivator Tat 20 antagonists, and GPIIbIIa, reverse transcriptase and ras farnesyltransferase inhibitors. The benzodiazepine structure has been disjoined into a 2-aminobenzophenone, an amino acid, and an alkylating agent. 25 See Bunin, et al., Proc. Nat. Acad. Sci. USA, 91:4708 (1994). Since only a few 2-aminobenzophenone derivatives are commercially available, it was later disjoined into 2aminoarylstannane, an acid chloride, an amino acid, and an alkylating agent. Bunin, et al., Meth. Enzymol., 267:448 30 (1996). The arylstannane may be considered the core structure upon which the other moieties are substituted, or all four may be considered equals which are conjoined to make each library member. A basic library synthesis plan and member structure is 35 shown in Figure 1 of Fowlkes, et al., U.S. Serial No. 08/740,671, incorporated by reference in its entirety. acid chloride building block introduces variability at the R1 The R^2 site is introduced by the amino acid, and the R³ site by the alkylating agent. The R⁴ site is inherent in

75 the arylstannane. Bunin, et al. generated a 1, 4benzodiazepine library of 11,200 different derivatives prepared from 20 acid chlorides, 35 amino acids, and 16 alkylating agents. (No diversity was introduced at R4; this 5 group was used to couple the molecule to a solid phase.) According to the Available Chemicals Directory (HDL Information Systems, San Leandro CA), over 300 acid chlorides, 80 Fmoc-protected amino acids and 800 alkylating agents were available for purchase (and more, of course, 10 could be synthesized). The particular moieties used were chosen to maximize structural dispersion, while limiting the numbers to those conveniently synthesized in the wells of a microtiter plate. In choosing between structurally similar compounds, preference was given to the least substituted 15 compound. The variable elements included both aliphatic and aromatic groups. Among the aliphatic groups, both acyclic and cyclic (mono- or poly-) structures, substituted or not, (While all of the acyclic groups were linear, 20 it would have been feasible to introduce a branched The aromatic groups featured either single and. multiple rings, fused or not, substituted or not, and with heteroatoms or not. The secondary substitutents included -NH₂, -OH, -OMe, -CN, -C1, -F, and -COOH. While not used, 25 spacer moieties, such as -O-, -S-, -OO-, -CS-, -NH-, and -NR-, could have been incorporated. Bunin et al. suggest that instead of using a 1, 4benzodiazepine as a core structure, one may instead use a 1, 4-benzodiazepine-2, 5-dione structure. 30 As noted by Bunin et al., it is advantageous, although not necessary, to use a linkage strategy which leaves no trace of the linking functionality, as this permits construction of a more diverse library. Other combinatorial nonoligomeric compound libraries 35 known or suggested in the art have been based on carbamates, mercaptoacylated pyrrolidines, phenolic agents, aminimides, N-acylamino ethers (made from amino alcohols, aromatic hydroxy acids, and carboxylic acids), N-alkylamino ethers

76 (made from aromatic hydroxy acids, amino alcohols and aldehydes) 1, 4-piperazines, and 1, 4-piperazine-6-ones. DeWitt, et al., Proc. Nat. Acad. Sci. (USA), 90:6909-13 (1993) describe the simultaneous but separate, synthesis of 40 discrete hydantoins and 40 discrete benzodiazepines. 5 They carry out their synthesis on a solid support (inside a gas dispersion tube), in an array format, as opposed to other conventional simultaneous synthesis techniques (e.g., in a well, or on a pin). The hydantoins were synthesized by first simultaneously deprotecting and then treating each of 10 five amino acid resins with each of eight isocyanates. benzodiazepines were synthesized by treating each of five deprotected amino acid resins with each of eight 2-amino benzophenone imines. 15 Chen, et al., J. Am. Chem. Soc., 116:2661-62 (1994) described the preparation of a pilot (9 member) combinatorial library of formate esters. A polymer beadbound aldehyde preparation was "split" into three aliquots, each reacted with one of three different ylide reagents. The reaction products were combined, and then divided into 20 three new aliquots, each of which was reacted with a different Michael donor. Compound identity was found to be determinable on a single bead basis by gas chromatography/mass spectroscopy analysis. 25 Holmes, USP 5,549,974 (1996) sets forth methodologies for the combinatorial synthesis of libraries of thiazolidinones and metathiazanones. These libraries are made by combination of amines, carbonyl compounds, and thiols under cyclization conditions. 30 Ellman, USP 5,545,568 (1996) describes combinatorial synthesis of benzodiazepines, prostaglandins, beta-turn mimetics, and glycerol-based compounds. Sèe also Ellman, USP 5,288,514. Summerton, USP 5,506,337 (1996) discloses methods of 35 preparing a combinatorial library formed predominantly of morpholino subunit structures.

Heterocylic combinatorial libraries are reviewed generally in Nefzi, et al., Chem. Rev., 97:449-472 (1997).

77 For pharmacological classes, see, e.g., Goth, Medical Pharmacology: Principles and Concepts (C.V. Mosby Co.: 8th ed. 1976); Korolkovas and Burckhalter, Essentials of Medicinal Chemistry (John Wiley & Sons, Inc.: 1976). For 5 synthetic methods, see, e.g., Warren, Organic Synthesis: The Disconnection Approach (John Wiley & Sons, Ltd.: 1982); Fuson, Reactions of Organic Compounds (John Wiley & Sons: 1966); Payne and Payne, How to do an Organic Synthesis (Allyn and Bacon, Inc.: 1969); Greene, Protective Groups in 10 Organic Synthesis (Wiley-Interscience). For selection of substituents, see e.g., Hansch and Leo, Substituent Constants for Correlation Analysis in Chemistry and Biology (John Wiley & Sons: 1979). The library is preferably synthesized so that the 15 individual members remain identifiable so that, if a member is shown to be active, it is not necessary to analyze it. Several methods of identification have been proposed, including: (1) encoding, i.e., the attachment to each member of an identifier moiety which is more readily 20 identified than the member proper. This has the disadvantage that the tag may itself influence the activity of the conjugate. (2) spatial addressing, e.g., each member is 25 synthesized only at a particular coordinate on or in a matrix, or in a particular chamber. might be, for example, the location of a particular pin, or a particular well on a microtiter plate, or inside a "tea bag". 30 The present invention is not limited to any particular form of identification. However, it is possible to simply characterize those members of the library which are found to be active, based on the characteristic spectroscopic indicia of the various 35 building blocks. Solid phase synthesis permits greater control over which derivatives are formed. However, the solid phase could interfere with activity. To overcome this problem,

78 some or all of the molecules of each member could be liberated, after synthesis but before screening. Examples of candidate simple libraries which might be evaluated include derivatives of the following: 5 Cyclic Compounds Containing One Hetero Atom Heteronitrogen pyrroles pentasubstituted pyrroles pyrrolidines 10 pyrrolines prolines indoles beta-carbolines pyridines 15 dihydropyridines 1,4-dihydropyridines pyrido[2,3-d]pyrimidines tetrahydro-3H-imidazo[4,5-c] pyridines Isoquinolines 20 tetrahydroisoquinolines quinolones beta-lactams azabicyclo[4.3.0] nonen-8-one amino acid Heterooxygen 25 furans tetrahydrofurans 2,5-disubstituted tetrahydrofurans pyrans hydroxypyranones 30 tetrahydroxypyranones gamma-butyrolactones Heterosulfur sulfolenes Cyclic Compounds with Two or More Hetero atoms 35 Multiple heteronitrogens

> imidazoles pyrazoles piperazines diketopiperazines

	79
	arylpiperazines
	benzylpiperazines
	benzodiazepines
	1,4-benzodiazepine-2,5-diones
5	hydantoins
	5-alkoxyhydantoins
	dihydropyrimidines
	1,3-disubstituted-5,6-dihydopyrimidine-2,4
10	diones
	cyclic ureas
	cyclic thioureas
	quinazolines
	chiral 3-substituted-quinazoline-2,4-
15	diones
	triazoles
	1,2,3-triazoles
	purines
	Heteronitrogen and Heterooxygen
20	dikelomorpholines
	isoxazoles
	isoxazolines
	Heteronitrogen and Heterosulfur
	thiazolidines
25	N-axylthiazolidines
	dihydrothiazoles
	2-methylene-2,3-dihydrothiazates
	2-aminothiazoles
	thiophenes
30	3-amino thiophenes
	4-thiazolidinones
	4-melathiazanones
	benzisothiazolones
	For details on synthesis of libraries, see Nefzi, et
35	al., Chem. Rev., 97:449-72 (1997), and references cited
	therein.

Pharmaceutical Methods and Preparations

The preferred animal subject of the present invention is a mammal. By the term "mammal" is meant an individual belonging to the class Mammalia. The invention is particularly useful in the treatment of human subjects, although it is intended for veterinary and nutritional uses as well. Preferred nonhuman subjects are of the orders Primata (e.g., apes and monkeys), Artiodactyla or Perissodactyla (e.g., cows, pigs, sheep, horses, goats), Carnivora (e.g., cats, dogs), Rodenta (e.g., rats, mice, guinea pigs, hamsters), Lagomorpha (e.g., rabbits) or other pet, farm or laboratory mammals.

The term "protection", as used herein, is intended to include "prevention," "suppression" and "treatment."
"Prevention", strictly speaking, involves administration of the pharmaceutical prior to the induction of the disease (or other adverse clinical condition). "Suppression" involves administration of the composition prior to the clinical appearance of the disease. "Treatment" involves administration of the protective composition after the appearance of the disease.

It will be understood that in human and veterinary medicine, it is not always possible to distinguish between "preventing" and "suppressing" since the ultimate inductive event or events may be unknown, latent, or the patient is not ascertained until well after the occurrence of the event or events. Therefore, unless qualified, the term "prevention" will be understood to refer to both prevention in the strict sense, and to suppression.

The preventative or prophylactic use of a pharmaceutical usually involves identifying subjects who are at higher risk than the general population of contracting the disease, and administering the pharmaceutical to them in advance of the clinical appearance of the disease. The effectiveness of such use is measured by comparing the subsequent incidence or severity of the disease, or of particular symptoms of the disease, in the treated subjects against that in untreated subjects of the same high risk group.

81

While high risk factors vary from disease to disease, in general, these include (1) prior occurrence of the disease in one or more members of the same family, or, in the case of a contagious disease, in individuals with whom the subject has come into potentially contagious contact at a time when the earlier victim was likely to be contagious, (2) a prior occurrence of the disease in the subject, (3) prior occurrence of a related disease, or a condition known to increase the likelihood of the disease, in the subject; (4) appearance of a suspicious level of a marker of the disease, or a related disease or condition; (5) a subject who is immunologically compromised, e.g., by radiation treatment, HIV infection, drug use,, etc., or (6) membership in a particular group (e.g., a particular age, sex, race, ethnic group, etc.) which has been epidemiologically associated with that disease.

5

10

15

20

25

30

35

In some cases, it may be desirable to provide prophylaxis for the general population, and not just a high risk group. This is most likely to be the case when essentially all are at risk of contracting the disease, the effects of the disease are serious, the therapeutic index of the prophylactic agent is high, and the cost of the agent is low.

A prophylaxis or treatment may be curative, that is, directed at the underlying cause of a disease, or ameliorative, that is, directed at the symptoms of the disease, especially those which reduce the quality of life.

It should also be understood that to be useful, the protection provided need not be absolute, provided that it is sufficient to carry clinical value. An agent which provides protection to a lesser degree than do competitive agents may still be of value if the other agents are ineffective for a particular individual, if it can be used in combination with other agents to enhance the level of protection, or if it is safer than competitive agents. It is desirable that there be a statistically significant (p=0.05 or less) improvement in the treated subject relative to an appropriate untreated control, and it is desirable that this improvement be at least 10%, more preferably at least 25%,

82 still more preferably at least 50%, even more preferably at least 100%, in some indicia of the incidence or severity of the disease or of at least one symptom of the disease. At least one of the drugs of the present invention may be administered, by any means that achieve their intended 5 purpose, to protect a subject against a disease or other adverse condition. The form of administration may be systemic or topical. For example, administration of such a composition may be by various parenteral routes such as subcutaneous, intravenous, intradermal, intramuscular, 10 intraperitoneal, intranasal, transdermal, or buccal routes. Alternatively, or concurrently, administration may be by the oral route. Parenteral administration can be by bolus injection or by gradual perfusion over time. A typical regimen comprises administration of an 15 effective amount of the drug, administered over a period ranging from a single dose, to dosing over a period of hours, days, weeks, months, or years. It is understood that the suitable dosage of a drug of the present invention will be dependent upon the age, sex, 20 health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired. However, the most preferred dosage can be tailored to the individual subject, as is understood and determinable by one of skill in the art, without undue 25 experimentation. This will typically involve adjustment of a standard dose, e.g., reduction of the dose if the patient has a low body weight. Prior to use in humans, a drug will first be evaluated for safety and efficacy in laboratory animals. 30 clinical studies, one would begin with a dose expected to be safe in humans, based on the preclinical data for the drug in question, and on customary doses for analogous drugs (if any). If this dose is effective, the dosage may be decreased, to determine the minimum effective dose, if 35 If this dose is ineffective, it will be cautiously desired. increased, with the patients monitored for signs of side effects. See, e.g., Berkow et al, eds., The Merck Manual, 15th edition, Merck and Co., Rahway, N.J., 1987; Goodman et

83 al., eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th edition, Pergamon Press, Inc., Elmsford, N.Y., (1990); Avery's Drug Treatment: Principles and Practice of Clinical Pharmacology and Therapeutics, 3rd 5 edition, ADIS Press, LTD., Williams and Wilkins, Baltimore, MD. (1987), Ebadi, Pharmacology, Little, Brown and Co., Boston, (1985), which references and references cited therein, are entirely incorporated herein by reference. The total dose required for each treatment may be administered by multiple doses or in a single dose. 10 protein may be administered alone or in conjunction with other therapeutics directed to the disease or directed to other symptoms thereof. Typical pharmaceutical doses, for adult humans, are in 15 the range of 1 ng to 10g per day, more often 1 mg to 1g per day. The appropriate dosage form will depend on the disease, the pharmaceutical, and the mode of administration; possibilities include tablets, capsules, lozenges, dental pastes, suppositories, inhalants, solutions, ointments and 20 parenteral depots. See, e.g., Berker, supra, Goodman, supra, Avery, supra and Ebadi, supra, which are entirely incorporated herein by reference, including all references cited therein. 25 In the case of peptide drugs, the drug may be administered in the form of an expression vector comprising a nucleic acid encoding the peptide; such a vector, after incorporation into the genetic complement of a cell of the patient, directs synthesis of the peptide. Suitable vectors 30 include genetically engineered poxviruses (vaccinia), adenoviruses, adeno-associated viruses, herpesviruses and lentiviruses which are or have been rendered nonpathogenic. In addition to at least one drug as described herein, a pharmaceutical composition may contain suitable 35 pharmaceutically acceptable carriers, such as excipients, carriers and/or auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. See, e.g., Berker, supra, Goodman, supra, Avery, supra and Ebadi, supra, which are entirely

84 incorporated herein by reference, included all references cited therein. Assay Compositions and Methods 5 Target Organism The invention contemplates that it may be appropriate to ascertain or to mediate the biological activity of a substance of this invention in a target organism. The target organism may be a plant, animal, or 10 microorganism. In the case of a plant, it may be an economic plant, in which case the drug may be intended to increase the disease, weather or pest resistance, alter the growth characteristics, or otherwise improve the useful 15 characteristics or mute undesirable characteristics of the plant. Or it may be a weed, in which case the drug may be intended to kill or otherwise inhibit the growth of the plant, or to alter its characteristics to convert it from a weed to an economic plant. The plant may be a tree, shrub, crop, grass, etc. The plant may be an algae (which are in 20 some cases also microorganisms), or a vascular plant, especially gymnosperms (particularly conifers) and angiosperms. Angiosperms may be monocots or dicots. plants of greatest interest are rice, wheat, corn, alfalfa, 25 soybeans, potatoes, peanuts, tomatoes, melons, apples, pears, plums, pineapples, fir, spruce, pine, cedar, and oak. If the target organism is a microorganism, it may be algae, bacteria, fungi, or a virus (although the biological activity of a virus must be determined in a virus-infected 30 The microorganism may be human or other animal or plant pathogen, or it may be nonpathogenic. It may be a soil or water organism, or one which normally lives inside other living things. If the target organism is an animal, it may be a 35 vertebrate or a nonvertebrate animal. Nonvertebrate animals are chiefly of interest when they act as pathogens or parasites, and the drugs are intended to act as biocidic or biostatic agents. Nonvertebrate animals of interest include worms, mollusks, and arthropods.

i.e., a mammal, bird, reptile, fish or amphibian. Among mammals, the target animal preferably belongs to the order Primata (humans, apes and monkeys), Artiodactyla (e.g., cows, pigs, sheep, goats, horses), Rodenta (e.g., mice, rats) Lagomorpha (e.g., rabbits, hares), or Carnivora (e.g., cats, dogs). Among birds, the target animals are preferably of the orders Anseriformes (e.g., ducks, geese, swans) or Galliformes (e.g., quails, grouse, pheasants, turkeys and chickens). Among fish, the target animal is preferably of the order Clupeiformes (e.g., sardines, shad, anchovies, whitefish, salmon).

Target Tissues

5

10

15

20

25

30

35

The term "target tissue" refers to any whole animal, physiological system, whole organ, part of organ, miscellaneous tissue, cell, or cell component (e.g., the cell membrane) of a target animal in which biological activity may be measured.

Routinely in mammals one would choose to compare and contrast the biological impact on virtually any and all tissues which express the subject receptor protein. The main tissues to use are: brain, heart, lung, kidney, liver, pancreas, skin, intestines, adipose, stomach, skeletal muscle, adrenal glands, breast, prostate, vasculature, retina, cornea, thyroid gland, parathyroid glands, thymus, bone marrow, bone, etc.

Another classification would be by cell type: B cells, T cells, macrophages, neutrophils, eosinophils, mast cells, platelets, megakaryocytes, erythrocytes, bone marrow stomal cells, fibroblasts, neurons, astrocytes, neuroglia, microglia, epithelial cells (from any organ, e.g. skin, breast, prostate, lung, intestines etc), cardiac muscle cells, smooth muscle cells, striated muscle cells, osteoblasts, osteocytes, chondroblasts, chondrocytes, keratinocytes, melanocytes, etc.

Of course, in the case of a unicellular organism, there is no distinction between the "target organism" and the "target tissue".

86

Screening Assays

5

10

15

20

25

30

Assays intended to determine the binding or the biological activity of a substance are called preliminary screening assays.

Screening assays will typically be either in vitro (cell-free) assays (for binding to an immobilized receptor) or cell-based assays (for alterations in the phenotype of the cell). They will not involve screening of whole multicellular organisms, or isolated organs. The comments on diagnostic biological assays apply mutatis mutandis to screening cell-based assays.

In Vitro vs. In Vivo Assays

The term in vivo is descriptive of an event, such as binding or enzymatic action, which occurs within a living organism. The organism in question may, however, be genetically modified. The term in vitro refers to an event which occurs outside a living organism. Parts of an organism (e.g., a membrane, or an isolated biochemical) are used, together with artificial substrates and/or conditions. For the purpose of the present invention, the term in vitro excludes events occurring inside or on an intact cell, whether of a unicellular or multicellular organism.

In vivo assays include both cell-based assays, and organismic assays. The cell-based assays include both assays on unicellular organisms, and assays on isolated cells or cell cultures derived from multicellular organisms. The cell cultures may be mixed, provided that they are not organized into tissues or organs. The term organismic assay refers to assays on whole multicellular organisms, and assays on isolated organs or tissues of such organisms.

In vitro Diagnostic Methods and Reagents

35

The in vitro assays of the present invention may be applied to any suitable analyte-containing sample, and may be qualitative or quantitative in nature.

Sample

The sample will normally be a biological fluid, such as blood, urine, lymph, semen, milk, or cerebrospinal fluid, or a fraction or/derivative thereof, or a biological tissue, in the form of, e.g., a tissue section or homogenate. However, the sample conceivably could be (or derived from) a food or beverage, a pharmaceutical or diagnostic composition, soil, or surface or ground water. If a biological fluid or tissue, it may be taken from a human or other mammal, vertebrate or animal, or from a plant. The preferred sample is blood; or a fraction or derivative thereof.

87

Binding and Reaction Assays

The assay may be a binding assay, in which one step involves the binding of a diagnostic reagent to the analyte, or a reaction assay, which involves the reaction of a reagent with the analyte. The reagents used in a binding assay may be classified as to the nature of their interaction with analyte: (1) analyte analogues, or (2) analyte binding molecules (ABM). They may be labeled or insolubilized.

In a reaction assay, the assay may look for a direct reaction between the analyte and a reagent which is reactive with the analyte, or if the analyte is an enzyme or enzyme inhibitor, for a reaction catalyzed or inhibited by the analyte. The reagent may be a reactant, a catalyst, or an inhibitor for the reaction.

An assay may involve a cascade of steps in which the product of one step acts as the target for the next step. These steps may be binding steps, reaction steps, or a combination thereof.

Signal Producing System (SPS)

In order to detect the presence, or measure the amount, of an analyte, the assay must provide for a signal producing system (SPS) in which there is a detectable difference in the signal produced, depending on whether the analyte is present or absent (or, in a quantitative assay, on the

20

15

5

10

25

30

88 The detectable signal may be one amount of the analyte). which is visually detectable, or one detectable only with instruments. Possible signals include production of colored or luminescent products, alteration of the characteristics (including amplitude or polarization) of absorption or 5 emission of radiation by an assay component or product, and precipitation or agglutination of a component or product. The term "signal" is intended to include the discontinuance of an existing signal, or a change in the rate of change of an observable parameter, rather than a change in its 10 absolute value. The signal may be monitored manually or automatically. In a reaction assay, the signal is often a product of the reaction. In a binding assay, it is normally provided 15 by a label borne by a labeled reagent. Labels The component of the signal producing system which is most intimately associated with the diagnostic reagent is 20 called the "label". A label may be, e.g., a radioisotope, a fluorophore, an enzyme, a co-enzyme, an enzyme substrate, an electron-dense compound, an agglutinable particle. The radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography. Isotopes which are particularly useful 25 for the purpose of the present invention include 3H, 125I, ¹³¹I, ³⁵S, ¹⁴C, ³²P and ³³P. ¹²⁵I is preferred for antibody labeling. The label may also be a fluorophore. When the fluorescently labeled reagent is exposed to light of the 30 , proper wave length, its presence can then be detected due to fluorescence. Among the most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, ophthaldehyde and fluorescamine. 35 Alternatively, fluorescence-emitting metals such as 125 Eu, or others of the lanthanide series, may be incorporated into a diagnostic reagent using such metal

89 chelating groups as diethylenetriaminepentaacetic acid (DTPA) of ethylenediamine-tetraacetic acid (EDTA). The label may also be a chemiluminescent compound. presence of the chemiluminescently labeled reagent is then 5 determined by detecting the presence of luminescence that arises during the course of a chemical reaction. of particularly useful chemiluminescent labeling compounds are luminol, isolumino, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester. 10 Likewise, a bioluminescent compound may be used for labeling. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by 15 detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin. Enzyme labels, such as horseradish peroxidase and alkaline phosphatase, are preferred. When an enzyme label 20 is used, the signal producing system must also include a substrate for the enzyme. If the enzymatic reaction product is not itself detectable, the SPS will include one or more additional reactants so that a detectable product appears. An enzyme analyte may act as its own label if an enzyme 25 inhibitor is used as a diagnostic reagent. Binding Assay Formats Binding assays may be divided into two basic types, heterogeneous and homogeneous. In heterogeneous assays, the 30 interaction between the affinity molecule and the analyte does not affect the label, hence, to determine the amount or presence of analyte, bound label must be separated from free In homogeneous assays, the interaction does affect the activity of the label, and therefore analyte levels can 35 be deduced without the need for a separation step. In one embodiment, the ABM is insolubilized by coupling it to a macromolecular support, and analyte in the sample is allowed to compete with a known quantity of a labeled or specifically labelable analyte analogue. The "analyte

90

analogue" is a molecule capable of competing with analyte for binding to the ABM, and the term is intended to include analyte itself. It may be labeled already, or it may be labeled subsequently by specifically binding the label to a moiety differentiating the analyte analogue from analyte. The solid and liquid phases are separated, and the labeled analyte analogue in one phase is quantified. The higher the level of analyte analogue in the solid phase, i.e., sticking to the ABM, the lower the level of analyte in the sample.

In a "sandwich assay", both an insolubilized ABM, and a labeled ABM are employed. The analyte is captured by the insolubilized ABM and is tagged by the labeled ABM, forming a ternary complex. The reagents may be added to the sample in either order, or simultaneously. The ABMs may be the same or different. The amount of labeled ABM in the ternary complex is directly proportional to the amount of analyte in the sample.

The two embodiments described above are both heterogeneous assays. However, homogeneous assays are conceivable. The key is that the label be affected by whether or not the complex is formed. Conjugation Methods

A label may be conjugated, directly or indirectly (e.g., through a labeled anti-ABM antibody), covalently (e.g., with SPDP) or noncovalently, to the ABM, to produce a diagnostic reagent. Similarly, the ABM may be conjugated to a solid phase support to form a solid phase ("capture") diagnostic reagent.

Suitable supports include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, agaroses, and magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention.

The support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to its target. Thus the support configuration may be spherical, as in a bead, or

35

5

10

15

20

25

30

91
cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may

5 Biological Assays

10

15

20

25

30

35

A biological assay measures or detects a biological response of a biological entity to a substance.

be flat such as a sheet, test strip, etc.

The biological entity may be a whole organism, an isolated organ or tissue, freshly isolated cells, an immortalized cell line, or a subcellular component (such as a membrane; this term should not be construed as including an isolated receptor). The entity may be, or may be derived from, an organism which occurs in nature, or which is modified in some way. Modifications may be genetic (including radiation and chemical mutants, and genetic engineering) or somatic (e.g., surgical, chemical, etc.). In the case of a multicellular entity, the modifications may affect some or all cells. The entity need not be the target organism, or a derivative thereof, if there is a reasonable correlation between bioassay activity in the assay entity and biological activity in the target organism.

The entity is placed in a particular environment, which may be more or less natural. For example, a culture medium may, but need not, contain serum or serum substitutes, and it may, but need not, include a support matrix of some kind, it may be still, or agitated. It may contain particular biological or chemical agents, or have particular physical parameters (e.g., temperature), that are intended to nourish or challenge the biological entity.

There must also be a detectable biological marker for the response. At the cellular level, the most common markers are cell survival and proliferation, cell behavior (clustering, motility), cell morphology (shape, color), and biochemical activity (overall DNA synthesis, overall protein synthesis, and specific metabolic activities, such as utilization of particular nutrients, e.g., consumption of oxygen, production of CO_2 , production of organic acids, uptake or discharge of ions).

92 The direct signal produced by the biological marker may be transformed by a signal producing system into a different signal which is more observable, for example, a fluorescent or colorimetric signal. The entity, environment, marker and signal producing 5 system are chosen to achieve a clinically acceptable level of sensitivity, specificity and accuracy. In some cases, the goal will be to identify substances which mediate the biological activity of a natural 10 biological entity, and the assay is carried out directly with that entity. In other cases, the biological entity is used simply as a model of some more complex (or otherwise inconvenient to work with) biological entity. event, the model biological entity is used because activity in the model system is considered more predictive of 15 activity in the ultimate natural biological entity than is simple binding activity in an in vitro system. entity is used instead of the ultimate entity because the former is more expensive or slower to work with, or because ethical considerations forbid working with the ultimate 20 entity yet. The model entity may be naturally occurring, if the model entity usefully models the ultimate entity under some conditions. Or it may be non-naturally occurring, with 25 modifications that increase its resemblance to the ultimate entity. Transgenic animals, such as transgenic mice, rats, and rabbits, have been found useful as model systems. In cell-based model assays, where the biological 30 activity is mediated by binding to a receptor (target protein), the receptor may be functionally connected to a signal (biological marker) producing system, which may be endogenous or exogenous to the cell. There are a number of techniques of doing this. 35 "Zero-Hybrid" Systems In these systems, the binding of a peptide to the target protein results in a screenable or selectable phenotypic change, without resort to fusing the target

protein (or a ligand binding moiety thereof) to an endogenous protein. It may be that the target protein is endogenous to the host cell, or is substantially identical to an endogenous receptor so that it can take advantage of the latter's native signal transduction pathway. Or sufficient elements of the signal transduction pathway normally associated with the target protein may be engineered into the cell so that the cell signals binding to the target protein.

10

15

20

25

30

35

5

"One-Hybrid" Systems

In these systems, a chimera receptor, a hybrid of the target protein and an endogenous receptor, is used. The chimeric receptor has the ligand binding characteristics of the target protein and the signal transduction characteristics of the endogenous receptor. Thus, the normal signal transduction pathway of the endogenous receptor is subverted.

Preferably, the endogenous receptor is inactivated, or the conditions of the assay avoid activation of the endogenous receptor, to improve the signal-to-noise ratio.

See Fowlkes USP 5,789,184 for a yeast system.

Another type of "one-hybrid" system combines a peptide: DNA-binding domain fusion with an unfused target receptor that possesses an activation domain.

"Two-Hybrid" System

In a preferred embodiment, the cell-based assay is a two hybrid system. This term implies that the ligand is incorporated into a first hybrid protein, and the receptor into a second hybrid protein. The first hybrid also comprises component A of a signal generating system, and the second hybrid comprises component B of that system.

Components A and B, by themselves, are insufficient to generate a signal. However, if the ligand binds the receptor, components A and B are brought into sufficiently close proximity so that they can cooperate to generate a signal.

94
Components A and B may naturally occur, or be substantially identical to moieties which naturally occur,

5

10

15

20

25

30

35

as components of a single naturally occurring biomolecule, or they may naturally occur, or be substantially identical to moieties which naturally occur, as separate naturally occurring biomolecules which interact in nature.

Two-Hybrid System: Transcription Factor Type

In a preferred "two-hybrid" embodiment, one member of a peptide ligand:receptor binding pair is expressed as a fusion to a DNA-binding domain (DBD) from a transcription factor (this fusion protein is called the "bait"), and the other is expressed as a fusion to a transactivation domain (TAD) (this fusion protein is called the "fish", the "prey", or the "catch"). The transactivation domain should be complementary to the DNA-binding domain, i.e., it should interact with the latter so as to activate transcription of a specially designed reporter gene that carries a binding site for the DNA-binding domain. Naturally, the two fusion proteins must likewise be complementary.

This complementarity may be achieved by use of the complementary and separable DNA-binding and transcriptional activator domains of a single transcriptional activator protein, or one may use complementary domains derived from different proteins. The domains may be identical to the native domains, or mutants thereof. The assay members may be fused directly to the DBD or TAD, or fused through an intermediated linker.

The target DNA operator may be the native operator sequence, or a mutant operator. Mutations in the operator may be coordinated with mutations in the DBD and the TAD. An example of a suitable transcription activation system is one comprising the DNA-binding domain from the bacterial repressor LexA and the activation domain from the yeast transcription factor Gal4, with the reporter gene operably linked to the LexA operator.

It is not necessary to employ the intact target receptor; just the ligand-binding moiety is sufficient.

95 The two fusion proteins may be expressed from the same or different vectors. Likewise, the activatable reporter gene may be expressed from the same vector as either fusion protein (or both proteins), or from a third vector. Potential DNA-binding domains include Gal4, LexA, and 5 mutant domains substantially identical to the above. Potential activation domains include E. coli B42, Gal4 activation domain II, and HSV VP16, and mutant domains substantially identical to the above. 10 Potential operators include the native operators for the desired activation domain, and mutant domains substantially identical to the native operator. The fusion proteins may comprise nuclear localization signals. 15 The assay system will include a signal producing system, too. The first element of this system is a reporter gene operably linked to an operator responsive to the DBD and TAD of choice. The expression of this reporter gene will result, directly or indirectly, in a selectable or 20 screenable phenotype (the signal). The signal producing system may include, besides the reporter gene, additional genetic or biochemical elements which cooperate in the production of the signal. Such an element could be, for example, a selective agent in the cell growth medium. 25 may be more than one signal producing system, and the system may include more than one reporter gene. The sensitivity of the system may be adjusted by, e.g., use of competitive inhibitors of any step in the activation or signal production process, increasing or decreasing the 30 number of operators, using a stronger or weaker DBD or TAD, etc. When the signal is the death or survival of the cell in question, or proliferation or nonproliferation of the cell in question, the assay is said to be a selection. 35 signal merely results in a detectable phenotype by which the signaling cell may be differentiated from the same cell in a nonsignaling state (either way being a living cell), the assay is a screen. However, the term "screening assay" may be used in a broader sense to include a selection. When the

96 narrower sense is intended, we will use the term "nonselective screen". Various screening and selection systems are discussed in Ladner, USP 5,198,346. 5 Screening and selection may be for or against the peptide: target protein or compound:target protein interaction. Preferred assay cells are microbial (bacterial, yeast, algal, protozooal), invertebrate, vertebrate (esp. mammalian, particularly human). The best developed two-10 hybrid assays are yeast and mammalian systems. Normally, two hybrid assays are used to determine whether a protein X and a protein Y interact, by virtue of their ability to reconstitute the interaction of the DBD and 15 the TAD. However, augmented two-hybrid assays have been used to detect interactions that depend on a third, nonprotein ligand. For more guidance on two-hybrid assays, see Brent and Finley, Jr., Ann. Rev. Genet., 31:663-704 (1997); Fremont-20 Racine, et al., Nature Genetics, 277-281 (16 July 1997); Allen, et al., TIBS, 511-16 (Dec. 1995); LeCrenier, et al., BioEssays, 20:1-6 (1998); Xu, et al., Proc. Nat. Acad. sci. (USA), 94:12473-8 (Nov. 1992); Esotak, et al., Mol. Cell. Biol., 15:5820-9 (1995); Yang, et al., Nucleic Acids Res., 23:1152-6 (1995); Bendixen, et al., Nucleic Acids Res., 25 22:1778-9 (1994); Fuller, et al., BioTechniques, 25:85-92 (July 1998); Cohen, et al., PNAS (USA) 95:14272-7 (1998); Kolonin and Finley, Jr., PNAS (USA) 95:14266-71 (1998). See also Vasavada, et al., PNAS (USA), 88:10686-90 (1991) (contingent replication assay), and Rehrauer, et al., J. 30 Biol. Chem., 271:23865-73 91996) (LexA repressor cleavage assay). Two-Hybrid Systems: reporter Enzyme type 35 In another embodiment, the components A and B reconstitute an enzyme which is not a transcription factor.

97 As in the last example, the effect of the reconstitution of the enzyme is a phenotypic change which may be a screenable change, a selectable change, or both. 5 In vivo Diagnostic Uses Radio-labeled ABM may be administered to the human or animal subject. Administration is typically by injection, e.g., intravenous or arterial or other means of administration in a quantity sufficient to permit subsequent dynamic and/or static imaging using suitable radio-detecting 10 The dosage is the smallest amount capable of providing a diagnostically effective image, and may be determined by means conventional in the art, using known radio-imaging agents as a guide. 15 Typically, the imaging is carried out on the whole body of the subject, or on that portion of the body or organ relevant to the condition or disease under study. amount of radio-labeled ABM accumulated at a given point in time in relevant target organs can then be quantified. 20 A particularly suitable radio-detecting device is a scintillation camera, such as a gamma camera. scintillation camera is a stationary device that can be used. to image distribution of radio-labeled ABM. The detection device in the camera senses the radioactive decay, the 25 distribution of which can be recorded. Data produced by the imaging system can be digitized. The digitized information can be analyzed over time discontinuously or continuously. The digitized data can be processed to produce images, called frames, of the pattern of uptake of the radio-labeled 30 ABM in the target organ at a discrete point in time. most continuous (dynamic) studies, quantitative data is obtained by observing changes in distributions of radioactive decay in target organs over time. In other words, a time-activity analysis of the data will illustrate 35 uptake through clearance of the radio-labeled binding protein by the target organs with time. Various factors should be taken into consideration in selecting an appropriate radioisotope. The radioisotope must be selected with a view to obtaining good quality

98 resolution upon imaging, should be safe for diagnostic use in humans and animals, and should preferably have a short physical half-life so as to decrease the amount of radiation received by the body. The radioisotope used should preferably be pharmacologically inert, and, in the 5 quantities administered, should not have any substantial physiological effect. The ABM may be radio-labeled with different isotopes of iodine, for example 123I, 125I, or 131I (see for example, U.S. 10 Patent 4,609,725). The extent of radio-labeling must, however be monitored, since it will affect the calculations made based on the imaging results (i.e. a diiodinated ABM will result in twice the radiation count of a similar monoiodinated ABM over the same time frame). 15 In applications to human subjects, it may be desirable to use radioisotopes other than 125I for labeling in order to decrease the total dosimetry exposure of the human body and to optimize the detectability of the labeled molecule (though this radioisotope can be used if circumstances 20 require). Ready availability for clinical use is also a factor. Accordingly, for human applications, preferred radio-labels are for example, 99mTc, 67Ga, 68Ga, 90Y, 111In, ^{113m}In, ¹²³I, ¹⁸⁶Re, ¹⁸⁸Re or ²¹¹At. The radio-labeled ABM may be prepared by various 25 These include radio-halogenation by the chloramine - T method or the lactoperoxidase method and subsequent purification by HPLC (high pressure liquid chromatography), for example as described by J. Gutkowska et al in "Endocrinology and Metabolism Clinics of America: 30 (1):183. Other known methods of radio-labeling can be used, such as IODOBEADS™. There are a number of different methods of delivering the radio-labeled ABM to the end-user. It may be administered by any means that enables the active agent to 35 reach the agent's site of action in the body of a mammal. Because proteins are subject to being digested when administered orally, parenteral administration, i.e., intravenous, subcutaneous, intramuscular, would ordinarily

99 be used to optimize absorption of an ABM, such as an antibody, which is a protein.

5

EXAMPLES

We are utilizing a mouse model of diet-induced obesity that progresses to diabetes. The diet is high in fat and has been documented to lead to diabetes in C57BL/6J mice (Surwit at al., 1988). After weaning, C57BL/6J mice were fed either the high fat diet or a standard lab chow diet for 16 weeks. Body weight was monitored bi-weekly. Fasting glucose and insulin levels were measured after 2, 4, 8, and 16 weeks on the diets. At each time point, several diabetic and control mice were sacrificed and a number of tissues collected. For further analysis, RNA was extracted from the gastrocnemius muscles at each time point and used in DNA microarray analyses.

Animal Models.

Obesity and subsequent hyperinsulinemia and hyperglycemia were induced by feeding a group of 3 week old mice (50 C57BL/6 males) a high-fat diet (Bio-Serve, Frenchtown, NJ, #F1850 High Carbohydrate-High Fat; 56% of calories from fat, 16% from protein and 27% from carbohydrates). Another group of 3 week old mice (20 C57B1/6 males) were fed the normal control diet (PMI Nutrition International Inc., Brentwood, MO, Prolab RMH3000; 14% of calories from fat, 16% from protein and 60% from carbohydrates). The mice were placed onto the respective diets immediately following weaning. Animal weights were determined weekly. Fasting blood-glucose and plasma insulin measurements were determined after 2, 4, 8 and 16 weeks on the respective diets.

The day after obtaining body weight measurements at the indicated time points, mice were fasted 8 hours and blood glucose concentrations were measured via tail blood samples using a One Touch Glucometer (Lifescan). For insulin measurements, blood was collected into heparinized tubes, plasma obtained by centrifugation and insulin concentrations determined using an Ultra-Sensitive Rat Insulin ELISA kit (ALPCO) as instructed by the manufacturer. Values were adjusted by a factor of 1.23 as determined by the manufacturer to correct for species difference in cross-

101 reactivity with the antibody (bottom panel). Results reflect mean ± SE of 50 mice on the HF diet and 20 mice on the Std diet. Normal weight, normal fasting blood glucose and normal fasting plasma insulin levels are defined as the respective 5 mean values of the animals fed the control diet. Two of the "most typical" animals were selected for each group (Control, hyperinsulinemic and Diabetic) at each time point (2,4, 8, and 16 weeks after commencement of 10 diet) for sacrifice. The selected mice were sacrificed and muscle tissue obtained and immediately processed for RNA isolation. Fasting Blood Glucose Levels. 15 Blood glucose levels was measured from a drop of blood taken from the tip of the tail of fasted (8 hr) mice using a Lifescan Genuine One Touch glucometer. All measurements occurred between 2:00 pm and 5:00 pm. 20 Plasma insulin measurements. Blood was collected from the tail of fasted (8 hr) mice into a heparinized capillary tube and stored on ice. collections occurred between 2:00 pm and 5:00 pm. was separated from red blood cells by centrifugation for 10 25 minutes at 8000 x g and then stored at -20°C. Insulin concentrations were determined using the Rat Insulin ELISA kit and rat insulin standards (ALPCO) essentially as instructed by the manufacturer. Values were adjusted by a factor of 1.23 as determined by the manufacturer to correct 30 for the species difference in cross-reactivity with the antibody. RNA isolation. Total RNA was isolated from muscle (skeletal muscle, 35 specifically, gastrocnemius) of two mice at each time point during the progression of HF diet-induced type 2 diabetes, as well as age-matched controls on the Std diet, using the RNA STAT-60 Total RNA/mRNA Isolation Reagent according to the manufacturer's instructions (Tel-Test, Friendswood, TX).

102

Sample Quantification and Quality Assessment

Total RNA was quantified and assessed for quality on a Bioanalyzer RNA 6000 Nano chip (Agilent). Each chip contained an interconnected set of gel-filled channels that allowed for molecular sieving of nucleic acids. Pinelectrodes in the chip were used to create electrokinetic forces capable of driving molecules through these microchannels to perform electrophoretic separations. Ribosomal peaks were measured by fluorescence signal and displayed in an electropherogram. A successful total RNA sample featured 2 distinct ribosomal peaks (18S and 28S rRNA).

Biotinylated cRNA Hybridization Target.

Total RNA was prepared for use as a hybridization target as described in the manufacturer's instructions for CodeLink Expression Bioarrays(TM) (Amersham Biosciences). The CodeLink Expression Bioarrays utilize nucleic acid hybridization of a biotin-labeled complementary RNA(cRNA) target with DNA oligonucleotide probes attached to a gel matrix.

The biotin-labeled cRNA target is prepared by a linear amplification method. Poly (A) + RNA (within the total RNA population) is primed for reverse transcription by a DNA oligonucleotide containing a T7 RNA polymerase promoter 5' to a (dT) 24 sequence. After second-strand cDNA synthesis, the cDNA serves as the template in an *in vitro* transcription (IVT) reaction to produce the target cRNA. The IVT is performed in the presence of biotinylated nucleotides to label the target cRNA. This procedure results in a 50-200 fold linear amplification of the input poly (A) + RNA.

Hybridization Probes.

The oligonucleotide probes were provided by the Codelink Uniset Mouse I Bioarray (Amersham, product code 300013). Amine-terminated oligonucleotide probes are attached to a three-dimensional polyacrylamide gel matrix. There are 10,000 oligonucleotide probes, each specific to a well-characterized mouse gene. Each mouse gene is

35

30

5

10

15

20

25

103
representative of a unique gene cluster from the fourth
quarter 2001 Genbank Unigene build. There are also 500
control probes.

The sequences of the probes are proprietary to

Amersham However for each probe Amersham identifies to

Amersham. However, for each probe, Amersham identifies the corresponding mouse gene by NCBI accession number, OGS, LocusLink, Unigene Cluster ID, and description (name). This information should be available from Amersham. In the case of the differentially expressed probes, this information is duplicated in master table 1. For the complete list, see http://www4.amershambiosciences.com/aptrix/upp01077.nsf/Content/codelink_literature

Under "Gene Lists", select "Uniset Mouse I", and a gene list, in Excel format, can be downloaded.

Hybridization

Using the cRNA target, the hybridization reaction mixture is prepared and loaded into array chambers for bioarray processing as set forth in the manufacturer's instructions for CodeLink Gene Expression BioarraysTM (Amerhsam Biosciences). Each sample is hybridized to an individual microarray. Hybridization is at 37°C. The hybridization buffer is prepared as set forth in the Motorola instructions. Hybridization to the microarray is detected with an avidinated fluorescent reagent, Streptavidin-Alexa Fluor [®] 647 (Amersham).

Mouse Gene Expression Analysis

Processed arrays were scanned using a GenePix 4000B Microarray Scanner (Axon Instruments, Inc.); array images were acquired using the Amersham CodeLink™ Analysis Software (Release 2.2). The Amersham CodeLink™ Analysis Software gives an integrated optical density (IOD) value for every spot; a unique background value for that spot is subtracted, resulting in "raw" data points. Individual chips are then normalized by the Amersham Codelink™ software according to the median raw intensity for all 10,000 genes. A negative

30

35

5

10

20

25

104
control threshold (0.2) is also calculated according to the control probes. The expression data was analyzed to identify genes whose expression levels changed significantly with respect to:

Normal mice compared to hyperinsulinemic mice at 2, 4, 8 and 16 weeks on normal vs. high-fat diet.

Normal mice compared to hyperinsulinemic/hyperglycemic

10

15

20

25

30

35

diet.

Hyperinsulinemic compared to hyperinsulinemic/hyperglycemic mice at 2, 4, 8 and 16 weeks on high-fat diets.

mice at 2, 4, 8 and 16 weeks on normal vs. high-fat

Database Searches Nucleotide sequences and predicted amino acid sequences were compared to public domain databases using the Blast 2.0 program (National Center for Biotechnology Information, National Institutes of Health). Nucleotide sequences were displayed using ABI prism Edit View 1.0.1 (PE Applied Biosystems, Foster City, CA).

Nucleotide database searches were conducted with the then current version of BLASTN 2.0.12, see Altschul, et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res., 25:3389-3402 (1997). Searches employed the default parameters, unless otherwise stated.

For blastN searches, the default was the blastN matrix (1,-3), with gap penalties of 5 for existence and 2 for extension.

Protein database searches were conducted with the thencurrent version of BLAST X, see Altschul et al. (1997), supra. Searches employed the default parameters, unless otherwise stated. The scoring matrix was BLOSUM62, with gap costs of 11 for existence and 1 for extension. The standard low complexity filter was used.

"ref" indicates that NCBI's RefSeq is the source database. The identifier that follows is a RefSeq accession

number, not a GenBank accession number. "RefSeq sequences are derived from GenBank and provide non-redundant curated data representing our current knowledge of known genes. Some records include additional sequence information that was never submitted to an archival database but is available in the literature. A small number of sequences are provided through collaboration; the underlying primary sequence data is available in GenBank, but may not be available in any one GenBank record. RefSeq sequences are not submitted primary sequences. RefSeq records are owned by NCBI and therefore can be updated as needed to maintain current annotation or to incorporate additional sequence information." See also https://www.ncbi.nlm.nih.gov/LocusLink/refseq.html

It will be appreciated by those in the art that the exact results of a database search will change from day to day, as new sequences are added. Also, if you query with a longer version of the original sequence, the results will change. The results given here were obtained at one time and no guarantee is made that the exact same hits would be obtained in a search on the filing date. However, if an alignment between a particular query sequence and a particular database sequence is discussed, that alignment should not change (if the parameters and sequences remain unchanged).

Northern Analysis.

Northern analysis may be used to confirm the results. Favorable and unfavorable genes, identified as described above, or fragments thereof, will be used as probes in Northern hybridization analyses to confirm their differential expression. Total RNA isolated from subject mice will be resolved by agarose gel electrophoresis through a 1% agarose, 1 % formaldehyde denaturing gel, transferred to positively charged nylon membrane, and hybridized to a probe labeled with [32P] dCTP that was generated from the aforementioned gene or fragment using the Random Primed DNA Labeling Kit (Roche, Palo Alto, CA), or to a probe labeled with digoxigenin (Roche Molecular Biochemicals,

Indianapolis, IN), according to the manufacturer's instructions.

Real-Time RNA Analysis.

5

10

15

20

25

30

Real-time RNA analysis may also be used for confirmation. For "real-time" RNA analysis, RNA will be converted to cDNA and then probed with gene-specific primers made for each clone. "Real-time" incorporation of fluorescent dye will be measured to determine the amount of specific transcript present in each sample. Sample differences (control vs. hyperinsulinemic, hyperinsulinemic vs. diabetic, or control vs. diabetic) will be evaluated. Confirmation using several independent animals is desirable.

In situ Hybridization

Another form of confirmation may be provided by nonisotopic in situ hybridizations (NISH) on selected human (obtained by Tissue Informatics) and mouse tissues using cRNA probes generated from mouse genes found to be up- or down-regulated during the disease progression. hybridizations may also be performed on mouse tissues using cRNA probes generated from differentially expressed DNAs. These cRNA's will hybridize to their corresponding messenger RNA's present in cells and will provide information regarding the particular cell types within a tissue that is expressing the particular gene as well as the relative level of gene expression. The cRNA probes may be generated by in vitro transcription of template cDNA by Sp6 or T7 RNA polymerase in the presence of digoxigenin-11-UTP (Roche Molecular Biochemicals, Mannheim, Germany; Pardue, M.L. In: In situ hybridization, Nucleic acid hybridization, a practical approach: IRL Press, Oxford, 179-202).

35 Transgenic Animals.

Transgenic expression may be used to confirm the results. In one embodiment, a mouse is engineered to overexpress the favorable or unfavorable mouse gene in question. In another embodiment, a mouse is engineered to express the

corresponding favorable or unfavorable human gene. In a third embodiment, a nonhuman animal other than a mouse, such as a rat, rabbit, goat, sheep or pig, is engineered to express the favorable or unfavorable mouse or human gene.

5

10

15

20

25

30

35

Hyperquantitative Tissue Analysis

In addition to gene expression analysis the tissue sections can also be analyzed using TissueInformatics, Inc.'s TissueAnalytics™ software. A single representative section may be cut from each tissue block, placed on a slide, and stained with H&E. Digital images of each slide may be acquired using an research microscope and digital camera (Olympus E600 microscope and Sony DKC-ST5). These images may be acquired at 20x magnification with a resolution of 0.64 mm/pixel. A hyperquantitative analysis may be performed on the resulting images: First a digital image analysis can identify and annotate structural objects in a tissue using machine vision. These objects, which are constituents of the tissue, can be annotated because they are visually identifiable and have a biological meaning. Subsequently a quantification of these structures regarding their geometric properties like area or stain intensities and their relationship to the field of view or per unit area in terms of a % coverage may be performed. Features or parameters for hyper-quantification are specific for each tissue, and may also include relations between features, measures of overall heterogeneity, including orientation, relative locations, and textures.

Correlation Analysis

Mathematical statistics provides a rich set of additional tools to analyze time resolved data sets of hyperquantitative and gene expression profiles for similarities, including rank correlation, the calculation of regression and correlation coefficients, and clustering. Continuous functions may also be fitted through the data points of individual gene and tissue feature data. Relation between gene expression and hyper-quantitative tissue data may be

linear or non-linear, in synchronous or asynchronous arrangements.

Example 1

5

10

15

20

25

30

35

Obesity is increasing at an alarming rate in the United States. In parallel, the incidence of type II diabetes is also rising. We are interested in defining alterations in gene expression that correlate with the development of these conditions in the hopes of reversing these dangerous trends.

Insulin plays a major role in regulating blood glucose levels. It stimulates the uptake of glucose in adipose tissue and striated muscle for storage as intracellular triglycerides and glycogen. Insulin also inhibits the release of glucose from the liver. Normally, this would prevent the rise in blood sugar concentration that occurs after eating. However, in the early stages of type 2 diabetes, resistance to insulin is seen.

Muscle plays a major role in glucose metabolism. Thus, it also is a major contributor to the development of type 2 diabetes. In normal situations, muscle cells respond to increasing levels of insulin by increasing glucose uptake from the bloodstream. However, during the very early stages of type 2 diabetes, muscle tissue becomes resistant to insulin, requiring the pancreatic beta cells to increase insulin secretion. Eventually, the beta cells become unable to compensate for this increasing insulin resistance from muscle and other cells, and insulin production drops. Thus, clinical type 2 diabetes results from the combination of insulin resistance and impaired beta cell function.

Defects in muscle glycogen synthesis are known to play a role in the development of insulin resistance (Petersen and Shulman, 2002). At least three steps - those mediated by glycogen synthase, hexokinase, and GLUT4 - have been reported to be defective in patients with type 2 diabetes. Fatty acids also can induce insulin resistance, and it has been suggested that this was a consequence of altered insulin signaling through PI3-kinase.

109 We are utilizing a mouse model of diet-induced obesity that progresses to diabetes. The diet is high in fat, an increasing component in the U.S. diet, and has been documented to lead to diabetes in C57BL/6J mice (Surwit et al., 1988). After weaning, C57BL/6J mice were fed either 5 the high fat diet or a standard lab chow diet for 16 weeks. Body weight was monitored bi-weekly. Fasting glucose and insulin levels were measured after 2, 4, 8, and 16 weeks on the diets. 10 Consumption of the HF diet resulted in significant, levels in comparison to consumption of the Std diet. Fasting glucose levels of mice on the HF diet were 15

progressive increases in body weight and fasting insulin dramatically increased at the first time point assayed (2 weeks) and remained high through the duration of the experiment (16 weeks).

At each time point, several diabetic and control mice were sacrificed and a number of tissues collected. RNA was extracted from the gastrocnemius muscle at each time point.

In order to identify additional muscle genes involved in the development of type 2 diabetes, we used microarray analysis to compare RNA expression levels of 10,000 genes in muscle of high fat diet fed and control diet fed mice at various time points in the progression of type 2 diabetes. Microarray analysis provides a more global picture of gene regulation, allowing the identification of families or groups of genes showing similar expression patterns that potentially imply similar or coordinated roles in disease progression.

Consumption of the HF diet resulted in significant, progressive increases in body weight and fasting insulin levels in comparison to consumption of the Std diet. Fasting glucose levels of mice on the HF diet were dramatically increased at the first time point assayed (2 weeks) and remained high through the duration of the experiment (16 weeks).

Of 10,000 genes analyzed, 121 were up-regulated but only 7 down-regulated greater than two-fold in the diabetic

20

30

35

25

relative to non-diabetic mice. These genes are listed in Master Table 1.

This distribution of up- and down-regulated genes was much different from that seen for other organs (liver, pancreas, and white adipose tissue) where there was a much closer balance between the number of up- and down-regulated genes. Actin, alpha, cardiac (Actc1, NM_009608) was one of the most down-regulated genes when comparing HF to Std mice. It was consistently expressed at lower levels in the HF diabetic mice in comparison to the Std mice and also steadily decreased over the 16 week study.

Example 2

5

10

15

20

25

30

35

Interestingly, further analysis of the time points and exploration of gene pathways and functionally related genes revealed a subset of actin-related and actin-binding genes exhibiting a consistent decrease in expression (although less than two-fold) in the diabetic mice; 9 of 37 functionally related genes were decreased in diabetic muscle at all four time points and an additional 9 were decreased at three of the four time points. Only two of these genes had been included in the original list of 7 down-regulated genes using the two-fold cut-off criterion.

It is possible that this subtle but coordinated down-regulation of actin-related or actin-binding genes reflects a role in the decreased glucose uptake by skeletal muscle that occurs in diabetes. With nearly half (18 of 37) of the genes in a related family of genes being consistently down-regulated in a study that did not identify a large number of down regulated genes, we feel that actin and genes in actin-related pathways may prove to play key roles in muscle as obesity and diabetes progress.

The actin-related and actin-binding mouse genes in question have been included at the end of Master Table 1, subtable 1A.

Introduction to Master Tables

The master tables reflect applicants' analysis of the gene chip data.

5

For each probe corresponding to a differentially expressed mouse gene, Master Table 1 identifies

- Col. 1: The mouse gene (upper) and mouse protein (lower) database accession #s.
 - Col. 2: The corresponding mouse Unigene Cluster, as of the $4^{\rm th}$ Quarter 2001 build.
- 15 Col. 3: The behavior (differential expression) observed for the mouse gene. This column identifies the gene as favorable(F) or unfavorable (U) on the basis of its strongest differential behavior at the ages tested. There are three possible comparisons, HI-D, C-HI, and C-D, where C=control (normal), HI=hyperinsulinemic, and D=diabetic. If HI>D, C>HI, or C>D, the behavior for that subject comparison is considered unfavorable. If the inequality is reversed, the behavior for that subject comparison is considered favorable.
- In the Master Table, the numerical value is the ratio of the greater value to the lesser value. If this ratio is at least two fold, the degree of differential expression is considered strong. Usually only mouse genes exhibiting at least one strong differential expression behavior are listed in the Master Table; exceptions are noted in the Examples.

In Master Table 1, subtables 1A and 2A, the fold
expression values are negative. Likewise, in subtables 1G
and 2C, the fold expression values for the favorable
behaviors are negative. This does not have its usual

mathematical meaning; it is merely a flag that in at least
one comparison (HI-D, C-HI, and C-D), the former value was
less than the latter one, i.e., the behavior was favorable.
For the purpose of applying the teachings of the
specification concerning desired ratios, any negative value

- Col. 4: A related human protein, identified by its database accession number. Usually, several such proteins are identified relative to each mouse gene. These proteins have been identified by BLAST searches, as explained in cols. 6-8.
 - Col. 5: The name of the related human protein.

15

20

25

- Col. 6: The score (in bits) for the alignment performed by the BLAST program.
- Col. 7: The E-value for the alignment performed by the BLAST program. It is worth noting that Unigene considers a Blastx E Value of less than 1e-6 to be a "match" to the reference sequence of a cluster.
 - Unless otherwise indicated, the bit score and E-value for the alignment is with respect to the alignment of the mouse DNA of col. 1 to the human protein of col. 4 by BlastX, according to the default parameters.
- Master Table 1 is divided into three subtables on the basis of the behavior in col. 3. If a gene has at least one significantly favorable behavior, and no significantly unfavorable ones, it is put into Subtable 1A. In the opposite case, it is put into Subtable 1B. If its behavior is mixed, i.e., at least one significantly favorable and at least one significantly unfavorable, it is put into Subtable 1C. Note that this classification is based on the strongest observed differential expression behaviors for each of the three subject comparisons, C-HI, HI-D and C-D.

The corresponding human gene clusters are also of interest. These may be obtained in a number of ways. First, one may

search on Unigene

5

10

(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene) for the identified human protein. Review the "hits" (each of which is a Unigene record) for those prefixed by "Hs." Secondly, one may access the Unigene record for the mouse gene cluster (which is given in Master Table 1), and then click on "Homologene". This will bring up a new page which includes the section "Possible Homologous Genes". One of the entries should be a Homo sapiens gene (considered by Unigene to be the most related human gene); click on its Unigene record link.

Additional information of interest may be accessed by searching with the mouse gene accession # in the Mouse Gene Informatics database, at http://www.informatics.jax.org/.

MASTER TABLE 1 SIGNIFICANTLY DIFFERENTIALLY EXPRESSED MOUSE GENES/PROTEINS AND CORRESPONDING HUMAN PROTEINS

Subtable 1A: Wholly Favorable Genes and Proteins

Mouse Gene Protein	Unigene	Unigene Behavior	Human Proteins	Human Protein Name	Score	E-value
X82786 CAA58026.1	Mm.4078	F:(IR-D) -3.33	NP_002408.2	antigen identified by monoclonal antibody Ki-67; Proliferation-related Ki-67 antigen	1711 0	
,			P46013	KI67 HUMAN Antigen KI-67	1711	
			A48666	cell proliferation antigen Ki-67, long form		
			CAA46519.1	antigen of the monoclonal antibody Ki-67	_	
			CAA46520.1	antigen of the monoclonal antibody Ki-67	1215	
			B48666	cell proliferation antigen Ki-67, short form	1376	
NM_013788 NP_038816.1	Mm.90135 F:(IR-D)	F:(IR-D) -2.74	BAB86352.1	GSK-3beta binding protein FRAT1	205	205 8E-54
			34476.1	frequently rearranged in advanced T-cell lymphomas	200	53 11
			05470 1	005470 frequently restranced in Atomost T. con 1 in the content of the content	107	204 1E-33
			097837	FRT1 LITIMAN Prote Concentration 1-cell lympholinas	204	204 2E-53
			2020	lymphomas)	204	204 2E-53
			AAB97096.2	proto-oncogene	204	204 25 53
NM_019641 NP_062615.1	Mm.28479 F:(IR-D)		NP_005554.1	stathmin 1; metablastin; prosolin; oncoprotein 18; phosphoprotein 19; stathmin;	286	286 8E-78
		T	0,00,00	remember associated phosphologin p16		
			P16949	STN1_HUMAN Stathmin (Phosphoprotein p19) (pp19) (Oncoprotein 18) (Op18) (Leukemia-associated phosphoprotein p18) (pp17) (Prosolin) (Metablastin) (Pr22	286	286 8E-78
				protein)		
			A40936	stathmin	286 5	286 RE-78
			77660.1	Pr22 protein	286 8F-78	F-78
			37391.1	stathmin	286 8E-78	78 78
			AAA59971.1	oncoprotein 18	27-78 587 786 8E 78	2/2
			AAA59980.1	protein p18	286 SE 78	0,70
			54398.1	Pr22	07-70 007	9 6
			Г	d112513.1 (leukernia-associated nhosnhonrotein n18 (stathmin))	0 007	0/-1
				AAH14353 Cimilar to chathain 1/2200000000000000000000000000000000000	7-70 007	0/-1
			1 TO COL 1 TO CO. T.	recent of Statement to Statement Proncoprotein 18	285 2E-77	E-77

		O9H169	STN4 HIMAN Stathmin 4 (Stathmin, like arrotein D2) (DD2)	١	4
		CAC22254 1	RB3 mratein	2 3	194 45-50
		CAB66503.1	hynothetical protein	194	4E-50
		NP 110422.2		194	4E-50
		AAH11520.1	AAH11520 Similar to stathmin-like-protein PR3		194 4E-50
Mm.4237	F:(IR-D)	NP 001058.2	DNA tonoisomerase II alnha isozumer tonoisomerana (DNA) II alnha (1701-D), DNA		194 4E-50
!	-2.33	l 	topoisomerase II, 170 kD	2463 0	<u> </u>
		P11388	TP2A HUMAN DNA topoisomerase II. alnha isozyme	2462	
		AAC77388.1	topoisomerase II alpha	2463	ی د
		AAA61209.1	DNA topoisomerase II (EC 5.99.1.3)	2463	
		CAA09762.1	DNA topoisomerase (ATP-hydrolysing): topoisomerase II alpha	24540	2 0
		A40493	DNA topoisomerase (ATP-hydrolyzing) (EC 5.99.1.3) alpha	24410	ی د
		Q02880	TP2B HUMAN DNA topoisomerase II, beta isozyme	1023	> <
		A39242	DNA topoisomerase (ATP-hydrolyzing) (EC 5.99.1.3) beta_splice form 2	1023 0	> <
		NP_001059.2	DNA topoisomerase II, beta isozyme; topo II beta; DNA topoisomerase II, 180 kD;	1923 0	0
1			topoisomerase (DNA) II beta (180kD)		
1		CAA48197.1	DNA topoisomerase II	1923 0	0
		AAC77432.1	DNA topoisomerase II beta	1918	0
		AAA61210.1	topoisomerase II	1494 0	0
71001					
Mm.41925 F:(IK-D)	r:(IK-D)	NP_076947.1	J/6947.1 hypothetical protein MGC2601	457	457 e-128
	77.7				
		CAB56188.1	c380A1.2.1 (novel protein (isoform 1))	457	P-128
		AAH00662.1	Unknown (protein for MGC:2601)	457	457 e-128
			AE006464 15 unknown	457	457 e-128
			c380A1.2.2 (novel protein (isoform 2))	300	300 3E-81
Mm.8245 F:	F:(R-D) -2.18	CAA26443.1	EPA glycoprotein	270	270 IE-72
		NP_003245.1	tissue inhibitor of metalloproteinase 1 precursor; Erythroid-potentiating activity (tissue inhibitor of metalloproteinases): erythroid potentiating activity	270	270 1E-72
		P01033	TIM1_HUMAN Metalloproteinase inhibitor 1 precursor (TIMP-1) (Erythroid potentiating activity) (EPA) (Tissue inhibitor of metallomoteinases) (Ribacklant	270	270 1E-72
			TOTAL		

collagenase inhibitor) (Collagenase inhibitor)
A26902.1
A52436.1
A63234.1
014009.1
AAH00866.1 AAH00866 tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor)
1107278A erythroid potentiating activity
1308125A metalloproteinase inhibitor
Į.A
T
AAH07097.1 AAH07097 tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor)
NP_000358.1 thiopurine S-methyltransferase
9
27277.1
50130.1
_
AAC51865.1 thiopurine S-methyltransferase
$\overline{}$
П
71626.1
\neg
AAB71629.1 thiopurine methyltransferase
\Box T
Т
AAB80747.1 thiopurine S-methyltransferase

2. 43 }

_						
			AAC50129.1		265	265 9F-84
			XP 031946.2	similar to thiopurine methyltransferase	396	265 AE 02
U08020 AAA88912.1	Mm.22621	F:(IR-D) -2.16	P02452	CA11_HUMAN Collagen alpha 1(I) chain precursor	486	486 e-136
			AAB94054.2	pro alpha 1(I) collagen	707	137
			NP 000079.1		\$	480 e-130
				imperfecta type IV; collagen of skin, tendon and bone, alpha-1 chain	484	484 e-136
			CAA98968.1	prepro-alpha1(I) collagen		
			CGHUIS	collagen alpha 1(f) chain precursor	484	e-136
			AAA51995 1	aluha 1 (1) chain momentials	483	483 e-136
			A A H36531 1	Information (motion for a food 33,00)	482	482 e-135
			1.1000011111 A A D 27066 1	Outstown (protein 101 INIGC: 53668)	480	480 e-135
			CA 4 20005 1	type I collagen pro alpha 1(1) chain propeptide	469	e-131
			CAA29003.1	C-refminal propeptide domain	435	e-121
			CAA29604.1	pro-alpha 1 (II) collagen (313 AA; AA 975-271c)	372	372 e-102
			NP_001835.2	alpha 1 type II collagen isoform 1; collagen II, alpha-1 polypeptide; cartilage collagen; chondrocalcin, included; COL111A3 formerly	372	372 e-102
			AAC41772.1	alpha-1 type II collagen	27.0	5
					7/7	e-107
NM_023043 Mr	m.18075	Mm.18075 F:(IR-D)	NP_036541.1	036541.1 prion gene complex, downstream	283	783 11 75
		-2.14			707	
			Q9UKY0	PRND HUMAN Prion-like protein doppel precursor (PrPLP) (Prion protein 2)	283	1F_75
			AAF02424.1	AF106918 1 prion-like protein		10 75
				dJ1068H6.4 (prion protein like protein doppel)		27-21
				prion-like protein	207	202 2E-75
				AF187843 1 dopped protein	707	
NM_009464 Mn	Mm.6254	F:(IR-D)		uncoupling protein 3, isoform UCP3L	531	240 2E-04 531 e-151
NP 033490.1		-4.07				
			P55916	UCP3_HUMAN Mitochondrial uncoupling protein 3 (UCP 3)	\$31	151
			JC5522	uncoupling protein UCP3, mitochondrial		151
				UCP3		151
			AAC51369.1	uncoupling protein 3		15]
			7		531 e-151	-151

			T		
		AAC51767.1	uncoupling protein-3	531	531 e-151
		AAG02284.1	AF050113_1 uncoupling protein-3	531	e-151
		AAC18822.1	uncoupling protein 3	525	e-149
		AAC51785.1	uncoupling protein 3	510	e-144
			uncoupling protein 3, isoform UCP3S	464	e-131
			UCP3S	464	464 e-131
		AAB48411.1	uncoupling protein-2	457	e-129
		NP_003346.2	uncoupling protein 2	456	456 e-128
		P55851	UCP2_HUMAN Mitochondrial uncoupling protein 2 (UCP 2) (UCPH)	456	456 e-128
		A A C < 1336 1		456	e-128
		AAC31330.1	7100	2	071
		AAC39690.1	uncoupling protein 2	456	456 e-128
		AAD21151.1	uncoupling protein-2	456	e-128
		AAH11737.1	AAH11737 uncoupling protein 2 (mitochondrial, proton carrier)	456	e-128
		AAB53091.1	uncoupling protein homolog	456	456 e-128
		CAA11402.1	uncoupling protein 2	456	456 e-128
		NP 068605.1	uncoupling protein 1; mitochondrial brown fat uncoupling protein	345	7E-95
		G01858	uncoupling protein 1, mitochondrial	345	345 7E-95
		AAA85271.1	uncoupling protein	345	345 7E-95
		P25874	UCP1_HUMAN Mitochondrial brown fat uncoupling protein 1 (UCP 1) (Thermogenin)	342	342 6E-94
		CAA36214.1	uncoupling protein	342	6E-94
		AAH08392.1	AAH08392 Similar to uncoupling protein 3 (mitochondrial, proton carrier)	214	214 2E-55
AK014626 M 1 XP 138942.1	Mm.10557 F:(IR-D)	CAC07336.1	dJ137F1.2 (novel member of the potassium channel subfamily K)	309	309 9E-84
		91.1	potassium channel, subfamily K, member 16; pancreatic 2P domain potassium channel TALK-1	285	285 2E-76
		Q96T55	CIWG_HUMAN Potassium channel subfamily K member 16 (TWIK-related alkaline pH activated K+ channel 1) (2P domain potassium channel Talk-1)	285	285 2E-76
		AAK49532.1	AF358909 .1 2P domain potassium channel Talk-1	285	285 2E-76

	255 SE-67	SE-67	255 5E-67	255 SE-67	255 SE-67	255 5E-67	255 5E-67	255 SE-67	255 SE-67	255 SE-67	255 SE-67	255 SE-67	255 5E-67	255 5E-67	255 5E-67	254 1E-66	250 2E-65	250 2E-65	249 3E-65	249 3E-65	223 2E-57	448 e-125	446 e-125	446 e-125	446 e-125	446 e-125	446 e-125	446 e-125	446 e-125
	255	255	255	255	255	255	255	255	255	255	255	255	255	255	255	254	. 250	250	249	249	223	448	446	446	446	446	446	446	446
119	000603.1 insulin-like growth factor 2 (somatomedin A); somatomedin A	IGF2_HUMAN Insulin-like growth factor II precursor (IGF-11) (Somatomedin A)	nsulin-like growth factor II precursor [validated]	1GF-11 precursor	precursor polypeptide (AA -24 to 156)	preproinsulin-like growth factor II, domains A-E	insulin-like growth factor	insulin-like growth factor II precursor	insulin-like growth factor I1	insulin-like growth factor II; IGF-11	AF217977 1 unknown	AAH00531 insulin-like growth factor 2 (somatomedin A)	AF517226 1 insulin-like growth factor 2 (somatomedin A)	insulin-like growth factor II precursor	insulin-like growth factor II	insulin-like growth factor II precursor	insulin-like growth factor II, domains A-E	preproinsulin-like growth factor II, domains A-E	insulin-like growth factor II precursor, splice form II.	put. IGF-II	precursor polypeptide (AA -24 to 140)	AAH07725 ceroid-lipofuscinosis, neuronal 8 (epilepsy, progressive with mental retardation)	ceroid-lipofuscinosis, neuronal 8 (epilepsy, progressive with mental retardation)	CLN8_HUMAN CLN8_protein	AF123757 1 putative transmembrane protein	AF123758 1 putative transmembrane protein	AF123759 1 putative transmembrane protein	AF123760 1 putative transmembrane protein	AF123761 1 putative transmembrane protein
	NP_000603.1	P01344	1GHU2	CAA25426.1	CAA29516.1	AAA52442.1	AAA52535.1	AAA52545.1	AAA60088.1	AAB34155.1	AAG17220.1	AAH00531.1	AAM51825.1	1009249A	1203258B	AAA52544.1	167610	AAA52443.1	S02423	CAA27249.1	CAA29517.1	AAH07725.1	NP 061764.1	Q9UBY8	AAF13115.1	AAF13116.1	AAF13117.1	AAF13118.1	AAF13119.1
	F:(IR-D) -2.06																					F:(IR-D) -2.09							
	Mm.3862																					Mm.21578							
	NM_010514 NP_034644.1																					NM_012000 NP_036130.1							

345 2E-94	2E-94	1E-93	1E-93	342 1E-93	1E-93	249 1E-65	1E-65	1E-65	249 1E-65	1E-65	248 2E-65	245 2E-65	217 SE-56	5E-56	5E-56	7E-53	206 7E-53	0		0	0	0	e-143	e-140	499 e-140	499 e-140
345	345	342	342	342	342	249	249	249	249	249	248	245	217	217	217	206	206	0 808		807	807 0	807	507	499	499	499
170521.1 similar to data source:MGD, source key:MGI:98241, evidence:ISS~putative~superiorcervical ganglia, neural specific 10	AAH06302 Similar to superiorcervical ganglia, neural specific 10		_	STN2_HUMAN Stathmin 2 (SCG10 protein) (Superior cervical ganglion-10 protein)	silencer element	2 SCG10-like-protein	STN3 HUMAN Stathmin 3 (SCG10-like protein)	SCG10 like-protein	bK3184A7.2 (SCG10-like protein (SCLIP) (ortholog of rabbit neuroplasticin-2 (NPC2)))	AAH09381 Unknown (protein for MGC:16668)		unnamed protein product	STN4 HUMAN Stathmin 4 (Stathmin-like protein B3) (RB3)	RB3 protein	hypothetical protein	2 stathmin-like-protein RB3	AAH11520 Similar to stathmin-like-protein RB3			1 nuclear factor I/B	NFIB_HUMAN Nuclear factor 1 B-type (Nuclear factor 1/B) (NF1-B) (NF1-B) (NF-I/B) (CCAAT-box binding transcription factor) (CTF) (TGGCA-binding protein)	nuclear factor I-B2	nuclear factor 1 B-type	1 nuclear factor I/C (CCAAT-binding transcription factor)		
XP_170521.1	AAH06302.1	NP_008960.1	AAB36428.1	Q93045	BAA23326.1	NP 056978.2	Q9NZ72	AAF35245.1	CAC16222.1	AAH09381.1	AAD12730.1	BAC11252.1	О9Н169	CAC22254.1	CAB66503.1	NP 110422.2	AAH11520.1	AAH01283.1		NP 005587.1	000712	AAB41899.1	AAA93125.1	NP 005588.1	CAA63440.1	AAH12120.1
1																		F:(C-IR) -2.69								
Mm.29580 F:(C-IR)																		Mm.4025								
NM_025285 NP_079561.1																		WM_008687	NP 032713.1							

			P08651	NFIC_HUMAN Nuclear factor 1 C-type (Nuclear factor 1/C) (NF1-C) (NF1-C) (NF-L/C) (CCAAT-box binding transcription factor) (CTF) (TGGCA-binding protein)	487 e-137	137
			B33416	nuclear factor I	484 e-136	136
			BAA92677.1	KIAA1439 protein	484 e-136	136
			Q128 <i>57</i>	NFIA_HUMAN Nuclear factor 1 A-type (Nuclear factor 1/A) (NF1-A) (NF1-A) (NF-1/A) (CCAAT-box binding transcription factor) (CTF) (TGGCA-binding protein)	483 e-136	136
			XP 046827.7	similar to transcription factor NF1	483 e-	e-136
				Nuclear Pactor IA	483 e-136	136
AK013022 Q9NZJ3	Mm.28026 F;(C-IR)		O9NZJ3	SELT_HUMAN Selenoprotein T	334 2E-91	3-91
			NP 057359.1	selenoprotein T	326 4E-89	3-89
			AAF13696.1	selenoprotein T	326 41	4E-89
			XP 088553.	similar to Selenoprotein T	317 21	2E-86
			AAD20063.1	Unknown	284 2E-76	3-76
			136738.1	Unknown (protein for MGC:45090)	284 2E-76	3-76
NM_019643	Mm.18637 F:(C-IR)	F:(C-IR)	NP_067061.1	TERA protein	402 e-111	111
NP_062617.1		-2.4				
			T46918	hypothetical protein DKFZp762L137.1	402 e-	e-1111
			CAB75656.1	hypothetical protein	402 e-111	111
			AAF87322.1	AF212220 1 TERA	402 e-111	111
			BAB15592.1	unnamed protein product	402 e-111	111
			AAH00024.1	AAH100024 TERA protein	402 e-	e-111
NM_022314 NP_071709.1	Mm.17306 F:(C-IR)	F:(C-IR) -2.32	P06753	TPM3_HUMAN Tropomyosin alpha 3 chain (Tropomyosin 3) (Tropomyosin gamma)	365 e-101	101
			XP 036829.5	similar to tropomyosin, fibroblast	365 e-	e-101
			A24199	tropomyosin NM, skeletal muscle	365 e-	e-101
			CAA27798.1	skeletal muscle tropomyosin (AA 1-285)	365 e-	e-101
			AAH08407.1	AAH08407 Unknown (protein for MGC:14532)	365 e-101	101
			AAH08425.1	AAH08425 Unknown (protein for MGC:14582)	365 e-101	101

			1000001	And the second s	365	101
			1209280A	ropomyosm	ဂ္ဂ	101-5
			P09493	TPM1 HUMAN Tropomyosin 1 alpha chain (Alpha-tropomyosin)	345	8E-95
			A25825	tropomyosin alpha chain, cardiac and skeletal muscle	345	8E-95
			AAA61225.1	skeletal muscle tropomyosin	345	345 8E-95
			P07951	TPM2 HUMAN Tropomyosin beta chain (Tropomyosin 2) (Beta-tropomyosin)	326	326 3E-89
			S00922	tropomyosin beta, skeletal muscle	326	326 3E-89
			CAA29971.1	beta-tropomyosin (AA 1-284)	326	3E-89
			AAH07433.1	AAH07433 Similar to tropomyosin 1 (alpha)	325	7E-89
			NP 689476.1	tropomyosin 3	315	9E-86
			BAC03946.1	unnamed protein product	315	315 9E-86
			AAA61226.1	skeletal muscle tropomyosin	310	310 2E-84
			BAB14554.1	unnamed protein product	300	300 2E-81
			NP 000357.2	tropomyosin 1 (alpha)	281	1E-75
			A27674	tropomyosin 3, fibroblast	281	1E-75
			AAA36771.1	nsovmodon	281	1E-75
			T08796	nisoymogon	278	1E-74
			CAB43309.1	hypothetical protein	278	1E-74
NM_011825 NP_035955.1	Mm.25760 F:(C-IR)	_	NP_071914.1	071914.1 hypothetical protein FLJ21195 similar to protein related to DAC	308	308 SE-83
			BAB15026.1	unnamed protein product	308	SE-83
NM_009831	Mm.2103	F:(C-IR) -2.2	NP_004051.1 cyclin G1	cyclin G1	543	543 e-154
11100000 111			P51959	CGG1_HUMAN Cyclin G1 (Cyclin G)	543	e-154
			G02401	cyclin G1	543	543 e-154
			AAC41977.1	cyclin G1	543	543 e-154
			AAC50688.1	cyclin G1	543	e-154
			BAA11353.1	cyclin G	543	e-154
			AAH00196.1	cyclin G1	543	e-154
			2210321A	cyclin G1	543	543 e-154
			AAH07093.	cyclin G1	541	e-154

			BAA13007.1	cyclin G	514	514 e-146
			CAA54821.1	cyclin G1	462	462 e-130
			G02523	cyclin G	421	421 e-117
			AAB03903.1	cyclin G	421	421 e-117
			AAH32518.1	Similar to cyclin G2	292	292 8E-79
			NP_004345.1	cyclin G2	292	8E-79
			Q16589	CGG2_HUMAN Cyclin G2	292	8E-79
			AAC41978.1	cyclin G2	292	292 8E-79
			AAC50689.1	cyclin G2	292	8E-79
			AAN40704.1	cyclin G2	292	292 8E-79
			2210321B	cyclin G2	292	8E-79
NM_021282	Mm.21758 F:(C-IR)	F:(C-IR)	NP_000764.1	cytochrome P450, subfamily IIE, polypeptide 1; microsomal monooxygenase;	792 0	0
INF_00/237.1		F:(C-D) -		xenopione monooxygenase; navoprotein-inked monooxygenase; cytochrome r450, subfamily IIE (ethanol-inducible)		
		7.5		The second control of		
			P05181	CPE1 HUMAN Cytochrome P450 2E1 (CYPIIE1) (P450-1)	792	0
			A31949	cytochrome P450 2E	792 0	0
			AAA52155.1	cytochrome P450IIE1	792 0	0
			AAA35743.1	cytochrome P450j	792	0
			AAF13601.1	AF182276_1 cytochrome P450-2E1	190	0
			AAD13753.1	cytochrome P450 2E1	751	0
			NP_000760.1	cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19; mephenytoin 4'-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase;	557	557 e-158
				flavoprotein-linked monooxygenase		
			P33261	CPCJ_HUMAN Cytochrome P450 2C19 (CYPIIC19) (P450-11A) (Mephenytoin 4-hydroxylase) (CYPIIC17) (P450-254C)	557	e-158
			AAB59426.1	суюстот	557	e-158
			NP_000763.1	cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 18; cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 17;	556	556 e-158
			AAB59356.1	cytochrome	356	2.158
			P33260	CPCI HUMAN Cytochrome P450 2C18 (CYPIIC18) (P450-6B/29C)	553	P-157
			A61269	cytochrome P450 2C18	553	553 e-157
			30.1	cytochrome P-4502C18	553	553 e-157
			ı			

			BAA00123.1	cytochrome P-450	550	550 le-156
			NP_000762.2	cytochrome P450, subfamily IIC, polypeptide 9; cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 10; mephenytoin 4-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase	550	550 e-156
			P11712	CPC9_HUMAN Cytochrome P450 2C9 (CYPIIC9) (P450 PB-1) (P450 MP-4) (S-mephenytoin 4-hydroxylase) (P-450MP)	550	550 e-156
			B38462	S-mephenytoin 4-hydroxylase (EC 1.14.14) cytochrome P450 2C9	550	e-156
			1313295A	cytochrome P450	550	550 e-156
			F38462	S-mephenytoin 4'-hydroxylase (EC 1.14.14) cytochrome P450 2C19	550	550 e-156
			AAB23864.2	cytochrome P-450	545	545 e-155
AK019452	Mm.29952 F:(C-IR)	F:(C-IR)	NP_078847.1	078847.1 hypothetical protein FLJ22940	258	258 9E-69
BAB31728.1		-2.13				
			AAH01381.1	polymerase (RNA) III (DNA directed) polypeptide K (12.3 kDa)	258	258 9E-69
			AAH09179.1	hypothetical protein FLJ22940	258	258 9E-69
			AAK61211.1	AE006462_3 Minus -99 protein	258	258 9E-69
			BAB15505.1	unnamed protein product	256	256 4E-68
NM_008832	Mm.42254 F:(C-IR)		NP_002628.1	phosphorylase kinase, alpha 1 (muscle); phosphorylase kinase, alpha 1 (muscle), muscle	2244 0	0
NP_032858.1		-2.18		glycogenosis; Phosphorylase kinase, muscle, alpha polypeptide		
			P46020	KPB1_HUMAN Phosphorylase B kinase alpha regulatory chain, skeletal muscle isoform (Phosphorylase kinase alpha M subunit)	2244 0	0
			I38111	phosphorylase kinase (EC 2.7.1.38) alpha-1 chain	2244	0
			CAA52083.1	phosphorylase kinase	2244 0	0
				phosphorylase kinase, alpha 2 (liver); Phosphorylase kinase deficiency, liver (glycogen storage disease; phosphorylase kinase, alpha 2 (liver), glycogen storage disease IX	1628 0	0
			P46019	KPB2_HUMAN Phosphorylase B kinase alpha regulatory chain, liver isoform (Phosphorylase kinase alpha L subunit)	1628 0	
			CAA56662.1	phosphorylase kinase	1628 0	
			BAA07606.1	phosphorylase kinase alpha subunit	1628 0	0

			AAD32846.1	phosphorylase kinase alpha subunit	162810	0
			AAH14036.1	AAH14036 Similar to phosphorylase kinase, alpha 2 (liver)	1624	0
			CAB86408.1	dJ499B10.2 (phosphorylase kinase, alpha 2 (liver) (PYK))	631	e-180
			AAB27307.1	phosphorylase kinase alpha subunit liver isoform, PHKA2 (EC 2.7.1.38) [human, hepatoma, Peptide Partial, 377 aa]	473	473 e-132
			S74251	phosphorylase kinase (EC 2.7.1.38) beta chain	461	e-129
			AAH33657.1	Similar to phosphorylase kinase, beta	461	e-129
NM_023831 NP_076320.1	Mm.30006 F:(C-IR)	F:(C-IR) -2.16	CAB96537.1	hypothetical protein	465	465 e-131
			CAB66868.1	hypothetical protein	465	465 e-131
			AAH11647.1	AAH11647 Similar to hypothetical protein	465	465 e-131
			AAH12802.1	AAH12802 Similar to hypothetical protein	465	465 e-131
			AAH22856.1	hypothetical protein	465	e-131
			NP 064538.2	hypothetical protein FLJ21827	465	e-131
			BAB15146.1	unnamed protein product	465	e-131
AK004839	Mm.2605	F:(C-R)	NP_006735.1	retinol-binding protein 4, plasma precursor	343	343 2E-94
XP 129259.1		-2.13				
			pir VAHU	plasma retinol-binding protein precursor	343	343 2E-94
			CAA24959.1	precursor RBP	343	343 2E-94
			P02753	Plasma retinol-binding protein precursor (PRBP) (RBP) (PRO2222)	341	1E-93
			AAH20633.1	Similar to retinol binding protein 4, plasma	341	1E-93
			XP 005907.5	similar to Plasma retinol-binding protein precursor (PRBP) (RBP) (PRO2222)	341	1E-93
			1RBP	Retinol Binding Protein	340	340 2E-93
	-		1BRP	Retinol Binding Protein (Holo Form)	340	340 2E-93
			1BRQ	Retinol Binding Protein (Apo Form)	340	340 2E-93
			1401251A	retinol binding protein	340	340 2E-93
			1QАВ	E Chain E, The Structure Of Human Retinol Binding Protein With Its Carrier Protein Transthyretin Reveals Interaction With The Carboxy Terminus Of Rbp	328	328 9E-90
			1QAB	F Chain F, The Structure Of Human Retinol Binding Protein With Its Carrier Protein	328	328 9E-90
				Transthyretin Reveals Interaction With The Carboxy Terminus Of Rbp		
			AAF69622.1	AF119917 30 PRO2222	288	288 6E-78

engal established Tempolitikan Tempolitikan

			CAA26553.1	RBP	199	199 SE-51
NM_011823 NP_035953.1	Mm.89979	F:(C-IR) -2.12	AAD50531.1	AF039686_1 G-protein coupled receptor GPR34	0 869	0
			NP 005291.1	G protein-coupled receptor 34	<i>L</i> 69	0
			Q9UPC5	GP34 HUMAN Probable G protein-coupled receptor GPR34	269	0
			AAD17248.1	orphan G protein-coupled receptor	269	0
			BAB55362.1	unnamed protein product	0 269	
			AAH20678.1	AAH20678 G protein-coupled receptor 34	0 269	
NM_025950 NP_0802261	Mm.78875	F:(C-IR)	CAC12705.1	bA6J24.4 (A novel protein similar to cell division cycle control protein 37(CDC37))	514	514 e-145
		20.5				
			AAH14133.1	AAH14133 Unknown (protein for MGC:20783)	514	e-145
			NP 060383.1	Hsp90-associating relative of Cdc37; hypothetical protein FLJ20639	513	e-145
			BAA91304.1	unnamed protein product	513	e-145
			BAA91206.1	unnamed protein product	303	1E-81
			NP_008996.1	CDC37 homolog; CDC37 (cell division cycle 37, S. cerevisiae, homolog); CDC37 (S.	210	210 9E-54
				cerevisiae) nomolog		
			Q16543	CC37_HUMAN Hsp90 co-chaperone Cdc37 (Hsp90 chaperone protein kinase-targeting subunit) (p50Cdc37)	210	210 9E-54
			G02313	CDC37 homolog	210	210 9E-54
			AAB63979.1	CDC37 homolog	210	210 9E-54
			AAB04798.1	CDC37 homolog	210	210 9E-54
			AAH00083.1	AAH00083 CDC37 (cell division cycle 37, S. cerevisiae, homolog)	210	210 9E-54
			AAH08793.1	AAH08793 CDC37 (cell division cycle 37, S. cerevisiae, homolog)	210	210 9E-54
NM_008452	Mm.26938 F:(C-IR)	F:(C-IR)	AAD55891.1	AF134053_1 Kruppel-like factor LKLF	431	e-120
NP_032478.1		-2.05				
			_	AF123344 1 Kruppel-like zinc finger transcription factor	429	e-120
				Kruppel-like factor	429	429 e-120
			Q9Y5W3	KLF2 HUMAN Kruppel-like factor 2 (Lung kruppel-like factor)	429	429 e-120
				AF205849 1 Kruppel-like factor	429	429 e-120

			AAC03462.1	EZF	213	213 SE-55
			043474	KLF4 HUMAN Kruppel-like factor 4 (Epithelial zinc-finger protein F7F) (Gut.	213	213 SE-55
				enriched Krueppel-like factor)	C17	00-70
			AAD42165.1	AF105036 1 zinc finger transcription factor GKLF	213	SE-55
			AAH29923.1	Kruppel-like factor 4 (gut)	213	5E-55
			NP 004226.1		213	5E-55
			AAB48399.1	hezf	213	SE-55
			AAH30811.1	Similar to Kruppel-like factor 4 (gut)	213	213 SE-55
╗			AAH35342.1	Similar to Kruppel-like factor 2 (lung)	211	211 3E-54
NM_020007 N NP_064391.1 3	Mm.14199 3	9 F:(C-IR) -2.04	AAK94915.1	AF401998_1 muscleblind 41kD isoform	695	569 e-166
			NP 066368.1	muscleblind (Drosophila)-like	546	546 e-160
			BAA24858.1	KIAA0428	546	546 e-160
			Q9NR56	MBNL_HUMAN Muscleblind-like protein (Triplet-expansion RNA-binding protein)	537	537 e-157
			CAA74155.1	MBNL protein	537	537 e-157
			NP 659002.1	muscleblind-like protein MBLL39 isoform 1	449	449 e-125
			AAM09798.1	AF491866 1 muscleblind-like protein MLP1	449	e-125
				muscleblind-like protein MBLL39	427	e-119
			NP 060858.2	CHCR isoform G	387	387 e-106
			Q9NUK0	MBXL_HUMAN Muscleblind-like X-linked protein (Cys3His CCG1-required protein) (HCHCR protein)	387	387 e-106
			AAL65661.1	CHCR isoform G	387	e-106
			BAB85648.1	hCHCR-G	387	e-106
			CAD20869.1	CHCR protein	387	e-106
			AAM09533.1	AF491305 1 MBLX39		e-106
			NP 005748.1	muscleblind-like protein MBLL39 isoform 2	377	377 e-103
			AAC67242.1	zinc finger protein	377	377 e-103
			BAB85649.1	hCHCR-R	343	343 1E-93
	ļ		CAD20870.1	CHCR protein	343	1E-93
			AAL87670.1	AF467070 1 Cys3His CCG1-required protein isoform R	343	1E-93
Т	,		82889.1	AF395876 1 36 kDa muscleblind protein EXP36	286	286 7E-82
NM 009883 M	Mm.4863	F:(C-IR)	CAC14276.1	bA112L6.1 (CCAAT/enhancer binding protein (C/EBP), beta)	271	271 2E-72

	271 2E-72	271 2E-72	271 2E-72	271 2E-72	271 2E-72	271 2E-72	271 2E-72	271 2E-72	282 4E-76		282 4E-76	282 4E-76	282 4E-76	2 4B-76	9 3E-75	634 0		3 0	633 0	30	30	30	2 0	
	27	2,	27	27	27	27	27	27	88		78	78	28	282	279	63		633	63	633	633	633	632	İ
	Unknown (protein for MGC:15409)	AF289608_1 unknown	Unknown (protein for MGC:32080)	CCAAT/enhancer binding protein (C/EBP), beta	CCAAT/enhancer binding protein (C/EBP), beta; CCAAT/enhancer-binding protein (C/EBP), beta (transcription factor-5)	CEBB_HUMAN CCAAT/enhancer binding protein beta (C/EBP beta) (Nuclear factor NF-IL6) (Transcription factor 5)	transcription factor NF-IL6	nuclear factor NF-IL6 (AA 1-345)	five-lipoxygenase activating protein (FLAP)		arachidonate 5-lipoxygenase-activating protein; five-lipoxygenase activating protein; MK-886-binding protein	FLAP_HUMAN. 5-lipoxygenase activating protein (FLAP) (MK-886-binding protein)	5-lipoxygenase-activating protein	5-lipoxygenase activating protein	lipoxygenase activating protein	serine (or cysteine) proteinase inhibitor, clade G (C1 inhibitor), member 1		IC1_HUMAN Plasma protease C1 inhibitor precursor (C1 Inh) (C1Inh)	complement C1 inhibitor precursor [validated	C1 inhibitor	C1 inhibitor	AF435921_1 C1 esterase inhibitor	complement component 1 inhibitor precursor; serine (or cysteine) proteinase inhibitor, clade G (C1 inhibitor), member 1	
	AAH07538.1	AAL55792.1	AAH21931.1	AAN86350.1	NP_005185.1	P17676	S12788	CAA36794.1	CAA36441.1		NP_001620.2	P20292	A39824	AAA35845.1	1603359A	AAH11171.1		P05155	ITHUCI	CAA38358.1	CAA30314.1	AAM21515.1	NP_000053.1	
-2.03									F:(C-IR) -2.02							F:(C-IR)	-2.02							
									Mm.19844 F:(C-IR)							Mm.38888 F.(C-IR)								
NP 034013.1									AK004002	BAB23117.1						9/1600_MIN	NP 033906.1							

		-			
		P58340	MLF1_HUMAN Myeloid leukemia factor 1 (Myelodysplasia-myeloid leukemia factor 1)	435	435 e-122
		AAA99997.1	t(3,5)(q25.1;p34) fusion gene	435	e-122
		AAH07045.1	AAH07045 myeloid leukemia factor 1	435	435 e-122
		BAC04885.1	unnamed protein product	396	396 e-110
		BAB71320.1	unnamed protein product	383	383 e-106
NM_028784 Mm.17403 NP_083060.1	403 F:(C-IR) -2.01	CAC36886.1	bA525021.1 (coagulation factor XIII, A1 polypeptide)	482	482 e-135
		1F13	A Chain A, Recombinant Human Cellular Coagulation Factor Xiii	482	e-135
		1F13	B Chain B, Recombinant Human Cellular Coagulation Factor Xiii	482	482 e-135
		1GGT	A Chain A, Coagulation Factor Xiii (A-Subunit Zymogen) (E.C.2.3.2.13) (Protein-Glutamine Gamma-Glutamyltransferase A Chain)	482	482 e-135
		1GGT	B Chain B, Coagulation Factor Xiii (A-Subunit Zymogen) (E.C.2.3.2.13) (Protein-Glutamine Gamma-Glutamyltransferase A Chain)	482	482 e-135
		1GGU	B Chain B, Human Factor Xiii With Calcium Bound In The Ion Site	482	482 e-135
			B Chain B, Human Factor Xiii With Ytterbium Bound In The Ion Site	482	e-135
		K	B Chain B, Human Factor Xiii With Strontium Bound In The Ion Site	482	e-135
			A Chain A, Human Factor Xiii With Ytterbium Bound In The Ion Site	482	482 e-135
		1GGU	A Chain A, Human Factor Xiii With Calcium Bound In The Ion Site	482	482 e-135
		\neg	A Chain A, Human Factor Xiii With Strontium Bound In The Ion Site	482	482 e-135
		5833.1	similar to coagulation factor XIII, A1 polypeptide	482	e-135
			AF418272 1 coagulation factor XIII, A1 polypeptide	482	e-135
		415.1	factor XIII a subunit	481	e-135
		1EVU	A Chain A, Human Factor Xiii With Calcium Bound In The Ion Site	481	481 e-135
		_	B Chain B, Human Factor Xiii With Calcium Bound In The Ion Site	481	481 e-135
		0120.1	coagulation factor XIII A1 subunit precursor; Coagulation factor XIII, A polypeptide; Tgase	481	e-135
	_	AAA52488.1	clotting factor XIIIa precursor (EC 2.3.2.13)	481	e-135
			F13A_HUMAN Coagulation factor XIII A chain precursor (Protein-glutamine gamma-glutamyltransferase A chain) (Transplutaminase A chain)	481	e-135
		EKHUX	protein-glutamine gamma-glutamyltransferase (EC 2.3.2.13), plasma	481	e-135
		1FIE	B Chain B, Recombinant Human Coagulation Factor Xiii	481 e-135	-135
			A Chain A, Recombinant Human Coagulation Factor Xiii	481 e-135	-135

AAA52489.1
AAH27963.1 coagulation factor XIII, A1 polypeptide
NP_002119.1 high-mobility group box 1; high mobility group box 1; high-mobility group (nonhistone chromosomal) protein 1
P09429 HMG1 HUMAN High mobility group protein 1 (HMG-1)
CAA31110.1 HMG-1 protein (AA 1-215)
AAB08987.1 on-histone chromatin protein HMG1
AAH30981.1 high-mobility group (nonhistone chromosomal) protein
_
_
_
_
AAH00903.2 AAH00903 high-mobility group (nonhistone chromosomal) protein 2
P26583 HWG2 HUMAN High mobility group protein 2 (HMG-2)
T
44395.1
AAA58659.1 high mobility group 2 protein
AAH01063.1 AAH01063 high-mobility group (nonhistone chromosomal) protein 2
1363A high mobility group protein 2
086648.2 similar to dJ579F20.1 (high-mobility group (nonhistone chromosomal) protein 1-like 1)
NP_005333.1 high-mobility group box 3; high-mobility group (nonhistone chromosomal) protein 4
O15347 HMG4_HUMAN High mobility group protein 4 (HMG-4) (High mobility group protein 2a) (HMG-2a)
CAA71143.1 high mobility group protein 2a

	370 e-102	358 4E-99	352 5E-97	340 1E-93	340 1E-93	340 1E-93	340 1E-93	340 1E-93			329 4E-90	329 4E-90	329 4E-90	329 4E-90	329 4E-90	329 4E-90	328 8E-90	324 1E-88	324 1E-88	372 e-103	-	372 e-103	372 e-103	372 e-103	372 e-103	372 e-103	370 e-102
		<u>س</u>	3	<u>۳</u>	F.	3	3		3	3	3	3	3	3	3	3	1	3	3	3		3	3,	3,	3,	3,	3,
132	CFAD_HUMAN Complement factor D precursor (C3 convertase activator) (Properdin factor D) (Adipsin)	adipsin/complement factor D precursor	complement factor D (EC 3.4.21.46) precursor [validated]	A Chain A, Proenzyme Of Human Complement Factor D, Recombinant Profactor D	B Chain B, Proenzyme Of Human Complement Factor D, Recombinant Profactor D	D Chain D, Proenzyme Of Human Complement Factor D, Recombinant Profactor D	C Chain C, Proenzyme Of Human Complement Factor D, Recombinant Profactor D	Unknown (protein for IMAGE:4780594)	Mutant Of Factor D With Enhanced Catalytic Activity	Human Complement Factor D In Complex With Isatoic Anhydride Inhibitor	A Chain A, Structure Of 3,4-Dichloroisocoumarin-Inhibited Factor D	A Chain A, Human Factor D, Complement Activating Enzyme	Human Complement Factor D In A P21 Crystal Form	A Chain A, Factor D Inhibited By Diisopropyl Fluorophosphate	B Chain B, Factor D Inhibited By Diisopropyl Fluorophosphate	B Chain B, Human Factor D, Complement Activating Enzyme	similar to Complement factor D precursor (C3 convertase activator) (Properdin factor D) (Adipsin)	adipsin/complement factor D precursor	adipsin/complement factor D	RTP801		unnamed protein product	hypothetical protein	hypothetical protein	RTP801	REDD-1	hypothetical protein
	P00746	CAC48304.1	DBHU	IFDP	IFDP	1FDP	IFDP	AAH34529.1	1DST	1BIO	1DIC	1DSU	1HFD	1DFP	1DFP	1DSU	XP_084037.1	NP 001919.1	AAA35527.1	NP_061931.1 RTP801		BAA91214.1	AAH07714.1	AAH15236.1	AAL38424.1	AAM10442.1	CAB66603.1
	F:(C-IR) -2.13																			F:(C-D) -	2.38						
	Mm.4407																			Mm.21697							
	NM_013459 NP_038487.1																			AK017926	BAB31006.1						

364 e-100		364 e-100	364 e-100	364 e-100	364 e-100	364 e-100	361 e-100	360 3E-99	359 4E-99	350 3E-96	317 e-136		317 e-136		313 e-135	313 e-135	1196 0	1196 0	1196 0	1196 0	1196 0	11960	1195 0	1195 0	1023 0
_				1	<u></u>	3	3	3		2	3		100	3	3		=	<u> </u>				Ē	Ē	115	10,
	SH2 protein 2	similar to Suppressor of cytokine signaling 2 (SOCS-2) (Cytokine-inducible SH2 protein 2) (CIS-2) (STAT induced STAT inhibitor 2) (SSI-2)	SOC2_HUMAN Suppressor of cytokine signaling 2 (SOCS-2) (Cytokine-inducible SH2 protein 2) (CIS-2) (STAT induced STAT inhibitor 2) (SSI-2)	STAT induced STAT inhibitor-2	STAT-induced STAT inhibitor-2	STAT induced STAT inhibitor-2	STAT induced STAT inhibitor 2	cytokine-inducible SH2 protein 2	CIS2	suppressor of cytokine signalling-2; HSSOCS-2	unknown		similar to SET domain and mariner transposase fusion gene	Similar to SET domain and mariner transposase fusion gene		orf; encodes putative chimeric protein with SET domain in N-terminus with similarity to several other human, Drosophila, nematode and yeast proteins		TFR1_HUMAN Transferrin receptor protein 1 (TfR1) (TfR) (TfR) (Trff) (CD71 antigen) (T9) (p90)	transferrin receptor	put. transferrin receptor (aa 1-760)	transferrin receptor	transferrin receptor	AF187320 1 transferrin receptor	AAH01188 transferrin receptor (p90, CD71)	C Chain C, Hemochromatosis Protein Hfe Complexed With Transferrin Receptor
NP_003868.1		XP_170547.1	014508	BAA22429.1	AAC34745.1	AAH10399.1	JC5626	JC5760	BAA22536.1	AAC98896.1	AAC09350.1		XP · 057054.6	AAH11635.1	NP 006506.1	AAC52012.1	NP_003225.1	P02786	JXHU	CAA25527.1	AAA61153.1	1011297A	AAF04564.1	AAH01188.1	1DE4
F:(C-D) - NP	2.03										F:(C-D) -	70.7													
Mm.4132											Mm.56539 F:(C-D) -						Mm.26069 F:(C-D) -								
902700_MN	NP 031732.1									П	AK017895	XP 132692.1					NM_011638 NP_035768.1								

11	1DE4	F Chain F, Hemochromatosis Protein Hfe Complexed With Transferrin Receptor	1023 0	0
11	1DE4	I Chain I, Hemochromatosis Protein Hfe Complexed With Transferrin Receptor	1023 0	0
10	1CX8	A Chain A, Crytal Structure Of The Ectodomain Of Human Transferrin Receptor	1020	0
10	CX8	B Chain B, Crytal Structure Of The Ectodomain Of Human Transferrin Receptor	1020 0	0
10	CX8	C Chain C, Crytal Structure Of The Ectodomain Of Human Transferrin Receptor	1020	0
10	2X8	D Chain D, Crytal Structure Of The Ectodomain Of Human Transferrin Receptor	1020 0	0
, 10	:X8	E Chain E, Crytal Structure Of The Ectodomain Of Human Transferrin Receptor	1020 0	0
10	CX8	F Chain F, Crytal Structure Of The Ectodomain Of Human Transferrin Receptor	1020 0	0
10	CX8	G Chain G, Crytal Structure Of The Ectodomain Of Human Transferrin Receptor	1020	
01	1CX8	H Chain H, Crytal Structure Of The Ectodomain Of Human Transferrin Receptor	1020 0	0
8	9UP52	TFR2_HUMAN Transferrin receptor protein 2 (TfR2)	545	545 e-154
A	AD45561.1	AF067864 1 transferrin receptor 2 alpha	545	545 e-154
Ŋ	P 003218.1	003218.1 transferrin receptor 2	498	e-140
AA		transferrin-receptor2	498	498 e-140
BA		unnamed protein product	315	315 2E-85
AA		prostate-specific membrane antigen	228	228 2E-59
ďΝ	P_004467.1	folate hydrolase (prostate-specific membrane antigen) 1; folate hydrolase 1 (prostate-specific membrane antigen)	228	228 3E-59
00	Q04609	FOH1_HUMAN Glutamate carboxypeptidase II (Membrane glutamate	228	228 3E-59
		carboxypeptidase) (mGCP) (N-acetylated-alpha-linked acidic dipeptidase I) (NAALADase I) (Pteroylpoly-gamma-glutamate carboxypeptidase) (Folylpoly-gamma-		
		glutamate carboxypeptidase) (FGCP) (Folate hydrolase 1) (Prostate-specific membrane antigen) (PSMA) (PSM)		
A5	A56881	prostate-specific membrane antigen	228	228 3E-59
AAA		prostate- specific membrane antigen	228	228 3E-59
AA	AAD51121.1	AF176574 1 folylpoly-gamma-glutamate carboxypeptidase	228	228 3E-59
AA		prostate-specific membrane antigen	228	228 3E-59
XP_1	65392.1	similar to folate hydrolase (prostate-specific membrane antigen) 1; folate hydrolase 1	224	224 6E-58
		(prostate-specific membrane antigen)		

	0	0	0	178	178	177	169	164	153	153	126	-63	0	0	0
(free gra	835	786	745	623 e-178	623 e-178	619 e-177	594 e-169	575 e-164	541 e-153	541 e-153	450 e-126	340 5e-93	765	759	753
diffeentelly existes society exidetion of less mentivy fold toop mentive to the second of the figure of the base use. In the society of the second of the se	60kDa BRG-1/Brm associated factor subunit c isoform 2	SWI/SNF-related matrix-associated actin-dependent regulator of chromatin d3; Rsc6p; mammalian chromatin remodeling complex BRG1-associated factor 60C; Swp73-like protein; chromatin remodeling complex BAF60C subunit; SWI/SNF complex 60 kDa subunit C	SWI/SNF¹complex 60 KDa subunit	SWI/SNF-related matrix-associated actin-dependent regulator of chromatin d1 isoform a; Rsc6p; mammalian chromatin remodeling complex BRG1-associated factor 60A; chromatin remodeling complex BAF60A subunit; Swp73-like protein; SWI/SNF complex 60 kDa subunit A	SMARCD1 protein	SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin D1	SWI/SNF-related matrix-associated actin-dependent regulator ofchromatin d2; Rsc6p; mammalian chromatin remodeling complex BRG1-associated factor 60B; Swp73-like protein; chromatin remodeling complex BAF60B subunit; SWI/SNF complex 60 kDa subunit B	SWI/SNF complex 60 KDa subunit	SWI/SNF-related matrix-associated actin-dependent regulator of chromatin d1 isoform b; Rsc6p; mammalian chromatin remodeling complex BRG1-associated factor 60A; chromatin remodeling complex BAF60A subunit; Swp73-like protein; SWI/SNF complex 60 kDa subunit A	SWI/SNF complex 60 KDa subunit		unknown	alpha 1 actin precursor; alpha skeletal muscle actin	cardiac muscle alpha actin proprotein; smooth muscle actin	alpha 2 actin; alpha-cardiac actin
araj izworzilany Skrajnia dreny) AAR88510.1	NP_003069.2	AAC50697.1	NP_003067.2	AAH09368.2	AAD23390.1	NP_003068.2	AAC50696.1	NP_620710.1	AAC50695.1	AAS02031.1	AAS00380.1	말 :		NP_001604.1
	F:(C-D)											F:(C-D)	-1.69		
Move (International												_	4950 -		
iontrol intessing	Mm.2.												Mm.214950 -1.69		
Sells role 11/A e The mouse ge mine bees of a	NP_080167.2 Mm.279751											M12866	AAA37164.1		_

748 0			721 0	721 0	720 0	718 0	716 0	715 0	701	0 669	0 989	0 0/9	0 699	0 899	0 999	0 999	0 09	571 e-162	504 e-142	443 e-124	430 e-120	430 6-120		423 e-118	421 e-117	
	domin, gamma z propeptide, acim, alpita-3	actin, gamma 1 propeptide; actin, cytoplasmic 2; deafness, autosomal dominant 26: deafness, autosomal dominant 20: extendibled common actions	co, cominoso, autocoma dominam co, cytoskeletal gamma-actin	gamma-actin - human	beta actin; beta cytoskeletal actin	Beta actin	mutant beta-actin (beta'-actin)	actin, beta	vtein for IMAGE:3538275)		DNA 4732495G21 gene	•	PKSG30			similar to pote protein; Expressed in prostate, ovary, testis, and placenta		ed pseudogene	ACTG1 protein	gamma-actin		ARP1 actin-related protein 1 homolog B, centractin beta; centractin beta; ARP1 (actin-related protein 1, yeast) homolog B (centractin beta); PC3; ARP1, yeast homolog B	I (actin-related actin-RPV;		actin-related protein	
1.000 100 IN	l	NP 001605.1	105040	81800	NP_001092.1	AAH16045.1	CAA45026.1	AAH08633.1	AAH17450.1	AAH12854.1	XP_293924.1	XP_3/1558.2	XP_065237.5	AAG50355.1	XP_372957.1	XP_292982.4	AAA51586.1	0902248A	AAH23548.1	AAA51580.1	AAH06372.1	NP_005726.1		NP_005727.1	1818358A	

	137	
ARM1_HUMA N	A Actin related protein M1	389 e-108
NP_115876.2	2 actin related protein M1	385 e-106
AAH07289.1	Actin related protein M1	384 e-106
CAA57692.1	beta-centractin	380 e-105
NP_612146.1	1 actin-related protein T1	366 e-101
AAM00432.1 NP_536356.3	actin-related protein T1 3 actin-related protein M2; actin-related protein hArpM2; actin-related protein T2	366 e-101 363 e-100
AAP20055.1	HSD27	362 e-100
BAB85862.1	actin-related protein hArpM2	362 1e-99
NP_005713.	l actin-related protein 2; ARP2 (actin-related protein 2, yeast) homolog	361 2e-99
AAH29499.1		359 6e-99
AAH14546.1	Actin-related protein 2	358 2e-98
AAP37280.1	actin alpha 1 skeletal muscle protein	332 7e-91
XP_208204.1	similar to actin-related protein 2	331 2e-90
XP_377904.1		
AAH36253.1	ACTR2 protein	
AAH10417.2	ACTG1 protein	
NP_006678.1	actin-like 7A; actin-like 7-alpha	
NP_006677.1	actin-like 7B; actin-like 7-beta	310 3e-84
AAH09544.1	Unknown (protein for IMAGE:3897065)	310 5e-84
NP_848620.1		300 3e-81
AAP20052.1	HSD21'.	
XP_377631.1	similar to beta actin	299 9e-81
<u>(</u>) !
-1.33 NP_U01604.1		765 0
ATHUSM	actin alpha 2, aortic smooth muscle	762 0

	0 99/	754 0	753 0					0 002			707			67.1						575 e-163	506 e-143	445 6-124	434 0-120	2	429 e-120	422 6 410	421 6-117	1 2 2	387 e-107
in all series of the series of	de de de la compara de la propriorent, smooth muscre actin	actin, gamma 2 propeptide; actin, alpha-3	alpha 1 actin precursor; alpha skeletal muscle actin	actin, gamma 1 propeptide; actin, cytoplasmic 2; deafness, autosomal dominant 26; deafness, autosomal dominant 20.	compositive control continued to the control of the	beta actin: beta cytoskeletal actin	Beta actin	mutant beta-actin (beta'-actin)	actin, beta	ACTB protein	Unknown (protein for IMAGE:3538275)	similar to RIKEN cDNA 4732495G21 gene	similar to FKSG30	similar to FKSG30	FKSG30	similar to pote protein; Expressed in prostate, ovary, testis, and placenta	similar to FKSG30	actin prepeptide		actin beta related pseudogene	ACTG1 protein	gamma-actin	ARP1 actin-related protein 1 homolog B. centractin beta	ARP1 actin-related protein 1 homolog B, centractin beta; centractin beta; ARP1 (actin-related protein 1, yeast) homolog B (centractin beta); PC3; ARP1, yeast	homolog B	ARP1 actin-related protein 1 homolog A, centractin alpha; ARP1 (actin-related protein 1, yeast) homolog A (centractin alpha); centractin alpha; actin-RPV; centrosome-associated actin homolog: ARP1 veast homolog.	actin-related protein		Actin related protein M1
NP 005150 1	NI 004000 1	NP_001606.1	NP_001091.1	NP 001605.1	.IC5818	NP 001092.1	AAH16045.1	CAA45026.1	AAH08633.1	AAH12854.1	AAH17450.1	XP_293924.1	XP_371558.2	XP_065237.5	AAG50355.1	XP_292982.4	XP_372957.1	AAA51586.1	0902248A		AAH23548.1	AAA51580.1	AAH06372.1		NP_005726.1	NP 005727.1	1818358A	ARM1_HUMA	z

382 e-105 382 e-105 380 e-105 369 e-102 369 e-102	369 e-102 367 e-101	365 e-100 356 6e-98	5e-97 2e-89	7e-89	2e-88	86-88 86-88	1e-86	9e-86	2e-84	6e-82	8e-82	2e-81		-	_	0	_	0	-0		0
382 382 380 360 360	369	365	353 328	326	325	323	318	316	311	303	303	301	168	5	144	0	141	0	140 7	134	œ
	 actin-related protein M2; actin-related protein hArpM2; actin-related protein T2 actin-related protein hArpM2 HSD27 	Actin-related protein M2 actin-related protein 2, yeast) homolog			similar to cytopiasmic beta-actin actin albha 1 skeletal muscle protein	-	ACTR2 protein	actin-like 7B; actin-like 7-beta	Unknown (protein for IMAGE:3897065)	unnamed protein product	actin-like	HSD21		skeletal Itiuscie specific actinin, aipna 3	c - Jahr	acuilli, aipila z		Journas, Francisco, Fr	alpha-actinin 1 - human		004915.2 actinin, alpha 4
NP_115876.2 AAH07289.1 CAA57692.1 NP_612146.1 AAM00432.1	NP_536356.3 BAB85862.1 AAP20055.1	AAH29499.1 NP_005713.1 AAH14546.1	NP_006678.1	XP_208204.1 XP_272064.4	AP37280.1	AAH10417.2	AAH36253.1	NP_006677.1	AAH09544.1	BAB/1690.1	NP_848620.1	AAP20052.1	F:(C-D)	ا کا	ND 004004 4	14E0100-14:1	A 0004000 GIA		FAHUAA		NP_004915.2
												042456	NP 038484 1 Mm 5316								

BAA2447.1 alpha actinin 4	4	134	0
alpha actinin ACTN4 protein	· · ·	125 5 924	0
alpha-actinin		668	-
unnamed protein product	tein product	869	0
Chain A, Cryst	Chain A, Crystal Structure Of The Rod Domain Of Alpha-Actinin	753	0
Chain B, Crystal Structur similar to actinin, alpha 4	Chain B, Crystal Structure Of The Rod Domain Of Alpha-Actinin similar to actinin, alpha 4	753 0	0 (
spectrin, beta, (beta-fodrin).	spectrin, beta, non-erythrocytic 1 isoform 2; Spectrin, beta, nonerythrocytic-1 (beta-fodrin)	437 6-140	ξ <u>4</u>
spectrin, beta, (beta-fodrin)	spectrin, beta, non-erythrocytic 1 isoform 1; Spectrin, beta,nonerythrocytic-1 (beta-fodrin)	426 e-118	- 4
NP_008877.1 spectrin, beta,	spectrin, beta, non-enythrocytic 2	415 e-115	115
spectrin Rouen	spectrin Rouen (beta-220-218) mutant coding sequence	405 e-112	112
spectrin, beta, e erythrocytic; sp	spectrin, beta, erythrocytic (includes spherocytosis, clinical type I); Spectrin, beta, erythrocytic; spectrin, beta, erythrocytic (includes sperocytosis, clinical type I)	405 e-112	112
Spectrin beta c	Spectrin beta chain, erythrocyte (Beta-I spectrin)	405 e-112	112
beta spectrin IV	>	399 e-110	110
spectrin beta IV	>	399 e-110	10
spectrin, beta, r Spectrin beta cl	NP_066022.1 spectrin, beta, non-erythrocytic 4 SPCQ_HUMA_Spectrin beta chain, brain 3 (Spectrin, non-erythroid beta chain 3)(Beta-IV	399 e-110	10
spectrin)		399 e-110	9
spectrin, beta, r	spectrin, beta, non-erythrocytic 4	396 e-110	10
betalV spectrin	betalV spectrin isoform sigma2	396 e-110	10

AAF93173.1	betalV spectrin isoform sigma4	394 e-109
1QUU A	Chain A, Crystal Structure Of Two Central Spectrin-Like Repeats From Alpha-Actinin	379 e-104
NP_057726.1	spectrin, beta, non-enythrocytic 5; beta V spectrin	344 5e-94
AAB41498.1	alpha II spectrin	264 7e-70
AAH53521.1	SPTAN1 protein	264 7e-70
NP_003118.1	spectrin, alpha, non-erythrocytic 1 (alpha-fodrin)	259 2e-68
NP 000436.2	plectin 1 isoform 1; hemidesmosomal protein 1; epidermolysis bullosa simplex 1 (Oana)	245 30.64
G02520		245 3e-64
NP_958782.1	plectin 1 isoform 6; hemidesmosomal protein 1; epidermolysis bullosa simplex 1 (Ogna)	245 3e-64
NP_958785.1	plectin 1 isoform 10; hemidesmosomal protein 1; epidermolysis bullosa simplex 1 (Ogna)	245 3e-64
NP_958784.1	plectin 1 isoform 8; hemidesmosomal protein 1; epidermolysis bullosa simplex 1 (Ogna)	245 3e-64
NP_958786.1	plectin 1 isoform 11; hemidesmosomal protein 1; epidermolysis bullosa simplex 1 (Ogna)	245 3e-64
NP_958781.1	plectin 1 isoform 3; hemidesmosomal protein 1; epidermolysis bullosa simplex 1 (Ogna)	245 3e-64
NP_958780.1	plectin 1 isoform 2; hemidesmosomal protein 1; epidermolysis bullosa simplex 1 (Ogna)	245 3e-64
NP_958783.1	plectin 1 isoform 7; hemidesmosomal protein 1; epidermolysis bullosa simplex 1 (Ogna)	245 3e-64
PLE1_HUMA N	Plectin 1 (PLTN) (PCN) (Hemidesmosomal protein 1) (HD1)	241 4e-63
139160	dystonin isoform 1 - human (fragment)	231 4e-60
BPA1_HUMA N		231 4e-60
NP_899236.1	bullous pemphigoid antigen 1 isoform 1; bullous pemphigoid antigen 1 (230/240kD); dystonin; hemidesmosomal plaque protein	231 4e-60
MACF_HUMA P	Microtubule-actin crosslinking factor 1, isoforms 1/2/3 (Actin cross-linking family protein 7) (Macrophin 1) (Trabeculin-alpha) (620 kDa actin-binding protein)	224 8e-58

224 8e-58	 8e-58	2e-57	3e-55	7e-54	1e-51		8e-79	1e-76	211 4e-54	5e-54		0		0		0		0	0	220 1e-56	326 5e-89	322 1e-87		0		0	
224	224	223	215	211	203		293	285	211	210	121	က	121	0	120	വ	112	2	975	220	326	322	130	7	130	വ	127
actin binding protein ABP620	cross-linking family protein 7	trabeculin-alpha	actin-crosslinking protein ACF7 - human (fragment)	Chain A, Crystal Structure Of The Actin Binding Domain Of Plectin	alpha-spectrin		actin related protein 2/3 complex subunit 5; Arp2/3 protein complex subunit p16	ARPC5 protein		actin related protein 2/3 complex, subunit 5-like			SWI/SNF-related matrix-associated actin-dependent regulator of chromatin a-like	-		HepA-related protein HARP		hypothetical protein DKFZp434B1050.1 - human (fragment)	unnamed protein product	unnamed protein product	actin related protein 2/3 complex subunit 4; Arp2/3 protein complex subunit p20	ARPC4 protein	actin-binding LIM protein 1 isoform a; LIM actin-binding protein 1; limatin;	actin-binding LIM protein		actin-binding double-zinc-finger protein	KIAA0059
BAA83821.1	NP_U36222.3	AAF06360.1	S66292	1MB8_A	CAA60503.1	9	NP_005708.1	AAH57237.1	AAP97155.1	NP_112240.1		NP_054859.2		AAH16482.1		AAF 24984.1	1	134557	BAA90955.1	BAC04536.1	NP_005709.1	AAH12596.2		NP_002304.2	A AC 54676 4	AAC31076.1	BAA06681.2
						F:(C-D)	38.				F:(C-D)	1.37									(C-D)		<u></u>				
							39/4 -				<u>د </u> ا	232 -						•			306 -1		ш ;	 618 			
						NM_026369 F:(C-	VIM.282				į	NP_061287.1 Mm.274232 -1.37									NM_026552 F:(C-D) NP_080828.1 Mm.289306 -1.35			NP_848803.2 Mm.244618 -1.35			
						369	40. -				17	87.1 N									52 28.1 N		_	03.2 N			
						NM_026369	7,0806				NM_018817	-0612									A_0265 '_0808;		AF316037	_8488_ _			
						ΣZ	Z				₹ 2) Z									M N P N		AF31	5 7			

		111	756	651			Ψ	യ	ф	ď	e-1				4	1-6						3- 17	7.	7	7	17
				Ö	651	518 e-146	508 e-143	506 e-143	501 e-141	433 e-121	401 e-111	χ.	2 5	2 5	561 e-160	430 e-120	755	753	3	709	708	616 e-176	425 e-118	425 e-118	425 e-118	424 e-118
*	143		actin-binding LIM protein 1 isotorm s; LIM actin-binding protein 1; limatin; 2 actin-binding LIM protein	KIAA0843 protein	1 actin binding LIM protein family, member 3			-	unnamed protein product	ABLIM1 protein	ABLIM3 protein	I uncharacterized hypothalamus protein HARP11		unnamed protein product	unnamed protein product	unnamed protein product	ARP1 actin-related protein 1 homolog A, centractin alpha; ARP1 (actin-related protein 1, yeast) homolog A (centractin alpha); centractin alpha; actin-RPV; centrosome-associated actin homolog; ARP1, yeast homolog	actin-related protein			ARP1 actin-related protein 1 homolog B, centractin beta	beta-centractin	actin, gamma 1 propeptide; actin, cytoplasmic 2; deafness, autosomal dominant 26; deafness, autosomal dominant 20;		cardiac muscle alpha actin proprotein; smooth muscle actin	beta actin; beta cytoskeletal actin
		NP_006710.2	NP_006711.2	BAA74866.2	NP_055760.1	AAH67214.1	BAB47437.1	NP_115808.2	BAC04414.1	AAH02448.1	AAH01665.1	NP_060947.1	BAA91243.1	BAB14083.1	CAD62610.1	CAD61940.1	NP_005727.1	1818358A		NP_005/26.1	AAH06372.1	CAA57692.1	NP_001605.1	JC5818	NP_005150.1	NP_001092.1
												F:(C-D) -1.32					F:(C-D) -1.31									
			×.									Mm.29317					Mm.3118									
	_											NM_019785 NP_062759.1 Mm.29317					NM_016860 NP_058556.1 Mm.3118							•		

-	<u>∞</u>	8	8		_	_		9	4	က			- 2	~	-2			<u></u>			2	,	2	က	က	~		-	<u></u>	6
	424 e-118	424 e-118	423 e-118	423 e-118	422 e-117	422 e-117	422 e-117	417 e-116	410 e-114	408 e-113	408 e-113	408 e-113	404 e-112	404 e-112	404 e-112	355 2e-97		330 6e-90	322 2e-87	318 2e-86	6e-85		314 6e-85	309 1e-83	2e-83	308 2e-83	7e-8	6e-80	1e-7	4e-7
	424	424	423	423	422	422	422	417	410	408	408	408	404	404	404	355		330	322	318	314	•	314	309	309	308	307 7e-83	297	296 1e-79	295 4e-79
	-	.1 Beta actin	.1 mutant beta-actin (beta'-actin)	1.1 alpha 1 actin precursor; alpha skeletal muscle actin			actin alpha 2, aortic smooth muscle	1.1 similar to RIKEN cDNA 4732495G21 gene	.1 Unknown (protein for IMAGE:3538275)	.1 ACTB protein	.1 FKSG30	7.5 similar to FKSG30	3.2 similar to FKSG30	2.4 similar to pote protein; Expressed in prostate, ovary, testis, and placenta		1 actin prepeptide		actin beta related pseudogene	1.1 actin-related protein 2; ARP2 (actin-related protein 2, yeast) homolog		.2 actin related protein M1		Actin related protein M1	.3 actin-related protein M2; actin-related protein hArpM2; actin-related protein T2		1 actin-related protein hArpM2	1 Actin-related protein M2	1 ACTG1 protein	.1 similar to actin-related protein 2	.1 actin-related protein T1
A A LICERS 4	CCOOOLLAN	AAH16045.1	CAA45026.1	NP_001091.1	NP_001604.1	NP_001606.1	ATHUSM	XP_293924.1	AAH17450.1	AAH12854.1	AAG50355.1	XP_065237.5	XP_371558.2	XP_292982.4	XP_372957.1	AAA51586.1	0902248A		NP_005713.1	AAH14546.1	NP_115876.2	ARM1_HUMA	z	NP_536356.3	AAH07289.1	BAB85862.1	AAH29499.1	AAH23548.1	XP_208204.1	NP_612146.1

	AAM00432.1	actin-related protein T1	295 4e-79
	AAP20055.1	HSD27	291 4e-78
	AAH36253.1	ACTR2 protein	287 8e-77
	NP_006678.1	actin-like 7A; actin-like 7-alpha	267 6e-71
	NP_006677.1	actin-like 7B; actin-like 7-beta	260 16-68
	AAA51580.1	gamma-actin	253 9e-67
	BAB71690.1	unnamed protein product	248 4e-65
	NP_848620.1	actin-like	247 7e-65
	AAP20052.1	HSD21	246 2e-64
	NP_065178.1	actin-related protein 3-beta; actin-related protein 3-beta; actin-related protein Arp11; actin-related protein Arp11	235 3e-61
	NP_005712.1	ARP3 actin-related protein 3 homolog; ARP3 (actin-related protein 3, yeast) homolog	235 3e-61
	NP_057272.1	BAF53b; actin-related protein; hArpN alpha	213 16-54
	CAB66543.1	hypothetical protein	203 1e-51
NM_020618 F:(C-D) NP_065643.1 Mm.27330 -1.30	-D) NP_003070.3	SWI/SNF-related matrix-associated actin-dependent regulator of chromatin e1; mammalian chromatin remodeling complex BRG1-associated factor 57	597 e-170
	AAH07082.1	SWI/SNF-related matrix-associated actin-dependent regulator of chromatin e1	594 e-169
F:(C-D) Mm.320560 -1.30	-D) T47172	hypothetical protein DKFZp762H186.1 - human (fragment)	954
	NP_055140.1	coronin, actin binding protein, 1C; coronin, actin-binding protein, 1C; coronin 1C	946 0
	NP_065174.1	coronin, actin binding protein, 1B	758 0
	NP 009005 1	coronin, actin binding protein, 1A; coronin, actin-binding, 1A; coronin, actin-binding protein 1A; coronin-1	9
	AAA77058.1	coronin-like protein	644 0
	BAA76769.1	KIAA0925 protein	e-11⁄
	NP_006082.1	coronin, actin binding protein, 2B; clipin C; coronin, actin-binding, 2B; coronin, actin-binding protein, 2B	411 e-114
	CO2B_HUMA N	Coronin 2B (Coronin-like protein C) (ClininC) (Protein FC96)	400 0 113
			403 6-110

408 e-113 408 e-113	404 e-112 389 e-107	314 7e-85 311 5e-84	311 6e-84 234 6e-61	171 2 0	141	139 4 0	139	136	136	126 5 0	941 0	891 0	891 0	0 288	835 0	524 e-148
coronin, actin binding protein, 2A; coronin, actin-binding protein, 2A; coronin 2A; 1 coronin-like protein B; WD-repeat protein 2; WD protein IR10 coronin, actin binding protein, 2A; coronin, actin-binding protein, 2A; coronin 2A; 2 coronin-like protein B; WD-repeat protein2; WD protein IR10		unknown 1 hypothetical protein FLJ14871	Unknown 1 hypothetical protein FLJ22021	j actinin, alpha 2	1 skeletal muscle specific actinin, alpha 3	_001093.1 actinin, alpha 1	alpha-actinin 1 - human	2 actinin, alpha 4	alpha actinin 4	alpha actinin .	ACTN4 protein	Chain A, Crystal Structure Of The Rod Domain Of Alpha-Actinin	Chain B, Crystal Structure Of The Rod Domain Of Alpha-Actinin	alpha-actinin	unnamed protein product	similar to actinin, alpha 4
NP_438171.1 NP_003380.2	AAB47807.1 T47174	AAS48630.1 NP_116243.1	AAQ04659.1 NP_078811.1	NP_001094.1	NP_001095.1	NP_001093.1	FAHUAA	NP_004915.2	BAA2447.1	AAC17470.1	AAH15620.2	HCI_A	1HCI_B	CAA38970.1	CAD62344.1	XP_293669.4
				NP_150371.2 Mm.195067 -1.29				_								_

NP_008877.1 spectrin, beta, non-erythrocytic 2 spectrin, beta, non-erythrocytic 1 isoform 2; Spectrin, beta, nonerythrocytic 2 spectrin, beta, non-erythrocytic 1 isoform 1; Spectrin, beta, nonerythrocytic-1 NP_003119.1 (beta-fodrin) spectrin, beta, non-erythrocytic (includes sperocytosis, clinical type 1) spectrin, beta, erythrocytic (includes sperocytosis, clinical type 1) SPCB_HUMA NP_000338.2 erythrocytic; spectrin, beta, erythrocytic (includes sperocytosis, clinical type 1) SPCB_HUMA NP_06022.1 spectrin Rouen (beta-220-218) mutant coding sequence AAG42473.1 spectrin beta chain, brain 3 (Spectrin, non-erythroid beta chain 3)(Beta-IV spectrin) AAQ14859.1 beta spectrin IV NP_065022.1 spectrin, beta, non-erythrocytic 4 AAF93171.1 betaIV spectrin isoform sigma2 AAF93173.1 betaIV spectrin isoform sigma4 NP_057726.1 spectrin, beta, non-erythrocytic 5; beta V spectrin AAB4198.1 alpha II spectrin AAB4198.1 spectrin, alpha II spectrin AAB4198.1 spectrin, alpha II spectrin AAB4198.1 spectrin, alpha II spectrin	Chain A, Crystal Structure Of Two Central Spectrin-Like Repeats From Alpha-Actinin	455 e-127
	7	412 e-114
		408 e-113
	·	407 e-113
SPCB_HUMA N Spectrin beta chain, erythrocyte (Beta-I spectrin) AAA60578.1 spectrin Rouen (beta-220-218) mutant coding sequence AAG42473.1 spectrin beta IV NP_066022.1 spectrin, beta, non-erythrocytic 4 SPCQ_HUMA Spectrin beta chain, brain 3 (Spectrin, non-erythroid beta chain) AAQ14859.1 beta spectrin IV NP_079489.1 spectrin, beta, non-erythrocytic 4 AAF93173.1 betaIV spectrin isoform sigma2 AAF93173.1 betaIV spectrin isoform sigma4 NP_057726.1 spectrin, beta, non-erythrocytic 5; beta V spectrin AAB41498.1 alpha II spectrin AAH53521.1 SPTAN1 protein NP_003118.1 spectrin, alpha, non-erythrocytic 1 (alpha-fodrin)	eta,	391 e-108
AAA60578.1 spectrin Rouen (beta-220-218) mutant coding sequence AAG42473.1 spectrin beta IV NP_066022.1 spectrin, beta, non-erythrocytic 4 SPCQ_HUMA Spectrin beta chain, brain 3 (Spectrin, non-erythroid beta chain) AAQ14859.1 beta spectrin IV NP_079489.1 spectrin, beta, non-erythrocytic 4 AAF93171.1 betaIV spectrin isoform sigma2 AAF93173.1 betaIV spectrin isoform sigma4 NP_057726.1 spectrin, beta, non-erythrocytic 5; beta V spectrin AAB41498.1 alpha II spectrin AAH53521.1 SPTAN1 protein NP_003118.1 spectrin, alpha, non-erythrocytic 1 (alpha-fodrin)		391 e-108
AAG42473.1 spectrin beta IV NP_066022.1 spectrin, beta, non-erythrocytic 4 SPCQ_HUMA Spectrin beta chain, brain 3 (Spectrin, non-erythroid beta chain) AAQ14859.1 beta spectrin IV NP_079489.1 spectrin, beta, non-erythrocytic 4 AAF93171.1 betaIV spectrin isoform sigma2 AAF93173.1 betaIV spectrin isoform sigma4 NP_057726.1 spectrin, beta, non-erythrocytic 5; beta V spectrin AAB41498.1 alpha II spectrin AAH53521.1 SPTAN1 protein NP_003118.1 spectrin, alpha, non-erythrocytic 1 (alpha-fodrin)		391 e-108
NP_066022.1 spectrin, beta, non-erythrocytic 4 SPCQ_HUMA Spectrin beta chain, brain 3 (Spectrin, non-erythroid beta chain) NP_079489.1 spectrin IV AAC14859.1 beta spectrin isoform sigma2 AAF93171.1 betaIV spectrin isoform sigma4 AAF93173.1 betaIV spectrin isoform sigma4 NP_057726.1 spectrin, beta, non-erythrocytic 5; beta V spectrin AAB41498.1 alpha II spectrin AAH53521.1 SPTAN1 protein NP_003118.1 spectrin, alpha, non-erythrocytic 1 (alpha-fodrin)		381 e-105
AAQ14859 1 beta spectrin IV NP_079489.1 spectrin, beta, non-erythrocytic 4 AAF93171.1 betaIV spectrin isoform sigma2 AAF93173.1 betaIV spectrin isoform sigma4 NP_057726.1 spectrin, beta, non-erythrocytic 5; beta V spectrin AAB41498.1 alpha II spectrin AAH53521.1 SPTAN1 protein NP_003118.1 spectrin, alpha, non-erythrocytic 1 (alpha-fodrin)		381 e-105
		381 e-105
	8	381 e-105
	8	375 e-103
	3	375 e-103
		373 e-103
		322 2e-87
		284 5e-76
		284 5e-76
		279 2e-74
CAA60503.1 alpha-spectrin	2	231 5e-60

224 6e-58	224 8e-58	223 1e-57	223 1e-57	223 1e-57	223 1e-57	223 1e-57	223 1e-57	223 1e-57	222 2e-57	222 20-57	20 000	25.0 le-30	219 2e-56		213 1e-54	213 1e-54	213 1e-54	211 7e-54
plectin 1 isoform 2; hemidesmosomal protein 1; epidermolysis bullosa simplex 1 (Ogna)	plectin 1 isoform 8; hemidesmosomal protein 1; epidermolysis bullosa simplex 1 (Ogna)	plectin 1 isoform 11; hemidesmosomal protein 1; epidermolysis bullosa simplex 1 (Ogna)	plectin 1 isoform 6; hemidesmosomal protein 1; epidermolysis bullosa simplex 1 (Ogna)	plectin 1 isoform 10; hemidesmosomal protein 1; epidermolysis bullosa simplex 1 (Ogna)	plectin 1 isoform 7; hemidesmosomal protein 1; epidermolysis bullosa simplex 1 (Ogna)	plectin 1 isoform 1; hemidesmosomal protein 1; epidermolysis bullosa simplex 1 (Ogna)	plectin - human	plectin 1 isoform 3; hemidesmosomal protein 1; epidermolysis bullosa simplex 1 (Ogna)	bullous pemphigoid antigen 1 isoform 1; bullous pemphigoid antigen 1 (230/240kD); dystonin; hemidesmosomal plaque protein	dystonin isoform 1 - human (fragment)	Plectin 1 (PLTN) (PCN) (Hemidesmosomal profein 1) (HD4)	Bullous pemphigoid antigen 1 isoforms 1/2/3/4/5/8 (230 kDa bullous pemphigoid	antigen) (BPA) (Hemidesmosomal plaque protein) (Dystonia musculorum protein)		(ABPOZU)	actin binding protein ABP620	microfilament and actin filament cross-linker protein isoform a; 620 kDa actin binding protein; actin cross-linking factor; macrophin 1; trabeculin-alpha; actin cross-linking family protein 7	trabeculin-alpha
NP_958780.1	NP_958784.1	NP_958786.1	NP_958782.1	NP_958785.1	NP_958783.1	NP_000436.2	G02520	NP_958781.1	NP_899236.1	139160	PLE1_HUMA N	BPA1_HUMA	z	MACF_HUMA	2	BAA83821.1	NP_036222.3	AAF06360.1

210 16-53	209 2e-53	850 0		667	e-17(348 3e-95	344 4e-94	253 8e-67	252 2e-66	249 2e-65	248 3e-65	248 3e-65		248 4e-65	248 4e-65	248 5e-65	247 6e-65	247 8e-65	247 8e-65	246 1e-64	246 1e-64	246 2e-64	245 3e-64	239 2e-62	236 1e-61
A Spectrin alpha chain, erythrocyte (Erythroid alpha-spectrin)	actin-crosslinking protein ACF7 - human (fragment)	ARP3 actin-related protein 3 homolog; ARP3 (actin-related protein 3, yeast) 1 homolog	actin-related protein 3-beta; actin-related protein 3-beta; actin-related protein		ARP3BETA protein	1 similar to actin-related protein Arp11	actin-related protein Arp11 - human	FKSG74	FKSG72	FKSG73	Beta actin	l beta actin; beta cytoskeletal actin		-	gamma-actin - human	l alpha 1 actin precursor; alpha skeletal muscle actin	mutant beta-actin (beta'-actin)	actin, beta	cardiac muscle alpha actin proprotein; smooth muscle actin	similar to RIKEN cDNA 4732495G21 gene	actin alpha 2, aortic smooth muscle - human	alpha 2 actin; alpha-cardiac actin	actin, gamma 2 propeptide; actin, alpha-3	nknown (protein for IMAGE:3538275)	ARP1 actin-related protein 1 homolog B, centractin beta; centractin beta; ARP1 (actin-related protein 1, yeast) homolog B (centractin beta); PC3; ARP1, yeast homolog B
SPCA_HUMA N	S66292	F:(C-D) Mm.183102 -1.23 NP_005712.1	NP 065178.1	AAP97150.1	AAH15207.1	XP_374583.1	JC7580	AAK31778.1	AAK31776.1	AAK31777.1	AAH16045.1	NP_001092.1	ND 001605 1	1,500,000;	JC5818	NP_001091.1	CAA45026.1	AAH08633.1	NP_005150.1	XP_293924.1	ATHUSM	NP_001604.1	NP_001606.1	AAH17450.1	NP_005726.1
		AA118546 NP_076224																							

236 2e-61	235 3e-61	234 4e-61	234 4e-61	223 1e-57	223 1e-57	223 1e-57	223 1e-57	223 2e-57	211 5e-54	211 6e-54	203 1e-51	203 16-51		828 0	745 0		622 e-178	619 e-177	596 e-170	589 e-168
ACTB protein	ARP1 actin-related protein 1 homolog A, centractin alpha; ARP1 (actin-related protein 1, yeast) homolog A (centractin alpha); centractin alpha; actin-RPV; centrosome-associated actin homolog; ARP1, yeast homolog A	actin-related protein	ARP1 actin-related protein 1 homolog B, centractin beta		similar to FKSG30	FKSG30	similar to pote protein; Expressed in prostate, ovary, testis, and placenta		actin prepeptide	beta-centractin	Actin-related protein 2	actin-related protein 2; ARP2 (actin-related protein 2, yeast) homolog	SWI/SNF-related matrix-associated actin-dependent regulator of chromatin d2; Rsc6p; mammalian chromatin remodeling complex BRG1-associated factor 60B; Swp73-like protein; chromatin remodeling complex BAF60B subunit; SWI/SNF	complex 60 kDa subunit B	SWI/SNF complex 60 KDa subunit	SWI/SNF-related matrix-associated actin-dependent regulator of chromatin d3; Rsc6p; mammalian chromatin remodeling complex BRG1-associated factor 60C; Swp73-like protein; chromatin remodeling complex BAF60C subunit; SWI/SNF	complex 60 kDa subunit C	60kDa BRG-1/Brm associated factor subunit c isoform 2	SWI/SNF complex 60 KDa subunit	SMARCD1 protein
AAH12854.1	NP_005727.1	1818358A	AAH06372.1	XP_372957.1	XP_065237.5	AAG50355.1	XP_292982.4	XP_371558.2	AAA51586.1	CAA57692.1	AAH14546.1	NP_005713.1		1.21 NP_003068.2	AAC50696.1		NP_003069.2	AAR88510.1	AAC50697.1	AAH09368.2
														NP_114084.1 MM.21772 -		·				

589 e-168	582 e-165	505 e-142	505 e-142	366 e-100	261 5e-69	159 2e-38	2 2e-36			0	533 e-151	357 2e-98		- 0					
58	58	201	20	36(26,	156	152	730		723	533	357		754	749	7.28	710	685	
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin d1 isoform a; Rsc6p; mammalian chromatin remodeling complex BRG1-associated factor 60A; chromatin remodeling complex BAF60A subunit; Swp73-like protein; SWI/SNF complex 60 kDa subunit A			SWI/SNF complex 60 KDa subunit	unknown	unknown	SMARCD2 protein	PRO2451	actin related protein 2/3 complex subunit 1A; actin binding protein (Schizosaccharomyces pombe sop2-like); SOP2-like protein			actin related protein 2/3 complex subunit 1B; ARP2/3 protein complex subunit p41; actin related protein 2/3 complex, subunit 1A (41 kD)	unknown	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1; sucrose nonfermenting, yeast, homolog-like 1; integrase		 SWI/SNF related, matrix associated, actin dependent regulator of chromatin subfamily B member 1 (Integrase interactor 1 protein) (hSNF5) (BAF47) 		unnamed protein product	SNF5/INI1 protein	
NP_003067.2	AAD23390.1	NP_620710.1	AAC50695.1	AAS02031.1	AAS00380.1	AAH18953.2	AAF20280.1	NP_006400.2	AR1A_HUMA	z	NP_005711.1	AAS00381.1		NP_003064.2	SNF5_HUMA N	CAA09759.1	BAB14784.1	CAA76639.1	
							•	F:(C-D) -1.18					F:(C-D)	-1.14					
								Mm.34695						Mm.279751					
								NM_019767 NP_062741.1 Mm.34695		·-			NM_011418 F:(C-D)	NP_035548.1					

Subtable 1B: Wholly Unfavorable Genes and Proteins

Mouse Gene Protein	Unigene	Behavior	Human Proteins	Human Protein Name	Score (bits)	E-value
NM_007588		U:(IR-D)				
NP 031614.1	Mm.4642	3.8	AAC50300.1	calcitonin receptor	758	0
			BAA86929.1	calcitonin receptor	758	0
			BAA86928.1	calcitonin receptor	758	0
			NP 001733.1	calcitonin receptor	754	0
			137217	calcitonin receptor	754	0
			CAA49541.1	human calcitonin receptor	754	0
			CAA57849.1	truncated isomer of calcitonin receptor	754	0
			AAB83945.1	Calcitonin Receptor, alternatively spliced form	754	0
			P30988	CALR HUMAN Calcitonin receptor precursor (CT-R)	748	0
			S34486	calcitonin receptor	748	0
			AAA35640.1	calcitonin receptor	748	0
			AAB83944.1	Calcitonin Receptor, alternatively spliced form	744	0
			AAC50301.1	calcitonin receptor isoform	731	0
			NP 005786.1	calcitonin receptor-like	511	e-144
			Q16602	CGRR_HUMAN Calcitonin gene-related peptide type 1 receptor precursor (CGRP type 1 receptor)	511	e-144
			JC2477	calcitonin receptor-like protein	511	e-144
			AAA62158.1	calcitonin-like receptor	511	e-144
			AAC41994.1	CGRP type 1 receptor	511	e-144
			NP 000307.1	parathyroid hormone receptor 1	237	1e-61
			Q03431	PTRR_HUMAN Parathyroid hormone/parathyroid hormone-related peptide receptor precursor (PTH/PTHR receptor)	237	1e-61
			A49191	parathyroid hormone/PTH-related peptide receptor	237	1e-61

			AAA36525.1	parathyroid hormone receptor	227	10 61
			CAA48589.1	parathyroid hormone receptor	237	1e-61
			AAA56774.1	parathyroid hormone/parathyroid hormone related peptide receptor	237	1e-61
			AAB60657.1	parathyroid hormone/PTH-related peptide receptor	237	1e-61
			2119172A	parathyrin receptor	237	1e-61
			Q13324	CRF2 HUMAN Corticotropin releasing factor receptor 2 precursor (CRF-R 2) (CRF2) (Corticotropin-releasing hormone receptor 2) (CRH-R 2)	221	66-57
			AAC71653.1	corticotropin-releasing factor receptor	221	6e-57
			BAC05922.1	seven transmembrane helix receptor	221	6e-57
			AAB94503.1	corticotropin releasing hormone receptor type 2 beta isofor	221	8e-57
			AAB94562.1	corticotropin releasing hormone receptor type 2 gamma isoform; CRH type 2 gamma receptor	220	16-56
			AAC71654.1	corticotropin releasing hormone receptor type 2 gamma isoform; match to AF019381 (PID:g2738889)	220	16-56
AK007657						
BAB25167.1	U:(D Mm.45138 3.55	U:(RP-D) 3.55	NP 115744.2	leucine zipper and CTNNBIP1 domain containing	305	96-83
			BAB72100.1	Leucine zipper & ICAT homologous protein LZIC	305	0. 83
AK007999						3
.1	U:(I Mm.35718 3.3	U:(IR-D) 3.3	XP 114275.1	similar to RIKEN cDNA 2010001C09	244	18-64
AF282730 U:(II AAF97239.1 Mm.36851 2.78	Mm.36851	U:(IR-D) 2.78	NP_003247.1	tissue inhibitor of metalloproteinase 4 precursor	409	e-114
			Q99727	TIM4_HUMAN Metalloproteinase inhibitor 4 precursor (TIMP-4) (Tissue inhibitor of metalloproteinases-4)		e-114
			AAB40391.1	tissue inhibitor of metalloproteinase 4	409	e-114
			AAC34422.1	tissue inhibitor of metalloproteinase 4	409	e-114
			AAH10553.1	AAH10553 tissue inhibitor of metalloproteinase 4	409	e-114
			NP 003246.1	NP 003246.1 tissue inhibitor of metalloproteinase 2 precursor	216	3e-56

			TIM2 HIMAN Metallonrofeinase inhihitor? precursor (TIMP 2) (Tiscus inhihitor of		
		P16035	metalloproteinases-2) (CSC-21K)	216	3e-56
		A37128	metalloproteinase inhibitor 2 precursor	216	3e-56
		AAB19474.1	tissue inhibitor of metalloproteinase 2; TIMP-2	216	3e-56
		AAA59581.1	metalloproteinase inhibitor precursor	. 216	3e-56
		AAA61186.1	metalloproteinase-2 inhibitor precursor	216	3e-56
		AAC50729.1	tissue inhibitor of metalloproteinases-2	216	3e-56
		1GXD	C Chain C, Prommp-2TIMP-2 Complex	214	1e-55
		1GXD	D Chain D, Prommp-2TIMP-2 Complex	214	1e-55
		1BR9	Human Tissue Inhibitor Of Metalloproteinase-2	214	1e-55
		AAB24785.1	TIMP-2, CSC-21K=tissue inhibitor of metalloproteinase	211	9e-55
		AAA21815.1	metalloproteinase-3 tissue inhibitor	200	3e-51
		NP_000353.1	tissue inhibitor of metalloproteinase 3; Tissue inhibitor of metalloproteinase-3; K222 expressed in degenerative retinas	199	4e-51
		P35625	TIM3_HUMAN Metalloproteinase inhibitor 3 precursor (TIMP-3) (Tissue inhibitor of metalloproteinases-3) (MIG-5 protein)		4e-51
		S45317	metalloproteinase inhibitor 3 precursor	199	4e-51
		AAA17672.1	tissue inhibitor of metalloproteinase-3 precurso	199	4e-51
		CAA53813.1	tissue inhibitor of metalloproteinases-3	199	4e-51
		AAB60373.1	tissue inhibitor of metalloproteinases-3	199	4e-51
		AAB34532.1	TIMP-3	199	4e-51
		AAC50393.1	tissue inhibitor of metalloproteinases-3	199	4e-51
		AAB07547.1	tissue inhibitor of metalloproteinase-3	199	4e-51
		AAH14277.1	AAH14277 Similar to tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, pseudoinflammatory)	199	4e-51
			Tissue inhibitor of metalloproteinases, Type-2	199	6e-51
NM_008302	U:(IR-D)		beat shock 90kDa protein 1. beta: heat shock 90kD protein 1. heta: Heat-shock 90kD		
NP 032328.1 Mm.2180	_	NP 031381.2	protein-1, beta	1202	0

		P08238	HS9B HUMAN Heat shock protein HSP 90-beta (HSP 84) (HSP 90)	1202	_
		AAA36026.1	90 kD heat shock protein	1202	
		AAH04928.1	AAH04928 Unknown (protein for MGC:10493)	1202	
		AAH12807.1	AAH12807 Unknown (protein for MGC:3483)	1202	
		AAH14485.1	AAH14485 Unknown (protein for MGC:23206)	1202	0
		AAH16753.1	AAH16753 Unknown (protein for MGC:1138)	1202	0
		HHHU84	heat shock protein 90-beta [validated]	1197	0
		AAA36025.1	90kDa heat shock protein	1197	0
		1307197A	heat shock protein 90k	1197	0
		T46243	hypothetical protein DKFZp761K0511.1	1170	0
		CAB66478.1	hypothetical protein	1170	0
		NP 005339.1	heat shock 90kDa protein 1, alpha; heat shock 90kD protein 1, alpha	1099	0
		нини86	heat shock protein 90-alpha	1099	0
		AAA63194.1	heat shock protein	1099	0
		AAF82792.1	AF275719 1' chaperone protein HSP90 beta	1052	0
		AAH09206.1	AAH09206 heat shock 90kD protein 1, beta	1052	0
		AAH23006.1	Unknown (protein for MGC:30059)	961	0
		AAH00987.1	AAH00987 Unknown (protein for IMAGE:3446372)	800	0
		AAC25497.1	Hsp89-alpha-delta-N	750	0
		AAH07989.1	AAH07989 Similar to heat shock 90kD protein 1, alpha	969	0
NM_009056	(a. a.)				
NP 033082.1 Mm.102	U:(IR-D) 2.63	NP 602309.1	regulatory factor X2, isoform b; trans-acting regulatory factor 2; DNA binding protein RFX2; HLA class II regulatory factor RFX2	1166	C
		P48378	RFX2 HUMAN DNA-binding protein RFX2	1153	C
		B55926	DNA binding protein RFX2	1153	0
		CAA53705.1	DNA binding protein RFX2	1153	0
		NP 000626.2	regulatory factor X2, isoform a; trans-acting regulatory factor 2; DNA binding 000626.2 protein RFX2; HLA class II regulatory factor RFX2	1152	0

			AAH28579.1	128579.1 regulatory factor X, 2 (influences HLA class II expression)	1151	
			NP 602304.1	regulatory factor X3 isoform b; DNA binding protein RFX3	773	0
			AAH22191.1	AAH22191 Unknown (protein for MGC:3664)	773	C
			NP 002910.1	regulatory factor X3 isoform a; DNA binding protein RFX3	751	0
			P48380	RFX3 HUMAN DNA-binding protein RFX3	751	0
			D55926	DNA binding protein RFX3	751	C
			CAA53706.1	DNA binding protein RFX3	751	0
			P22670	RFX1_HUMAN MHC class II regulatory factor RFX1 (RFX) (Enhancer factor C) (EF-C)	686	
			A35913	regulatory factor X	989	٥
			CAA41730.1	MHC class II regulatory factor RFX	989	°
			NP 002909.2	regulatory factor X1; trans-acting regulatory factor 1; enhancer factor C; MHC class II regulatory factor RFX	989	0
			CAC88163.1	bA32F11.1.2 (regulatory factor X, 3 (influences HLA class II expression), putative isoform 2)	507	e-143
			CAC88164.1	bA32F11.1.1 (regulatory factor X, 3 (influences HLA class Ilexpression), isoform 1)	486	e-136
NM_026346 Mm.4 NP_080622.1 6	4046	Mm.4046 U:(IR-D) NP_4 6 2.28	NP_478136.1	78136.1 F-box only protein 32 isoform 1; muscle atrophy F-box protein; atrogin-1	710	0
			Q969P5	FX32_HUMAN F-box only protein 32 (Muscle atrophy F-box protein) (MAFbx) (Atrogin-1)	710	0
	1		AAL16407.1	musele atrophy F-box protein	710	0
			BAB71333.1	unnamed protein product	710	0
			CAD12251.1	F-box only 32	710	0
			BAB85128.1	F-box domain Fbx25-containing protein	446	e-124
			NP 680482.1	F-box only protein 32 isoform 2; muscle atrophy F-box protein; atrogin-1	422	e-117
			AAH24030.1	similar to RIKEN cDNA 4833442G10 gene	417	e-116
			AAF04526.1	AF174605 1 F-box protein Fbx25	354	4e-97
			NP 036305.1	NP 036305.1 F-box only protein 25; F-box protein Fbx25	353	6e-97

NM 009244						
_ NP 033270.1	Mm.19341 U:(IR-D) 8	U:(IR-D) 2.26	AAA51547.1	AAA51547.1 alpha-1-antitrypsin precursor	508	P-144
			AAH15642.1	AAH15642 Similar to serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1	508	e-144
			1012287A	antitrypsin alpha1 mutant	507	e-143
			P01009	A1AT_HUMAN Alpha-1-antitrypsin precursor (Alpha-1 protease inhibitor) (Alpha-1-antiproteinase) (PRO0684/PRO2209)	507	e-143
			ITHU	alpha-1-antitrypsin precursor [validated]	507	e-143
			CAA25838.1	alpha 1-antitrypsin	507	e-143
			AAB59375.1	alpha-1-antitrypsin	507	e-143
			AAG35496.1	AF130117 27 PRO2209	507	e-143
			NP_000286.2	serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitypsin), member 1; Protease inhibitor (alpha-1-antitrypsin); protease inhibitor 1 (anti-elastase), alpha-1-antitrypsin	306	F-143
			AAH11991.1	AAH11991 Similar to serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1	909	e-143
			AAF29581.1	AF113676 1 PRO0684	502	e-142
			AAB59495.1	alpha-1-antitrypsin	504	e-142
			AAA51546.1	alpha-1-antitrypsin	501	e-141
:			1HP7	Chain A, A 2.1 Angstrom Structure Of An Uncleaved Alpha-1- Antitypsin Shows Variability Of The Reactive Center And Other Loops	499	e-141
			1KCT	Alpha1-Antitrypsin	498	e-141
NM_009194		(44) 11				
NP 033220.1 Mm.4168	Mm.4168	U:(IR-D) 2.16	NP 001037.1	solute carrier family 12 (sodium/potassium/chloride transporters), member 2; Solute carrier family 12 (sodium/potassium/chloride transporters),	1978	0
			P55011	S122_HUMAN Solute carrier family 12 member 2 (Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1) (Basolateral Na-K-Cl symporter)	1978	0
			A57187	burnetanide-sensitive Na-K-Cl cotransporter	1978	0
			AAC 0561.1	burnetanide-sensitive Na-K-Cl cotransporter	1978	0

		AAH33003.1	Similar to solute carrier family 12 (sodium/potassium/chloride transporters), member 2	1851	0
		NP 000329.1	sodium potassium chloride cotransporter 2; Solute carrier family 12 (sodium/potassium/chloride transporters),	1294	0
		Q13621	S121_HUMAN Solute carrier family 12 member 1 (Bumetanide-sensitiv sodium-(potassium)-chloride cotransporter 2) (Kidney-specific Na-K-Cl symporter)	1294	0
		AAB07364.1	bumetanide-sensitive Na-K-2Cl cotransporter	1294	0
		NP_000330.1	solute carrier family 12 (sodium/chloride transporters), member 3; Solute carrier family 12 (sodium/potassium/chloride transporters)	1028	0
		AAC50355.1	thiazide-sensitive Na-Cl	1028	0
		P55017	S123_HUMAN Solute carrier family 12 member 3 (Thiazide-sensitive sodium-chloride cotransporter) (Na-Cl symporter)	1024	0
		G01202	NaCl electroneutral Thiazide-sensitive cotransporter	1021	0
		CAA62613.1	NaCl electroneutral Thiazide-sensitive cotransporter	1021	0
		AAL32454.1	AF439152 1 sodium-potassium-chloride cotransporter	865	e-170
		PC4180	thiazide-sensitive sodium-chloride cotransporter	413	e-114
		AAH40138.1	Similar to solute carrier family 12 (sodium/potassium/chloride	403	-111
		1 4001004			5
		AAK 1006.1	cauon-cnionde conansponer-interacting protein 1	761]e-68
NM_009254 NP_033280.1 Mm.2623	U:(IR-D) 2.15	NP_004559.2	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 6; protease inhibitor 6 (placental thrombin inhibitor)	549	e-156
		P35237	PTI6_HUMAN Placental thrombin inhibitor (Cytoplasmic antiproteinase) (CAP)(Protease inhibitor 6) (PI-6)	549	e-156
		AAB30320.1	cytoplasmic antiproteinase; CAP	549	e-156
		AAH01394.1	AAH01394 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 6	549	e-156
		A48681	placental thrombin inhibitor	548	e-156
		CAA80373.1	thrombin inhibitor	548	e-156
		NP 002631.1	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 8; protease inhibitor 8 (ovalbumin type)	459	e-129

P50	50452	SPB8_HUMAN Cytoplasmic antiproteinase 2 (CAP2) (CAP-2) (Protease inhibitor 8)(Serpin B8)	450	P-120
A	A59273	proteinase inhibitor 8	459	6-129
AA	AC41939.1	cytoplasmic antiproteinase 2	459	e-179
NP	P_004146.1	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 9; protease inhibitor 9 (ovalbumin type)	445	P-175
P50	50453	SPB9_HUMAN Cytoplasmic antiproteinase 3 (CAP3) (CAP-3) (Protease inhibitor 9)(Serpin B9)	445	e-125
B,	B59273	proteinase inhibitor 9	445	e-125
¥	AAC41940.1	cytoplasmic antiproteinase 3	445	e-125
A.	AAC50793.1	serine proteinase inhibitor	445	e-125
A.	AAH02538.1	AAH02538 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 9	445	e-125
B,	BAB91078.1	serine protease inhibitor 9	445	e-125
<u> </u>	P 109591.1	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 1; protease inhibitor 2 (anti-elastase), monocyte/neutrophil; protease inhibitor 2 (anti-elastase), monocyte/neutrophil derived	330	3-00
P3	P30740	ILEU_HUMAN Leukocyte elastase inhibitor (LEI) (Monocyte/neutrophil elastase inhibitor) (MNEI) (EI)	330	36-00
S27.	7383	elastase inhibitor '	330	3e-90
. ¥	AAC31394.1	monocyte/neutrophil elastase inhibitor	330	3e-90
AAI	H09015.1	AAH09015 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 1	330	3e-90
Ř	036951.4	similar to Squamous cell carcinoma antigen 2 (SCCA-2) (Leupin)	327	2e-89
P4	P48594	SCC2 HUMAN Squamous cell carcinoma antigen 2 (SCCA-2) (Leupin)	327	2e-89
CA	161420.1	leupin	327	2e-89
AAA	197553.1	squamous cell carcinoma antigen 2	327	2e-89
AA/	192602.1	squamous cell carcinoma antigen	327.	2e-89
BA	BAB21525.1	squamous cell carcinoma antigen 2	327	2e-89
AA	401.1	AAH17401 Unknown (protein for MGC:27150)	327	2e-89
138	138202	leupin precursor	327	2e-89

		138201	squamous cell carcinoma antigen 1	325	7e-89
		NP_008850.1	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 3; squamous cell carcinoma antigen 1	325	9e-89
		P29508	SCC1_HUMAN Squamous cell carcinoma antigen 1 (SCCA-1) (Protein T4-A)	325	9e-89
		AAA86317.1	squamous cell carcinoma antigen	325	9e-89
		AAA97552.1	squamous cell carcinoma antigen 1	325	9e-89
		AAH05224.1	AAH05224 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 3	325	9e-89
		AAB20405.1	squamous cell carcinoma antigen; SCC antigen	325	96-89
NM_019431 Mm.1037 NP_062304.1 24	037 U:(IR-D) 2.09	D) NP_055220.1	voltage-dependent calcium channel gamma-4 subunit; neuronal voltage-gated calcium channel gamma-4 subunit	540	e-153
		Q9UBN1	CCG4_HUMAN Voltage-dependent calcium channel gamma-4 subunit (Neuronal voltage-gated calcium channel gamma-4 subunit)	540	e-153
		AAF03090.1	calcium channel gamma 4 subunit	240	e-153
		AAF14538.1	AF162692 1 putative voltage-gated calcium channel gamma-4 subunit	540	e-153
		AAH34532.1	calcium channel, voltage-dependent, gamma subunit 4	540	e-153
		NP_006069.1	voltage-dependent calcium channel gamma-2 subunit; stargazin; neuronal voltage-gated calcium channel gamma-2 subunit	303	2e-82
		09Y698	CCG2_HUMAN Voltage-dependent calcium channel gamma-2 subunit (Neuronal voltage-gated calcium channel gamma-2 subunit)	303	2e-82
		AAD22738.1	AF096322 1 neuronal voltage-gated calcium channel gamma-2 subunit	303	2e-82
		AAL50049.1	AF361354 1 voltage-dependent calcium channel gamma-8 subunit	302	4e-82
		NP_114101.4	voltage-dependent calcium channel gamma-8 subunit; neuronal voltage-gated calcium channel gamma-8 subunit	300	2e-81
		Q8WXS5	CCG8_HUMAN Voltage-dependent calcium channel gamma-8 subunit (Neuronal voltage-gated calcium channel gamma-8 subunit)	300	2e-81
		AAK20031.1	AF288388 1 calcium channel gamma subunit 8	300	2e-81
		NP_006530.1	voltage-dependent calcium channel gamma-3 subunit; neuronal voltage-gated calcium channel gamma-3 subunit	298	8e-81
	_	060359	CCG3! HUMAN Voltage-dependent calcium channel gamma-3 subunit (Neuronal voltage-gated calcium channel gamma-3 subunit)	298	8e-81

			-			
			AAC15246.1	Unknown gene product	298	8e-81
			AAD22739.1	AF100346 1 neuronal voltage gated calcium channel gamma-3 subunit	298	8e-81
			AAF42975.1	AF134640 1 calcium channel gamma subunit 3	298	8e-81
			AAH40005.1	calcium channel, voltage-dependent, gamma subunit 3	298	8e-81
			XP 050231.1	similar to calcium channel gamma subunit 8	270	26.77
			AAK15019.1	AF234892 1 putative voltage gated calcium channel gamma-8 subunit CACNG8		71-27
NM_019999 N NP_064383.1 7	/m.1772 2	U:(R-D) 2.05	NP_072094.1	Mm.1772 U.(IR-D) NP_072094.1 KIAA1184 protein 72 2.05	659	0
			AAH02937.1	AAH02937. Similar to hypothetical protein MNCb-5687	650	
			BAA86498.1	KIAA1184 protein	579	9-165
			AAH36457.1	Unknown (protein for MGC:33461)	579	e-165
AK002297	00,00	(a. 0)				
BAB21996.1 2	ım. 18130	14m. 18130 U:(C-1R) 2 6.3	NP 060464.1	hypothetical protein FLJ10099		
			BAA91444.1	unnamed protein product	620	e-177
			AAH08675.1	hypothetical protein FLJ10099	620	e-177
			AAH12562.1	Similar to hypothetical protein FLJ10099	620	e-177
			AAH10519.1	Similar to hypothetical protein FLJ10099	385	e-106
		U:(C-IR)	NP_478137.1		1031	0
NM_013744 Mi NP_038772.1 0	Mm.7467 0	U:(IR-D) 2.04				
			BAB71556.1	unnamed protein product	1031	To
			AAD05335.1	zinc finger protein EZNF	958	0
			NP 005640.1	transcription factor 17	957	0
			060765	TC17 HUMAN Transcription factor 17 (Zinc finger protein eZNF)	957	0

			BAA25182.1	HKL1	957	0
			NP 009080.1	zinc finger protein 184 (Kruppel-like)	567	e-161
			AAH22992.1	Unknown (protein for MGC:29879)	567	e-161
			AAC51180.1	kruppel-related zinc finger protein	567	e-161
			XP 166367.1	similar to Zinc finger protein 184	566	e-161
			929660	Z184_HUMAN Zinc finger protein 184	566	e-161
			CAA17278.1	b3418.1 (zinc finger protein 184 (Kruppel-like))	566	e-161
			XP 032054.2	similar to EZFIT-related protein 1	536	e-152
			AAK30252.1	AF352026_1 EZFIT-related protein 1	536	e-152
			CAD38551.1	hypothetical protein	536	e-152
			XP 091988.1	similar to zinc finger protein 91 (HPF7, HTF10)	533	e-151
			AAH36110.1	Similar to zinc finger protein 208	531	e-150
NM_018764 NP_061234.1	Mm.1196 4	U:(C-IR) 4.56	NP_002580.2	protocadherin 7, isoform a precursor; BH-pcdh; BH-protocadherin (brain-heart); brain-heart protocadherin	1856	0
			060245	PCH7_HUMAN Protocadherin 7 precursor (Brain-heart protocadherin) (BH-Pcdh)	1855	0
			BAA25194.1	PCDH7 (BH-Pcdh)a	1855	0
			NP_115832.1	protocadherin 7, isoform b precursor; BH-pcdh; brain-heart protocadherin; BH-protocadherin (brain-heart)	1838	0
			T00041	BH-protocadherin PCDH7 (clone BH-Pcdh-b)	1837	0
			BAA25195.1	PCDH7 (BH-Pcdh)b	1837	0
			NP_115833.1	protocadherin 7, isoform c precursor; BH-pcdh; brain-heart protocadherin; BH-protocadherin (brain-heart)	1691	0
			T00042	BH-protocadherin PCDH7 (clone BH-Pcdh-c)	1690	0
			BAA25196.1	PCDH7 (BH-Pcdh)c	1690	0
			NP_115796.1	protocadherin 1, isoform 2 precursor; protocadherin 42; cadherin-like protein 1	817	0
			AAH35812.1	Similar to protocadherin 1 (cadherin-like 1)	816	0
,			NP_002578.1	protocadherin 1, isoform 1 precursor; protocadherin 42; cadherin-like protein 1	816	0
			Q08174	PCH1_HUMAN Protocadherin 1 precursor (Protocadherin 42) (PC42) (Cadherin-like protein 1)	816	0

			AAA36419.1	protocadherin 42	816	0
			NP_065136.1	protocadherin 9 precursor; cadherin superfamily protein VR4-11	575	e-163
			AAF89689.2	AF169692_1 protocadherin-9	575	e-163
NM_008121 NP_032147.1	U:(C-IR 4.51 Mm.19038 U:(C-D) 6	U:(C-IR) 4.51 U:(C-D) 2.06		gap junction protein, alpha 5,40kDa (connexin 40); gap junction protein, alpha 5, 40kD (connexin 40)	580	e-165
			P36382	CXA5_HUMAN Gap junction alpha-5 protein (Connexin 40) (Cx40)	580	e-165
			AAA91833.1	connexin 40	580	e-165
			AAD37801.1	AF151979_1 connexin 40	280	e-165
			AAA60457.2	connexin40 1	580	e-165
			AAH13313.1	gap junction protein, alpha 5, 40kD (connexin 40)	580	e-165
			138429	connexin40	575	e-164
			NP_068.773.2	gap junction protein, alpha 3, 46kDa (connexin 46); gap junction protein, alpha 3, 46kD (connexin 46)	301	16-81
			CAC16957.1	bA26414.3 (novel connexin (gap junction protein)	301	1e-81
			о9У6Н8	CXA3_HUMAN Gap junction alpha-3 protein (Connexin 46) (Cx46)	301	1e-81
			AAD42925.1	gap-junction protein alpha 3	301	1e-81
			NP_005258.1	gap junction protein, alpha 8, 50kDa (connexin 50); gap junction membrane channel protein alpha-8; connexin 50; Gap junction membrane channel protein alpha-8 (connexin 50); gap junction protein, alpha 8, 50kD (connexin 50)	299	4e-81
			139176	intrinsic membrane protein MP70	299	4e-81
			AAA77062.1	gap junction membrane channel protein alpha-8	299	4e-81
			P48165	CXA8_HUMAN Gap junction alpha-8 protein (Connexin 50) (Cx50) (Lens fiber protein MP70)	296	3e-80
			AAF32309.1	AF217524 1 gap junction protein alpha 8	296	3e-80
			AAK55516.1	AF271261_1 connexin 58	282	5e-76
			NP_110399.1	connexin 59; gap junction alpha 10	282	5e-76
			P57773	CXAA HUMAN Gap junction alpha-10 protein (Connexin 59) (Cx59)	282	5e-76

-. .

			AAG09406.1	AF179597_1 connexin 59	282	Se-76
			AAD56533.1	AF180815_1 truncated connexin 37 polymorph	270	2e-72
			NP_115991.1	connexin 62	267	2e-71
			AAK51676.1	AF296766_1 connexin 62	267	2e-71
			CAC93847.1	connexin62	267	2e-71
NM_008314		U:(C-IR) 4.49 II:(C-D)				
NP_032340.1	Mm.4835	2.43	137107	5-HT5A serotonin receptor	584	e-166
			CAA57168.1	5-HT5A serotonin receptor	584	e-166
			AAM21132.1	AF498985_1 5-hydroxytryptamine receptor 5A	584	e-166
			BAA94458.1	5-hydroxytryptamine (serotonin) receptor 1E	212	2e-54
			NP_000856.1	5-hydroxytryptamine (serotonin) receptor 1E	212	2e-54
			P28566	5H1E_HUMAN 5-hydroxytryptamine 1E receptor (5-HT-1E) (Serotonin receptor) (5-HT1E) (S31)	212	2e-54
			A45260	serotonin receptor 1E	212	2e-54
			CAA77558.1	serotonin receptor	212	2e-54
			AAA58353.1	serotonin receptor	212	2e-54
			AAA58355.1	serotonin receptor	212	2e-54
			CAC10582.1	bA76H14.2 (5-hydroxytryptamine (serotonin) receptor 1E)	212	2e-54
			AAM21127.1	AF498980_1 5-hydroxyttyptamine receptor 1E	212	2e-54
			NP_000857.1	5-hydroxytryptamine (serotonin) receptor 1F; 5-hydroxytryptamine receptor 1F	209	1e-53
			P30939	5H1F_HUMAN 5-hydroxytryptamine 1F receptor (5-HT-1F) (Serotonin receptor)	500	1e-53
			A47321	serotonin receptor 1F	209	1e-53
			AAA36605.1	serotonin receptor	209	1e-53
			AAA36646.1	serotonin receptor	209	1e-53
			AAM21128.1	AF498981_1 5-hydroxytryptamine receptor 1F	500	1e-53
			BAA90453.1	5-hydroxytryptamine (serotonin) receptor 1F	209	1e-53

XP_003692.2	similar to 5-hydroxytryptamine 1A receptor (5-HT-1A) (Serotonin receptor) (5-HT1A) (G-21)	205	19.57
P08908	5H1A_HUMAN 5-hydroxytryptamine 1A receptor (5-HT-1A) (Serotonin receptor) (5-HT1A) (G-21)	300	25 21
138209	serotonin receptor 1A	205	16-32 16-57
CAA40962.1	serotonin 5-HT1a receptor	205	1e-52
AAA66493.1	serotonin receptor	205	1e-52
BAA94488.1	serotonin receptor 1A	205	18-57
AAM21125.1	AF498978_1 5-hydroxytryptamine receptor 1A	205	16-57
XP_092299.1	similar to KIAA0622 protein - human (fragment)	205	1e-52
NP_000854.1	5-hydroxytryptamine (serotonin) receptor 1B; 5-HT1B; 5-HT1DB	204	2e-52
P28222	5H1B_HUMAN 5-hydroxytryptamine 1B receptor (5-HT-1B) (Serotonin receptor)(5-HT-1D-beta) (Serotonin 1D beta recentor) (S12)	207	25.67
JN0268	serotonin receptor 1B	204	26-37
AAA58675.1	serotonin 1Db receptor	204	26-52
AAA36029.1	serotonin receptor	204	26-52
AAA36030.1	5-hyroxytryptamine 1D receptor	204	26-57
BAA01763.1	serotonin 1B receptor	204	2e-52
AAA60316.1	serotonin 1D receptor	204	2e-52
CAB51537.1	dJ501M23.1 (5-hydroxytryptamine (serotonin) receptor 1B)	204	2e-52
BAA94455.1	5-hydroxytryptamine (serotonin) receptor 1B	204	2e-52
2209242B	serotonin receptor:ISOTYPE=1D-beta	204	2e-52
NP_000515.1	5-hydroxytryptamine (serotonin) receptor 1A	202	2e-51
CAA31908.1	receptor protein (AA 1 - 421)	202	2e-51
AAA36440.1	guanine nucleotide-binding regulatory protein-coupled recepto	202	2e-51
1311340A	G protein coupled receptor	202	2e-51

				·		
NM 009183	- ·	U:(C-IR) 4.19		*		
	U:(C-D) Mm.10701 2.35	U:(C-D) 2.35	NP_005659.1	sialyltransferase 8D (alpha-2, 8-polysialytransferase); Polysialyltransferase; sialyltransferase 8 (alpha-2, 8-polysialytransferase) D	714	0
			Q92187	SI8D_HUMAN CMP-N-acetylneuraminate-poly-alpha-2,8-sialyl transferase (Alpha-2,8-sialyltransferase 8D) (ST8Sia IV) (Polysialyltransferase-1)	714	0
			I59403	alpha-2,8-polysialyltransferase	714	0
	·		AAC41775.1	alpha-2,8-polysialyltransferase	714	0
			2116443A	polysialyltransferase	714	0
			NP_006002.1	sialyltransferase 8B (alpha-2, 8-sialytransferase); Sialyltransferase X; sialyltransferase 8 (alpha-2, 8-sialytransferase) B	429	e-119
			Q92186	SI8B_HUMAN Alpha-2,8-sialyltransferase 8B (ST8Sia II) (Sialyltransferase X)(STX)	429	e-119
			139169	sialyltransferase	429	e-119
			AAC24458.1	sialyltransferase	429	e-1:19
			AAB51242.1	sialyltransferase X	429	e-119
			2123358A	sialyltransferase STX	429	e-119
			B54898	STX protein	330	2e-89
			AAA36613.1	sialyltransferase	330	2e-89
			AAH27866.1	Similar to sialyltransferase 8D (alpha-2, 8-polysialytransferase)	320	1e-86
			AAC15901.1	alpha-2,8-sialyltransferase III	219	3e-56
			NP_056963.1	sialyltransferase 8C (alpha2,3Galbeta1,4GlcNAcalpha 2,8-sialyltransferase); alpha-2,8-sialyltransferase III	215	8e-55
			043173	SI8C_HUMAN Sia-alpha-2,3-Gal-beta-1,4-GlcNAc-R:alpha 2,8-sialyltransferase (Alpha-2,8-sialyltransferase 8C) (ST8Sia III)	215	8e-55
			AAB87642.1	Sia alpha2,3Galbeta1,4GlcNAcalpha 2,8-sialyltransferase	215	8e-55
NM_009520		U:(C-IR) 4.15		wingless-type MMTV integration site family, member 2B, isoform WNT-2B2;		
NP_033546.1 Mm.10740 3.21	Mm.10740	3.21	NP_078613.1	wingless-type inner a megration site family, member 15; AWN 12, Xenopus, homolog of	726	0
			093097	WN2B_HUMAN WNT-2B protein precursor (WNT-13)	726	0

			0
NP_004176.2	wingless-type MMTV integration site family, member 2B, isoform WNT-2B1; wingless-type MMTV integration site family, member 13; XWNT2, Xenopus, homolog of	702	0
BAB11984.1	WNT-2B Isoform 1	702	0
T09612	secreted glycoprotein Wnt-13	969	0
CAA96283.1	Wnt-13	969	0
NP_003382.1	wingless-type MMTV integration site family member 2 precursor, int-1 related protein, oncogene INT1-like 1; secreted growth factor	535	e-152
P09544	WNT2_HUMAN WNT-2 protein precursor (IRP protein) (Int-1 related protein)	535	e-152
S00834	int-1-like protein 1 precursor	535	e-152
CAA30725.1	Irp protein (AA·1-360)	535	e-152
AAH29854.1	wingless-type MMTV integration site family member 2	535	e-152
AAB67043.1	secreted growth factor	404	e-112
NP_003383.1	wingless-type MMTV integration site family, member 5A precursor; proto-oncogene Wnt-5A precursor; WNT-5A protein precursor	360	2e-99,
P41221	WN5A_HUMAN WNT-5A protein precursor	360	2e-99
A48914	proto-oncogene Wnt-5A precursor	360	2e-99
AAA16842.1	hWNTSA	360	2e-99
NP_116031.1	wingless-type MMTV integration site family, member 5B precursor; WNT-5B protein precursor	358	1e-98
NP_110402.2	wingless-type MMTV integration site family, member 5B precursor;	358	1e-98
WNT-5B protein			
precursor		358	1e-98
Q9H1J7	WNSB_HUMAN WNT-5B protein precursor	358	1e-98
AAH01749.1	AAH01749 Similar to wingless-related MMTV integration site 5B	358	1e-98
BAB62039.1	WNTSB	358	1e-98
NP 478679.1	wingless-type MMTV integration site family, member 7B precursor	355	1e-97

			P56706	WN7B HUMAN WNT-7B protein precursor	326	
			BAB68399.1	WNT7B	355	16-97
			AAH34923.1	wingless-type MMTV integration site family member 7B	355	16-97
			AAN32640.1	AF416743_1 WNT7B	355	16-97
			NP_004616.2	wingless-type MMTV integration site family, member 7A precursor; proto-oncogene Wnt7a protein	348	16-95
			AAH08811.1	Unknown (protein for MGC:10346)	348	1e-95
			AAG38659.1	WNT5b precursor	348	2e-95
		U:(C-IR) 3.61				
AK011231		U:(C-D) 2.66				
BAB27481.1 Mm.22533 2.42	Mm.22533	U:(IR-D) 2.42	NP_055330.1	CCR4-NOT transcription complex, subunit 2; NOT2 (negative regulator of transcription 2, yeast) homolog	877	
			AAF29827.1	AF180473_1:Not2p	877	
			AAH02597.1	CCR4-NOT transcription complex, subunit 2	877	
			AAH11826.1	Similar to CCR4-NOT transcription complex, subunit 2	877	0
			BAA91313.1	unnamed protein product	751	
			AAF29095.1	AF161480_1 HSPC131	729	0
			AAG39297.1	AF113226_1 MSTP046	728	O
			T46494	hypothetical protein DKFZp434M0572.1	326	8e-89
			CAB70869.1	hypothetical protein	326	8e-89
NM 009613		U:(C-IR) 3.6				
U:(C NP_033743.1 Mm.89854 2.86	Mm.89854	U:(C-D) 2.86	NP_002381.2	a disintegrin and metalloprotease domain 11, isoform 1 preproprotein; metalloproteinase-like, disintegrin-like, cysteine-rich protein	1454	
			BAA32352.1	MDC/ADAM11	1454	0
		_	075078	AD11_HUMAN ADAM 11 precursor (A disintegrin and metalloproteinase domain 11) (Metalloproteinase-like, disintegrin-like, and cysteine-rich protein) (MDC)	1451	
			165967	disintegrin-like metalloproteinase (EC 3.4.24), splice form 2	1345	٥
					101	5

			BAA06670.1	metalloprotease/disintegrin-like protein	1340	0
			NP_067625.1	a disintegrin and metalloprotease domain 11, isoform 2 preproprotein; metalloproteinase-like, disintegrin-like, cysteine-rich protein	1011	0
			S38539	disintegrin-like metalloproteinase (EC 3.4.24), splice form 1	1011	0
			AAB29191.1	MDC=metalloprotease/disintegrin-like cysteine-rich protein [human, cerebellum, Peptide, 524 aa]	1011	, 0
			BAA04213.1	MDC protein	1011	0
			BAA06671.1	metalloprotease/disintegrin-like protein	1008	0
			NP_068367.1	a disintegrin and metalloproteinase domain 22 isoform 5 proprotein; MDC2 delta	825	0
			BAA32350.1	MDC2 beta	825	0
			AAF22476.2	AF073291_1 MDC2	825	0
			NP_057435.2	a disintegrin and metalloproteinase domain 22 isoform 3 proprotein; MDC2 delta	825	0
			NP_068368.2	a disintegrin and metalloproteinase domain 22 isoform 2 proprotein; MDC2 delta	825	0
AK002979	U:(C-IR) 3.58	U:(C-IR) 3.58				
BAB22492.1	Mm.19588 1	U:(C-D) 2.07	NP_056537.1 calcyon	calcyon	336	5e-92
			Q9NYX4	D1IP_HUMAN D1 doparmine receptor-interacting protein calcyon	336	5e-92
			AAF34714.1	AF225903_1 D1 dopamine receptor interacting protein calcyon	336	Se-92
			AAH38978.1	Similar to calcyon; D1 dopamine receptor-interacting protein	336	5e-92
NM 008714		U:(C-IR) 3.55				
_	U:(C-D) Mm.31255 2.19	U:(C-D) 2.19	P46531	NTC1_HUMAN Neurogenic locus notch homolog protein 1 precursor (Notch 1) (hN1) (Translocation-associated notch protein TAN-1)	4646	0
			AAG33848.1	AF308602_1 NOTCH 1	4646	0
			A40043	notch protein homolog TAN-1 precursor	4528	0
			AAA60614.1	TANI	4482	0
			NP_077719.2	notch 2 preproprotein	2628	0
			AAG37073.1	AAG37073.1 AF315356 1 NOTCH2 protein	2627	0

			004721	NTC2_HUMAN Neurogenic locus notch homolog protein 2 precursor (Notch 2)	2076	•
			407/21	(7,111)	/707	
			AAA36377.2	NOTCH 2	2627	0
			AAC14346.1	Notch3	2065	0
			NP_000426.1	Notch homolog 3	2065	0
			Q9UM47	NTC3_HUMAN Neurogenic locus notch homolog protein 3 precursor (Notch 3)	2065	0
			S78549	notch3 protein	2065	0
			AAB91371.1	Notch3	2065	0
			AAC15789.1	Notch 3	2065	0
			NP_004548.1	Notch homolog 4 (Drosophila); Notch, drosophila, homolog of, 4; Notch (Drosophila) homolog 4	1023	0
			Q99466	NTC4_HUMAN Neurogenic locus notch homolog protein 4 precursor (Notch 4) (hNotch 4)	1023	0
			AAC32288.1	Notch4	1023	0
AK012553		U:(C-IR) 3.54				
BAB28313.1	U:(C Mm.45628 2.46	U:(C-D) 2.46	NP_001575.1	chromosome 11 open reading frame 8; 239FB	627	e-180
			Q1 <i>5777</i>	239F_HUMAN Fetal brain protein 239	627	e-180
			AAC50564.1	239FB gene product	627	e-180
			AAH31582.1	chromosome 11 open reading frame 8	627	e-180
			2122285A	239FB gene	627	e-180
			NP_001576.2	chromosome 22 open reading frame 1; 239AB	518	e-147
			015442	239A_HUMAN Adult brain protein 239	518	e-147
			AAC51673.2	239AB	518	e-147
			AAH28035.1	Unknown (protein for MGC:40027)	518	e-147
			CAC48257.1	CAC48257.1 [dJ873F21.1 (brain protein 239)	284	2e-76
			CAC10467.1	dJ710M3.1 (chromosome 11 open reading frame 8(Fetal brain protein 239))	253	5e-67

		e-160				e-160		5e-50	Se-50	Se-50			C			0	0	0	C	0	ō	0	0	e-115
		563	563	563	563	563	197	197	197	197	196		1192	1192	1191	1191	1165	728	728	728	728	728	714	412
172		adrenomedullin receptor; G-protein-coupled receptor similar to the adrenomedullin I receptor	ADMR_HUMAN Adrenomedullin receptor (AM-R)		G-protein coupled receptor	adrenomedullin receptor	RDC1_HUMAN G protein-coupled receptor RDC1 homolog	G protein-coupled receptor RDC1	orphan receptor	similar to G protein-coupled receptor RDC1 homolog	Unknown (protein for MGC:33224)	-	ARN2_HUMAN Aryl hydrocarbon receptor nuclear translocator 2 (ARNT protein 2)	AF185610_1 aryl-hydrocarbon receptor nuclear translocator 2		_	Unknown (protein for MGC:33872)	aryl hydrocarbon receptor nuclear translocator	ARNT_HUMAN Aryl hydrocarbon receptor nuclear translocator (ARNT protein) (Dioxin receptor, nuclear translocator) (Hypoxia-inducible factor 1 beta) (HIF-1 beta)	aryl hydrocarbon receptor nuclear translocator Arnt [imported]	Arnt	aryl hydrocarbon receptor nuclear translocator, ARNT	hypothetical protein	aryl bydrocarbon receptor nuclear translocator; Arnt
		NP_009195.1	015218	JC5784	CAA73910.1	AAH34761.1	P25106	A39714	AAA62370.1	XP_051522.2	AAH36661.1		Q9HBZ2	AAG15310.1	NP_055677.1	BAA20766.1	AAH36099.1	NP_001659.1	P27540	I59550	AAA51777.1	CAC21446.1	CAD38953.1	AAC03365.1
	U:(C-IR) 3.52	U:(C-D) 3.08											U:(C-IR) 3.41											
		Mm.2857											Mm.4813											
	NM_007412	NP_031438.1										NM_007488	NP_031514.1											

			000327	BMAL_HUMAN BMAL1 protein (Brain and muscle ARNT-like 1) (Member of PAS protein 3) (Basic-helix-loop-helix-PAS orphan MOP3) (BHLH-PAS protein JAP3)	301	2e-81
			BAA19968.1	BMAL1a	301	2e-81
			NP_001169.2	NP_001169.2 aryl hydrocarbon receptor nuclear translocator-like	301	2e-81
			AAB37248.1	bHLH-PAS protein JAP3	301	2e-81
			AAC24353.1	basic-helix-loop-helix-PAS orphan MOP3	301	2e-81
			AAC51213.1	PAS protein 3	301	3e-81
			JC5405	brain and muscle Ah receptor nuclear translocator-like protein, BMAL1b	300	5e-81
			BAA19935.1	BMAL1b	300	5e-81
NM 009004		U:(C-IR)				
l	Mm.19663 U:(C-D)	U:(C-D)				
NP_033030.1	8	2.41		005724.1 RAB6 interacting, kinesin-like (rabkinesin6)	1345	0
			095235	RB6K_HUMAN Rabkinesin-6 (RAB6-interacting kinesin-like protein) (GG10_2)	1345	0
			AAC83230.1	rabkinesin6	1345	0
			AAD37806.1	AF153329_1 RAB6KIFL	1345	0
			AAH12999.1	AAH12999.1 AAH12999 Similar to RAB6 interacting, kinesin-like (rabkinesin 6)	1345	0
			NP_057279.1	M-phase phosphoprotein 1; mitotic kinesin-like protein	333	9e-91
			T17272	hypothetical protein DKFZp434B0435.1	333	9e-91
			CAB55962.1	hypothetical protein	333	9e-91
			BAB69456.1	mitotic kinesin-related protein	326	1e-88
			NP_004847.2	NP_004847.2 kinesin-like 5 isoform 2; mitotic kinesin-like 1	201	4e-51
			Q02241	KNS5_HUMAN Mitotic kinesin-like protein-1 (Kinesin-like protein 5)	201	4e-51
			CAA47628.2	mitotic kinase-like protein-1	201	4e-51
			NP_612565.1	NP_612565.1 kinesin-like 5 isoform 1; mitotic kinesin-like 1	. 201	4e-51
			AAH17705.1	AAH17705 kinesin-like 5 (mitotic kinesin-like protein 1)	201	4e-51

	5003 0	4987 0	4987 0	2961 0	2769 0	1046 0	893 0	518 e-146	518 e-146	497 e-139	464 e-129	461 e-129	370 e-102		orphic 368 e-101	nucin) (PEM) 368 e-101 ucin) ut-reactive 27 antigen)	368 e-101	325 2e-88	317 4e-86	317 46-86	
	NP_004361.2 alpha 1 type XII collagen, long isoform precursor	CA1C_HUMAN Collagen alpha 1(XII) chain precursor	collagen type XII alpha-1	alpha 1 type XII collagen, short isoform precursor	dJ238D15.1 (collagen, type XII, alpha 1)	dJ234P15.1 (collagen, type XII, alpha 1)	type XII collagen	undulin 1	undulin 1	collagen type XIV	CAC19497.1 bA209D8.1 (collagen type XII, alpha 1)	Unknown (protein for MGC:15451)	mucin 1 precursor, repetitive splice form A [validated]		002447.2 mucin 1, transmembrane; peanut-reactive urinary mucin; episialin; polymorphic epithelial mucin; epithelial membrane antigen; DF3 antigen; H23 antigen	MUC1_HUMAN Mucin 1 precursor (MUC-1) (Polymorphic epithelial mucin) (PEM) (PEMT) (Episialin) (Tumor-associated mucin) (Carcinoma-associated mucin) (Tumor-associated epithelial membrane antigen) (EMA) (H23AG) (Peanut-reactive urinary mucin) (PUM) (Breast carcinoma-associated antigen DF3) (CD227 antigen)	mucin	precursor polypeptide (AA -21 to 494)	polymorphic epithelial mucin	polymorphic epithelial mucin	
	NP_004361.2	Q99715	AAC51244.1	NP_542376.1	CAB71222.1	CAB65984.1	AAC01506.1	A40970	AAA36794.1	CAA72402.1	CAC19497.1	AAH14640.1	A35175		NP_002447.2	P15941	AAA60019.1	CAA36478.1	AAA59876.1	AAB53150.1	
U:(C-IR) 3.18 II:(C-I)	2.18												U:(C-IR)	3.17 U:(C-D) 3.4							
														Mm.1619 3							
NM_007730	NP_031756.1 Mm.3819			_										NM_013605 Mm.1619 U:(C-D) NP_038633.1 3 3.4							

			AAA35805.1	A35805.1 episialin variant A precursor	208	20.80
			AAA35807.1	episialin variant B precursor	20%	28-80
			AAD10858.1	AAD10858.1 MUC-1/Z mucin short variant	274	\$e-73
			S48146	mucin 1 precursor, non-repetitive splice form Y [validated]	272	1e-72
			CAA56734.1	MUCI	272	1e-72
			AAD10857.1	AAD10857.1 MUC-1/Y mucin short variant	272	1e-72
			AAD27842.1	AAD27842.1 AF125525_1 MUC1/Y mucin precursor	271	3e-72
			AAD10856.1	AAD10856.1 MUC-1/X mucin short variant	214	4e-56
NM_008652		U:(C-IR)				
NP_032678.1 Mm.4594	Mm.4594	U:(C-D) 2	NP_002457.1	v-myb myeloblastosis viral oncogene homolog (avian)-like 2; B-MYB; v-myb avian myeloblastosis viral oncogene homolog-like 2	1123	C
			P10244	MYBB_HUMAN Myb-related protein B (B-Myb)	1123	0
			S01991	transforming protein B-myb	1123	C
			CAA31655.1	B-myb protein (AA 1-700)	1123	0
			CAC08392.1	dJ1028D15.3 (v-myb avian myeloblastosis viral oncogene homolog-like 2)	1123	P
			AAH07585.1	v-myb avian myeloblastosis viral oncogene homolog-like 2	1123	0
				MYBA_HUMAN Myb-related protein A (A-Myb)	280	1e-74
			S03423	transforming protein A-myb	280	1e-74
			CAA31656.1	A-myb N-terminal region)2341 is 2nd base in codon)	280	1e-74
			AAB49038.1	alternatively spliced product using exon 9A	276	1e-73
			CAA36371.1	MYB protein (AA 1-637)	276	1e-73
				v-myb myeloblastosis viral oncogene homolog (avian); v-myb avian myeloblastosis viral oncogene homolog; Avian myeloblastosis viral (v-myb) oncogene homolog:		
			NP_005366.1	c-myb	276	1e-73
			AAA52032.1	c-myb	276	1e-73
			XP_004256.3	similar to Myb proto-oncogene protein (C-myb)	276	1e-73
			P10242	MYB_HUMAN Myb proto-oncogene protein (C-myb)	276	1e-73
			AAB49039.1	c-myb gene product	276	1e-73

			AAC96326.1	MYB proto-oncogene protein	276	1e-73
			TVHUMB	transforming protein myb, splice form containing exon 9A	276	1e-73
			AAB49035.1	alternatively spliced product using exon 9B	276	1e-73
			AAB49036.1	alternatively spliced product using exon 8A	276	1e-73
		U:(C-IR) 2.99				
NM_008168		2.57				
NP_032194.1	Mm.2879	U:(IR-D) 2.41	Q16478	GLK5_HUMAN Glutamate receptor, ionotropic kainate 5 precursor (Glutamate receptor KA-2) (KA2) (Excitatory amino acid receptor 2) (EAA2)	1757	0
			157936	glutamate receptor subunit	1757	0
			AAB22591.1	glutamate receptor subunit; EAA2; excitatory amino acid receptor 2	1757	0
			NP_002079.2	glutamate receptor, ionotropic, kainate 5	1625	0
	į		CAC80547.1	kainate receptor subunit KA2a	1625	0
			NP_055434.1	glutamate receptor, ionotropic, kainate 4; excitatory amino acid receptor 1	1254	0
			Q16099	GLK4_HUMAN Glutamate receptor, ionotropic kainate 4 precursor (Glutamate receptor KA-1) (KA1) (Excitatory amino acid receptor 1)(EAA1)	1254	0
			лн0826	glutamate ionotropic receptor EAA1 chain precursor	1254	0
			AAB29311.1	excitatory amino acid receptor 1; kainate receptor subunit EAA1	1254	0
			A54260	glutamate receptor 6 kainate-preferring precursor	704	0
			AAB31362.1	GluR6 kainate receptor-ionotropic-type glutamate receptor	704	0
			NP_068775.1	glutamate receptor, ionotropic, kainate 2	704	0
			Q13002	GLK2_HUMAN Glutamate receptor, ionotropic kainate 2 precursor (Glutamate receptor 6) (GluR-6) (GluR6) (Excitatory amino acid receptor 4) (EAA4)	704	0
			AAC50420.1	EAA4	704	0
		·	CAC67487.1	GluR6 kainate receptor	689	0
			CAC81020.1	kainate receptor subunit	289	0
			Q13003	GLK3_HUMAN Glutamate receptor, ionotropic kainate 3 precursor (Glutamate receptor 7) (GluR-7) (GluR7) (Excitatory amino acid receptor 5) (EAA5)	289	0
			NP 000822.1	glutamate receptor, ionotropic, kainate 3	289	0

_
"
\sim
_

		AAB60407.1	EAA5	289	
		AAA95961.1	EAA3	685	C
	U:(C-IR) 2.93				
m.22695	U:(C-D) Mm.22695 2.6	NP_001304.1	collapsin response mediator protein 1; collapsin response mediator protein 1 (dihydropyrimidinase-like 1)	1036	
		Q14194	DPY1_HUMAN Dihydropyrimidinase related protein-1 (DRP-1) (Collapsin response mediator protein 1) (CRMP-1)	1036	
		JC5316	dihydropyrimidinase related protein 1	1036	
		BAA11190.1	dihydropyrimidinase related protein-1	1036	
		AAH00252.1	collapsin response mediator protein 1	1036	
		AAH07613.1	collapsin response mediator protein 1	1036	
		AAK55500.1	collapsin response mediator protein 1	963	
		AAA93201.1	hCRMP-1	919	0
		NP_001377.1	dihydropyrimidinase-like 2; collapsin response mediator protein hCRMP-2	847	0
		Q16555	DPY2_HUMAN Dihydropyrimidinase related protein-2 (DRP-2) (Collapsin response mediator protein 2) (CRMP-2) (N2A3)	847	0
		JC5317	dihydropyrimidinase-related protein 2	847	0
		AAA93202.1	hCRMP-2	847	C
		BAA11191.1	dihydropyrimidinase related protein-2	847	0
		AAC05793.1	N2A3 .	847	0
		BAA86991.1	dihydropyrimidinase related protein 2	847	0
		NP_001378.1	dihydropyrimidinase-like 3	813	0
		Q14195	DPY3_HUMAN Dihydropyrimidinase related protein-3 (DRP-3) (Unc-33-like phosphoprotein) (ULIP protein) (Collapsin response mediator protein 4) (CRMP-4)	813	0
		JC5318	dihydropyrimidinase related protein 3	813	0
		BAA11192.1	dihydropyrimidinase related protein-3	813	0
		AAH39006.1	dihydropyrimidinase-like 3	813	0
		CAA69153.1	ULIP	810	C
					-

			NP_006417.1	006417.1 dihydropyrimidinase-like 4	781	0
			014531	DPY4_HUMAN Dihydropyrimidinase related protein-4 (DRP-4) (ULIP4 protein)	781	0
			BAA21886.1	dihydropyrimidinase related protein 4	781	0
			CAA71872.1	cytosolic phosphoprotein	749	0
			AAH07898.1	Similar to collapsin response mediator protein 1	712	0
NM_009872 NP_034002.1	U:(C-IR) 2.86 Mm.15383 U:(C-D) 3	U:(C-IR) 2.86 U:(C-D) 2.61	NP 003927.1	cyclin-dependent kinase 5, regulatory subunit 2; cyclin-dependent kinase 5 activator isoform p39i; NEURONAL CDK5 activator isoform	783	721 9
			013319	CD5S_HUMAN Cyclin-dependent kinase 5 activator 2 precursor (CDK5 activator 2) (Cyclin-dependent kinase 5 regulatory subunit 2) (P39)(P391)	483	6-136
			139172	cyclin-dependent kinase 5 activator isoform p39i	483	e-136
			AAC50278.1	cyclin-dependent kinase 5 activator isoform p39i	483	e-136
			2202258A	cyclin-dependent kinase 5	483	e-136
			NP_003876.1	cyclin-dependent kinase 5, regulatory subunit 1; regulatory partner for cdk5 kinase; TPKII regulatory subunit	228	16-59
		· · · · · · · · · · · · · · · · · · ·	015078	CD5R_HUMAN Cyclin-dependent kinase 5 activator 1 precursor (CDK5 activator 1) (Cyclin-dependent kinase 5 regulatory subunit 1) (Tau protein kinase II 23 kDa subunit) (TDVII regulatory subunit (DD2) (DD2)		
			S50861	cyclin-dependent kinase 5 regulatory chain p35	378	16-59
			CAA56587.1	regulatory partner for cdk5 kinase	228	1e-59
			AAH20580.1	AAH20580 cyclin-dependent kinase 5, regulatory subunit 1 (p35)	228	1e-59
			2019431A	cyclin-dependent kinase 5:SUBUNIT=p35	228	1e-59
			AAH26347.1	cyclin-dependent kinase 5, regulatory subunit 1 (p35)	226	4e-59
			AAH30792.1	cyclin-dependent kinase 5, regulatory subunit 1 (p35)	226	4e-59
			1H4L	D Chain D, Structure And Regulation Of The Cdk5-P25(Nck5a) Complex	217	2e-56
			1H4L	E Chain E, Structure And Regulation Of The Cdk5-P25(Nck5a) Complex	217	2e-56

Suthiat to Ditaj nomolog subtamily B member 8 (mDJ6)	XP_093388.1
-	
hypothetical protein MGC33884	ypot
Similar to DnaJ (Hsp40) homolog, subfamily B, member 8	imil
DnaJ (Hsp40) homolog, subfamily B, member 6 isoform b; Heat shock protein J2	Jaa
	ME
AF075601_1 heat shock J2 protein	띩
AF060703_1 DNAj homolog	Ē
DnaJ homolog	[Ba
hypothetical protein	odki
AAH00177 Similar to DnaJ (Hsp40) homolog, subfamily B, member 6	3
similar to DnaJ homolog	Ē
DnaI (Hsp40) homolog, subfamily B, member 6 isoform a; Heat shock protein J2	盾
DIB6_HUMAN DnaJ homolog subfamily B member 6 (Heat shock protein 12) (HSJ-1) (HSJ-1) (HHDJ1) (MRJ)	HS E
DnaJ homolog	[a]
AAH02446 MRJ gene for a member of the DNAJ protein family	ا₹
-	
potassium voitage-gated channel, shaker-related subfarmly, member 2; voltage-gated potassium channel protein Kv1.2; potassium channel	otas
CIK2_HUMAN Potassium voltage-gated channel subfamily A member 2 (Potassium channel Kv1.2) (RBK2) (HBK5) (NGK1) (MK2) (HUK1V)	hanr
potassium channel	otass
potassium channel	otas
potassium voltage-gated channel, shaker-related subfamily, member 1	otas
CIK1_HUMAN Potassium voltage-gated channel subfamily A member 1 (Potassium	IKI

067651	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
000107	potassium channel NCINA I	662	0
AAA36139.1	potassium channel	662	0
NP_002223.2	potassium voltage-gated channel, shaker-related subfamily, member 3; potassium channel protein; voltage-gated potassium channel; voltage-gated potassium channel protein Kv1.3; type n potassium channel	800	121
.00004	CIK3_HUMAN Potassium voltage-gated channel subfamily A member 3 (Potassium	3	
P22001	channel Kv1.3) (HPCN3) (HGK5) (HUKIII) (HLK3)	009	e-171
AAB88073.1	voltage-gated potassium channel	009	e-171
AAH35059.1	potassium voltage-gated channel, shaker-related subfamily, member 3	009	e-171
A38101	potassium channel KCNA3	599	e-171
AAA59457.1	potassium channel protein	500	0.171
AAC31761.1	potassium channel	50%	P-171
AAA36425.1	potassium channel protein	595	e-170
	potassium voltage-gated channel, shaker-related subfamily, member 4; potassium voltage-gated channel, shaker-related subfamily, member 4-like; potassium channel KCNA4; shaker-related potassium channel Kv1.4; voltage-gated potassium channel; potassium channel protein; type A potassium channel; rapidly inactivating potassium channel; fetal skeletal muscle potassium channel; cardiac potassium channel.		
NP_002224.1	potassium channel 2; voltage-gated potassium channel protein Kv1.4	543	e-154
A39922	potassium channel KCNA4	543	e-154
AAA36140.1	potassium channel	543	e-154
AAA61275.1	voltage-gated potassium channel	543	e-154
P22459	CIK4_HUMAN Potassium voltage-gated channel subfamily A member 4 (Potassium channel Kv1.4) (HK1) (HPCN2) (HBK4) (HUK1I)	541	e-153
AAA60034.1	potassium channel protein	541	e-153
NP_002226.1	potassium voltage-gated channel, shaker-related subfamily, member 6; voltage-gated potassium channel protein Kv1.6; human brain potassium channel-2	519	e-147
P17658	CIK6_HUMAN Potassium voltage-gated channel subfamily A member 6 (Potassium channel Kv1.6) (HBK2)	519	P-147
CAA35623.1	put. HBK2 protein (AA 1-529)	519	e-147
S12787	potassium channel KCNA2	517	e-146

		U:(C-IR)	<u>\$</u>	000757.2 cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 13	563	e-160
NM_013809 NP_038837.1	Mm.1023 12	U:(C-D) 2.22				
			AAG35775.1	cytochrome P450 2A13	563	e-160
			016696	CPAD_HUMAN Cytochrome P450 2A13 (CYPIIA13)	558	e-158
			AAB40519.1	cytochrome P450	558	e-158
			O4HUA6	coumarin 7-hydroxylase (EC 1.14.14) cytochrome P450 2A6	555	e-158
			AAA52067.1	cytochrome P450IIA3	555	e-158
			NP_000753.2	cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 6; coumarin 7-hydroxylase; cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 3; xenobiotic monooxygenase; flavoprotein-linked monooxygenase	553	e-157
			P11509	CYP2A3) (P450(I))	552	e-157
			CAA32118.1	P-450 IIA4 protein (AA 1-494)	552	e-157
			AAF13600.1	AF182275_1 cytochrome P450-2A6	551	e-157
			1609083A	cytochrome P450IIA	551	e-156
			CAA32097.1	cytochrome P-450IIA (AA 1 - 489)	551	e-156
			P20853	CPA7_HUMAN Cytochrome P450 2A7 (CYPIIA7) (P450-IIA4)	543	e-154
			AAA52138.1	cytochrome P450IIA4	543	e-154
			C34271	cytochrome P450 2A4	543	e-154
NM_017402 NP_059098.1		U:(C-IR) 2.74 U:(C-D) 2.8	NP_003890.1	Rho guanine nucleotide exchange factor 7 isoform a; SH3 domain-containing proline-rich protein; PAK-interacting exchange factor beta	1135	0
			Q14155	PIXB_HUMAN Rho guanine nucleotide exchange factor 7 (PAK-interacting exchange factor beta) (Beta-Pix) (COOL-1) (p85)	1135	0
			BAA09763.1	The KIAA0142 gene is related to human KIAA0006 gene.	1135	0
			CAD38906.1	hypothetical protein	1014	0
			NP_663788.1	Rho guanine nucleotide exchange factor 7 isoform b; SH3 domain-containing proline-rich protein; PAK-interacting exchange factor beta	1014	0

			BAA04985.1	this sequence overlaps D13631, it covers 9544359 of this sequence.	751	0
			XP_042963.2	similar to Rho guanine nucleotide exchange factor 6 (PAK-interacting exchange factor alpha) (Alpha-Pix) (COOL-2)		0
			NP_004831.1	Rac/Cdc42 guanine nucleotide exchange factor 6; PAK-interacting exchange factor, alpha; Rac/Cdc42 guanine exchange factor (GEF) 6; rho guanine nucleotide exchange factor 6	751	0
			Q15052	ARH6_HUMAN Rho guanine nucleotide exchange factor 6 (PAK-interacting exchange factor alpha) (Alpha-Pix) (COOL-2)	751	0
			AAH39856.1	Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6	751	0
			BAA02796.1	KIAA0006	504	e-142
			1BY1	A Chain A, Dbl Homology Domain From Beta-Pix	385	e-106
			AAH33768.1	Similar to Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6	301	4e-81
NM_009819		U:(C-IR) 2.7				
NP_033949.1	U:(C-D) Mm.34637 2.71	U:(C-D) 2.71	NP_004380.1	catenin (cadherin-associated protein), alpha 2; Catenin, alpha-2(cadherin-associated protein, related)	1684	
			P26232	CTN2_HUMAN Alpha-2 catenin (Alpha-catenin related protein) (Alpha N-catenin)	1684	0
			AAA58407.2	cadherin-associated protein-related	1684	0
			A45011	alpha-catenin 2	1317	0
			XP_038221.1	038221.1 sirnilar to Alpha-1 catenin (Cadherin-associated protein) (AlphaE-catenin)	1317	0
			P35221	CTN1_HUMAN Alpha-1 catenin (Cadherin-associated protein) (Alpha E-catenin)	1317	0
			N0607	alpha-catenin 1	1317	0
			BAA02979.1	alpha-catenin	1317	0
			AAC99459.1	alphaE-catenin	1317	0
			AAH00385.1	Unknown (protein for MGC:8429)	1317	0
			BAA03530.1	'human alpha-catenin'	1313	0
			Ą	alpha catenin	1313	0
			JC2542	alpha-2(E)-catenin	1290	0
			AAA18949.1	alpha2(E)-catenin	1290	0

1286	1286 0	974 0	974 0	841 0	389 e-107	389 e-107	380 e-105	3799 0	3799 0	3799 0	3797 0	0 8697	2698 0	0 . 984	0 982	486 e-136	257 2e-67	257 2e-67	257 2e-67	257 2e-67	250 20 66
catenin (cadherin-associated protein), alpha 1, 102kDa; catenin (cadherin-associated protein), alpha 1 (102kD); catenin (cadherin-associated protein), alpha 1 (102kD)	alpha1(E)-catenin	98.1 alpha-catenin-like protein	01.1 AF091606_1 alphaT-catenin	62.1 Similar to catenin (cadherin-associated protein), alpha 2	A Chain A, Alpha-Catenin M-Domain	B Chain B, Alpha-Catenin M-Domain	97.2 similar to alpha(E)-catenin	human immunodeficiency virus type I enhancer binding protein 2; human immunodeficiency virus type I enhancer-binding protein 2	HIV-EP2 enhancer-binding protein	MBP-2 (MHC Binding Protein-2)	human immunodeficiency virus type I enhancer-binding protein 2	ZEP2_HUMAN HUMAN IMMUNODEFICIENCY VIRUS TYPE I ENHANCER-BINDING PROTEIN 2 (HIV-EP2)	HIV-EP2/Schnurri-2	078779.1 human immunodeficiency virus type I enhancer-binding protein 3	82.1 AF278765_1 kappa B and V(D)J recombination signal sequences binding protein	31.1 KIAA1555 protein	05.1 human immunodeficiency virus type I enhancer binding protein 1; human immunodeficiency virus type I enhancer-binding protein 1	ZEP1_HUMAN Zinc finger protein 40 (Human immunodeficiency virus type I enhancer-binding protein 1) (HIV-EP1) (Major histocompatibility complex binding protein 1) (MBP-1) (Positive regulatory domain II binding factor 1) (PRDII-BF1)	DNA-binding protein PRDII-BF1	98.1 PRDII-BF1 protein (AA 1-2717)	1 DNA-hinding protein
NP 001894.1	AAA86430.1	NP_037398.1	AAF21801.1	AAH31262.1	1H6G	1H6G	XP_068797.2	NP_006725.2	WMHUE2	CAA46596.1	AAF81365.1	P31629	AAB88218.1	NP_07877	AAK01082.1	BAB13381.1	NP_002105.1	P15822	A34203	CAA35798.1	A A A 17534 1
								U:(C-IR) 2.68													
								Mm.4215 7			,										
								NM_010437 NP_034567.1													

	2e-94	2000	2e-94	2e-94	2e-94	2e-94								0	_	0	0	0	0	0	0	0
	343	343	343	343	343	343		2285	2282	2282	2027	2362	2149	2149	1484	1484	1484	1484	1484	1467	1420	1022
	008950.1 ubiquitin-conjugating enzyme E2C; ubiquitin carrier protein E2-C	UBCC_HUMAN Ubiquitin-conjugating enzyme E2 C (Ubiquitin-protein ligase C) (UbcH10)	cyclin-selective ubiquitin carrier protein	ubiquitin-conjugating enzyme E2 H10 (isoform 1)		ubiquitin-conjugating enzyme E2C		AAB52902.i'	ATPase, Cu++ transporting, beta polypeptide (Wilson disease); ATPase, Cu++ transporting, beta polypeptide	AT7B_HUMAN Copper-transporting ATPase 2 (Copper pump 2) (Wilson disease-associated protein)	copper-transporting ATPase (EC 3.6.1) beta		Cu transporting ATPase P	copper-transporting ATPase (EC 3.6 1) beta chain	AT7A_HUMAN Copper-transporting ATPase 1 (Copper pump 1) (Menkes disease-associated protein)	copper-transporting ATPase (EC 3.6.1) alpha chain	Menkes disease	ATPase, Cu++ transporting, alpha polypeptide		AAA96010.1 Menkes disease gene	Menkes Disease (ATP7A)	ORF
	NP_008950.	000762	AAB53362.1	CAB66118.1	AAH07656.1	AAH16292.1		AAB52902.1	NP_000044.1	P35670	S78555	AAA92667.1	2001422A	S40525	Q04656	S36149	CAB94714.1	NP_000043.1	AAA35580.1	4AA96010.1	CAB08162.2	AAA79212.1
U:(C-IR) 2.62	U:(C-D) 2.18						(II.(C.TB)	2.62														
	U:(C-D) Mm.89830 2.18							Mm.87854 2.62														
AK003722	BAB22959.1						NM_007511	NP_031537.1														

			AAA16173.1	AAA16173.1 Wilson disease-associated protein	809	e-173
NM_008356		U:(C-IR) 2.61				
NP_032382.1 Mm.20855 2.38	Mm.20855	U:(C-D)	NP_000631.1	interleukin 13 receptor, alpha 2 precursor, interleukin 13 binding protein; interleukin 13 receptor alpha 2 chain; IL-13 receptor	431	e-120
			Q14627	1132 HUMAN Interleukin-13 receptor alpha-2 chain precursor (Interleukin-13 binding protein)	431	e-120
			CAA64617.1	interleukin 13 receptor	431	e-120
			AAB17170.1	interleukin-13 receptor	431	e-120
			CAA70021.1	IL-13 receptor	431	e-120
			CAD18962.1	dA204F4.1 (interleukin 13 receptor, alpha 2)	431	e-120
			AAH20739.1	interleukin 13 receptor, alpha 2	431	e-120
			AAH33705.1	interleukin 13 receptor, alpha 2	431	e-120
		U:(C-IR) 2.59 U:(C-D)	AAG17965.1	AF089087_1 G-protein-coupled receptor	411	e-114
NM_022320 NP_071715.1	Mm.1527 80	3.35 U:(IR-D) 2.3				
			NP_005292.1	005292.1 G protein-coupled receptor 35	409	e-113
			О9НС97	GP35_HUMAN Probable G protein-coupled receptor GPR35	409	e-113
			AAC52028.1	G protein-coupled receptor	409	e-113
NM_010174 NP_034304.1	Mm.2222 0	U:(C-IR) 2.54	CAA71305.1	mammary-derived growth inhibitor	241	5e-64
			NP_004093.1	fatty acid binding protein 3	240	1e-63
			XP_049316.1	similar to Fatty acid-binding protein, heart (H-FABP) (Muscle fatty acid-binding protein) (M-FABP) (Mammary-derived growth inhibitor) (MDGI)	240	1e-63
			P05413	FABH_HUMAN Fatty acid-binding protein, heart (H-FABP) (Muscle fatty acid-binding protein) (M-FABP) (Mammary-derived growth inhibitor) (MDGI)	240	1e-63
			FZHUC	fatty acid-binding protein, cardiac and skeletal muscle - human	240	1e-63

			CA A 30880 1			
			11200501	\neg	240	le-63
			AAB02555.1	fatty acid binding protein FABP	240	1e-63
			AAC99800.1	fatty acid binding protein	240	1e-63
			AAH07021.1	AAH07021 fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)	240	1e-63
			1G5W	A Chain A, Solution Structure Of Human Heart-Type Fatty Acid Binding Protein	238	6e-63
			1HMR	Fatty Acid Binding Protein (Human Muscle, M-Fabp) Complexed With One Molecule Of Elaidic Acid	238	6e-63
			IHIMS	Fatty Acid Binding Protein (Human Muscle, M-Fabp) Complexed With One Molecule Of Elaidic Acid	238	66-63
			1HMT	Fatty Acid Binding Protein (Human Muscle, M-Fabp) Complexed With One Molecule Of Elaidic Acid	238	66-63
			2HMB	Fatty Acid Binding Protein (Holo Form, Human Muscle) (M-Fabo)	238	66-63
			1714345A	fatty acid-binding protein	237	18-63
			AAB29294.1	heart fatty acid binding protein; hFABP	214	8
70000 344		U:(C-IR)				3
MIM_00/034		2.52 U:(C-D)				
NP_031660.1	Mm.4008	2.12	AAB60342.1	cyclin F	1206	C
			P41002	CG2F_HUMAN G2/mitotic-specific cyclin F	1205	
			AAH12349.1	cyclin F :	1205	0
			NP_001752.1	cyclin F; G2/mitotic-specific cyclin F; F-box only protein 1	1197	0
			A55501	cyclin F	1197	0
			CAA85308.1	cyclin F [Homo sapiens]	1197	0
		U:(C-IR)	NP_002338.1	lymphocyte antigen 6 complex, locus H	209	2e-54
		U:(C-D)				
NM_011837 NP_035967.1	Mm.2215 1	2.06 2.06				
			094772	LY6H_HUMAN Lymphocyte antigen Ly-6H precursor	209	2e-54

			AAG53403.1	AF322642 1 caspase recruitment domain protein 14	1257	0
			AAK54453.1	CARD-containing MAGUK 2 protein	1257	0
			AAH18142.1	Similar to caspase recruitment domain protein 14	953	0
			NP 438170.1	caspase recruitment domain protein 14 isoform 2; CARD-containing	407	e-113
			AAH01326.1	Unknown (protein for MGC:5551)	407	e-113
			Q9BXL7	CARB_HUMAN Caspase recruitment domain protein 11 (CARD-containing MAGUK protein	202	3e-51
			AAG53402.1	AF322641_1 caspase recruitment domain protein 11	202	3e-51
			NP_115791.2	caspase recruitment domain family, member 11; card-maguk protein 1;	202	3e-51
			AAL34460.1	AF352576_1 CARD-containing MAGUK protein CARMA1	202	3e-51
			BAB84875.1	FLJ00120 protein	202	3e-51
NM_009203		U:(C-IR) 2.49				
I	U:(C-D) Mm.12846 2.42	U:(C-D) 2.42	P_653186.2	urate anion exchanger 1 isoform a; organic anion transporter 4-like; urate transporter 1; solute carrier family 22 member 12	780	
			AAK68156.1	AC044790_3 RST	780	0
			BAB96750.1	URATI	780	0
			BAB68364.1	organic anion transpoter 4 like protein	889	0
			NP 060954.1	solute carrier family 22 member 11; organic anion transporter 4	205	e-142
			BAA95316.1	organic anion transporter 4	502	e-142
			AAK68155.1	AC044790_2 OAT4	502	e-142
			AAH34384.1	solute carrier family 22 (organic anion/cation transporter), member 11	502	e-142
			NP_695008.1	solute carrier family 22 member 6 isoform b; renal organic anion transporter 1; para-aminohippurate transporter	457	e-128
			AAD19356.1	organic anion transporter 1	457	e-128
			BAA75073.1	hOATI-2 :	457	e-128
			AAD55356.1	AF124373_1 organic anion transporter 1	457	e-128
			AAH33682.1	solute carrier family 22 (organic anion transporter), member 6	457	e-128
			AAC70004.1	putative renal organic anion transporter 1	457	e-128

			NP_004781.2	solute carrier family 22 member 6 isoform a; renal organic anion transporter 1; para-aminohippurate transporter	456	e-128
			BAA75072.1 hOAT1-1	hOAT1-1	456	e-128
			CAB77184.1	organic anion transporter	456	e-128
			AAD10052.1	para-aminohippurate transporter	455	e-128
			NP_700357.1	NP_700357.1 urate anion exchanger 1 isoform b; organic anion transporter 4-like; urate transporter 1; solute carrier family 22 member 12	434	e-121
			NP_695011.1	solute carrier family 22 member 6 isoform e; renal organic anion transporter 1; para-aminohippurate transporter	428	e-119
			BAB47393.1	organic anion transporter 3	418	e-116
NM_023434 Mm NP_075923.1 3	Mm.2855 3	U:(C-IR) 2.47	NP_055643.1	KIAA0737 gene product	891	0
			BAA34457.1	KIAA0737 protein	891	0
			AAH13689.1	AAH13689 KIAA0737 gene product	891	0
			XP_049037.5	similar to CAGF9	241	4e-63
·						
				-		
NM_011356 NP_035486.1 Mm	Mm.3246	U:(C-IR) 2.45	092765	FRZB_HUMAN Frizzled-related protein precursor (Frzb-1) (Frezzled) (Fritz)	595	e-169
			AAC51217.1	frezzled	595	e-169
			AAH27855.1	Unknown (protein for MGC:34598)	595	e-169

e-169	0 150	6 160	26-84	2e-84	0	0	0	10	e-152	e-152	e-151	e-151	e-151	e-150	e-150	e-149	e-149	e-149	e-148	e-148	e-148	2e-71	2e-71
593	502	503	317	312	1033	1033	1033	1033	536	535	534	534	532	531	530	526	526	526	523	523	523	268	268
 frizzled-related protein; Fritz; Frzb-1; fre; frizzled (Drosophila) homolog-related; fzrb; hfiz 	Frzb precursor		secreted frizzled-related protein 4; secreted frizzled-related protein 4		acyl-Coenzyme A oxidase 2, branched chain; Peroxisomal branched chain acyl-CoA oxidase	CAO2_HUMAN Acyl-coenzyme A oxidase 2, peroxisomal (Branched-chain acyl-CoA oxidase) (BRCACox) (Trihydroxycoprostanoyl-CoA oxidase) (THCA-CoA oxidase)	branched chain acyl-CoA oxidase	peroxisomal branched chain acyl-CoA oxidase	peroxisomal acyl-coenzyme A oxidase	CAO1_HUMAN Acyl-coenzyme A oxidase 1, peroxisomal (Palmitoyl-CoA oxidase) (AOX)	acyl-CoA oxidase (EC 1.3.3.6), peroxisomal	peroxisomal acyl-CoA oxidase	AAH08767 Similar to acyl-Coenzyme A oxidase 1, palmitoyl	AAH10425 Unknown (protein for MGC:15225)	peroxisomal fatty acyl-coA oxidase	acyl-Coenzyme A oxidase isoform b; acyl-coenzyme A oxidase 1	acyl-CoA oxidase (EC 1.3.3.6), peroxisomal splice form I	acyl-CoA oxidase	acyl-Coenzyme A oxidase isoform a; acyl-coenzyme A oxidase 1	acyl-CoA oxidase (EC 1.3.3.6), peroxisomal splice form II	acyl-CoA oxidase	NP_003492.1 acyl-Coenzyme A oxidase 3, pristanoy1	CAO3_HUMAN Acyl-coenzyme A oxidase 3, peroxisomal (Pristanoyl-CoA oxidase)
NP_001454.1	AAC50736.1	AAB51298.1	NP_003005.1	AAC04617.1	NP_003491.1	Q99424	CAA64489.1	CAB65596.1	AAB30019.2	Q15067	138095	CAA50574.1	AAH08767.1	AAH10425.1	AAA18595.1	NP_009223.1	A54942	AAA19113.1	NP_004026.1	B54942	AAA19114.1	NP_003492.1	015254
					U:(C-IR) 2.42																		
					Mm.2870 0																		
					NM_053115 NP_444345.1																		

			CAA72214.1	pristanoyl-CoA oxidase	268	2e-71
		U:(C-IR) 2.42	NP_001731.1	calbindin 2 full length protein isoform; calbindin 2, (29kD, calretinin); calbindin D29K	371	e-102
			P22676	CLB2_HUMAN Calretinin (CR) (29 kDa calbindin)	371	e-102
			A60253	calretinin	371	e-102
			CAA39991.1	calretinin	371	e-105
			1709139B	calretinin	371	e-102
			AAH15484.1	AAH15484 calbindin 2, (29kD, calretinin)	371	e-102
			NP_004920.1	calbindin 1; calbindin 1, (28kD)	249	5e-66
			P05937	CABV_HUMAN Calbindin (Vitamin D-dependent calcium-binding protein, avian-type) (Calbindin D28) (D-28K)	249	5e-66
			S00234	calcium-binding protein, vitamin D-dependent	249	\$e-66
			CAA29860.1	calbindin (AA 1-261)	249	5e-66
			AAC62230.1	27kDa calbindin	249	5e-66
			AAD08724.1	calbindin 1·	249	5e-66
			AAH06478.1	AAH06478 calbindin 1, (28kD)	249	5e-66
			AAH20864.1	AAH20864 calbindin 1, (28kD)	249	99-e5
			1403296A	calbindin 27kD	249	2e-66
			1709139A	calbindin D28K	249	2e-66
			NP_009019.1	calbindin 2 isoform 22k; calbindin 2, (29kD, calretinin); calbindin D29K	199	1e-50
			NP_009018.1	009018.1 calbindin 2 isoform 20k; calbindin 2, (29kD, calretinin); calbindin D29K	198	1e-50
NM_013612 NP_038640.1 Mr	Mm.2913	U:(C-IR) 2.38	XP_002585.4	similar to Natural resistance-associated macrophage protein 1 (NRAMP 1)	905	0
			P49279	NRM1_HUMAN Natural resistance-associated macrophage protein 1 (NRAMP 1)	905	0
			629551	integral membrane protein	905	0
			AAA57521.1	integral membrane protein	905	0
			BAA08908.1	Угаптр .	905	0
			AAG15405.1	natural resistance-associated macrophage protein 1	905	0

			BAA08907.1	Nramp	904	0
			JC4095	natural resistance-associated macrophage protein NRAMP 1	889	0
			NP_000569.1	solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1; natural resistance-associated macrophage protein 1 (might include Leishmaniasis); solute carrier family 11 (sodium/phosphate symporters), member 1	887	0
			CAA57541.1	NRAMP	887	0
			BAA07370.1	Nramp	818	0
			CAD38517.1	divalent metal transporter	649	0
			NP_000608.1	solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2; natural resistance-associated macrophage protein 2	649	0
			BAA24933.1	NRAMP2	649	0
			AAC21460.1	natural resistance-associated macrophage protein 2	649	0
			AAC18078.1	NRAMP2 iron transporter	649	0
			AAH02592.1	AAH02592 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2	649	0
			P49281	NRM2_HUMAN Natural resistance-associated macrophage protein 2 (NRAMP 2) (Divalent metal transporter 1) (DMT1)	648	0
			AAC21459.1	natural resistance-associated macrophage protein 2 non-IRE form	648	0
			AAC21461.1	natural resistance-associated macrophage protein 2	648	0
			BAB93467.1	natural resistance-associated macrophage protein 2 non-IRE form	648	0
			BAA34374.1	natural resistance-associated macrophage protein 2	633	0
			157022	integral membrane protein	629	e-180
			AAA79219.1	integral membrane protein	629	e-180
NM_020503 NP_065249.1	Mm.1038 03	U:(C-IR) 2.38	NP_062545.1	taste receptor T2R1; taste receptor, family B, member 7; taste receptor, type 2, member 1	260	2e-69
			AAF43902.1	AF227129_1 candidate taste receptor T2R1	260	2e-69
NM_026091 NP_080367.1	Mm.2771 1	U:(C-IR) 2.36	BAB14854.1	unnamed protein product	323	4e-88
			CAC17545.1	dJ1009E24.3 (novel protein)	323	4e-88

46-88	46-88	18-87	100	Ie-8/			0	0	0	0	86-01	8-01	8e-91	8e-91	26-83	2e-83	2e-83	2e-83	2e-83	2e-83	2e-83	4e-75	4e-75
373	373	321	22.1	321		629	629	229	673	673	332	33	332	332	308	308	308	308	308	308	308	280	280
1 AAH12196 Unknown (protein for MGC:4349)						CXA8_HUMAN Gap junction alpha-8 protein (Connexin 50) (Cx50) (Lens fiber protein MP70)	AF217524_1 gap junction protein alpha 8	gap junction protein, alpha 8, 50kDa (connexin 50); gap junction membrane channel protein alpha-8; connexin 50; Gap junction membrane channel protein alpha-8 (connexin 50); gap junction protein, alpha 8, 50kD (connexin 50)	intrinsic membrane protein MP70	gap junction membrane channel protein alpha-	gap junction protein, alpha 3, 46kDa (connexin 46); gap junction protein, alpha 3, 46kD (connexin 46)	bA26414.3 (novel connexin (gap junction protein))	CXA3_HUMAN Gap junction alpha-3 protein (Connexin 46) (Cx46)		gap junction protein, alpha 5, 40kDa (connexin 40); gap junction protein, alpha 5, 40kD (connexin 40)	CXA5_HUMAN Gap junction alpha-5 protein (Connexin 40) (Cx40)		AF151979_i connexin 40	connexin40	AAH13313 gap junction protein, alpha 5, 40kD (connexin 40)8	connexin40	AF271261_1 connexin 58	connexin 59; gap junction alpha 10
AAH12196.1	AAH24036.1	NP_060344.1	BAA91252.1			P48165	AAF32309.1	 NP_005258.1	139176	AAA77062.1	NP_068773.2	CAC16957.1	8Н9Х6О	AAD42925.1	NP_005257.2	P36382	AAA91833.1	AAD37801.1	AAA60457.2	AAH13313.1	I38429	AAK55516.1	NP_110399.1
						U:(C-R) 2.35																	
						U:(C Mm.56907 2.35								1									
					NM_008123																		

	P57773	CXAA_HUMAN Gap junction alpha-10 protein (Connexin 59) (Cx59)	280	4e-75
	AAG09406.1	1 AF179597_1 connexin 59	280	4e-75
	NP_115991.1	.1 connexin 62	279	8e-75
	AAK51676.1	1 AF296766_1 connexin 62	279	8e-75
	CAC93847.1	1 connexin62	279	8e-75
	AAD56533.1	1 AF180815_1 truncated connexin 37 polymorph	267	3e-71
NM_013473 U:(C NP_038501.2 Mm.3267 2.35	U:(C-IR) XP_036593.2 2.35		969	e-170
	AAH04376.1	1 AAH04376 annexin A8	596	e-170
	NP_001621.1	.1 annexin VIII; Annexin VII	595	e-169
	P13928	ANX8_HUMAN Annexin A8 (Annexin VIII) (Vascular anticoagulant-beta) (VAC-beta)	565	e-169
	CAA34650.1	1 vascular anticoagulant-beta (AA 1 - 327)	595	e-169
	LUHU8	annexin VIII	593	e-169
	AAB46383.1	1 anexin VIII	590	e-168
	XP_054475.4	4 similar to annexin A8	575	e-165
	P09525	ANX4_HUMAN Annexin A4 (Annexin IV) (Lipocortin IV) (Endonexin I) (Chromobindin 4) (Protein II) (P32.5) (Placental anticoagulant protein II) (PAP-II) (PP4-X) (35-beta calcimedin) (Carbohydrate-binding protein P33/P41) (P33/41)	337	4e-92
	NP_001144.1	l annexin IV; annexin IV (placental anticoagulant protein II); placental anticoagulant protein II	337	4e-92
	XP_031596.2	2 similar to annexin IV; annexin IV (placental anticoagulant protein II); placental anticoagulant protein II	337	4e-92
	A42077	annexin IV	337	4e-92
	AAA51740.1	annexin IV (placental anticoagulant protein II)	337	4e-92
	BAA11227.1	annexin IV (carbohydrtate-binding protein p33/41)	337	4e-92
	AAH00182.1	1 AAH00182 annexin A4	337	4e-92
	AAH11659.1	1 AAH11659 Similar to annexin A4	337	4e-92
	AAC41689.1	protein PP4-X	337	4e-92

	195		
]1ANW	A Chain A, Annexin V	328	2e-89
1ANW	B Chain B, Annexin V	328	2e-89
IANX	A Chain A, Annexin V	328	2e-89
1ANX	B Chain B, Annexin V	328	2e-89
1ANX	C Chain C, Annexin V	328	2e-89
NP_001145.1	annexin V; endonexin II; anchorin CII; lipocortin V; placental anticoagulant protein I	328	2e-89
P08758	ANX5_HUMAN Annexin V (Lipocortin V) (Endonexin II) (Calphobindin I) (CBP-1) (Placental anticoagulant protein I) (PAP-1) (PP4) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha) (Anchorin CII)	328	2e-89
AQHUP	annexin V [validated]	328	2e-89
1AVH	A Chain A, Annexin V (Hexagonal Crystal Form)	328	2e-89
1AVH	B Chain B, Annexin V (Hexagonal Crystal Form)	328	2e-89
IHAK	A Chain A, Crystal Structure Of Recombinant Human Placental Annexin V Complexed With K-201 As A Calcium Channel Activity Inhibitor	328	2e-89
1HAK	B Chain B, Crystal Structure Of Recombinant Human Placental Annexin V Complexed With K-201 As A Calcium Channel Activity Inhibitor	328	2e-89
1AVR	Annexin V (Rhombohedral Crystal Form)	328	2e-89
CAA30985.1	VAC protein (AA 1-320)	328	2e-89
AAA35570.1	anticoagulant precursor (5' end put.); putative	328	2e-89
AAA52386.1	endonexin II	328	2e-89
AAB59545.1	anticoagulant protein 4	328	2e-89
BAA00122.1	blood coagulation inhibitor	328	2e-89
AAA36166.1	lipocortin-V	328	2e-89
AAB40047.1	annexin V	328	2e-89
AAB60648.1	annexin V	328	2e-89
AAH01429.1	AAH01429 annexin A5	328	2e-89
AAH04993.1	AAH04993 annexin A5	328	2e-89
AAH12804.1	AAH12804 Similar to annexin A5	328	2e-89
AAH12822.1	AAH12822 Similar to annexin A5	328	2e-89

			1512315A	calphobindin	328	2e-89
			1313303A	coagulation inhibitor	328	2e-89
NM_008075						
NP_032101.1	U:(C Mm.14116 2.33	U:(C-IR) 2.33	NP_002033.1	gamma-aminobutyric acid (GABA) receptor, rho 1; gamma-aminobutyric acid (GABA) A receptor, rho-1	881	0
			P24046	GAR1_HUMAN Gamma-aminobutyric-acid receptor rho-1 subunit precursor (GABA(A) receptor)	881	0
			A38627	gamma-aminobutyric acid receptor A rho-1 chain precursor	881	0
	1		AAA52509.1	gamma-aminobutyric acid receptor type A rho-1 subunit	881	0
			P28476	GAR2_HUMAN Gamma-aminobutyric-acid receptor rho-2 subunit precursor (GABA(A) receptor)	654	0
			CAC07339.1	dI131H7.1 (gamma-aminobutyric acid (GABA) receptor rho 2)	654	0
			NP_002034.1	gamma-aminobutyric acid (GABA) receptor, rho 2 precursor	652	0
			A38079	gamma-aminobutyric acid receptor rho-2 chain precursor	652	0
			AAA52510.1	gamma-amino butyric acid	652	0
			XP 1160362	similar to Gamma-aminobutyric-acid receptor rho-3 subunit precursor (GABA(A)	3,	6
			7.000017 77	(roldson)	404	6-179
			NP_068712.1	gamma-aminobutyric acid (GABA) A receptor, beta 3, isoform 2 precursor	315	2e-85
			NP_000805.1	garuma-aminobutyric acid (GABA) A receptor, beta 3, isoform 1 precursor	315	2e-85
			P28472	GAB3_HUMAN Gamma-aminobutyric-acid receptor beta-3 subunit precursor (GABA(A) receptor)	315	2e-85
			A55275	gamma-aminobutyric acid A receptor beta 3 chain splice form 1	315	2e-85
			AAA52511.1	GABA-alpha receptor beta-3 subunit	315	2e-85
			AAH10641.1	gannna-aminobutyric acid (GABA) A receptor, beta 3	312	1e-84
			NP_000806.1	gamma-aminobutyric acid (GABA) A receptor, delta	305	2e-82
			014764	GAD_HUMAN Gamma-aminobutyric-acid receptor delta subunit precursor (GABA(A) receptor)	305	2e-82
			AAB70007.1	GABA-A receptor delta subunit	305	2e-82
			AAH33801.1	ganuna-aminobutyric acid (GABA) A receptor, delta	302	2e-81

			NP 000804.1	gamma-aminobutyric acid (GABA) A receptor, beta 2, isoform 2	302	2e-81
			P47870	GAB2_HUMAN Gamma-aminobutyric-acid receptor beta-2 subunit precursor (GABA(A) receptor)	302	2e-81
			AAB29370.1	gamma-aminobutyric acid A receptor beta 2 subunit; (GABA)A receptor beta 2 subunit	302	2e-81
			AAB33983.1	GABAA receptor beta 2 subunit	302	2e-81
NM_008009						
NP_032035.1 M	Mm.46053 2	U:(C-IR) 2.32	NP_005121.1	heparin-binding growth factor binding protein	268	2e-71
			A41178	heparin-binding growth factor-binding protein precurso	268	2e-71
			AAA58636.1	heparin binding protein	268	2e-71
			AAD39216.1	AF149412_1 HBP17 heparin-binding and FGF-binding protein	268	2e-71
			AAH03628.1	heparin-binding growth factor binding protein	268	2e-71
			AAH08910.1	heparin-binding growth factor binding protein	268	2e-71
NM_008352	72	U:(C-IR) 2.29		interleukin 12B precursor; natural killer cell stimulatory factor-2; interleukin 12B;		
NP_032378.1	2	U:(C-D) 2.24	NP_002178.2	cytotoxic lymphocyte maturation factor 2, p40; interkeukin-12 beta chain; interleukin 12, p40; natural killer cell stimulatory factor, 40 kD subunit; IL23, subuint p40	431	e-120
			P29460	I12B_HUMAN Interleukin-12 beta chain precursor (IL-12B) (Cytotoxic lymphocyte maturation factor 40 kDa subunit) (CLMF p40) (NK cell stimulatory factor chain 2) (NKSF2)	431	e-120
			A38957	interleukin 12B precursor	431	e-120
			AAA35695.1	cytotoxic lymphocyte maturation factor 40 kDa subunit	431	e-120
			AAD56386.1	AF180563_1 interleukin 12, P40	431	e-120
			AAG32620.1	interleukin 12 p40 subunit	431	e-120
	-		AAM34792.1	AF512686_1 interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40)	431	e-120
			AAA59938.1	natural killer cell stimulatory factor	429	e-120
			1F42	A Chain A, The P40 Domain Of Human Interleukin-12	400	e-1111
			1F45	A Chain A, Human Interleukin-12	400	e-1111

		U:(C-IR) BAB: 2.28	BAB32547.1	332547.1 small integral membrane protein of lysosome/late endosome	234	5e-61
NM_019980 Mm.2111 U:(C-D)	2111	U:(C-D)				
NP_064364.1 9	_ `	2.11				
			NTD 00/052 1	004052 1 FDG :- 1-1- F-1-1- F-1-1		T
				Lr S-induced 1 Nr-appa factor	178	3e-56

		Q99732	LITF HUMAN Lipopolysaccharide-induced tumor necrosis factor-alpha factor (LPS-induced TNF-alpha factor) (P53-induced protein 7)	178	3e-56
		AAB36550.1	LPS-Induced TNF-Alpha Factor	178	3e-56
		AAC39530.1	Pig7	178	3e-56
					3
		·			
				-	
	U:(C-IR) 2.28	AAH22393.1	. (22393.1 teratocarcinoma-derived growth factor 1	239	1e-62
NM_011562 NP_035692.1 Mm.5090					
		NP_003203.1	003203.1 teratocarcinoma-derived growth factor 1	238	2e-62
		P13385	CRI1_HUMAN Teratocarcinoma-derived growth factor 1 (Epidermal growth factor-like cripto protein CR1) (Cripto-1 growth factor) (CRGF)	238	2e-62
		A30362	teratocarcinoma-derived growth factor 1	238	2e-62
		CAA32467.1	cripto protein (AA 1-188)	238	2e-62
		AAA61134.1	teratocarcinoma-derived growth factor I	238	2e-62
		P51864	CRI2_HUMAN Teratocarcinoma-derived growth factor 2 (Epidermal growth factor-like cripto protein CR3) (Cripto-3 growth factor)	235	2e-61
		AAA61135.1	teratocarcinoma-derived growth factor 3	235	2e-61
		AAB46353.1	EGF repeat containing protein; HUMTDGF1A Human (clone CR) teratocarcinoma-derived growth factor 1 (TDGF1) gene P13385; coded for by human cDNAs M96956 (NID:g339432), X14253 (NID:g30220) and M96955 (NID:g339430)	235	2e-61
		AAG49538.1	AF251549_1 cripto 3	235	2e-61
		AAG49539.1	AF251550_1 cripto 3	235	2e-61
		A39787	teratocarcinoma-derived growth factor	235	2e-61
		XP_092153.1	similar to teratocarcinoma-derived growth factor 1	207	6e-53
NM_019871 NP_063924.1 Mm.6211	U:(C-IR) 2.27	XP_083967.1	similar to acyl-malonyl condensing enzyme	186	5e-88
		NP 689675.1	NP 689675.1 hypothetical protein FLJ40154	186	5e-88

			BAC05067.1	BAC05067.1 unnamed protein product	186	5e-88
			XP_083960.2	similar to acyl-malonyl condensing enzyme	184	2e-87
			NP_473369.1	acyl-malonyl condensing enzyme	182	2e-85
			CAC82744.1	acyl-malonyl condensing enzyme	182	2e-85
			XP_064583.3	similar to acyl-malonyl condensing enzyme	182	7e-85
			,			:
NM_009650		U:(C-IR) 2.26 11-(C-D)		AKA3_HUMAN A-kinase anchor protein 3 (Protein kinase A anchoring protein 3/PRKA3) (A-kinase anchor protein 110 kDa) (AKAP 110) (Sperm protein linding		
NP 033780.1 Mm.87748 2.43	Mm.87748	2.43	075969	protein) (Fibrousheathin I) (Fibrous sheath protein of 95 kDa) (FSP95	1170	0
			AAC63371.1	protein kinase A binding protein AKAP110	1170	0
			AAD21218.1	sperm oocyte binding protein	1167	0
			NP_006413.2	kinase (PRKA) anchor protein 3; sperm oocyte binding protein 1; fibrousheathin 1	1167	0
			AAC35854.1	fibrousheathin I	1163	0
		·	NP_647450.1	kinase (PRKA) anchor protein 4 isoform 2; A-kinase anchor protein 82 kd	375	e-103
	•		NP_003877.2	A kinase (PRKA) anchor protein 4 isoform 1; A-kinase anchor protein 82 kDa	375	e-103
			AAC79433.1	major sperm fibrous sheath protein precursor	371	e-102
			CAA75494.1	sperm protein	270	1e-72
			JC5986	A-kinase anchoring protein homolog	264	7e-71
NM_008166		(at 2).11				
NP 032192.1 Mm.7983	Mm.7983	2.26	BAA86534.1	KIAA1220 protein	1495	0
			XP_043613.7	similar to glutamate receptor delta-1 subunit	1379	0

AAH39263.1 Similar to	Similar to glutamate receptor, ionotropic, delta 1
NP_001501.1 glutamate	Ta-2
O43424 GRD2_H	GRD2_HUMAN Glutamate receptor delta-2 subunit precursor
AAC39579.1 glutamate	glutamate receptor delta-2 subunit
NP_000821.1 glutamate	glutamate receptor, ionofropic, kainate 1; human glutamate receptor (GLUR5)
GLK1_H P39086 receptor 5	GLK1_HUMAN Glutamate receptor, ionotropic kainate 1 precursor (Glutamate receptor 5) (GluR-5) (GluR-5) (Excitatory amino acid receptor 3) (EAA3)
I58178 glutamate	glutamate receptor
AAA52568.1 glutamate	glutamate receptor
CAC80546.1 glutamate	glutarnate receptor subunit GluR5
AAA95961.1 EAA3	
CAC80548.1 glutamate	glutamate/kainate receptor subtype GluR7
NP_000822.1 glutamate	glutamate receptor, ionotropic, kainate 3
AAB60407.1 EAAS	
17332.1 zinc finger protein	er protein
NP 005976.2 snail 1 ho	snail 1 homolog; snail 1 zinc finger protein 442
O95863 SNAI HT	SNAI HUMAN Zinc finger protein SNAI1 (Snail protein homolog) (Sna protein) 442
CAB52414.1 SNAI1 protein	rotein 442
AAD52986.1 AF15523;	AF155233_1 snail zinc finger protein 442
CAC07340.1 dJ710H13	dJ710H13.1 (snail 1 (drosophila homolog), zinc finger protein)
AAH12910.1 AAH1291	AAH12910 Unknown (protein for MGC:21748)
XP_065615.1 similar to	similar to snail 1 (drosophila homolog), zinc finger protein
AAF32527.1 AF131208	AF131208 1 snail protein 250
NP_003059.1 snail 2; ne protein	snail 2; neural crest transcription factor SLUG; slug (chicken homolog), zinc finger 249 protein
O43623 SLUG HUMAN (Snail homolog 2)	SLUG_HUMAN Zinc finger protein SLUG (Neural crest transcription factor Slug) 249 (Snail homolog 2)
AAC34288.1 zinc finger	zinc finger protein slug

			AAD55240.1	AF084243 1 zinc finger protein SLUG	240	99-99
			AAH14890.1	AAH14890 slug (chicken homolog), zinc finger protein	249	99-99
			AAH15895.1	AAH15895 slug (chicken homolog), zinc finger protein	249	99-99
NM_021546 N NP_067521.1 4	Mm.1437 48	U:(C-IR) 2.26	AAL01118.1	AF409141_1 NIP1	477	e-134
			NP_112508.1	anyloid beta (A4) precursor protein-binding, family A, member 2 binding protein, isoform 1; synaptotagmin interacting protein STIP3; X11L-binding protein 51; amyloid beta (A4) precursor protein-binding, family A, member 2; synaptotagmin interacting protein 2; neuronal calcium-binding protein NECAB3	475	e-134
			AAG28415.1	AF193759_1 neuronal calcium binding protein NECAB3	475	e-134
			CAD37360.1	dJ63M2.4.1 (amyloid beta (A4) precursor protein-binding family A, member 2 protein, variant 1)	397	e-110
			NP_112509.1	amyloid beta (A4) precursor protein-binding, family A, member 2 binding protein, isoform 2; synaptotagmin interacting protein STIP3; X11L-binding protein 51; amyloid beta (A4) precursor protein-binding, family A, member 2; synaptotagmin interacting protein 2; neuronal calcium-binding protein NECAB3	358	2e-98
			BAB16413.1	X11L-binding protein 51	358	2e-98
			NP 071746.1	synaptotagmin interacting protein 1	254	3e-67
			BAC04568.1	unnamed protein product	254	3e-67
			AAG28412.1	AF193756 1 neuronal calcium binding protein NECAB1	196	7e-50
NM_025746 M NP_080022.1 2	Mm.4614 2	U:(C-IR) 2.24	2208307A	PNG gene	206	9e-53
AK010751		U:(C-IR)				
AAN60072.1 M	Im.29522	Mm.29522 2.23	AAL23683.1	MARK4 serine/threonine protein kinase	183	9e-51
			BAC11510.1	unnamed protein product	183	9e-51
			AAM55491.1	MAP/microtubule affinity-regulating kinase-like 1	183	9e-51
			BAC03375.1	microtubule affinity-regulating kinase-like1	183	9e-51

			BAR55738 1	unnamed protein product	192	15.00
		U:(C-IR)		beta-1,3-N-acetylglucosaminyltransferase bGnT-3	208	e-144
NM_028189 NP_082465.1	Mm.2885 6	2.22 U:(C-IR) 2.41				
			NP_055071.1	beta-1,3-N-acetylglucosaminyltransferase bGnT-3; type II membrane protein; transmembrane protein; transmembrane protein 3; core 1 extending beta-1,3-N-acetylglucosaminyltransferase; beta-1,3-galactosyltransferase; beta-1,3-galactose; beta-1,3-galactose; beta-N-acetylglucosamine beta-1,3-galactosyltransferase 8; beta-3-GX-T8	909	e-143
			Q9Y2A9	B3G8_HUMAN Beta-1,3-galactosyltransferase 8 (Beta-1,3-GalTase 8) (Beta3Gal-T8) (b3Gal-T8) (UDP-galactose:beta-N-acetylglucosamine beta-1,3-galactosyltransferase 8) (UDP-Gal:beta-GlcNAc beta-1,3-galactosyltransferase 8) (Beta-3-Gx-T8) (Core 1 extending beta-1,3-N-acetylglucosaminyltransferase) (Core1-beta3GlcNAcT)	909	e-143
			BAA76497.1	type II membrane protein	506	e-143
			AAK00849.1	AF293973 1 core 1 extending beta-1,3-N-acetylglucosaminyltransferase	909	e-143
			CAC45044.1	beta-1,3-galactosyltransferase	909	e-143
			CAC82374.1	beta 1,6-GlcNAc-transferase	458	e-128
			NP 619651.1	beta-1,3-N-acetylglucosaminyltransferase protein	332	1e-90
			BAB8882.1	beta-1,3-N-acetylglucosaminyltransferase 6	332	1e-90
			AAH25357.1	Unknown (protein for IMAGE:4907098)	298	3e-80
			NP_660279.1	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7; hypothetical gene supported by AK000770	266	1e-70
			AAM61770.1	AF502430 1 beta 1,3-N-acetylglucosaminyltransferase 7	366	1e-70
			CAC45045.1	beta-1,3-galactosyltransferase	254	4e-67
			BAC04622.1	unnamed protein product	253	9e-67
			CAC82375.1	beta 1,3 galactosyltransferase	253	79-96
			AAL37219.1	AF321825 1 beta-1,3-galactosyltransferase-related protein	253	79-96
NM_008522		U:(C-IR)				
NP 032548.1 Mm.7612	Mm.7612	2.22	AAA59479.1	neutrophil lactoferrin	1038	0

		000200	TRFL_HUMAN Lactotransferrin precursor (Lactoferrin) [Contains: Lactoferroxin A;		
	-	FU2/00	Lactoleffoxin B; Lactoleffoxin C	1038	0
		TFHUL	lactotransferrin precursor	1038	0
		AAB60324.1	lactoferrin	1038	0
		AAH15822.1	lactotransferrin	1036	0
		AAH22347.1	lactotransferrin	1035	0
		CAA37116.1	precursor lactoferrin (709 AA)	1035	C
		AAA36159.1	lactoferrin	1035	0
		AAN11304.1	lactoferrin	1035	0
		AAA59511.1	lactoferrin	1035	0
		AAG48753.1	lactoferrin precursor	1034	6
		AAN63998.1	lactotransferrin precursor	1034	C
		AAH15823.1	lactotransferrin	1033	0
		NP_002334.1	002334.1 lactotransferrin	1032	
		CAA37914.1	precursor (AA -19 to 692)	1032	
NM_009637				7001	
NP 033767.1 Mm.86453	U:(C-IR) 53 2.22	XP_058567.1	similar to AE binding protein 2: AE-binding protein 2	242	0,160
		NP_694939.1	hypothetical protein MGC17922	562	e-160
		AAH15624.1	AAH15624 Similar to AE-binding protein 2	562	e-160
		AAH22220.1	Unknown (protein for MGC:17922)	562	e-160
NM_010198 Mm.572; NP_034328.1 8	Mm.5723 U:(C-IR) 8	NP_004103.1	NP_004103.1 fibroblast growth factor 11; fibroblast growth factor homologous factor 3	444	e-125
		092914	FGFB_HUMAN Fibroblast growth factor-11 (FGF-11) (Fibroblast growth factor homologous factor 3) (FHF-3)	444	e-125
		AAB18915.1	fibroblast growth factor homologous factor 3	444	e-125
		AAL15439.1	fibroblast growth factor 11	444	e-125
		AAM11871.1	AAM11871.1 fibroblast growth factor 11	444	e-125
		AAH32502.1	fibroblast growth factor 11	444	e-125

NP 004106.1	004106.1 fibroblast growth factor 14; fibroblast growth factor homologous factor 4	273	1e-73
Q92915	FGFE_HUMAN Fibroblast growth factor-14 (FGF-14) (Fibroblast growth factor homologous factor 4) (FHF-4)	273	1e-73
AAB18916.1	fibroblast growth factor homologous factor 4	273	1e-73
AAN16025.1	AE014303 1 FHF4	273	1e-73
NP_066360.1	fibroblast growth factor 12 isoform 1; fibroblast growth factor homologous factor 1; myocyte-activating factor; fibroblast growth factor 12B; fibroblast growth factor FGF-12b	273	2e-73
Q92912	FGFC_HUMAN Fibroblast growth factor-12 (FGF-12) (Fibroblast growth factor homologous factor 1) (FHF-1) (Myocyte-activating factor)	273	2e-73
AAB18913.1	fibroblast growth factor homologous factor 1	273	2e-73
CAA94239.1	fibroblast growth factor 11	261	5e-70
NP_004105.1	fibroblast growth factor 13, isoform 1A; fibroblast growth factor homologous factor 2	246	2e-65
Q92913	FGFD_HUMAN Fibroblast growth factor-13 (FGF-13) (Fibroblast growth factor homologous factor 2) (FHF-2)	246	2e-65
AAB18914.1	fibroblast growth factor homologous factor 2	246	2e-65
AAD16400.1	fibroblast growth factor 13 isoform 1A	246	2e-65
AAH12347.1	AAH12347 Unknown (protein for MGC:20109)	246	2e-65
AAH34340.1	fibroblast growth factor 13	246	2e-65
NP_004104.3	fibroblast growth factor 12 isoform 2; fibroblast growth factor homologous factor 1; myocyte-activating factor; fibroblast growth factor 12B; fibroblast growth factor FGF-12b	223	2e-58
JG0184	fibroblast growth factor - human	221	7e-58
AAB18786.3	fibroblast growth factor	221	7e-58
AAH22524.1	Unknown (protein for MGC:26659)	219	2e-57
NP_378668.1	fibroblast growth factor 13 isoform 1B; fibroblast growth factor homologous factor 2	213	1e-55
AAD16401.1	fibroblast growth factor 13 isoform 1B	213	1e-55

ficolin 1 precursor; ficolin (collagen/fibrinogen domain-containing) 1
FCN1_HUMAN Ficolin 1 precursor (Collagen/fibrinogen domain-containing protein 1) (Ficolin-A) (Ficolin A) (M-Ficolin)
ficolin (collagen/fibrinogen domain-containing) 1
ficolin
ficolin-1 precursor
ficolin
ficolin 2 isoform a precursor; ficolin (collagen/fibrinogen domain-containing lectin) 2 (hucolin); ficolin (collagen/fibrinogen domain-containing lectin) 2; hucolin
FCN2_HUMAN Ficolin 2 precursor (Collagen/fibrinogen domain-containing protein 2) (Ficolin-B) (Ficolin B) (Serum lectin p35) (EBP-37) (Hucolin) (L-Ficolin)
serum lectin P35
lectin P35
ficolin 2 isoform b precursor; ficolin (collagen/fibrinogen domain-containing lectin) 2 (hucolin); ficolin (collagen/fibrinogen domain-containing lectin) 2; hucolin
ficolin 3 precursor; ficolin (collagen/fibrinogen domain-containing) 3 (Hakata antigen)
FCN3_HUMAN Ficolin 3 precursor (Collagen/fibrinogen domain-containing protein 3) (Collagen/fibrinogen domain-containing lectin 3 p35) (Hakata antigen)
Hakata antigen
Similar to ficolin (collagen/fibrinogen domain-containing) 3 (Hakata antigen)
unnamed protein product
Unknown (protein for MGC:33476)
similar to Microfibril-associated glycoprotein 4
microfibrillar-associated protein 4; microfibril-associated glycoprotein 4
MFA4 HUMAN Microfibril-associated glycoprotein 4 precursor
microfibril-associated glycoprotein 4

			TE0091	tactic codium abound 1	200	-
			370071	וליטונס טעת מוון כוומודולין ז	503	2e-52
			BAA25897.1	sodium channel	203	5e-52
		U:(C-IR)	NP_057453.1	057453.1 claudin 18	424	e-118
NM_019815 Mm.3509 U.(C-D) NP_062789.1 0 2.12	Mm.3509 0	U:(C-D) 2.12	_			
			P56856	CLDI_HUMAN Claudin-18	424	e-118
			AAF26448.1	AF221069_1 Claudin-18	424	e-118
			AAL15637.1	AF349452_1 claudin-18A2.1	399	e-110
	· · · · · ·	U:(C-IR) 2.17	NP_443192.1	NP_443192.1 retinoid binding protein 7; putative cellular retinol-binding protein CRBP IV	259	2e-69
NM_022020 Mm.4602 U:(C-D) NP_071303.1 3 2.04	Mm.4602 3	U:(C-D) 2.04				
	j		Q96R05	RET7_HUMAN Retinol-binding protein IV, cellular (CRBP-IV) (Retinoid binding protein 7)	259	2e-69
			AAK85409.1	retinoid binding protein 7	259	2e-69
			AAN61071.1	putative cellular retinol-binding protein CRBP IV	259	2e-69
			AAH33883.1	Similar to retinoid binding protein 7	212	3e-55
NM_007702		(m)/11				
NP 031728.1	Mm.449	0:(~1K) 2.16	NP_001270.1	001270.1 cell death-inducing DFFA-like effector a	340	3e-93
			060543	CIDA_HUMAN Cell death activator CIDE-A (Cell death-inducing DFFA-like effector A)	340	3e-93
			AAC34987.1	cell death activator CIDE-A	340	3e-93
			AAH31896.1	Similar to cell death-inducing DFFA-like effector a	319	5e-87
NM_025639 NP_079915.1	Mm.2359 6	U:(C-IR) 2.16	NP_076958.1	076958.1 hypothetical protein MGC861	293	2e-79
			CAB77147.1	hypothetical protein	293	2e-79
			AAH00705.1	AAH00705 Unknown (protein for MGC:861)	293	2e-79
			AAH07495.1	AAH07495 hypothetical protein MGC861	293	2e-79

NM_025834 Mm.8079 U:(C-IR) NP_080110.1 8 2.16	Mm.8079	U:(C-IR) 2.16	NP_003882.1	protein Z, vitamin K-dependent plasma glycoprotein	260	e-159
			P22891	PRTZ_HUMAN Vitamin K-dependent protein Z precursor	260	e-159
			AAA36500.1	protein Z	999	e-159
			BAA85763.1	protein Z	999	e-159
			AAL27631.1	AF440358 1 protein Z, vitamin K-dependent plasma glycoprotein	999	e-159
			KXHUZ	plasma protein Z precursor	550	e-156
			AAA36501.1	protein Z	550	e-156
			BAA85764.1	protein Z spliced variant	550	e-156
			AAA36499.1	protein Z	454	e-127
			AAA51984.1	coagulation factor X precursor	214	7e-55
			1205236A	coagulation factor X	214	7e-55
			AAA52490.1	factor X prepeptide	213	1e-54
			NP_000495.1	coagulation factor X precursor; Prothrombinase	213	1e-54
			P00742	FA10_HUMAN Coagulation factor X precursor (Stuart factor)	213	1e-54
			EXHU	coagulation factor Xa (EC 3.4.21.6) precursor	213	1e-54
			AAA52421.1	coagulation factor X	213	1e-54
			AAA52764.1	coagulation factor X	213	1e-54
			AAM19347.1	AF503510_1: coagulation factor X	213	1e-54
				F9 (coagulation factor IX (plasma thromboplastic component, Christmas disease, haemophilia B))	201	6e-51
			NP_000124.1	coagulation factor IX; Coagulation factor IX (plasma thromboplastic component); Factor 9; Factor IX; Christmas factor	201	6e-51
			AAA52023.1	coagulation factor IX precursor	201	6e-51
		ì	AAA52763.1	factor IX (Christmas factor) precursor	201	6e-51
		•	AAM96188.1	coagulation factor IX (plasma thromboplastic component, Christmas disease, hemophilia B)	201	6e-51
			P00740	FA9 HUMAN Coagulation factor IX precursor (Christmas factor)	201	6e-51
			KFHU	coagulation factor IXa (EC 3.4.21.22) precursor	201	6e-51

			AAB59620.1	factor IX	201	6e-51
			AAA56822.1	factor IX	201	6e-51
			AAA98726.1	factor IX	199	3e-50
U16162 AAC52197.1	Mm.2212	U:(C-IR) 2.16	DAHUA1	procollagen-proline dioxygenase (EC 1.14.11.2) alpha chain precursor, splice form l	1001	0
			AAA59069.1	alpha-subunit of prolyl 4-hydroxylase	1001	0
			NP_000908.1	procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide I; procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide 1	991	0
			AAA36534.1	prolyl 4-hydroxylase alpha subunit (EC 1.14.11.2)	991	0
			P13674	P4H1_HUMAN Prolyl 4-hydroxylase alpha-1 subunit precursor (4-PH alpha-1) (Procollagen-proline, 2-oxoglutarate-4-dioxygenase alpha-1 subunit)	982	0
			DAHUA2	procollagen-proline dioxygenase (EC 1.14.11.2) alpha chain precursor, splice form 2	982	0
			AAA59068.1	alpha-subunit of prolyl 4-hydroxylase	982	0
			AAH34998.1	Similar to procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide I	982	0
			AAA36535.1	prolyl 4-hydroxylase alpha subunit (EC 1.14.11.2)	971	0
	·		NP_004190.1	procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide II; prolyl 4-hydroxylase, alpha polypeptide, type 2; prolyl-4-hydroxylase, alpha polypeptide, type II	629	0
			015460	P4H2_HUMAN Prolyl 4-hydroxylase alpha-2 subunit precursor (4-PH alpha-2) (Procollagen-proline, 2-oxoglutarate-4-dioxygenase alpha-2 subunit)	629	0
			AAB71339.1	prolyl 4-hydroxylase alpha (II) subunit	619	0
			CAC85689.1	Prolyl 4-hydroxylase alpha IIb subunit	629	0
	!		CAC85688.1	Prolyl 4-hydroxylase alpha IIa subunit	658	0
			AAH35813.1	Similar to procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide II	658	0
		U:(C-IR)	NP_002603.1	pyruvate dehydrogenase kinase, isoenzyme 4	764	0
NM_013743 N NP_038771.1	Mm.1028 U:(C-D) 3 2.04	U:(C-D) 2.04		·		

Q16654	PDK4_HUMAN [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 4, mitochondrial precursor (Pyruvate dehydrogenase kinase isoform 4)	764	0
AAC50669.1	pyruvate dehydrogenase kinase isoform 4	764	0
AAC50670.1	pyruvate dehydrogenase kinase isoform 4	767	0
AAB67048.1	pyruvate dehydrogenase kinase isoform 4	764	0
AAH40239.1	pyruvate dehydrogenase kinase, isoenzyme 4	767	0
NP_002601.1	pyruvate dehydrogenase kinase, isoenzyme 1	562	e-159
Q15118	PDK1_HUMAN [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 1, mitochondrial precursor (Pyruvate dehydrogenase kinase isoform 1)	562	e-159
155465	[pyruvate dehydrogenase (lipoamide)] kinase (EC 2.7.1.99) 1	562	e-159
AAC42009.1	pyruvate dehydrogenase kinase	562	e-159
AAH39158.1	Similar to pyruvate dehydrogenase kinase, isoenzyme 1	562	e-159
2203383A	pyruvate dehydrogenase kinase:ISOTYPE=1	562	e-159
NP_002602.2	pyruvate dehydrogenase kinase, isoenzyme 2	556	e-157
Q15119	PDK2_HUMAN [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 2, mitochondrial precursor (Pyruvate dehydrogenase kinase isoform 2)	556	e-157
AAH05811.1	AAH05811 pyruvate dehydrogenase kinase, isoenzyme 2	556	e-157
AAH40478.1	pyruvate dehydrogenase kinase, isoenzyme 2	556	e-157
170159	[pyruvate dehydrogenase (lipoamide)] kinase (EC 2.7.1.99) 2	554	e-157
AAC42010.1	pyruvate dehydrogenase kinase	554	e-157
2203383B	pyruvate dehydrogenase kinase:ISOTYPE=2	554	e-157
NP_005382.1	pyruvate dehydrogenase kinase, isoenzyme 3	527	e-149
Q15120	PDK3_HUMAN [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 3, mitochondrial precursor (Pyruvate dehydrogenase kinase isoform 3)	527	e-149
170160	[pyruvate dehydrogenase (lipoamide)] kinase (EC 2.7.1.99) 3	527	e-149
AAC42011.1	pyruvate dehydrogenase kinase	527	e-149
AAH15948.1	AAH15948 pyruvate dehydrogenase kinase, isoenzyme 3	527	e-149
2203383C	pyruvate dehydrogenase kinase:ISOTYPE=3	527	e-149

NP_080082.1	Mm.3311	U:(C-IR) NP_ 2.15		079105.1 hypothetical protein FLJ22662	870	0
			BAB15442.1	unnamed protein product	870	0
			AAH00909.2	AAH00909 hypothetical protein FLJ22662	397	e-11-
			XP_113725.2	similar to RIKEN cDNA 1300012G16	271	2e-72
			AAH30618.1	similar to RIKEN cDNA 1300012G16	271	2e-72
NM_008030		U:(C-IR) 2.14				
NP_032056.1	Mm.2900	U:(C-D) 2.22	P31513	FMO3_HUMAN Dimethylaniline monooxygenase [N-oxide forming] 3 (Hepatic flavin-containing monooxygenase 3) (FMO 3) (Dimethylaniline oxidase 3) (FMO II)	847	o
			AAC51932.1	flavin containing monooxygenase 3	847	0
				dJ127D3.1 (Hepatic Flavin-containing Monooxygenase 3 (Dimethylaniline Monooxygenase (N-Oxide forming) 3, EC1.14.13.8, Dimethylaniline Oxidase 3,		
			CAA15908.1	FMO II, FMO 3))	847	0
			AAH32016.1	flavin containing monooxygenase 3	847	0
			NP_008825.2	flavin containing monooxygenase 3; Flavin-containing monooxygenase-3	846	0
			S51130	dimethylaniline monooxygenase (N-oxide-forming) (EC 1.14.13.8) 3	846	0
			CAA87632.1	flavin-containing monooxygenase 3 (FMO3)	846	0
			A38228	dimethylaniline monooxygenase (N-oxide-forming) (EC 1.14.13.8), hepatic 2	795	0
			AAA86284.1	flavoprotein	795	0
			CAA15909.1	d1127D3.2 (Flavin-containing Monooxygenase family protein)	770	0
				FMO2_HUMAN Dimethylaniline monooxygenase [N-oxide forming] 2 (Pulmonary flavin-containing monooxygenase 2) (FMO 2) (Dimethylaniling oxide 3) (FMO		
			Q99518	1B1)	610	e-174
			NP_002012.1	flavin containing monooxygenase 1; Flavin-containing monooxygenase 1 (fetal liver)	280	e-165
				FMO1_HUMAN DIMETHYLANILINE MONOOXYGENASE [N-OXIDE FORMING] 1 (FETAL HEPATIC FLAVIN-CONTAINING MONOOXYGENASE		
			Q01740	1) (FMO 1) (DIMETHYLANILINE OXIDASE 1)	580	e-165
			_	dimethylaniline monooxygenase (N-oxide-forming) (EC 1.14.13.8), hepatic 1	280	e-165
			AAA52457.1	flavin-containing monooxygenase	580	e-165

			NP_001451.1	flavin containing monooxygenase 2; Flavin-containing monooxygenase 2 (adult liver)	561	e-159
			CAA70462.1	flavin-containing monooxygenase 2	561	e-159
			CAA15910.1	dJ127D3.3 (Flavin-containing Monooxygenase 2)	561	e-159
			AAH05894.1	flavin containing monooxygenase 2	561	e-159
				FMOS_HUMAN DIMETHYLANILINE MONOOXYGENASE [N-OXIDE FORMING] 5 (HEPATIC FLAVIN-CONTAINING MONOOXYGENASE 5) (FMO		
			P49326	5) (DIMETHYLANILINE OXIDASE 5)	546	e-155
			S71618	dimethylaniline monooxygenase (N-oxide-forming) (EC 1.14.13.8) FMO5	546	e-155
			AAA67849.1	flavin-containing monooxygenase 5	546	e-155
			NP_001452.1	flavin containing monooxygenase 5	545	e-155
			S51131	flavin-containing monooxygenase 5 (FMO5)	545	e-155
		_	CAA87633.1	flavin-containing monooxygenase 5 (FMO5)	545	e-155
NM_011012 NP_035142.1	Mm.2991	U:(C-IR) 2.14	NP_000904.1	opiate receptor-like 1; opioid receptor-like 1; kappa3-related opioid receptor	573	e-163
			P41146	OPRX_HUMAN Nociceptin receptor (Orphanin FQ receptor) (Kappa-type 3 opioid receptor) (KOR-3)	573	e-163
			S43087	orphan opioid receptor ORL1	573	e-163
			CAA54386.1	ORL1	573	e-163
			AAA84913.1	orphan opioid receptor	573	e-163
			AAK11714.1	AF348323_1 nociceptin receptor	573	e-163
			AAH38433.1	opiate receptor-like 1	573	e-163
			AAL54890.1	AF126470 1 KOR-3D	558	e-159
			AAA96251.1	opioid receptor-like protein	509	e-144
			2201468A	opioid orphan receptor	509	e-144
			CAC17003.1	dJ1022E24.1 (opiate receptor-like protein 1 (OPRL1))	445	e-125
			CAC15482.1	dJ366F13.1 (opioid receptor mu 1)	296	4e-80
			P35372	OPRM_HUMAN Mu-type opioid receptor (MOR-1)	296	4e-80
			156553	mu opiate receptor	296	4e-80
			AAA73958.1	opioid receptor	296	4e-80

			2108340A	mu opioid receptor	296	4e-80
			NP_000905.1	opioid receptor, mu 1	296	4e-80
			AAA20580.1	Mu opiate receptor	296	4e-80
			S65693	opioid receptor mu variant MOR1A	293	4e-79
			AAB60354.1	mu opioid receptor variant	293	4e-79
			AAN87342.1	DRG kappa 1 splice variant KOR 1A	285	8e-77
			P41143	OPRD_HUMAN Delta-type opioid receptor (DOR-1)	285	1e-76
			AAA83426.1	delta opiate receptor	285	1e-76
			CAA15671.1	dJ212P9.1	285	1e-76
NM_015750 NP_056565.1	Mm.4567 0	U:(C-IR) 2.14	NP_005374.1	sialidase 2; cytosolic sialidase; N-acetyl-alpha-neuraminidase 2; neuraminidase 2	539	e-153
			Q9Y3R4	NER2_HUMAN Sialidase 2 (Cytosolic sialidase) (N-acetyl-alpha-neuraminidase 2)	539	e-153
			CAB41449.1	neuraminidase; sialidase	539	e-153
			NP_006647.2	sialidase 3; neuraminidase 3; ganglioside sialidase; N-acetyl-alpha-neuraminidase 3	797	4e-71
			CAB96131.1	Nuraminidase	267	4e-71
	-		Q9UQ49	NER3_HUMAN Sialidase 3 (Membrane sialidase) (Ganglioside sialidase) (N-acetyl-alpha-neuraminidase 3)	264	3e-70
			BAA82611.1	ganglioside sialidase	264	3e-70
			CAC81904.1	sialidase	231	2e-60
			NP_542779.2	sialidase	231	3e-60
NM_031389 NP_113566.1	Mm.8479 U:(C-IR) 2 2.14			similar to PYRIN-containing APAF1-like protein 4; PAAD and NACHT-containing protein 2; ribonuclease inhibitor 2	758	0
			NP_604393.1	PYRIN-containing APAF1-like protein 4; PAAD and NACHT-containing protein 2; ribonuclease inhibitor 2	758	0
			Q96MN2	NAL4_HUMAN NACHT-, LRR- and PYD-containing protein 4 (PAAD and NACHT-containing protein 2) (PYRIN-containing APAF1-like protein 4) (Ribonuclease inhibitor 2)	758	0
			AAL35293.1	AF442488 1 NALP4	758	0
			AAL68396.1	PAAD and NACHT-containing protein 2	758	0

					ĺ	
			AAL87104.1	AF479747_1 PYRIN-containing APAF1-like protein 4	758	0
			BAB71254.1	unnamed protein product	758	0
			AAL88672.1	AF482706_1 ribonuclease inhibitor 2	749	0
			XP_062261.4	similar to PYRIN-containing APAFI-like Protein 7	495	e-139
			NP_659444.1	PYRIN-containing APAF1-like protein 6	427	e-119
			P59045	PYA6_HUMAN PYRIN-containing APAF1-like protein 6	427	e-119
			AAM14632.1	PYRIN-containing APAF1-like protein 6	427	e-119
			AAH34730.1	PYRIN-containing APAF1-like protein 6	427	e-119
			AAH16443.1	AAH16443 Unknown (protein for IMAGE:3448931)	391	e-108
			AAL78632.1	AF468522_1 NALP3 long isoform	379	e-104
			NP_004886.2	cold autoinflammatory syndrome 1; chromosome 1 open reading frame 7; angiotensin/vasopressin receptor AII/AVP-like; cryopyrin; PYRIN-containing APAF1-like protein 1	378	e-104
			Q96P20	CISI_HUMAN Cold autoinflammatory syndrome 1 protein (Cryopyrin) (NACHT., LRR-and PYD-containing protein 3) (PYRIN-containing APAF1-like protein 1) (Angiotensin/vasopressin receptor AII/AVP-like)	378	e-104
			AAL33908.1	AF410477_1 cryopyrin	378	e-104
			AAL12497.1	cryopyrin	378	e-104
			AAL65136.1	AF420469_1 PYRIN-containing APAF1-like protein 1	378	e-104
			XP_064988.5	similar to PYRIN-containing APAF1-like protein 4; PAAD and NACHT-containing protein 2; ribonuclease inhibitor 2	367	e-101
NM_025621 NP_079897.1	Mm.1442 59	U:(C-IR) 2.11	XP_088993.1	similar to RIKEN cDNA 2310050C09	229	Se-60
NM_011377 NP_035507.1	Mm.4775	U:(C-R) 2.09	NP_005060.1	single-minded (Drosophila) homolog 2 long isoform; human transcription factor SIM2, homolog of the Drosophila single-minded gene SIM1	939	0
			Q14190	SIM2_HUMAN Single-minded homolog 2	939	0
			AAB62396.1	transcription factor SIM2 long form	939	0
			BAA89433.1	single-minded 2 protein	939	0

NP_033664.1
B62397.1 transcription factor SIM2 short form
405055.1 human SIM2
005059.2 single-minded (Drosophila) homolog 1; Single-minded, drosophila, homolog of, 1
133 SIM1 HUMAN Single-minded homolog 1
362395.1 hSIM1
A58520 single-minded gene 2 protein
A12919.1 Sim
071406.1 basic-helix-loop-helix-PAS protein
335180.1 AF164438 1 basic-helix-loop-helix-PAS protein
BAB21221.1 NPAS3 (MOP6)
353756.1 NPAS3
AAM73657.1 solute carrier family 12 member 8
AAK94307.1 solute carrier family 12 member 8
AAH20506.1 hypothetical protein FLJ23188
solute carrier family 12 (potassium/chloride transporters), member 8; solute carrier family 12 (sodium/potassium/chloride transporters), member 8
315571.1 unnamed protein product
solute carrier family 12 (sodium/potassium/chloride transporters), member 2; Solute carrier family 12 (sodium/potassium/chloride transporters)
S122_HUMAN Solute carrier family 12 member 2 (Bumetanide-sensitive
bumetanide-sensitive Na-K-Cl cotransporter
50561.1 bumetanide-sensitive Na-K-CI cotransporter
AAH33003.1 Similar to solute carrier family 12 (sodium/potassium/chloride
300329.1 sodium potassium chloride cotransporter 2; Solute carrier family 12
S121 HUMAN Solute carrier family 12 member 1 (Bumetanide-sensitive
AAB07364.1 burnetanide-sensitive Na-K-2CI cotransporter

			P55017	\$123_HUMAN Solute carrier family 12 member 3 (Thiazide-sensitive sodium-chloride	201	4e-51
			NP_000330.1	solute carrier family 12 (sodium/chloride transporters), member 3; Solute carrier family 12 (sodium/potassium/chloride transporters),	201	4e-51
			AAC50355.1	thiazide-sensitive Na-Cl	201	4e-51
			G01202	NaCl electroneutral Thiazide-sensitive cotransporter	201	5e-51
			CAA62613.1	NaCl electroneutral Thiazide-sensitive cotransporter	201	5e-51
NM_008074		(01 2)/11				
NP_032100.1 M	Mm.1345	2.08	NP_150092.1	gamma-aminobutyric acid (GABA) A receptor, gamma 3	841	0
			AAB39369.1	GABAA receptor gamma 3 subunit	841	0
			Q99928	GAC3_HUMAN Gamma-aminobutyric-acid receptor gamma-3 subunit precursor (GABA(A) receptor)	838	0
			AAF99698.1	GABAA receptor gamma 3 subunit	838	0
			AAF63215.1	GABAA receptor gamma 3 subunit	836	0
			AAD50273.1	gamma-aminobutyric acid A receptor gamma 2	588	e-167
			NP_000807.1	gamma-aminobutyric acid A receptor, gamma 2 precursor	584	e-166
			P18507	GAC2_HUMAN Gamma-aminobutyric-acid receptor gamma-2 subunit precursor (GABA(A) receptor)	584	e-166
			S03905	gamma-aminobutyric acid/benzodiazepine receptor gamma-2 chain precursor	584	e-166
	:		CAA33437.1	GABA-A receptor gamma 2 subunit	584	e-166
			1506443A	GABAa receptor gamma2	584	e-166
			AAH31087.1	similar to GAMMA-AMINOBUTYRIC-ACID RECEPTOR GAMMA-1 SUBUNIT PRECURSOR (GABA(A) RECEPTOR)	576	e-164
			XP_094080.1	similar to Gamma-aminobutyric-acid receptor gamma-1 subunit precursor (GABA(A) receptor) [Homo sapiens]	925	e-164
			NP_004952.1	gamma-aminobutyric acid (GABA) A receptor, epsilon, isoform 1 precursor	378	e-104
			AAB49284.1	GABA-A receptor epsilon subunit	378	e-104
			P78334	GAE_HUMAN Gamma-aminobutyric-acid receptor epsilon subunit precursor (GABA(A) receptor)	378	e-104

			CAA70904.1	GABA receptor epsilon subunit	378	e-104
			AAB94645.1	GABA-A receptor epsilon subunit	378	e-104
			CAA70903.1	GABRE	374	e-103
NM_010899 NP_035029.1		Mm.1168 U:(C-IR) 02 2:08	Q13469	NFC2_HUMAN Nuclear factor of activated T-cells, cytoplasmic 2 (T cell transcription factor NFAT1) (NFAT pre-existing subunit)(NF-ATp)	1522	0
			AAC50887.1	transcription factor NFAT1 isoform C	1522	0
			NP_036472.1	nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2; nuclear factor of activated T-cells, cytoplasmic 2	1487	0
			G02326	transcription factor NFAT1 isoform B - human	1487	0
			AAC50886.1	transcription factor NFAT1 isoform B	1487	0
			CAC00528.1	d1994O24.1 (nuclear factor of activated T-cells, cytoplasmic 2 (isoforms B and C))	835	0
			CAB54871.1	dJ1009H6.1.2 (nuclear factor of activated T-cells, cytoplasmic 2, isoform C)	649	0
			CAC00529.1	dJ1009H6.1.1 (nuclear factor of activated T-cells, cytoplasmic 2, isoform B)	615	e-175
			1A02	N Chain N, Structure Of The Dna Binding Domains Of Nfat, Fos And Jun Bound To Dna	267	e-161
			AAD00451.1	transcription factor	551	e-156
			095644	NFC1_HUMAN Nuclear factor of activated T-cells, cytoplasmic 1 (NFAT transcription complex cytosolic component) (NF-ATc1) (NF-ATc)	550	e-156
			AAC50869.1	nuclear factor of activated T cells	523	e-148
			NP_006153.2	nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1; nuclear factor of activated T-cells, cytoplasmic 1	521	e-147
			AAD00450.1	transcription factor	521	e-147
		U:(C-IR)	NP_037504.1	cysteine knot superfamily 1, BMP antagonist 1; gremlin	311	2e-84
NM_011824 NP_035954.1	Mm.3046 U.(C-D) 5 2.59	U:(C-D) 2.59				
			AAC39725.1	gremlin	311	2e-84
			BAA84462.1	gremlin homologue	311	2e-84
				gremlin	311	2e-84
			AAG23891.1	AF154054 1 DRM	311	2e-84

			BAC04620.1	unnamed protein product	254	3e-67
			BAC04643.1	unnamed protein product	253	8e-67
AF193796 M AAL09298.1 2	Mm.20706 U:(C-IR) 2	U:(C-IR) 2.07	XP_006804.2	similar to Homeobox protein Hox-C13 (Hox-3G)		
			NP 059106.2	homeo box C13; homeobox protein Hox-C13; homeo box 3G	505	e-142
			P31276	HXCD_HUMAN Homeobox protein Hox-C13 (Hox-3G	505	e-142
			AAF73439.1	HOXC13	505	e-142
			AAH02754.1	homeo box C13	505	e-142
			AAF67760.1	homeoprotein C13	504	e-142
			BAB14786.1	unnamed protein product	280	7e-75
			P31271	HXAD_HUMAN Homeobox protein Hox-A13	218	4e-56
			AAC50993.1	transcription factor HOXA13	218	4e-56
			NP_000513.2	homeobox protein A13; homeobox protein HOXA13; homeo box 1J; transcription factor HOXA13	218	4e-56
			NP_000514.1	homeo box D13; homeo box 4I; homeobox protein Hox-D13	216	2e-55
			P35453	HXDD_HUMAN Homeobox protein Hox-D13 (Hox-41)	216	2e-55
			AAC51635.1	HOXD13	216	2e-55
			BAA95352.1	homeobox transcription factor	216	2e-55
NM_008152		(II-(C-IR)				i
NP_032178.1	Mm.2840	2.07	XP_007392.1	similar to G protein-coupled receptor 65; T-cell death-associated gene 8	527	e-149
			AAH35633.1	similar to G protein-coupled receptor	527	e-149
			NP_003599.1	G protein-coupled receptor 65; T-cell death-associated gene 8	521	e-147
			AAC31794.1	T cell-death associated protein	521	e-147
			S68207	G protein-coupled receptor 6C.1	196	8e-50
			AAA79061.1	G protein-coupled receptor	196	8e-50
			2124311B	G protein-coupled receptor	196	8e-50

			NP_005273.1	005273.1 G protein-coupled receptor 4	196	8e-50
			XP_009140.1	similar to Probable G protein-coupled receptor GPR4 (GPR19)	196	8e-50
			P46093	GPR4_HUMAN Probable G protein-coupled receptor GPR4 (GPR19)	196	8e-50
			A57641	G protein-coupled receptor 4	196	8e-50
			AAA98457.1	G protein-coupled receptor	196	8e-50
			153033	G protein-coupled receptor	196	8e-50
			AAA63180.1	G protein-coupled receptor	196	8e-50
NM_008324						
NP_032350.1 Mm.392	Mm.392	U:(C-IR) 2.07	NP_002155.1	indoleamine-pyrrole 2,3 dioxygenase; Indoleamine 2,3-dioxygenase; indole 2,3-dioxygenase	499	e-141
			P14902	123O_HUMAN Indoleamine 2,3-dioxygenase (IDO) (Indoleamine-рупоle 2,3-dioxygenase)	499	e-141
			PC1161	indoleamine-pyrrole 2,3-dioxygenase (EC 1.13.11.42)	499	e-141
			CAA35663.1	indoleamine 2,3-dioxygenase	499	e-141
			AAA36081.1	indoleamine 2,3-dioxygenase (IDO) (EC 1.13.11.17)	499	e-141
			AAH27882.1	indoleamine-pyrrole 2,3 dioxygenase	499	e-141
			XP_095645.4	similar to indoleamine 2,3-dioxygenase	313	4e-85
NM_009827		(GI 7).11	٠			
NP_033957.1 N	Mm.3521	2.07	NP_000721.1	cholecystokinin A receptor	693	0
			P32238	CCKR_HUMAN Cholecystokinin type A receptor (CCK-A receptor) (CCK-AR)	693	0
			JN0692	cholecystokinin type A receptor	693	0
			AAA35659.1	cholecystokinin A receptor	693	0
			AAA02819.1	cholecystokinin A receptor	693	0
			AAA91123.1	cholecystokinin type A receptor	693	0
			BAA90879.1	cholecystokinin type-A receptor	693	0
			2118221A	cholecystokinin A receptor	629	0
			P32239	GASR_HUMAN Gastrin/cholecystokinin type B receptor (CCK-B receptor) (CCK-BR)	350	8e-96

			A47430	gastrin/cholecystokinin receptor B, short splice form	350	8e-96
			AAA35660.1	cholecystokinin receptor	350	8e-96
			AAA35657.1	cholecystokinin-B/gastrin receptor	350	8e-96
			AAC37528.1	gastrin receptor	350	8e-96
			BAA02564.1	cholecystokinin receptor	350	8e-96
			AAH00740.1	AAH00740 cholecystokinin B receptor	350	8e-96
			AAA91831.1	cholecystokinin B receptor	348	2e-95
			AAB30766.2	cholecystokinin B, receptor	348	2e-95
			BAA04759.1	cholecystokinin-B receptor/gastrin receptor	348	4e-95
			AAC27510.1	gastrin\cholecystokinin brain receptor	345	3e-94
			AAK38351.1	CCK-B/gastrin receptor variant	243	1e-63
			AAN32829.	AF441129_1 cholecystokinin-C receptor	243	1e-63
			NP_000722.2	cholecystokinin B receptor	241	5e-63
			AAF67174.1	AF239668_1 CCK-B/gastrin receptor	241	5e-63
NM_013920 NP_038948.1	Mm.4198 5	U:(C-IR) 2.07	JC6095	hepatocyte nuclear factor 4 gamma chain	749	0
			2208436B	hepatocyte nuclear factor 4	749	0
			NP_004124.2	hepatocyte nuclear factor 4, gamma	739	0
			CAA89990.2	hepatocyte nuclear factor 4 gamma (HNF4gamma)	739	0
			Q14541	HN4G_HUMAN Hepatocyte nuclear factor 4-gamma (HNF-4-gamma)	738	0
			AAF00110.1	hepatocyte nuclear factor 4 gamma	738	0
			CAA61133.1	Hepatocyte nuclear factor 4A	585	e-166
			AAB48082.1	hepatocyte nuclear factor 4-alpha	579	e-165
			NP_000448.2	hepatocyte nuclear factor 4, alpha; transcription factor-14; hepatic nuclear factor 4, alpha	579	e-165
-			JC6096	hepatocyte nuclear factor 4 alpha2 chain	579	e-165
			CAA89989.1	hepatocyte nuclear factor 4 alpha (HNF4alpha4)	579	e-165
			2208436A	hepatocyte nuclear factor 4:ISOTYPE=alpha	579	e-165

			CAC01303.1	dJ1013A22.1 (hepatocyte nuclear factor 4, alpha)	578	e-165
			P41235	HN4A_HUMAN Hepatocyte nuclear factor 4-alpha (HNF-4-alpha) (Transcription factor 14)	578	e-165
			CAA54248.1	hepatocyte nuclear factor 4	576	e-164
			JC4937	hepatocyte nuclear factor 4, splice form B	575	e-164
			CAA61134.1	Hepatocyte nuclear factor 4B	575	e-164
NM_020028 NP_064412.1	Mm.2325 3	U:(C-IR) 2.07	NP_004711.2	endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 4; G protein-coupled receptor; lysophosphatidic acid receptor EDG4; LPA recentor EDG4	470	e-132
			О9НВ М0	EDG4_HUMAN Lysophosphatidic acid receptor Edg-4 (LPA receptor 2) (LPA-2)	470	e-132
			AAB61528.1	R33799_1	470	e-132
			AAF43409.1	AF233092_1 lysophosphatidic acid G protein-coupled receptor 4	470	e-132
			AAH25695.1	endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 4	470	e-132
			AAG28521.1	AF197929_1 lysophosphatidic acid receptor EDG4	468	e-131
			AAC27728.1	G protein-coupled receptor Edg-4	463	e-130
			NP_001392.2	lysophosphatidic acid receptor EDG2; ventricular zone gene 1; LPA receptor EDG2	255	2e-67
			NP_476500.1	lysophosphatidic acid receptor EDG2; ventricular zone gene 1; LPA receptor EDG2	255	2e-67
			092633	EDG2_HUMAN Lysophosphatidic acid receptor Edg-2 (LPA receptor 1) (LPA-1)	255	2e-67
			CAA70686.1	G protein-coupled receptor Edg-2	255	2e-67
			AAC00530.1	Edg-2 receptor	255	2e-67
			AAH30615.1	Unknown (protein for MGC:33156)	255	2e-67
			AAH36034.1	endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 2	255	2e-67
			JC5293	Jysophosphatidic acid receptor	255	2e-67
			AAC51139.1	1ysophosphatidic acid receptor homolog	255	2e-67
			CAA70687.1	G protein-coupled receptor Edg-2	255	2e-67
			NP_036284.1	endothelial cell differentiation gene 7; calcium-mobilizing lysophosphatidic acid receptor LP-A3; LPA receptor EDG7	225	3e-58
			Q9UBY5	EDG7_HUMAN Lysophosphatidic acid receptor Edg-7 (LPA receptor 3) (LPA-3)	225	3e-58
			AAD56311.1	AF127138 1 lysophosphatidic acid G protein-coupled receptor	225	3e-58

	3e-58	2e-57	5e-89	5e-89	e-170	e-170	e-170	9e-53	3e-52	3e-52	e-127	e-127	e-127	e-127	5e-66	2e-65	2e-65	2e-65	2e-65	2e-65	2e-65	
	225	222	137	137	593	592	592	206	205	205	453	453	453	453	249	248	248	248	248	248	248	
223	AF186380 1 calcium-mobilizing lysophosphatidic acid receptor LP-A3/Edg-7	G-protein coupled receptor EDG-7		unnamed protein product	Similar to kruppel-related zinc finger protein hcKrox	kruppel-related zinc finger protein hcKrox	kruppel-related zinc finger protein hcKrox	similar to HIV-1 inducer of short transcripts binding protein	HIV-1 inducer of short transcripts binding protein	HIV-1 inducer of short transcripts binding protein	G protein-coupled receptor 27; super conserved receptor expressed in brain 1	GP27_HUMAN Probable G protein-coupled receptor GPR27 (Super conserved receptor expressed in brain 1)	G-protein coupled receptor, SREB1	SREB1	similar to G protein-coupled receptor 85	G protein-coupled receptor 85; super conserved receptor expressed in brain 2	GP85_HUMAN Probable G protein-coupled receptor GPR85 (Super conserved receptor expressed in brain 2) (PKrCx1)	G-protein coupled receptor, SREB2	hypothetical protein	SREB2	AF250237. 1 orphan G protein-coupled receptor 85	
	AAF00530.1	AAF91291.1	NP 079065.1	BAB15385.1	AAH12070.1	NP_056956.1	AAC51847.1	XP_113971.1	NP_056982.1	AAC72973.1	NP_061844.1	<i>19</i> SN6O	JC7287	BAA96645.1	AAH30577.1	NP_061843.1	Q9NPD1	T47131	CAB82307.1	BAA96646.1	AAF79956.1	
			U:(C-IR) 2.06		U:(C-IR) 2.05 U:(C-D) 2.13						U:(C-IR) 2.05											
			U:(C Mm.40665 2.06		U:(C-IR 2.05 Mm.17068 U:(C-D) 4						U:(C-IR) Mm.35009 2.05											
			AK015988 XP_129281.1		NM_009565 NP_033591.1				:		NM_008158 NP_032184.1											

		BAC05911.1	seven transmembrane helix receptor	248	26-65
		NP_061842.1	super conserved receptor expressed in brain 3	233	3e-61
		99SN6Q	SRB3_HUMAN Super conserved receptor expressed in brain 3	233	3e-61
		JC7289	G-protein coupled receptor, SREB3	233	3e-61
		BAA96647.1	SREB3	233	3e-61
		AAH09861.1	AAH09861 super conserved receptor expressed in brain 3	233	3e-61
NM_019513 Mm.1170 NP_062386.1 15	170 U:(C-IR) 2.05	물	009151.1 carbonic anhydrase VB, mitochondrial precursor; carbonic dehydratase	909	e-173
		Q9Y2D0	CA5B_HUMAN Carbonic anhydrase VB, mitochondrial precursor (Carbonate dehydratase VB) (CA-VB)	909	e-173
		BAA76671.1	carbonic anhydrase VB	605	e-173
		AAH28142.1	carbonic anhydrase VB, mitochondrial	609	e-173
		NP_001730.1	carbonic anhydrase VA, mitochondrial precursor; carbonic anhydrase V, mitochondrial; carbonic dehydratase	384	e-106
		P35218	CAH5_HUMAN Carbonic anhydrase VA, mitochondrial precursor (Carbonate dehydratase VA) (CA-VA)	384	e-106
		CRHUS	carbonate dehydratase (EC 4.2.1.1) V precursor [validated]	384	e-106
		AAA02890.1	carbonic anhydrase V	384	e-106
		AAB47048.1	carbonic anhydrase V; CA V	384	e-106
		AAC99806.1	carbonic anhydrase V	384	e-106
		1UGD	Human Carbonic Anhydrase Ii[hcaii] (E.C.4.2.1.1) Mutant With Ala 65 Replaced By Ser (A65s)	286	4e-77
		1UGG	Human Carbonic Anhydrase Ii[hcaii] (E.C.4.2.1.1) Mutant With Ala 65 Replaced By Ser (A65s) - Orthorhombic Form	286	4e-77
	· -	IUGF	Human Carbonic Anhydrase Ii [hcaii] (E.C.4.2.1.1) Mutant With Ala 65 Replaced By Thr (A65t)	285	9e-77
		1G52	A Chain A, Carbonic Anhydrase Ii Complexed With 4-(Aminosulfonyl)-N-[(2,3-Difluorophenyl)methyl]-Benzamide	285	9e-77
		1G54	A Chain A, Carbonic Anhydrase Ii Complexed With . 4-(Arminosulfonyl)-N-[(2,3,4,5,6-Pentafluorophenyl)methyl]-Benzamide	285	9e-77

	A Chain A, Carbonic Anhydrase Ii Complexed With Al-6629 2h-Thieno[3,2-E]-1,2-Thiazine-6-Sulfonamide, 2-(3-Methoxyphenyl)-3-(4-Morpholinyl)-, 1,1-Dioxide	285	9e-77
1IF4	A Chain A, Carbonic Anhydrase Ii Complexed With 4-Fluorobenzenesulfonamide	285	9e-77
1G53	A Chain A, Carbonic Anhydrase Ii Complexed With 4-(Aminosulfonyl)-N-[(2,6-Difluorophenyl)methyl]-Benzamide	285	9e-77
1IF8	A Chain A, Carbonic Anhydrase Ii Complexed With (S)-N-(3-Indol-1-Y1-2-Methyl-Propyl)-4-Sulfamoyl-Benzamide	285	9e-77
1IF7	A Chain A, Carbonic Anhydrase Ii Complexed With (R)-N-(3-Indol-1-YI-2-Methyl-Propyl)-4-Sulfamoyl-Benzamide	285	9e-77
1190	A Chain A, Carbonic Anhydrase Ii Complexed With Al-8520 2h-Thieno[3,2-E]-1,2-Thiazine-6-Sulfonamide, 4-Amino-3,4-Dihydro-2-(3-Methoxypropyl)-, 1,1-Dioxide, ®	285	9e-77
1191	A Chain A, Carbonic Anhydrase Ii Complexed With Al-6619 2h-Thieno[3,2-E]-1,2-Thiazine-6-Sulfonamide, 2-(3-Hydroxyphenyl)-3-(4-Morpholinyl)-, 1,1-Dioxide	285	9e-77
1IF5	A Chain A, Carbonic Anhydrase Ii Complexed With 2,6-Difluorobenzenesulfonamide	285	9e-77
1F9	A Chain A, Carbonic Anhydrase Ii Complexed With N-[2-(1h-Indol-5-YI)-Butyl]-4-Sulfamoyl-Benzamide	285	9e-77
1G1D	A Chain A, Carbonic Anhydrase Ii Complexed With 4-(Aminosulfonyl)-N-[(2-Fluorophenyl)methyl]-Benzamide	285	9e-77
1IF6	A Chain A, Carbonic Anhydrase Ii Complexed With 3,5-Difluorobenzenesulfonamide	285	9e-77
1AM6	Carbonic Anhydrase Ii Inhibitor: Acetohydroxamate	285	9e-77
1F2W	A Chain A, The Mechanism Of Cyanamide Hydration Catalyzed By Carbonic Anhydrase Ii Revealed By Cryogenic X-Ray Diffraction	285	9e-77
10KM	Carbonic Anhydrase Ii Complex With The 10km Inhibitor 4-Sulfonamide-[1-(4-Aminobutane)]benzamide	285	9e-77
1BN1	Carbonic Anhydrase Ii Inhibitor	285	9e-77
1BN4	Carbonic Anhydrase Ii Inhibitor	285	9e-77
1BN3	Carbonic Anhydrase Ii Inhibitor	285	9e-77
1BNN	Carbonic Anhydrase Ii Inhibitor	285	9e-77

	1BNV	Carbonic Anhydrase Ii Inhibitor	285	9e-77
:	1BNM	Carbonic Anhydrase Ii Inhibitor	285	9e-77
	1CIL	Carbonic Anhydrase Ii (E.C.4.2.1.1) Complexed With The Inhibitor Ets	285	9e-77
	2CA2	Carbonic Anhydrase II (Carbonate Dehydratase) (HCA II) (E.C.4.2.1.1) Complex With Thiocyanate Ion	285	9e-77
	3CA2	Carbonic Anhydrase II (Carbonate Dehydratase) (HCA II) (E.C.4.2.1.1) Complex With 3-Mercuri-4-Aminobenzenesulfonamide (AMS).	285	9e-77
	1CA2	Carbonic Anhydrase II (Carbonate Dehydratase) (HCA II) (E.C.4.2.1.1)	285	9e-77
	1BNT	Carbonic Anhydrase Ii Inhibitor	285	9e-77
	IBNU	Carbonic Anhydrase Ii Inhibitor	285	9e-77
,	1A42	Human Carbonic Anhydrase Ii Complexed With Brinzolamide	285	9e-77
	1BNW	Carbonic Anhydrase Ii Inhibitor	285	9e-77
	1BNQ	Carbonic Anhydrase Ii Inhibitor	285	9e-77
	10KN	Carbonic Anhydrase Ii Complex With The 1okn Inhibitor 4-Sulfonamide-[1-(4-N-(5-Fluorescein Thiourea)butane)]	285	9e-77
	10KL	Carbonic Anhydrase Ii Complex With The 10kl Inhibitor 5-Dimethylamino-Naphthalene-1-Sulfonamide	285	9e-77
	1CRA	Carbonic Anhydrase Ii (E.C.4.2.1.1) Complex With 1,2,4-Triazole	285	9e-77
	1CAO	Carbonic Anhydrase Ii (E.C.4.2.1.1) Complex With Hydrogen Sulfide	285	9e-77
	2CBA	Carbonic Anhydrase Ii (E.C.4.2.1.1) (50 Mm Tris, 3 M Ammonium Sulfate, Ph 7.8)	285	9e-77
	2CBD	Carbonic Anhydrase Ii (E.C.4.2.1.1) (2.4 M Ammonium Sulfate, 0.3 M Sodium Bisulfite, Ph 7.3)	285	9e-77
	2CBB	Carbonic Anhydrase Ii (E.C.4.2.1.1) (80 Mm Sodium Citrate, 2.4 M Ammonium Sulfate, Ph 6.0)	285	9e-77
	1RAY	Carbonic Anhydrase Ii (E.C.4.2.1.1) Complex With Azide	285	9e-77
	1RZB	Carbonic Anhydrase Ii (E.C.4.2.1.1) With Zinc Replaced By By Cobalt(Ii) At Ph 6.0	285	9e-77
	2CBE	Carbonic Anhydrase Ii (E.C.4.2.1.1) (50 Mm Tris, 3 M Ammonium Sulfate, 2mm Dipicolinate, Ph 7.8)	285	9e-77
	2CBC	Carbonic Anhydrase Ii (E.C.4.2.1.1) (50 Mm Tris, 3 M Ammonium Sulfate, 0.2 Formate, Ph 7.6)	285	9e-77

1САН	Carbonic Anhydrase Ii (E.C.4.2.1.1) (Native Zinc Replaced By Cobalt) Complex With Bicarbonate	285	9e-77
IRZC	Carbonic Anhydrase Ii (E.C.4.2.1.1) With Zinc Replaced By Copper(Ii)	285	9e-77
1BCD	Carbonic Anhydrase Ii (E.C.4.2.1.1) Complex With Trifluoromethane Sulphonamide	285	9e-77
IRAZ	Carbonic Anhydrase Ii (E.C.4.2.1.1) Complex With Bromide	285	9e-77
1RZA	Carbonic Anhydrase Ii (E.C.4.2.1.1) With Zinc Replaced By Cobalt(Ii)	285	9e-77
1RZD	Carbonic Anhydrase Ii (E.C.4.2.1.1) With Zinc Replaced By Manganese(Ii)	285	9e-77
IRZE	Carbonic Anhydrase Ii (E.C.4.2.1.1) With Zinc Replaced By Nickel(Ii)	285	9e-77
1CAY	Carbonic Anhydrase Ii (E.C.4.2.1.1) Complex With Acetate	285	9e-77
SCAC	Carbonic Anhydrase Form C (E.C.4.2.1.1) Complex With Hydrogen Sulfite	285	9e-77
4CAC	Carbonic Anhydrase Form C (E.C.4.2.1.1) (Ph 6)	285	9e-77
1BV3	A Chain A, Human Carbonic Anhydrase Ii Complexed With Urea	285	9e-77
1AVN	Human Carbonic Anhydrase Ii Complexed With The Histamine Activator	285	9e-77
1LZV	A Chain A, Site-Specific Mutant (Tyr7 Replaced With His) Of Human Carbonic Anhydrase Ii	285	9e-77
NP_000058.1	carbonic anhydrase II; carbonate dehydratase II; carbonic dehydratase; carbonic anhydrase B	285	9e-77
P00918	CAH2_HUMAN Carbonic anhydrase II (Carbonate dehydratase II) (CA-II) (Carbonic anhydrase C)	285	9e-77
CRHU2	carbonate dehydratase (EC 4.2.1.1) II [validated]	285	9e-77
1EOU	A Chain A, Crystal Structure Of Human Carbonic Anhydrase Ii Complexed With An Anticonvulsant Sugar Sulfamate	285	9e-77
1CNX	Mol_id: 1; Molecule: Carbonic Anhydrase Ii; Chain: Null; Synonym: Carbonate Dehydratase, Hca Ii; Ec: 4.2.1.1; Heterogen: Benzenesulfonamide	285	9e-77
1CNW	Mol_id: 1; Molecule: Carbonic Anhydrase Ii; Chain: Null; Synonym: Carbonate Dehydratase, Hca Ii; Ec: 4.2.1.1; Heterogen: Ethylaminocarbonylbenzenesulfonamide	285	9e-77
ICNY	Mol_id: 1; Molecule: Carbonic Anhydrase Ii; Chain: Null; Synonym: Carbonate Dehydratase, Hca Ii; Ec: 4.2.1.1; Heterogen: Aminocarbonylbenzenesulfonamide	285	9e-77
4CA2	Carbonic Anhydrase II (Carbonate Dehydratase) (HCA II) (E.C.4.2.1.1)	285	9e-77
1CA3	Carbonic Anhydrase II (Carbonate Dehydratase) (HCA II) (E.C.4.2.1.1) (pH 5.7)	285	9e-77

			1HCA	Carbonic Anhydrase II (Carbonate Dehydratase) (HCA II) (E.C.4.2.1.1) (pH 6.5)	285	9e-77
			CAA68426.1	carbonic anhydrase II (AA 1-260)	285	9e-77
			AAA51908.1	carbonic anhydrase II	285	9e-77
			AAA51909.1	carbonic anhydrase II	285	9e-77
			AAA51911.1	carbonic anhydrase II	285	9e-77
			IUGB	Human Carbonic Anhydrase Ii[hcaii] (E.C.4.2.1.1) Mutant With Ala 65 Replaced By Gly (A65g)	285	1e-76
			ırgş	A Chain A, Crystal Structure Analysis Of The Hca Ii Mutant T199p In Complex With Beta-Mercaptoethanol	285	1e-76
			9971	A Chain A, Crystal Structure Analysis Of Hca Ii Mutant T199p In Complex With Thiocyanate	285	1e-76
			a971	A Chain A, Crystal Structure Analysis Of Hea Ii Mutant T199p In Complex With Bicarbonate	285	1e-76
068890 MM_008890		U:(C-IR)				
NP_032916.1 Mm.57030 2.04	Mm.57030	2.04	NP_002677.1	002677.1 phenylethanolamine N-methyltransferase	462	e-130
			P11086	PNMT_HUMAN Phenylethanolamine N-methyltransferase (PNMTase) (Noradrenaline N-methyltransferase)	462	e-130
			A28171	phenylethanolamine N-methyltransferase (EC 2.1.1.28)	462	e-130
			1HNN	B Chain B, Crystal Structure Of Human Pnmt Complexed With Sk&f 29661 And Adohcy(Sah)	462	e-130
			1HNN	A Chain A, Crystal Structure Of Human Pumt Complexed With Sk&f 29661 And Adohcy(Sah)	462	e-130
			AAA60130.1	phenylethanolamine N-methyltransferase	462	e-130
			CAA36944.1	phenylethanolamine n-methyltransferase	462	e-130
			AAH37246.1	phenylethanolamine N-methyltransferase	462	e-130
			AAA60131.1	phenylethanolamine N-methyltransferase	461	e-130
NM_008985		U:(C-IR)	•	protein tyrosine phosphatase, receptor type. N precursor: islet cell antigen 2: islet cell		
NP 033011.1 Mm.2902	Mm.2902	2.04	NP 002837.1	antigen 512; islet cell autoantigen 3; protein tyrosine phosphatase-like N precursor	1389	0

			Q16849	PTPN_HUMAN Protein-tyrosine phosphatase-like N precursor (R-PTP-N) (PTP IA-2)(Islet cell antigen 512) (ICA 512) (Islet cell autoantigen 3)	1389	0
			AAA90974.1	tyrosine phosphatase	1389	
			CAA44688.2	Islet Cell Antigen 512	972	0
			AAH07713.1	AAH07713 protein tyrosine phosphatase, receptor type, N	972	0
			137577	islet cell antigen 512	850	0
			NP_570857.1	protein tyrosine phosphatase, receptor type, N polypeptide 2, isoform 2 precursor; protein tyrosine phosphatase receptor pi; phogrin; tyrosine phosphatase IA-2 beta; IAR/receptor-like protein-tyrosine phosphatas	607	e-173
			AAB68603.1	protein tyrosine phosphatase receptor pi	607	e-173
			NP_002838.1	protein tyrosine phosphatase, receptor type, N polypeptide 2, isoform 1 precursor; protein tyrosine phosphatase receptor pi; phogrin; tyrosine phosphatase IA-2 beta; IAR/receptor-like protein-tyrosine phosphatase	607	e-173
			Q92932	PTPX_HUMAN Protein-tyrosine phosphatase X precursor (R-PTP-X) (Islet cell autoantigen related protein) (ICAAR) (IAR) (Phogrin)	607	e-173
			JC5062	phogrin precursor	209	e-173
			AAC50742.1	phogri	209	e-173
			JC5263	transmembrane tyrosine phosphatase-like protein, ICAAR	209	e-173
			CAA69880.	Islet Cell Autoantigen Releted	209	e-173
			AAB63600.1	IAR/receptor-like protein-tyrosine phosphatase precursor	209	e-173
			BAA20841.2	KIAA0387	209	e-173
			NP_570858.1	protein tyrosine phosphatase, receptor type, N polypeptide 2, isoform 3 precursor; protein tyrosine phosphatase receptor pi; phogrin; tyrosine phosphatase IA-2 beta; IAR/receptor-like protein-tyrosine phosphatase	579	e-164
			AAH34040.1	protein tyrosine phosphatase, receptor type, N polypeptide 2	579	e-164
		U:(C-IR) 2.03	AAK74066.1	odd-skipped-related 2A protein	481	e-152
NM_054049 NP_473390.1	Mm.4633 6	U:(C-IR) 2.46				
			BAC11035.1	unnamed protein product	484	e-152
			AAH16936.1	AAH16936 odd-skipped-related 2A protein	509	e-144

			NP_443727.1	443727.1 odd-skipped-related 2A protein	507	e-143
			AAK74067.1	odd-skipped-related 2B protein	507	e-143
			XP_059439.2	similar to odd-skipped related 1 (Drosophila); odd-skipped related gene; odz (odd Oz/ten-m) homolog (Drosophila) related 1	347	2e-95
			NP_660303.1	similar to odd-skipped related 1 (Drosophila); odd-skipped related gene; odz (odd Oz/ten-m) homolog (Drosophila) related 1	347	2e-95
			AAH25712.1	Similar to odd-skipped related 1 (Drosophila)	347	2e-95
			BAB92079.1	zinc finger transcription factor	347	2e-95
			BAC11079.1	unnamed protein product	347	2e-95
NM_007924		11-(C.TR)				
NP_031950.1 Mm.1552	Mm.1552	2.03	NP_006523.1	ELL gene (11-19 lysine-rich leukemia gene)	880	0
			P55199	ELL_HUMAN RNA polymerase II elongation factor ELL (Eleven-nineteen lysine-rich leukemia protein)	880	0
			138880	eleven-nineteen lysine-rich leukemia gene (ELL) protein	880	0
			AAA57120.1	BIL	880	0
			AAB34056.1	MEN chimeric transcription factor	803	0
			NP_036213.1	ELL-related RNA polymerase II, elongation factor	371	e-102
			000472	ELL2_HUMAN RNA polymerase II elongation factor ELL2	371	e-102
			AAC51232.1	RNA polymerase II elongation factor ELL2	371	e-102
			AAH28412.1	ELL-RELATED RNA POLYMERASE II, ELONGATION FACTOR	371	e-102
NM_008521		TE.C. II)				
NP_032547.1 Mm.4088	Mm.4088	2.03	AAH29498.1	leukotriene C4 synthase	204	5e-53
			JC5398	leukotriene C4 synthase (EC 6)	204	7e-53
			NP_665874.1	leukotriene C4 synthase isoform 1	204	7e-53
			Q16873	LC4S_HUMAN Leukotriene C4 synthase (Leukotriene-C(4) synthase) (LTC4 synthase)	204	7e-53
			138595	leukotriene-C4·synthase (EC 2.5.1.37)	204	7e-53
			AAA20467.1	leukotriene C4 synthase	204	7e-53

			AAA50555.1	leukotriene-C4 synthase	204	7e-53
			AAC50476.1	leukotriene C4 synthase	204	7e-53
			AAB06723.1	leukotriene C4 synthase	204	7e-53
NM_010780 NP_034910.1	Mm.1252	U:(C-IR) 2.03	NP_001827.1	chymase 1, mast cell preproprotein; chymase, mast cell; chymase, heart; mast cell protease I	345	9e-95
			P23946	MCT1_HUMAN Chymase precursor (Mast cell protease I)	345	9e-95
			KYHUCM	chymase (EC 3.4.21.39) precursor [validated]	345	9e-95
			AAA52019.1	chymase	345	9e-95
			AAA52020.1	mast cell chymase	345	9e-95
			AAA52021.1	chymase	345	9e-95
			IKLT	Crystal Structure Of Pmsf-Treated Human Chymase At 1.9 Angstroms Resolution	333	2e-91
			AAB26828.1	chymase	333	2e-91
			1914144A	chymase	333	2e-91
			IPJP	A Chain A, The 2.2 A Crystal Structure Of Human Chymase In Complex With Succinyl-Ala-Pro-Phe-Chloromethylketone	331	1e-90
NM_021470 NP_067445.1	Mm.8735 U;(C-IR) 2	U:(C-IR) 2.03	NP_112198.1	ring finger protein 32	522	e-148
			CAB66808.1	hypothetical protein	522	e-148
			AAG50281.1	AF325690_1 FKSG33	522	e-148
			AAM18664.1	AF441222_1 ring finger protein RNF32	522	e-148
			AAD43189.1	AC005534 2 supported by human ESTs AA412402 (NID:g2070990) NH44021 (NID:g1182549), mouse EST AA065933 (NID:g1562789), and genscan	445	e-125
			AAH15416.1	AAH15416 Similar to hypothetical protein DKFZp434C135	319	4e-87
		*	AAH28120.1	Similar to ring finger protein 32	310	2e-84
NM_007513 NP_031539.1 Mm.5255	Mm.5255	U:(C-IR)	NP_003036.1	solute carrier family 7 (cationic amino acid transporter, y+ system), member 1; ecotropic retroviral receptor; Solute carrier family 7 (cationic amino acid transporter, y+ system),; amino acid transporter, cationic 1	066	0
			P30825	CTR1_HUMAN High-affinity cationic amino acid transporter-1 (CAT-1) (CAT1) (System Y+ basic amino acid transporter) (Ecotropic retroviral leukemia receptor homolog) (ERR) (Ecotropic retrovirus receptor homolog)	066	0

		CAA41869.1	retroviral receptor	066	0
		AAC27721.1	cationic amino acid transporter	990	0
		S29685	retroviral receptor	886	0
		CAA40560.1	RECIL	886	0
		P52569	CTR2_HUMAN Low-affinity cationic amino acid transporter-2 (CAT-2) (CAT2)	654	0
		BAA06271.1	cationic amino acid transporter 2	654	0
		NP 0030371	solute carrier family 7 (cationic amino acid transporter, y+ system), member 2; Solute carrier family 7 (cationic amino acid transporter, y+ system),; amino acid transporter,	073	
			hCAT-2A	648	0
		NP_116192.2	solute carrier family 7 (cationic amino acid transporter, y+ system), member 3	640	0
		AAL37184.1	cationic amino acid transporter	640	0
		BAC11353.1	unnamed protein product	640	0
		AAH33816.1	solute carrier family 7 (cationic amino acid transporter, y+ system), member 3	639	0
		BAC11253.1	unnamed protein product	637	0
		BAB55118.1	unnamed protein product	421	e-117
		XP_036892.1	similar to Cationic amino acid transporter-4 (CAT-4) (CAT4)	411	e-114
		AAH08814.1	Unknown (protein for MGC:10733)	411	e-114
·		NP_004164.1	solute carrier family 7 (cationic amino acid transporter, y+ system), member 4	393	e-109
		043246	CTR4_HUMAN Cationic amino acid transporter-4 (CAT-4) (CAT4)	393	e-109
		CAA04263.1	cationic amino acid transporter 3	393	e-109
NM_007962	U:(C-IR)				
NP 031988.1 Mm.33240 2.02	2.02	NP_005788.1	epithelial V-like antigen 1 precursor	330	3e-90
		NP_658911.1	epithelial V-like antigen 1 precursor	330	3e-90
		060487	EVA1_HUMAN Epithelial V-like antigen 1 precursor	330	3e-90
		AAC39762.1	epithelial V-like antigen precursor	330	3e-90
		AAF87240.1	AF275945_1 epithelial V-like antigen 1	330	3e-90
		AAG23183.1	AF304447 1 epithelial V-like antigen 1	330	3e-90

			AAH17774.1	epithelial V-like antigen 1	330	3e-90
NM_010393 NP_034523.1	Mm.1960 1 32	U:(C-IR) 2.02	P30461	1B05_HUMAN HLA class I histocompatibility antigen, B-13 B*1301 alpha chain precursor (B13.1)	420	e-117
			I54442	MHC class I histocompatibility antigen HLA-B13 precursor	420	e-117
			AAA52657.1	MHC HLA-B13 precursor	420	e-117
			AAA59660.1	MHC HLA-B13 chain	420	e-117
			BAA08822.1	HLA-B*1302 antigen	420	e-117
			CAC17136.1	MHC class I antigen	420	e-117
			CAC17137.1	MHC class I antigen	418	e-117
			A45850	MHC class I histocompatibility antigen HLA-B13.1	418	e-117
			AAA59627.1	HLA-B13 protein	418	e-117
			BAA08821.1	HLA-B*1301 antigen	418	e-117
			AAA59618.1	glycosylation aa 86, alpha domain 1 aa 1-24, alpha domain 2 aa 25-114, alpha domain 3 aa 207-298	418	e-117
			CAC29063.1	MHC class I antigen	418	e-117
			AAA73509.1	MHC class I lymphocyte antigen	416	e-116
			AAD00010.1	HLA-B38	416	e-116
			AAB06829.1	MHC antigen	415	e-116
			AAA98506.1	MHC class I antigen HLA-B precursor	414	e-116
			184488	lymphocyte antigen	413	e-115
			AAC31793.1	HLA class I antigen HLA-B	412	e-115
			P30476	1B32_HUMAN HLA class I histocompatibility antigen, B-39 B*3902 alpha chain precursor (B39.2)	412	e-115
			168850	MHC class I histocompatibility antigen precursor	412	e-115
			AAA52659.1	lymphocyte antigen	412	e-115
			AAA87396.1	MHC class I antigen	412	e-115
X99104	Mm.1976 95	U:(C-IR) 2.02	NP_084656.1	GLI-Kruppel family member GLI2 isoform beta; oncogene GLI2; tax helper protein 2; zinc finger protein GLI2; tax-responsive element-25-bp sequence binding protein; tax-responsive element-2 holding protein	1821	0

GLI-Kruppel family member GLI2 isoform alpha; oncogene GLI2; tax helper protein 2; zinc finger protein GLI2; tax-responsive element-25-bp sequence binding protein; tax-responsive element-2 holding protein GLI2_HUMAN Zinc finger protein GLI2 (Tax helper protein) hGLI2 GLI-Kruppel family member GLI2 isoform delta; oncogene GLI2; tax helper protein 2; zinc finger protein GLI2; tax-responsive element-2 holding protein hGLI2 hGLI2 clarated and the sequence binding protein; tax-responsive element-2 holding protein	1810 1810 1263 1263	0 0 0
HUMAN Zinc finger protein GLI2 (Tax helper protein) Luppel family member GLI2 isoform delta; oncogene GLI2; tax helper protein; finger protein GLI2; tax-responsive element-2-bp sequence binding protein; sponsive element-2 holding protein	1810 1810 1263 1263 1252	0 0 0
Luppel family member GLI2 isoform delta; oncogene GLI2; tax helper protein sponsive element-2 holding protein gronsive element-2 holding protein	1810 1263 1263 1252	0 0
Suppel family member GLI2 isoform delta; oncogene GLI2; tax helper protein finger protein GLI2; tax-responsive element-25-bp sequence binding protein; sponsive element-2 holding protein	1263 1263 1252	0
Tilinel family member G112 isoform commo, concessor C113, 62-1-1-2-	1263	0
ninnel family member GIT2 isoform cammo: casesang GIT2, tour Later	1252	
protein 2; zinc finger protein GL12; tax-responsive element-25-bp sequence binding protein; tax-responsive element-2 holding protein	_	0
hGL12	1252	C
GLI-Kruppel family member GLI3; oncogene GLI3; DNA-binding protein; zinc finger protein GLI3	1043	0
GLI3 protein	1043	0
GLI3_HUMAN Zinc finger protein GLI3	<u>5</u>	0
190K DNA-binding protein GL13	1004	0
DNA-binding protein	1004	0
Tax helper protein 1	730	0
Tax helper protein 2	719	0
glioma-associated oncogene homolog	445	e-124
GLI1_HUMAN Zinc finger protein GLI1 (Glioma-associated oncogene) (Oncogene GLI)	445	e-124
transforming protein gli	445	e-124
GLJ protein (AA 1-1106)	445	e-124
3000 Similar to glioma-associated oncogene homolog (zinc finger protein)	445	e-124
	445	e-124
[팔팔 팔집 티이종] [Tax helper protein 1 Tax helper protein 2 glioma-associated oncogene homolog GLII HUMAN Zinc finger protein GLII (Glioma-associated oncogene) (Oncogene GLI) transforming protein gli GLI protein (AA 1-1106) AAH13000 Similar to glioma-associated oncogene homolog (zinc finger protein) GLII	ne homolog er protein GL11 (Glioma-associated oncogene) (Oncogene oma-associated oncogene homolog (zinc finger protein)

		U:(C-IR) BA	BAA19667.1	A19667.1 Similar to Rat growth factor Arc (U19866)	765	0
NM_018790 NP_061260.1	Mm.2540 U.(C-D) 5 2.34	U:(C-D) 2.34				
			NP_056008.1	activity-regulated cytoskeleton-associated protein	763	0
			AAF07185.1	AF193421_1 ARC	763	0
			AAG33705.1	AF248637_1 activity-regulated cytoskeleton-associated protein	763	0
			AAH12321.1	AAH12321 Similar to activity-regulated cytoskeleton-associated protein	763	0
		U:(C-IR)	£'	066013.1 DDM36	2055	0
NM_020043 Mr NP_064427.1 41	Mm.1437 U:(C-D) 41 2.17	U:(C-D) 2.17				
			BAB86306.1	hDDM36	2055	0
			BAB13454.1	KIAA1628 protein	1539	0
			AAC51287.1	neogenin	260	2e-68
			NP_002490.1	neogenin homolog 1 (chicken); neogenin (chicken) homolog 1	260	2e-68
			Q92859	NEO1_HUMAN Neogenin precursor	260	2e-68
			AAB17263.1	neogenin	260	2e-68
			NP_005206.1	deleted in colorectal carcinoma	226	2e-58
			P43146	DCC_HUMAN Tumor suppressor protein DCC precursor (Colorectal cancer suppressor)	226	2e-58
			A54100	tumor suppressor protein DCC precursor	226	2e-58
			CAA53735.1	tumour suppressor	226	2e-58
			AAA35751.1	colorectal tumor suppressor (put.); putative	216	3e-55
			Q9UP79	ATS8_HUMAN ADAMTS-8 precursor (A disintegrin and metalloproteinase with thrombospondin motifs 8) (ADAM-TS 8) (ADAM-TS8) (METH-2) (METH-8)	1404	0
NM_013906 NP_038934.1	Mm.1005 U:(C-D) 82 2.16	U:(C-D) 2.16				<u></u>
			AAD48081.1	AF060153_1 METH2 protein	1404	0
			NP 008968.2	a disintegrin and metalloprotease with thrombospondin motifs-8	1403	0

			NP_008919.2	a disintegrin and metalloprotease with thrombospondin motifs-1 preproprotein; human metalloproteinase with thrombospondin type 1 motifs	799	0
			AAF23772.1	AF207664_1 matrix metalloprotease	799	0
			BAA95502.1	metalloprotease with thrombospondin type 1 motifs	66/	0
			AAD48080.1	AF060152_1 METH1 protein	298	0
			Q9UHI8	ATS1_HUMAN ADAMTS-1 precursor (A disintegrin and metalloproteinase with thrombospondin motifs 1) (ADAM-TS1) (METH-1)	862	0
			AAF15317.1	AF170084_1 metalloproteinase with thrombospondin type 1 motifs ADAMTS1	266	0
			BAA92584.1	KIAA1346 protein	862	0
			AAH36515.1	Unknown (protein for MGC:32979)	795	0
	-		NP_620686.1	a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 15 preproprotein	733	0
			CAC86014.1	metalloprotease disintegrin 15 with thrombospondin domains	733	0
NM_013866 Mm NP_038894.1 9	Mm.1409	U:(C-IR) 2.01	XP_028643.4	similar to DKFZP586G1122 protein	543	e-154
			NP_056296.1	DKFZP586G1122 protein	543	e-154
3		Ī	AAL08625.1	AF304052_1 hematopoietic zinc finger protein	543	e-154
			AAH29752.1	DKFZP586G1122 protein	543	e-154
			T17248	hypothetical protein DKFZp586G1122.1	426	e-119
			CAB55938.1	hypothetical protein	426	e-119
			BAB14910.1	unnamed protein product	321	3e-87
			NP_078973.1	hypothetical protein FLJ22419	279	1e-74
			BAB15350.1	unnamed protein product	279	1e-74
			AAH07212.1	AAH07212 hypothetical protein FLJ22419	279	1e-74
			BAC04870.1	unnamed protein product	266	1e-70
			NP_689733.1	hypothetical protein FLJ25270	263	1e-69
			BAB71629.1	unnamed protein product	263	1e-69
			XP_087103.1	similar to zinc finger protein 385; hematopoietic zinc finger	262	1e-69
			AAH38422.1	hypothetical protein FLJ25270	262	1e-69

NM_019762 NP_062736.1	Mm.2960 U:(C-IR) 3	U:(C-IR) 2.01	NP_009114.1	009114.1 plakophilin 3	1271	0
			Q9Y446	PKP3_HUMAN Plakophilin 3	1271	0
			CAB44310.1	plakophilin 3	1271	0
			AAF23050.1	AF053719_1 plakophilin-3 protein	1271	0
			AAH00081.1	AAH00081 plakophilin 3	1271	0
			CAA66265.1	plakophilin 2a	243	9e-64
			AAB97957.1	arm-repeat protein NPRAP/neurojungin	237	6e-62
			AAD00453.1	GT24	237	8e-62
			NP_001323.1	catenin (cadherin-associated protein), delta 2 (neural plakophilin-related arm-repeat protein); catenin (cadherin-associated protein), delta 2	237	8e-62
			BAA36163.1	neural plakophilin-related arm-repeat protein (NPRAP)	237	8e-62
			фуифвз	CTD2_HUMAN Catenin delta-2 (Delta-catenin) (Neural plakophilin-related ARM-repeat protein) (NPRAP) (Neurojungin) (GT24)	232	3e-60
			AAC63103.1	delta-catenin	232	3e-60
			S60712	band-6-protein	228	4e-59
			CAA55881.1	band-6-protein	228	4e-59
			NP_000290.1	plakophilin 1; Plakophilin-1	225	2e-58
			CAA84426.1	plakophilin	225	2e-58
			CAA98022.1	plakophilin 1	225	2e-58
			NP_004563.1	plakophilin 2	222	2e-57
			Q99959	PKP2_HUMAN Plakophilin 2	222	2e-57
			CAA66264.1	plakophilin 2b	222	2e-57
			NP_003619.1	plakophilin 4	222	3e-57
			099569	PKP4_HUMAN Plakophilin 4	222	3e-57
			CAA57478.1	p0071 protein	222	3e-57
NM_028089 NP_082365.1	Mm.1425 81	U:(C-IR)	NP_000763.1	cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 18; cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 17; microsomal monooxygenase; flavoprotein-linked monooxygenase	766	0

			AAB59356.1	cytochrome	992	0
			P33260	CPCI_HUMAN Cytochrome P450 2C18 (CYPIIC18) (P450-6B/29C)	764	0
			A61269	cytochrome P450 2C18	764	0
			AAA02630.1	cytochrome P-4502C18	764	0
			AAB23864.2	cytochrome P-450	736	0
			NP_000762.2	cytochrome P450, subfamily IIC, polypeptide 9; cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 10; mephenytoin 4-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase	736	0
			P11712	CPC9_HUMAN Cytochrome P450 2C9 (CYPIIC9) (P450 PB-1) (P450 MP-4) (S-mephenytoin 4-hydroxylase) (P-450MP)	736	0
			B38462	S-mephenytoin 4-hydroxylase (EC 1.14.14) cytochrome P450 2C9	736	0
			1313295A	cytochrome P450	736	0
			BAA00123.1	cytochrome P-450	736	0
			P11713	CPCA_HUMAN Cytochrome P450 2C10 (CYPIIC10) (P450 MP-8) (S-mephenytoin 4-hydroxylase) (P-450MP)	729	0
			D28951	cytochrome P450 2C10	729	0
			AAA52157.1	cytochrome P-450 S-mephenytoin 4-hydroxylase	729	0
			AAA52158.1	cytochrome P-450 S-mephenytoin 4-hydroxylase	729	0
			1506290A	cytochrome P450	728	0
			NP_000760.1	cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19; mephenytoin 4'-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase	726	0
			P33261	CPCJ_HUMAN Cytochrome P450 2C19 (CYPIIC19) (P450-11A) (Mephenytoin 4-hydroxylase) (CYPIIC17) (P450-254C)	726	0
			AAB59426.1	cytochrome	726	0
			F38462	S-mephenytoin 4'-hydroxylase (EC 1.14.14) cytochrome P450 2C19	722	0
		U:(C-IR)	CAA11218.1	36 kDa phosphothyrosine protein	231	2e-60
NM_010689 N NP_034819.1	Mm.1028 0	U:(C-D) 2.17				

			AAC39636.1	LAT	231	26-60
			AAH11563.1	AAH11563 Similar to linker for activation of T cells	231	2e-60
			NP_055202.1	linker for activation of T cells	215	1e-55
			043561	LAT HUMAN Linker for activation of T cells (36 kDa phospho-tyrosine adaptor protein) (pp36) (p36-38)	215	1e-55
			AAC39637.1	LAT	215	1e-55
NM_017370 NP_059066.1	Mm.2673 0	U:(C-D) 6.81	CAA25926.1	haptoglobin	599	e-171
			P00737	HPT1_HUMAN Haptoglobin-1 precursor	598	e-171
			HPHU1	haptoglobin precursor, allele 1 [validated]	598	e-171
			AAA52684.1	preprohaptoglobin	598	e-171
			CAA25267.1	haptoglobin alpha 1S	598	e-171
			AAC27432.1	haptoglobin	597	e-170
			NP_066275.2	haptoglobin-related protein; Haptoglobin-related locus	569	e-162
			P00739	HPTR_HUMAN Haptoglobin-related protein precursor	569	e-162
			HPHUR	haptoglobin-related protein precursor	569	e-162
			AAA88079.1	haptoglobin-related protein	995	e-162
			AAA88081.1	haptoglobin-related protein	569	e-162
			CAA25927.1	haptoglobin	895	e-162
			AAC27433.1	haptoglobin-related protein precursor	565	e-161
			CAA61501.1	haptoglobin-related protein	565	e-161
			AAA52687.1	haptoglobin precursor	559	e-159
			NP_005134.1	haptoglobin	559	e-159
			P00738	HPT2_HUMAN Haptoglobin-2 precursor	559	e-159
			нРНU2	haptoglobin precursor, allele 2	559	e-159
			CAA25137.1	haptoglobin precursor	559	e-159
			AAA88078.1	haptoglobin	559	e-159
			AAA88080.1	haptoglobin	559	e-159

			AAA52685.1	preprohaptoglobin	559	e-159
			1006264A	haptoglobin Hp2	808	e-144
NM_007424 NP_031450.1 Mm.2759	Mm.2759	U:(C-D) 4.11 U:(R-D) 3.08	NP_037359.1	aggrecan 1 isoform 2 precursor; Aggrecan-1 (chondroitin sulfate proteoglycan-1, large aggregating proteoglycan, antigen identifies by monoclonal antibody A0122); chondroitin sulfate proteoglycan 1, large aggregating proteoglycan	1795	0
			NP_001126.1	aggrecan 1 isoform 1 precursor; Aggrecan-1 (chondroitin sulfate proteoglycan-1, large aggregating proteoglycan, antigen identifies by monoclonal antibody A0122); chondroitin sulfate proteoglycan 1, large aggregating proteoglycan	1794	0
			AAA62824.1	large aggregating cartilage proteoglycan core protein	1794	0
			A39086	aggrecan precursor, cartilage long splice form	1792	0
			AAH36445.1	Similar to aggrecan 1 (chondroitin sulfate proteoglycan 1, large aggregating proteoglycan, antigen identified by monoclonal antibody A0122)	1253	0
			CAA35463.1	cartilage specific proteoglycan (600 AA)	823	0
			AAA35726.1	proteoglycan core protein	573	e-162
			AAH10571.1	chondroitin sulfate proteoglycan BEHAB/brevican	369	e-101
			AAG23134.1	AF228710_1 chondroitin sulfate proteoglycan BEHAB/brevican	369	e-101
			AAG23135.1	AF229053_1 chondroitin sulfate proteoglycan BEHAB/brevican	369	e-101
NM_009008 NP_033034.1	Mm.1972	U:(C-D) 2.85	NP_002863.1	ras-related C3 botulinum toxin substrate 2; Ras-related C3 botulinum toxin substrate 3 (rho family, small GTP-binding protein Rac2); rho family, small GTP binding protein Rac2	390	e-108
			P15153	RAC2_HUMAN Ras-related C3 botulinum toxin substrate 2 (p21-Rac2) (Small G protein) (GX)	390	e-108
			B34386	GTP-binding protein rac2	390	e-108
			1DS6	A Chain A, Crystal Structure Of A Rac-Rhogdi Complex	390	e-108
			AAA36538.1	ras-related C3 botulinum toxin substrate	390	e-108
			AAB22207.1	rac1 p21=small GTP-binding protein [human, HL60, Peptide, 192 aa]	390	e-108
			CAB45265.1	dJ151B14.2 (ras-related C3 botulinum toxin substrate 2 (rho family, mall GTP binding protein Rac2))	390	e-108
			AAH01485.1	AAH01485 ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2)	390	e-108

AAM21112.1	AF498965_1 small GTP binding protein RAC2	390	e-108
NP_008839.2	ras-related C3 botulinum toxin substrate 1 isoform Rac1; rho family, small GTP binding protein Rac1	367	e-101
P15154	RAC1_HUMAN Ras-related C3 botulinum toxin substrate 1 (p21-Rac1) (Ras-like protein TC25)	367	e-101
TVHUC1	GTP-binding protein rac1	367	e-101
114D	D Chain D, Crystal Structure Analysis Of Rac1-Gdp Complexed With Arfaptin (P21)	367	e-101
114L	D Chain D, Crystal Structure Analysis Of Rac1-Gdp In Complex With Arfaptin (P41)	367	e-101
AAA36537.1	ras-related C3 botulinum toxin substrate	367	e-101
AAB22206.1	rac1 p21=small GTP-binding protein [human, HL60, Peptide, 192 aa]	367	e-101
CAB53579.5	Rac1 protein	367	e-101
AAM21111.1	AF498964_1 small GTP binding protein RAC1	367	e-101
AAH04247.1	AAH04247 ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1)	367	e-101
AAA35941.1	small G protein	366	e-101
AAA36544.1	ras-like protein	366	e-101
114T	D Chain D, Crystal Structure Analysis Of Rac1-Gruppin In Complex With Arfaptin	365	e-100
1e+96	1e+96 A Chain A, Structure Of The RacP67PHOX COMPLEX	363	e-100
1HH4	A Chain A, Rac1-Rhogdi Complex Involved In Nadph Oxidase Activation	362	e-100
1HH4	B Chain B, Rac1-Rhogdi Complex Involved In Nadph Oxidase Activation	362	e-100
NP_005043.1	ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3); rho family, small GTP binding protein Rac3	358	1e-98
014658	RAC3_HUMAN Ras-related C3 botulinum toxin substrate 3 (p21-Rac3)	358	1e-98
AAC51667.1	Rac3	358	le-98
AAH15197.1	AAH15197 ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3):	358	1e-98
AAH09605.1	AAH09605 ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3)	358	1e-98
AAM21113.1	AF498966 1 small GTP binding protein RAC3	358	1e-98
		'	1

			NP 061485 1	ras-related C3 botulinum toxin substrate 1 isoform Rac1b; rho family, small GTP binding protein Rac1	356	\$6.98
			CAA10732.1	small GTPase rac1b	356	5e-98
			AAD30547.1	AF136373_1 ras-related C3 botulinum toxin substrate isoform	356	5e-98
			CAA10733.6	Rac1b protein	356	5e-98
AK013740		(d 2):11		-		
BAB28979.1	Mm.27579 2.82	2.82	NP_068747.1	068747.1 hypothetical protein FLJ22649 similar to signal peptidase SPC22/23	298	1e-80
			BAB15437.1	unnamed protein product	298	1e-80
			Q9H0S7	SP22_HUMAN Microsomal signal peptidase 23 kDa subunit (SPase 22 kDa subunit)	295	9e-80
			CAB66595.1	hypothetical protein	295	9e-80
X00496 CAA25191.1	Mm 7043	U:(C-D) 2.81	NP_004346.1	CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated); CD74 antigen (invariant polypeptide of major histocompatibility class II antigen-associated)	226	4e-59
			CAA25192.1	putative p33	226	4e-59
			AAA36033.1	cell surface glycoprotein	226	4e-59
			AAH18726.1	AAH18726 CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated)	226	4e-59
			HLHUG	class II histocompatibility antigen-associated gamma chain	226	4e-59
			CAA25193.1	putative p33	226	4e-59
			AAA36304.1	class II antigen gamma chain	226	4e-59
			CAA27047.1	gamma chain	225	9e-59
			P04233	HG2A_HUMAN HLA class II histocompatibility antigen, gamma chain (HLA-DR antigens associated invariant chain) (Ia antigen-associated invariant chain) (Ii) (p33) (CD74 antigen)	207	1e-53
		U:(C-D)	AAH36390.1	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 4 (GalNAc-T4)	1078	0
NM_015737 NP_056552.1	Mm.5699 U:(IR-D) 1	U:(IR-D) 2.1				·

NP_003765.1	polypeptide N-acetylgalactosaminyltransferase 4; UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 4; GalNAc transferase 4; UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase 4; protein-UDP acetylgalactosaminyltransferase 4	1073	0
CAA69875.1	UDP-GallNAc:polypeptide N-acetylgalactosaminyltransferase	1073	0
CAC80100.2	UDP-GalNAc-transferase 12	624	e-178
NP_078918.2	hypothetical protein FLJ21212; UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 12(GalNAc-T12)	622	e-178
BAC07181.1	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 12	622	e-178
NP_004473.1	polypeptide N-acetylgalactosaminyltransferase 3; protein-UDP acetylgalactosaminyltransferase	462	e-130
CAA63371.1	UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase (GalNAc-T3)	462	e-130
AAH35822.1	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (GalNAc-T6)	461	e-129
BAC11118.1	unnarned protein product	461	e-129
NP_009141.1	polypeptide N-acetylgalactosaminyltransferase 6; UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 6; protein-UDP acetylgalactosaminyltransferase 6; GalNAc transferase 6	459	e-129
CAA69876.1	UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase	459	e-129
BAB67811.1	KIAA1918 protein	417	e-116
NP_065207.2	polypeptide N-acetylgalactosaminyltransferase 1; UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1; GalNAc-T1; GalNAc transferase 1; protein-UDP acetylgalactosaminyltransferase 1; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 1	416	. e-116
Q10472	PAGT_HUMAN Polypeptide N-acetylgalactosaminyltransferase (Protein-UDP acetylgalactosaminyltransferase) (UDP-GalNAc:polypeptide, N-acetylgalactosaminyltransferase) (GalNAc-T1)	416	e-116
JC4223	polypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.41)	416	e-116
CAA59380.1	UDP-GalNAc:polypeptide N-acetylgalactosaminyl transferase	416	e-116

Mm.1011 U:(C-D) 6 2.65					
	[I-(C-D)				
Mm.14191	2.59	CAA48671.1	alpha1-antichymotrypsin	494	e-139
		XP_028322.1	028322.1 similar to Alpha-1-antichymotrypsin precursor (ACT)	490	e-138
		P01011	AACT_HUMAN Alpha-1-antichymotrypsin precursor (ACT)	490	e-138
		AAH03559.1	serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3	490	e-138
		AAH10530.1	Unknown (protein for MGC:18102)	490	e-138
		AAH34554.1	serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3	489	e-138
		AAD08810.1	alpha-1-antichymotrypsin precursor	478	e-134
		ITHUC	alpha-1-antichymotrypsin precursor	476	e-134
		AAA51560.1	alpha-1-antichymotrypsin precursor	470	e-132
		1QMN	A Chain A, Alpha1-Antichymotrypsin Serpin In The Delta Conformation (Partial Loop Insertion)	460	e-129
		1313184C	chymotrypsin inhibitor	441	e-123
		NP_001076.1	alpha-1-antichymotrypsin, precursor; alpha-1-antichymotrypsin; antichymotrypsin	439	e-123
		AAA51543.1	alpha-1-antichymotrypsin	439	e-123
		2ACH	A Chain A, Alphal Antichymotrypsin	434	e-121
Mm.2256 4	U:(C-D) 2.59	AAH07920.1	AAH07920 Unknown (protein for MGC:14111)	390	e-108
		AAL40069.1	L76133_1 lymphocyte antigen	390	e-108
	•	AAH08403.1	AAH08403 Similar to major histocompatibility complex, class II, DR beta 5	387	e-107
		CAC08827.1	MHC class II antigen	386	e-107
		I54448	MHC class II histocompatibility antigen DR beta 1 chain precursor	386	e-107
		AAA59713.1	precursor	386	e-107

			CAC08823.1	MHC class II antigen	386	e-107
			P20039	HB2I_HUMAN HLA class II histocompatibility antigen, DR-5 beta chain precursor	385	e-107
			A25324	class II histocompatibility antigen HLA-DR-5 beta chain precursor	385	e-107
			AAA36274.1	MHC HLA DR5 cell surface glycoprotein beta chain precursor	385	e-107
			CAC08826.2	MHC class II antigen	385	e-107
,			P13760	HB2H_HUMAN HLA class II histocompatibility antigen, DR-4 beta chain precursor (DRBI*0401)	385	e-107
			A29310	MHC class II histocompatibility antigen HLA-DR beta 1 chain DR4 precursor	385	e-107
			CAC19360.1	d1863G3.2 (major histocompatibility complex, class II, DR beta 1)	385	e-107
			CAB75359.1	human leucocyte antigen DRB1	385	e-107
			P01912	HB2B_HUMAN HLA class II histocompatibility antigen, DR-1 beta chain precursor (Clone P2-beta-3)	385	e-107
				pir HLHU3D MHC class II histocompatibility antigen HLA-DR beta 1 chain DR17 precursor	385	e-107
			CAA25295.1	precursor	385	e-107
			CAB06490.1	d193N13.3 (major histocompatibility complex, class II, DR beta 1 (clone P2-beta-3))	385	e-107
			•			
AK012581						
XP_126675.1	Mm.21687	U:(C-D) 2.55	, AAK67634.1	hypothetical protein SB143	240	2e-63
			NP_085053.1	hypothetical protein MGC10986	240	2e-63
			AAH04400.1	AAH04400.1 Unknown (protein for MGC:10986)	240	2e-63
			BAC03855.1	unnamed protein product	240	2e-63
NM_027209 NP_081485.1	Mm.2948 7	U:(C-D) 2.47	NP_690591.1	membrane-spanning 4-domains, subfamily A, member 6A isoform 1; CD20-like precusor; membrane-spanning 4-domains, subfamily A, member 6; four-span transmembrane protein 3.2; MS4A6A-polymorph; four-span transmembrane protein 3.1; HAIRB-iso	233	5e-61
			AAG41780.1	AF212240_1 CDA01	233	5e-61
			AAK37417.1	AF237908 1 MS4A6A protein	233	5e-61

			AAK37994.1	AF286866_1 MS4A6A-polymorph	233	5e-61
			AAH22854.1	membrane-spanning 4-domains, subfamily A, member 6A	232	8e-61
*			AAL56222.1	AF350502_1 four-span transmembrane protein 3.1	229	5e-60
			AAG44626.1	AF253977_1 HAIRB-iso	222	1e-57
			1	membrane-spanning 4-domains, subfamily A, member 6A isoform 2; CD20-like precusor; membrane-spanning 4-domains, subfamily A, member 6; four-span transmembrane protein 3.2; MS4A6A-polymorph; four-span transmembrane protein 3.1; HAIRB-iso	208	1e-53
			AAL07357.1	AF354930_1 MS4A6A	208	1e-53
			AAG27920.1	AF142409_1 CD20-like precusor	207	2e-53
			AAL56223.1	AF350503_1 four-span transmembrane protein 3.2	207	4e-53
NM_011116 NP_035246.1	Mm.6483	U:(C-D) 2.45	AAH36327.1	Similar to phospholipase D3	890	0
			AAH00553.1	AAH00553 similar to vaccinia virus HindIII K4L ORF	818	0
			NP_036400.1	similar to vaccinia virus HindIII.K4L ORF	816	0
			AAB16799.1	HU-K4	816	0
			NP_620145.1	620145.1 hypothetical protein BC015003	385	e-106
			AAH15003.1	AAH15003 Unknown (protein for MGC:23565)	385	e-106
			NP_689879.1	hypothetical protein FLJ40773	275	2e-73
ļ			BAC05230.1	unnamed protein product	275	2e-73
			BAC03722.1	unnamed protein product	223	9e-58
NM_013487 NP_038515.1	Mm.4527	U:(C-D) 2.39	NP_000723.1	CD3D antigen, delta polypeptide (TiT3 complex)	228	Se-60
			P04234	CD3D_HUMAN T-cell surface glycoprotein CD3 delta chain precursor (T-cell receptor T3 delta chain)	228	5e-60
			RWHUD1	T-cell surface glycoprotein CD3 delta chain precursor	228	5e-60
			CAA25683.1	20K T3 glycoprotein precursor	228	Se-60
	,		AAA51792.1	T3 antigen delta-chain	228	5e-60
			CAA27573.1	T3 delta protein	228	5e-60

			1101394A	protein delta T3,glyco	222	2e-58
AK004773		(d.0)[1				
XP_125911.2	U:() Mm.32580 2.27	U:(C-D) 2.27	NP_055686.1	KIAA0710 gene product	1150	0
			BAA31685.1	KIAA0710 protein	1150	0
			AAH24043.1	KIAA0710 gene product	1141	0
NM_007804		U:(C-D)				
NP_031830.1	Mm.5116	2.26	014529	CUT2_HUMAN Homeobox protein Cux-2 (Cut-like 2)	1950	0
		·	BAA22962.2	The human homolog of mouse Cux-2	1950	0
			XP_027045.6	027045.6 similar to Homeobox protein Cux-2 (Cut-like 2)	1949	0
			P39880	CUT1_HUMAN CCAAT displacement protein (CDP) (Cut-like 1)	892	0
			AAB26579.1	CCAAT displacement protein, CDP [human, Peptide, 1505 aa]	892	0
:			NP_001904.1	cut-like 1, CCAAT displacement protein; cut like 1, CCAAT displacement protein (Drosophila)	283	2e-75
			AAA35654.1	alternatively spliced	283	2e-75
			AAH25422.1	cut-like 1, CCAAT displacement protein (Drosophila)	283	2e-75
			AAG59620.1	AF271236_1 transcription factor CUX2	238	8e-62
NM_026384 NP_080660.1	Mm.1801 89	U:(C-D) 2.26	CAD38961.1	hypothetical protein	761	0
			NP_115953.2	diacylglycerol O-acyltransferase homolog 2; GS1999full	751	0
			AAH15234.1	AAH15234 Unknown (protein for MGC:17861)	751	0
			AAK84176.2	AF384161_1 diacylglycerol acyltransferase 2	751	0
			BAB40641.2	product is unknown	751	0
			CAD13492.1	bA351K23.5 (novel protein)	340	2e-93
			NP_477513.1	diacylglycerol O-acyltransferase 2 like 1; diacylglycerol acyltransferase 2-like	331	1e-90
			AAK84178.1	AF384163_1 diacylglycerol acyltransferase 2-like protein	331	1e-90
			AAD45832.1	AC004876_5 similar to predicted proteins AAB54240 (PID:g2088822) and S67138 (PID:g2132925)	295	1e-79

		i	XP_088691.1	similar to bA351K23.5 (novel protein)	251	1e-66
×			XP_088683.1	similar to bA351K23.5 (novel protein)	219	5e-57
			XP_093119.2	similar to bA351K23.5 (novel protein)	215	1e-55
			NP_079374.1	hypothetical protein FLJ22644	206	5e-53
			BAB15436.1	unnamed protein product	206	5e-53
AK004809		U:(C-D)				
BAB23580.1	Mm.28152 2.25	2.25	AAN41656.1	ezrin-binding protein PACE-1	1081	0
			CAB55300.1	hypothetica1 protein	956	0
			CAB52564.2	dJ97P20.1 (novel gene)	926	0
			AAN23123.1	ezrin-binding partner PACE-1	956	0
			NP_065156.4	065156.4 ezrin-binding partner PACE-1	954	0
			AAH14662.1	Similar to hypothetical protein LOC57147	954	0
NM_009151	Mm.22173	U:(C-D) 2.25	XP 006867.4	similar to P-selectin glycoprotein ligand 1 precursor (PSGL-1) (Selectin P ligand) (CD162 antieen)	286	Se-77
			∥ ++	SEPL_HUMAN P-selectin glycoprotein ligand 1 precursor (PSGL-1) (Selectin P ligand) (CD162 antigen)	286	Se-77
			A57468	P-selectin glycoprotein ligand PSGL-1 precursor, long splice form	286	5e-77
			AAA74577.1	P-selectin glycoprotein ligand	286	5e-77
			NP_002997.1	selectin P ligand	284	2e-76
			AAC50061.1	ligand for P-selectin	284	2e-76
			AAH29782.1	selectin P ligand	284	2e-76
			BAC05283.1	unnamed protein product	258	2e-68
NM_030255 NP_084531.1	Mm.8970 U:(C-D) 2.24	U:(C-D) 2.24	NP_660341.2	apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F; similar to Phorbolin 3 (APOBEC1-like)	200	7e-51
			AAH38808.1	apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F	199	1e-50
AK009960		U:(C-D)			6	
XP 153997.2 Mm.28248	Mm.28248	2.73	BAA9606/.1	KIAA1545 protein	388	e-108

			XP_048362.1	048362.1 similar to KIAA1543 protein	388	e-108
			CAD38783.1	hypothetical protein	388	e-108
			AAL55764.1	AF289580_1 unknown	320	1e-87
			XP_036589.2	similar to KIAA1078 protein	237	2e-62
			AAH11385.1	Unknown (protein for IMAGE:3870900)	237	2e-62
			BAA83030.2	KIAA1078 protein	237	2e-62
			T14744	hypothetical protein DKFZp586F0424.1	236	3e-62
			CAB53664.1	hypothetical protein	236	3e-62
			AAH12778.1	Unknown (protein for IMAGE:3939659)	227	1e-59
		·	CAD39184.1	hypothetica1 protein	227	1e-59
NM_024249 NP_077211.2	Mm.3310	U:(C-D) 2.23	NP_612637.1	hypothetical protein MGC15523	689	0
			AAH14642.1	AAH14642 Similar to RIKEN cDNA 1810073N04 gene	689	0
			BAC04027.1	unnamed protein product	275	1e-73
NM_030562 NP_085039.1	Mm.1832 64	U:(C-D) 2.21	BAA96008.1	KIAA1484 protein	701	0
			XP_046088.1	similar to hypothetical protein MGC7599; clone MGC:7599	0/9	0
			XP_085176.1	similar to hypothetical protein MGC2656	484	e-136
			NP_689660.1	hypothetical protein FLJ30803	484	e-136
	•		BAB70910.1	unnamed protein product	484	e-136
			BAA86560.1	KIAA1246 protein	466	e-131
			XP_166372.1	similar to hypothetical protein MGC2656	466	e-131
			NP_078785.1	hypothetical protein MGC2656	446	e-125
			AAH03578.1	AAH03578 Unknown (protein for MGC:2656)	446	e-125
			AAH25310.1	Similar to KIAA1484 protein	431	e-120
			NP 076941.2	hypothetical protein MGC3103	424	e-118
			AAH15581.2	similar to hypothetical protein MGC3103	424	e-118
			AAH14678.1	AAH14678 Unknown (protein for IMAGE:3860672)	274	2e-73

NM_033614 NP_291092.1	Mm.1969	U:(C-D) 2.15	JC4520	3',5'-cyclic-GMP phosphodiesterase (EC 3.1.4.35) alpha' chain	1489	0
			CAA64079.1	cone cGMP phosphodiesterase	1489	0
			2207224A	cGMP phosphodiesterase	1489	0
			P51160	CNRC_HUMAN Cone cGMP-specific 3,5'-cyclic phosphodiesterase alpha'-subunit	1484	0
			AAA92886.1	cone photoreceptor cGMP-phosphodiesterase alpha' subunit	1484	0
			NP_006195.2	phosphodiesterase 6C, cGMP-specific, cone, alpha prime	1478	0
			AAA96392.1	phosphodiesterase A' subunit	1478	0
			NP_000274.1	phosphodiesterase 6B, cGMP-specific, rod, beta	1092	0
			P35913	CNRB_HUMAN Rod cGMP-specific 3',5'-cyclic phosphodiesterase beta-subunit (GMP-PDE beta)	1092	0
			A42828	3,5'-cyclic-GMP phosphodiesterase (EC 3.1.4.35) beta chain	1092	0
			AAB22690.1	rod cGMP phosphodiesterase beta-subunit; PDEB	1092	0
			CAA46932.1	3',5'-cyclic-nucleotide phosphodiesterase	1092	0
			AAH00249.1	AAH00249 phosphodiesterase 6B, cGMP-specific, rod, beta (congenital stationary night blindness 3, autosomal dominant)	1089	0
			CAA44569.1	cGMP phosphodiesterase beta subunit	1085	0
			B34611	3',5'-cyclic-GMP phosphodiesterase (EC 3.1.4.35) alpha chain	1075	0
			NP_000431.1	phosphodiesterase 6A, alpha subunit	1074	0
			P16499	CNRA_HUMAN Rod cGMP-specific 3',5'-cyclic phosphodiesterase alpha-subunit (GMP-PDE alpha) (PDE V-B1)	1074	0
			AAB69155.1	cGMP phosphodiesterase	1074	0
			CAA62215.1	Rod cGMP phosphodiesterase	893	0
-			NP_058649.2	phosphodiesterase 11A; cyclic nucleotide phosphodiesterase 11A1	409	e-113
			BAB16371.1	phosphodiesterase 11A	409	e-113
			BAB62712.1	phosphodiesterase 11A4	409	e-113
NM_007441		U:(C-D)				
NP 031467.1 Mm.10112 2.14	Mm.10112	2.14	NP 006483.1	006483.1 aristaless-like homeobox 3	516	e-146

			920260	ALX3_HUMAN Homeobox protein aristaless-like 3 (Proline-rich transcription factor ALX3)	516	e-146
			AAD01418.1	homeobox protein	516	e-146
NM_017394 NP_059090.1	Mm.3556 7	U:(C-D) 2.14	NP_062823.1	062823.1 solute carrier family 7, member 10; asc-type amino acid transporter 1	904	0
			Q9NS82	AAA1_HUMAN Asc-type amino acid transporter 1 (Asc-1)	984	0
			BAB03213.1	asc-type amino acid transporter 1	904	0
			AAK93960.1	AF340165_1 amino acid transporter	904	0
			CAC81900.1	ASC1 protein	904	0
			AAH35627.1	similar to solute carrier family 7	904	0
			оэпніз	LAT2_HUMAN Large neutral amino acids transporter small subunit 2 (L-type amino acid transporter 2) (hLAT2)	699	0
			AAF20381.1	AF171669_1 glycoprotein-associated amino acid transporter LAT2	699	0
			BAB21519.1	L-type amino acid transporter 2	699	0
			NP_036376.1	solute carrier family 7 (cationic amino acid transporter, y+ system), member 8	999	0
			CAB40137.1	SLC7A8 protein	999	0
			AAF05695.1	AF135828_1 L amino acid transporter-2; LAT-2	534	e-151
			NP_003477.2	solute carrier family 7 (cationic amino acid transporter, y+ system), member 5; Membrane protein E16; Solute carrier family 7, member 5; 4F2 light chain	436	e-122
			Q01650	LAT1_HUMAN Large neutral amino acids transporter small subunit 1 (L-type amino acid transporter 1) (4F2 light chain) (4F2 LC) (4F2 LC) (CD98 light chain) (Integral membrane protein E16) (hLAT1)	436	e-122
			JG0165	LAT1 protein	436	e-122
			BAA33851.1	CD98 light chain	436	e-122
	:		AAD20464.1	L-type amino acid transporter subunit LAT1	436	e-122
			BAA84648.1	L-type amino acid transporter 1	436	e-122
			AAC61479.1	amino acid transporter E16	436	e-122
			AAH39692.1	Similar to solute carrier family 7 (cationic amino acid transporter, y^+ system), member 5	436	e-122

	-		BAA75746.1	4F2 light chain	434	e-121
			BAB70708.1	sodium-independent neutral amino acid transporter LAT1	434	e-121
			NP 003974.1	solute carrier family 7 (cationic amino acid transporter, y+ system), member 6	431	e-120
			BAA13376.1	Similar to Schistosoma mansoni amino acid permease (L25068).	431	e-120
			AAH28216.1	solute carrier family 7 (cationic amino acid transporter, y+ system), member 6	431	e-120
AK018130		(II-(C-D)			1	
BAB31085.1 N	Mm.5202	2.13	D59433	C. elegans protein Z37093 homolog [imported]	739	0
			BAA13212.1	similar to C. elegans protein (Z37093)	739	0
			AAC03237.1	D1013901	739	0
			XP_037574.1	similar to PTPL1-associated RhoGAP 1	739	0
			AAN04658.1	minor histocompatibility antigen HA-1	739	0
			AAH35564.1	Similar to PTPL1-associated RhoGAP 1	739	0
			NP_004806.1	PTPL1-associated RhoGAP 1	278	2e-74
			E59430	PTPL1-associated RhoGAP protein 1 [imported]	278	2e-74
			AAB81012.1	PTPL1-associated RhoGAP	278	2e-74
			NP_057657.1	Gem-interacting protein	265	2e-70
			D59435	Gem-interacting protein [imported]	265	2e-70
			AAF61330.1	AF132541_1 Gem-interacting protein	265	2e-70
AK014320		(4.0)11				
BAB29271.1	Mm.30114 2.12	2.12	AAL14103.1	AF391100_1 alsin	1569	0
			BAB13389.2	KIAA1563 protein	1569	0
			NP_065970.1	alsin	1569	0
			BAB69014.1	long form	1569	0
			NP_667340.1	hypothetical protein LOC259173	244	5e-64
			BAC04237.1	unnarned protein product	244	Se-64
			BAB84944.1	FLJ00189 protein	244	9e-64

AK014599					-	
BAB29454.1	U:(C Mm.66017 2.12	U:(C-D) 2.12	AAD43186.1	AC006029_1 Similar to Sperm Surface Protein PH-20;Similar to P38568 (PID:585674)	749	0
			NP_036401.1	hyaluronoglucosaminidase 4; hyaluronidase 4	749	0
			AAC98883.1	hyaluronidase 4	749	0
			NP_694859.1	sperm adhesion molecule 1 isoform 2; sperm surface protein PH-20; hyaluronoglucosaminidase	385	e-106
			P38567	HYAP_HUMAN Hyaluronidase PH-20 precursor (Sperm surface protein PH-20) (Sperm adhesion molecule 1)	385	e-106
			CAA59086.1	sperm adhesion molecule gene SPAM1	385	e-106
			NP_003108.2	sperm adhesion molecule 1 isoform 1; sperm surface protein PH-20; hyaluronoglucosaminidase	385	e-106
			AAH26163.1	sperm adhesion molecule 1 (PH-20 hyaluronidase, zona pellucida binding)	385	e-106
			AAC60607.2	PH-20	382	e-105
			S40465	sperm protein PH-20	382	e-105
			AAD24460.1	AF118821_1 hyaluronoglucosaminidase 1 isoform 2	337	9e-92
			AAD53277.1	AF173154_1 hyaluronoglucosaminidase 1 isoform 2	337	9e-92
	:		NP_009296.1	hyaluronoglucosaminidase 1 isoform 1; hyaluronidase 1; tumor suppressor LUCA-1; plasma hyaluronidase; hyaluronoglucosaminidase	336	16-91
			NP_149349.2	hyaluronoglucosaminidase 1 isoform 1; hyaluronidase 1; tumor suppressor LUCA-1; plasma hyaluronidase; hyaluronoglucosaminidase	336	16-91
			NP_695013.1	hyaluronoglucosaminidase 1 isoform 1; hyaluronidase 1; tumor suppressor LUCA-1; plasma hyaluronidase; hyaluronoglucosaminidase	336	1e-91
			AAD04190.1	hyaluronoglucosaminidase 1	336	1e-91
			AAD09137.2	putative tumor suppressor	336	1e-91
			AAH35695.1	hyaluronoglucosaminidase 1	336	1e-91
			JC5584	hyalurononglucosaminidase (EC 3.2.1.35) 1 precursor	333	7e-91
NM_008969 U:(C	Mm 2792	U:(C-D)	NP 000053.2	rostaglandin-endoperoxide synthase 1, isoform 1 precursor; prostaglandin G/H synthase and cyclooxygenase; PGH synthase 1; PG synthetase; prostaglandin	5	
100000	7/17	71.7		occess. Symmetrase, cycloony generact, prostagramming symmetrase 1	1040	٥

P23219	PGH1_HUMAN Prostaglandin G/H synthase 1 precursor (Cyclooxygenase -1) (COX-1) (Prostaglandin-endoperoxide synthase 1) (Prostaglandin H2 synthase 1) (PGH synthase 1) (PGHS-1) (PHS-1)	1043	0
JH0259	prostaglandin-endoperoxide synthase (EC 1.14.99.1) 1 precursor	1043	0
AAA03630.1	prostaglandin endoperoxide synthase	1043	0
AAB21215.1	prostaglandin endoperoxide synthase; cyclooxygenase	1043	0
AAB22217.1	prostaglandin G/H synthase; PGG/HS	1043	0
AAL33601.1	AF440204_1 prostaglandin-endoperoxide synthase 1	1043	0
AAH29840.1	Unknown (protein for MGC:34214)	1043	0
AAA36439.1	prostaglandin-endoperoxide synthase-1	1038	0
NP_542158.1	prostaglandin-endoperoxide synthase 1, isoform 2 precursor; prostaglandin G/H synthase and cyclooxygenase; PGH synthase 1; PG synthetase; prostaglandin synthetase; cyclooxygenase-1; prostaglandin H2 synthetase 1	956	0
AAB22216.1	prostaglandin G/H synthase; PGG/HS	956	0
NP_000954.1	prostaglandin-endoperoxide synthase 2 precursor; prostaglandin G/H synthase and cyclooxygenase; cyclooxygenase-2; endoperoxide synthase type II; prostaglandin synthase-2; PG synthetase	729	0
P35354	PGH2_HUMAN Prostaglandin G/H synthase 2 precursor (Cyclooxygenase -2) (COX-2)(Prostaglandin-endoperoxide synthase 2) (Prostaglandin H2 synthase 2) (PGH synthase 2) (PGHS-2) (PHS II)	729	0
AAA57317.1	cyclooxygenase-2	729	0
BAA05698.1	prostaglandin endoperoxide synthase-2	729	0
CAB41240.1	PTGS2 (prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase))	729	0
AAH13734.1	AAH13734 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)	729	0
A46150	prostaglandin-endoperoxide synthase (EC 1.14.99.1) 2 precursor	729	0
AAA58433.1	cyclooxygenase-2	729	0
AAA35803.1	endoperoxide synthase type II	727	0
AAN52932.1	cyclooxygenase 2b	380	e-105

NM_010225 NP_034355.1	Mm.6260	U:(C-D) 2.11	NP_001443.1	.001443.1 forkhead box F2; forkhead (Drosophila)-like 6	521	e-147
			Q12947	FXF2_HUMAN Forkhead box protein F2 (Forkhead-related protein FKHL6) (Forkhead-related transcription factor 2) (FREAC-2) (Forkhead-related activator-2)	521	e-147
			T09474	forkhead protein FREAC-2	521	e-147
			AAC32226.1	forkhead protein FREAC-2	521	e-147
			AAD19875.1	forkhead transcription factor	521	e-147
			2208384B	transcription factor FREAC-2	208	e-143
	;		NP_001442.1	forkhead box F1; forkhead (Drosophila)-like 5; Forkhead, drosophila, homolog-like 5; forkhead-related activator 1 [Homo sapiens]	251	3e-66
			Q12946	FXF1_HUMAN Forkhead box protein F1 (Forkhead-related protein FKHL5) (Forkhead-related transcription factor 1) (FREAC-1) (Forkhead-related activator-1)	251	3e-66
			AAC50399.1	FREAC-1	251	3e-66
			AAC61576.1	forkhead transcription factor	251	3e-66
			2208384A	transcription factor FREAC-1	251	3e-66
NM_028770 NP_083046.1	Mm.3338 5	U:(C-D) 2.1	XP_096612.2	similar to RIKEN cDNA 1200016G03	561	e-159
			CAB76832.1	cytokeratin	270	6e-72
			NP_004684.1	cytokeratin type II	270	1e-71
			CAA76730.1	cytokeratin type II	270	1e-71
			AAH24292.1	keratin 5 (epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types)	261	5e-69
			AAA36145.1	keratin K5	260	7e-69
			NP_000415.1	keratin 5; Keratin-5; 58 kda cytokeratin; keratin, type II cytoskeletal 5; cytokeratin 5	260	7e-69
			P13647	K2C5_HUMAN Keratin, type II cytoskeletal 5 (Cytokeratin 5) (K5) (CK 5) (58 kDa cytokeratin)	260	7e-69
			A29904	keratin 5, type II, epidermal	260	7e-69
			AAA36143.1	keratin type II	260	7e-69
			AAF97931.1	AF274874 1 keratin 5	260	7e-69

			NP 002264.1	keratin 8; Keratin-8	259	1e-68
			CAA52882.1	Keratin 8	259	1e-68
			AAB18966.1	human cytokeratin 8	259	1e-68
			AAH00654.1	AAH00654 keratin 8	259	1e-68
			A34720	keratin 8, type II cytoskeletal	259	1e-68
			P05787	K2C8_HUMAN Keratin, type II cytoskeletal 8 (Cytokeratin 8) (K8) (CK 8)	259	le-68
			AAA35763.1	cytokeratin 8	259	1e-68
NM_011671 NP_035801.1	Mm.1444 13	U:(C-D) 2.09	NP_003346.2	uncoupling protein 2	585	e-167
			P55851	UCP2_HUMAN Mitochondrial uncoupling protein 2 (UCP 2) (UCPH)	585	e-167
			AAC51336.1	UCP2	585	e-167
			AAC39690.1	uncoupling protein 2	585	e-167
			AAD21151.1	uncoupling protein-2	585	e-167
			AAH11737.1	AAH11737 uncoupling protein 2 (mitochondrial, proton carrier)	585	e-167
			AAB53091.1	uncoupling protein homolog	583	e-166
	,		CAA11402.1	uncoupling protein 2	583	e-166
			AAB48411.1	uncoupling protein-2	583	e-166
			NP_003347.1	uncoupling protein 3, isoform UCP3L .	451	e-127
			P55916	UCP3_HUMAN Mitochondrial uncoupling protein 3 (UCP 3)	451	e-127
			JC5522	uncoupling protein UCP3, mitochondrial	451	e-127
			AAC51367.1	UCP3	451	e-127
			AAC51369.1	uncoupling protein 3	451	e-127
			AAC51767.1	uncoupling protein-3	451	e-127
			AAG02284.1	AF050113_1 uncoupling protein-3	451	e-127
			AAC18822.1	uncoupling protein 3	445	e-125
		_	AAC51785.1	uncoupling protein 3	432	e-121
			NP_073714.1	uncoupling protein 3, isoform UCP3S	392	e-109
			AAC51356.1	UCP3S .	392	c-109

			NP_068605.1	uncoupling protein 1; mitochondrial brown fat uncoupling protein	353	2e-97
			G01858	uncoupling protein 1, mitochondrial	353	2e-97
			AAA85271.1	uncoupling protein	353	2e-97
			P25874	UCP1_HUMAN Mitochondrial brown fat uncoupling protein 1 (UCP 1) (Thermogenin)	350	2e-96
			CAA36214.1	uncoupling protein	250	2e-96
			AAH08392.1	AAH08392 Similar to uncoupling protein 3 (mitochondrial, proton carrier)	206	5e-53
NM_011933 NP_036063.1	Mm.3576 1	U:(C-D) 2.09	NP_065715.1	NP_065715.1 peroxisomal 2,4-dienoyl-CoA reductase	466	e-131
			CAB92744.1	c359F1.1 (novel protein (ortholog of mouse and rat peroxisomal 2,4-dienoyl-coA reductase (PDCR, DCR-AKL)))	466	e-131
			CAC05664.1	peroxisomal 2,4-dienoyl-CoA reductase	466	e-131
			AAK61231.1	AE006463_11 2-4-dienoyl-Coenzyme A reductase 2 peroxisomal like	466	e-131
			AAH10740.1	AAH10740 2,4-dienoyl CoA reductase 2, peroxisomal	466	e-131
			AAH11968.1	AAH11968 Similar to 2,4-dienoyl CoA reductase 2, peroxisomal	370	e-102
NM_019424 NP_062297.1	Mm.1948 06	U:(C-D) 2.08	AAL50684.1	AF450133_1 Hermansky-Pudlak syndrome	1065	0
			NP_000186.1	Hermansky-Pudlak syndrome protein; Hermansky-Pudlak syndrome gene; Hermansky-Pudlak syndrome	1064	0
			Q92902	HPS1_HUMAN Hermansky-Pudlak syndrome 1 protein	1064	0
			AAB17869.1	Hermansky-Pudlak syndrome protein	1064	0
			AAB70662.1	Hermansky-Pudlak syndrome protein	866	0
		_	AAH00175.1	AAH00175 Hermansky-Pudlak syndrome	411	e-114
			AAC52074.1	alternative Hermansky-Pudlak syndrome associated protein	409	e-114
NM_008433		(G.D)		intermediate conductance calcium activated notaccium channel nrotein 1. mutative		
NP_032459.1 Mm.9911	Mm.9911	2.06	NP_002241.1	erythrocyte intermediate conductance calcium-activated potassium Gardos channel	607	e-173
			015554	KCN4_HUMAN Intermediate conductance calcium-activated potassium channel protein 4 (SK4) (KCa4) (IKI) (IKCa1) (Putative Gardos channel)	209	e-173

	AAB82739.1	82739.1 calcium-activated potassium channel	209	e-173
	AAC36804.1	intermediate conductance calcium-activated potassium channel	209	e-173
	AAC23541.1	hIK1	209	e-173
	AAC51913.1	intermediate conductance calcium-activated potassium channel	209	e-173
	AAG26917.1	intermediate-conductance calcium-activated potassium channel 1	209	e-173
		potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4	209	e-173
	AAK81862.1	AF395661 $_{-1}$ potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4	909	e-173
	AAL10706.1	small-conductance calcium-activated potassium channel SK3	286	5e-77
	NP_002240.2	small conductance calcium-activated potassium channel protein 3 isoform a	285	1e-76
	Q9UGI6	KCN3_HUMAN Small conductance calcium-activated potassium channel protein 3 (SK3) (SKCa3)	285	1e-76
	CAB61331.1	SK3 protein	285	1e-76
	AAK15345.1	AF336797_1 small-conductance calcium-activated potassium channel	285	1e-76
	T09172	probable calcium-activated potassium channel KCNN3	282	1e-75
	AAC26099.1	calcium-activated potassium channel	282	1e-75
	Q92952	KCN1_HUMAN Small conductance calcium-activated potassium channel protein 1 (SK1)	278	2e-75
	AAB09562.1	small-conductance, calcium-activated potassium channel SK1	278	2e-75
_	AAD37507.1	small-conductance calcium-activated potassium channel 1	278	2e-75
	NP_002239.2	small conductance calcium-activated potassium channel protein 1	278	2e-75
	AAK84039.1	AF397175_1 small-conductance calcium-activated potassium channel	280	Se-75
	Q9H2S1	KCN2_HUMAN Small conductance calcium-activated potassium channel protein 2 (SK2)	279	7e-75
	AAG16728.1	AF239613_1 apamin-sensitive small-conductance Ca2+-activated potassium channel	279	7e-75
	NP 067627.2	small conductance calcium-activated potassium channel protein 2 isoform a; apamin-sensitive small-conductance Ca2+-activated potassium channel	279	7e-75

NM_013486 NP_038514.1	Mm.2284 U:(C-D) 2 2.06	U:(C-D) 2.06	RWHUC2	T-cell surface glycoprotein CD2 precursor	255	1e-67
			AAA35571.1	T-cell surface antigen CD2 precursor	255	1e-67
			AAA53095.1	T11 surface antigen	255	1e-67
			CAC14840.1	dJ655N15.1 (CD2 antigen (p50), sheep red blood cell receptor)	255	1e-67
			AAA51946.1	CD2 surface antigen	255	1e-67
			NP_001758.1	CD2 antigen (p50), sheep red blood cell receptor; lymphocyte-function antigen-2	252	8e-67
			P06729	CD2_HUMAN T-cell surface antigen CD2 precursor (T-cell surface antigen T11/Leu-5) (LFA-2) (LFA-3 receptor) (Erythrocyte receptor) (Rosette receptor)	252	8e-67
			AAA51738.1	surface antigen CD2 precursor	252	8e-67
			CAA30721.1	T-cell surface antigen	252	8e-67
			AAH33583.1	CD2 antigen (p50), sheep red blood cell receptor	252	8e-67
NM_029796 NP_084072.1	Mm.1769 46	U:(C-D) 2.06	NP_443204.1	leucine-rich alpha-2-glycoprotein	330	3e-90
			P02750	A2GL_HUMAN Leucine-rich alpha-2-glycoprotein precursor (LRG)	330	3e-90
			AAK95527.1	AF403428_1 leucine-rich alpha-2-glycoprotein	330	3e-90
			NBHUA2	leucine-rich alpha-2-glycoprotein	329	6e-90
			AAH34389.1	leucine-rich alpha-2-glycoprotein	327	2e-89
X71479 CAA50585.1	NOLL	U:(C-D) 2.06	CAA50586.1	cytochrome P450	268	2e-72
			NP_000769.1	cytochrome P450, subfamily IVA, polypeptide 11; fatty acid omega-hydroxylase; P450HL-omega; alkane-1 monooxygenase; lauric acid omega-hydroxylase	267	4e-72
			153015	fatty acid omega-hydroxylase (EC 1.14.15) cytochrome P450 4A11	267	4e-72
			AAB29502.1	fatty acid omega-hydroxylase; CYP4A11	267	4e-72
			165981	fatty acid omega-hydroxylase (EC 1.14.15) cytochrome P450 4A11	267	4e-72
			AAB29503.1	fatty acid omega-hydroxylase; CYP4A11v	267	4e-72
	*		Q02928	CP4Y_HUMAN Cytochrome P450 4A11 precursor (CYPIVA11) (Fatty acid omega-hydroxylase) (P-450 HK omega) (Lauric acid omega-hydroxylase) (CYP4AII) (P450-HL-omega)	265	2e-71

			JX0331	laurate omega-hydroxylase (EC 1.14.15.3) cytochrome P450 4A11 (HL24)	265	2e-71
			AAA58436.1	cytochrome P450	265	2e-71
			BAA05491.1	fatty acids omega-hydroxylase (cytochrome P450HL omega)	265	2e-71
			1908216A	fatty acid omega-hydroxylase (cytochrome P450 4A)	265	2e-71
			BAA02864.1	fatty acid omega-hydroxylase	265	2e-71
			AAF76722.1	AF208532_1 fatty acid omega-hydroxylase CYP4A11	261	2e-70
			CAB72105.1	dJ18D14.4 (cytochrome P450, subfamily IVA, polypeptide 11)	253	89-99
			AAH28102.1	Unknown (protein for MGC:40051)	202	1e-52
			BAC05226.1	unnamed protein product	202	1e-52
			BAC03751.1	unnamed protein product	202	1e-52
		U:(C-D)	014753	OVO1_HUMAN Putative transcription factor Ovo-like 1 (hOvo1)	468	e-131
NM_019935 NP_064319.1	Mm.3832 3	7.03 U:(IR-D) 2.41				-
			NP_004552.1	OVO-like 1 binding protein; putative transcription factor OVO-like 1; ovo (Drosophila) homolog-like 1	367	e-101
			AAB72084.1	OVO-like 1 binding protein	367	e-101
			NP_067043.1	zinc finger protein 339; ovo-like 2 (Drosophila)	275	3e-73
			BAB14002.1	unnamed protein product	275	3e-73
			Q9BRP0	Z339_HUMAN Zinc finger protein 339	271	2e-72
			AAH06148.1	AAH06148 putative zinc finger protein from EUROIMAGE 566589	271	2e-72
			CAB45151.1	hypothetical protein, similar to (AF134804) putative zinc finger transcription factor OVO1 [Mus musculus]	238	3e-62
NM_012006 NP_036136.1	Mm.1978	U:(C-D) 2.05	XP_170752.1	similar to peroxisomal long-chain acyl-coA thioesterase; peroxisomal long-chain acyl-coA thioesterase; putative protein	602	e-172
			P49753	PTE2_HUMAN Peroxisomal acyl-coenzyme A thioester hydrolase 2 (Peroxisomal long-chain acyl-coA thioesterase 2) (ZAP128)	009	e-171
			JC7367	second peroxisomal thioesterase	009	e-171
			AAF97985.1	peroxisomal long-chain acyl-coA thioesterase	009	e-171

			AAH04436.1	AAH04436 Unknown (protein for MGC:3983)	009	e-171
			AAH06500.1	AAH06500 Unknown (protein for MGC:2366)	009	e-171
			NP_006812.2	peroxisomal long-chain acyl-coA thioesterase; peroxisomal long-chain acyl-coA thioesterase; putative protein	665	e-171
			AAH06335.1	AAH06335 peroxisomal long-chain acyl-coA thioesterase	599	e-171
	_		BAA91989.1	unnamed protein product	298	e-171
			NP_689544.1	hypothetical protein FLJ31235	464	e-139
			BAC04313.1	unnamed protein product	494	e-139
			AAC42007.1	ORF; putative	405	e-113
			XP_090885.1	similar to Peroxisomal acyl-coenzyme A thioester hydrolase 2 (Peroxisomal long-chain acyl-coA thioesterase 2) (ZAP128)	280	4e-75
			NP_001692.1	bile acid Coenzyme A. amino acid N-acyltransferase; glycine N-choloyltransferase	265	2e-70
			A53965	bile acid-CoA amino acid N-acyltransferase	265	2e-70
			AAC37550.1	bile acid CoA: Amino acid N-acyltransferase	265	2e-70
			AAH09567.1	AAH09567 bile acid Coenzyme A: amino acid N-acyltransferase (glycine N-choloyltransferase)	265	2e-70
AK004963		(d D).11				
BAB23703.1	Mm.186	0:(C-D) 2.04	NP_055419.1	Tax interaction protein 1	243	46-64
			AAB84248.2	Tax interaction protein 1	243	4e-64
			AAG44368.1	AF234997_1 glutaminase-interacting protein 3	243	4e-64
			AAK69111.1	AF277318_1 tax-interacting protein 1	243	4e-64
			AAH23980.1	Tax interaction protein 1	243	4e-64
			AAF43104.1	TIP1	228	2e-59
AK008849		(4,0);				
BAB25928.1	Mm.45435 2.04	0.(C-D) 2.04	NP_079119.2	duodenal cytochrome b; hypothetical protein FLJ23462	391	e-109
			CAB66628.1	hypothetical protein	391	e-109
			BAB15661.1	unnamed protein product	386	e-107

			XP_166224.2	similar to data source:SPTR, source key:Q9H0Q8, evidence:ISS~homolog to HYPOTHETICAL 31.6 KDA PROTEIN~putative	196	6e-50
			NP_705839.1	hypothetical protein MGC20446	196	6e-50
			BAC11698.1	unnamed protein product	196	6e-50
NM_008532 NP_032558.1	Mm.4259	U:(C-D) 2.03	P16422	TTD1_HUMAN Tumor-associated calcium signal transducer 1 precursor (Major gastrointestinal tumor-associated protein GA733-2) (Epithelial cell surface antigen) (Epithelial glycoprotein) (EGP) (Adenocarcinoma-associated antigen) (KSA) (KS 1/4 antigen) (Cell surface glycoprotein Trop-1)	446	e-125
-			CAA32870.1	KSA preproantigen peptide	446	e-125
			AAA36151.1	adenocarcinoma-associated antigen precursor (KSA)	446	e-125
			AAA59543.1	KS1/4 antigen	446	e-125
			NP 002345.1	tumor-associated calcium signal transducer 1 precursor; membrane component, chromosome 4, surface marker (35kD glycoprotein); MK-1 antigen; antigen identified by monoclonal antibody AUA1	446	e-125
			B48149	epithelial glycoprotein antigen GA733-2 precurso	446	e-125
			AAA35861.1	carcinoma-associated antigen GA733-2	446	e-125
			AAB00775.1	carcinoma-associated antigen GA733-2	446	e-125
			AAH14785.1	tumor-associated calcium signal transducer 1	446	e-125
			AAA35723.1	epithelial glycoprotein (EGP) precursor	444	e-124
			A48149	carcinoma-associated antigen GA733-1 precursor	265	2e-70
			CAA31781.1	GA733-1 protein (AA 1-323)	265	2e-70
			CAA54801.1	gp50/TROP-2	265	2e-70
			AAH09409.1	Unknown (protein for MGC:10655)	265	2e-70
			NP_002344.1	tumor-associated calcium signal transducer 2 precursor; membrane component, chromosome 1, surface marker 1 (40kD glycoprotein, identified by monoclonal antibody GA733); epithelial glycoprotein-1	263	6e-70
			CAA54799.1	gp50/Trop-2	263	6e-70
			P09758	TTD2_HUMAN Tumor-associated calcium signal transducer 2 precursor (Pancreatic carcinoma marker protein GA733-1) (Cell surface glycoprotein Trop-2)	262	le-69
	:		AAA52505.1	GA733-1 protein precursor	262	1e-69

$^{\circ}$	
Ö	
Ñ	

NM 009780						
i		U:(C-D)				
NP 033910.1 Mm.16106 2.02	Mm.16106	2.02	P01028	CO4_HUMAN Complement C4 precursor [Contains: C4A anaphylatoxin]	2587	0
			C4HU	complement C4A precursor [validated]	2586	0
			AAA51855.1	complement component C4A	2586	0
			NP_009224.1	complement component 4A preproprotein; acidic C4; Rodgers form of C4; complement component 4S	2583	0
			CAB89302.	dJ34F7.4 (complement component 4A)	2582	0
			NP_000583.1	complement component 4B preproprotein; Chido form of C4; basic C4; complement component 4F	2581	0
			AAB67980.1	complement component C4	2581	0
			AAB59537.1	complement component C4A	2563	0
			AAA99717.1	complement C4B precursor	2465	0
			NP_000055.1	complement component 3 precursor	624	e-178
			P01024	CO3_HUMAN Complement C3 precursor	624	e-178
			сзни	complement C3 precursor [validated]	624	e-178
			AAA85332.1	complement component C3	624	e-178
			AAA59651.1	complement component C4B	573	e-163
			1HZF	A Chain A, C4adg Fragment Of Human Complement Factor C4a	544	e-154
NM_008874		(u-J):11			-	
NP_032900.1 Mm.6888	Mm.6888	2.(৩-2)	NP_000923.1	phospholipase C, beta 3 (phosphatidylinositol-specific)	2015	0
			Q01970	PIP3_HUMAN 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta 3 (PLC-beta-3) (Phospholipase C-beta-3)	2015	0
			138994	phospholipase C-beta-3	2015	0
			AAA77683.1	phospholipase C-beta-3	2015	0
			S52099	phospholipase C beta 3	1967	0
			CAA85776.1	phospholipase C beta 3	1967	0
			AAH32659.1	Similar to phospholipase C, beta 3	1824	0

-

			S27002	phospholipase C (EC 3.1.4.3), phosphatidylinositol-specific	1663	0
			CAA78903.1	phospholipase c	1663	0
			NP_056007.1	phospholipase C, beta 1 (phosphoinositide-specific); phosphoinositide-specific phospholipase C-beta 1; phospholipase C beta 1; phospholipase C, beta 1(phosphoinositide-specific)	1197	0
	,		99DN60	PIBI_HUMAN 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta (PLC-beta-1) (Phospholipase C-beta-1) (PLC-1) (PLC-154)	1197	0
			CAB98142.1	phospholipase C-beta-1a	1197	0
			CAB98143.1	phospholipase C-beta-1b	1192	0
			AAF86613.1	phospholipase C beta 1	1154	0
			BAA25507.	KIAA0581 protein	1047	0
			NP_004564.1	phospholipase C, beta 2	934	0
			Q00722	PIB2_HUMAN 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta 2 (PLC-beta-2) (Phospholipase C-beta-2)	934	0
			A43346	1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase (EC 3.1.4.11) beta-2	934	0
			AAA36453.1	phospholipase C-beta-2	934	0
			T46339	hypothetical protein DKFZp434A0814.1	885	0
			CAB70666.1	hypothetical protein	885	0
NM_010129 NP_034259.1	Mm.2082 9	U:(C-D) 2	NP_001416.1	epithelial membrane protein 3	250	1e-66
			P54852	EMP3_HUMAN Epithelial membrane protein-3 (EMP-3) (YMP protein) (Hematopoietic neural membrane protein) (HNMP-1)	250	1e-66
			AAC50920.1	YMP	250	1e-66
			AAC51730.1	hematopoietic neural membrane protein	250	1e-66
			AAH09718.1	AAH09718 epithelial membrane protein 3	250	1e-66
			JC5045	epithelial membrane protein 3	244	6e-65
			CAA64394.1	epithelial membrane protein-3	244	6e-65
NM_011644 NP_035774.1	Mm.8361 5	U:(C-D) 2	NP_004612.2	transient receptor potential cation channel, subfamily C, member 6; transient receptor potential channel 6	427	e-119

Q9Y210	TRP6_HUMAN Short transient receptor potential channel 6 (TrpC6)	427	e-119
CAA06943.1	transient receptor potential protein	427	e-119
AAC63289.2	transient receptor potential protein 6	427	e-119
CAC01684.1	transient receptor potential channel 6	427	e-119
NP_003296.1	transient receptor potential cation channel, subfamily C, member 3; transient receptor potential channel 3	421	e-117
Q13507	TRP3_HUMAN Short transient receptor potential channel 3 (TrpC3) (Htrp-3) (Htrp3)	421	e-117
CAA74083.1	transient receptor potential related channel 3 protein	421	e-117
AAC51653.1	calcium influx channel	421	e-117
NP_065122.1	putative capacitative calcium channel	411	e-114
09НСХ4	TRP7_HUMAN Short transient receptor potential channel 7 (TrpC7) (TRP7 protein)	441	e-114
CAC03489.1	putative capacitative calcium channel	411	e-114
CAD19069.1	short transient receptor potential channel 7	409	e-113
AAF22928.1	AF063823_1 trp-related protein 4 truncated variant beta	369	e-101
AAL24550.1	AF421359_1 transient receptor potential channel 4 beta splice variant	369	e-101
AAL24551.1	AF421360_1 transient receptor potential channel 4 epsilon splice variant	369	e-101
NP 057263.1	transient receptor potential 4; transient receptor potential channel 4	369	e-101
Q9UBN4	TRP4_HUMAN Short transient receptor potential channel 4 (TrpC4) (trp-related protein 4) (hTrp-4) (hTrp4)	369	e-101
AAD51736.1	AF175406_1 transient receptor potential 4	369	e-101
AAF22927.1	AF063822_1 trp-related protein 4	369	e-101
AAL24549.1	AF421358 1 transient receptor potential channel 4 alpha splice variant	369	e-101
AAF22929.1	AF063824 1 trp-related protein 4 truncated variant delta	369	e-101
NP_036603.1	transient receptor potential cation channel, subfamily C, member 5, transient receptor potential channel 5	359	2e-98
Q9UL62	TRP5_HUMAN Short transient receptor potential channel 5 (TrpC5) (Htrp-5) (Htrp5)	359	2e-98
AAF00002.1	AF054568 1 transient receptor potential calcium channel 5	359	2e-98
CAC01686.1	transient receptor potential channel 6, variant delta377-431	333	1e-90

Subtable 1C: Mixed Genes and Proteins

E-value	0	0 #	3 0	632 0	630 e-180	615 e-176	230 8E-60	228 2E-59	228 2E-59	204 6E-52	712 0		2 0	711 0	710 0	707 0	600 e-171	600 e-171	577 e-164		7 e-164
Score (bits)	1004 0	1004 0	1003	63.	63(61	23(228	228	707	71.		712	71	710	70,)09	09	57.		577
Human Protein Name	likely ortholog of mouse Shc SH2-domain binding protein 1; hypothetical protein FLJ22009	Unknown (protein for MGC:26900)	unnamed protein product	similar to Shc SH2-domain binding protein 1		AAH00960 Unknown (protein for IMAGE:3451160)		chromosome 1 open reading frame 14; GE36 gene	AF288398_1 Clorf14	AF288397 1 Clorf14	DPG2_HUMAN DNA polymerase gamma subunit 2, mitochondrial precursor (Mitochondrial DNA polymerase accessory subunit) (PolG-beta) (MtPolB) (DNA polymerase gamma accessory 55 kDa subunit) (p55)		AF142992_1 DNA polymerase gamma accessory subunit	AF177201_1 mitochondrial DNA polymerase accessory subunit precursor	AAH09194 Unknown (protein for MGC:15231)	AF184344 1 DNA polymerase accessory subunit precursor	polymerase (DNA directed), gamma 2, accessory subunit; mitochondrial DNA polymerase, accessory subunit	mitochondrial DNA polymerase accessory subunit precursor	NP_001777.1 cell division cycle 2 protein, isoform 1; cell division control protein 2 homolog;	cycim-dependent kinase 1; p34 protein kinase; cen cycle controller CDC2	CDC2_HUMAN Cell division control protein 2 homolog (p34 protein kinase)
Human Proteins		- AAH30699.1	BAB71049.1	XP 015700.2	BAB15208.1	AAH00960.1	AAG45336.1	NP_112195.1	AAG60617.1	AAG60616.1	-		AAD50382.1	AAD56640.1	AAH09194.1	AAD56542.1	NP_009146.1	AAC51321.1			P06493
Behavior	U.(C-IR) 2.88 F.(IR-D)	27.03									U:(C-IR) 2.74 F:(IR-D)	-3.23							U:(C-IR)	L./2 F:(IR-D) -2.86	
Unigene Behavior Human Proteins	Mm.37801										Mm.859								Mm.4761		
Mouse Gene Protein	NM_011369 NP_035499.1										NM_015810 NP_056625.1								NM_007659	NP_031685.1	

A29539	protein kinase (EC 2.7.1.37) cdc2	577	e-164
CAA28963.1	CDC2 polypeptide (CDC2) (AA 1-297)	577	e-164
CAA68376.1	CDC2 protein (AA 1-297)	577	577 e-164
AAH14563.1	Similar to cell division cycle 2, G1 to S and G2 to M	577	577 e-164
AAM34793.1	AF512554 1 cell division cycle 2, G1 to S and G2 to M	577	577 e-164
1306392A		577	e-164
NP_203698.1		409	409 e-114
BAA26001.1		409	409 e-114
NP 001249.1	cyclin-dependent kinase 3	393	393 e-109
Q0 <u>0</u> 526		393	393 e-109
S23382	protein kinase (EC 2.7.1.37) cdk	393	393 e-109
CAA47001.1	serine/threonine protein kinase [Homo sapiens]	393	393 e-109
CAA43807.1	cell division kinase. CDC2 homolog	390	390 e-108
NP_001789.2	cyclin-dependent kinase 2, isoform 1; cdc2-related protein kinase; cell devision kinase	389	389 e-108
P24941	CDK2 HUMAN Cell division protein kinase 2 (p33 protein kinase)	389	e-108
A41227	protein kinase (EC 2.7.1.37) cdk2	389	389 e-108
IKE5	A Chain A, Cdk2 Complexed With N-Methyl-4-{[(2-Oxo-1,2-Dihydro-3h-Indol-3-Ylidene)methyl]amino}benzenesulfonamide	389	389 e-108
1KE6	A Chain A, Cyclin-Dependent Kinase 2 (Cdk2) Complexed With N-Methyl-{4-[2-(7-Oxo-6,7-Dihydro-8h-[1,3]thiazolo[5,4-E]indol-8-Ylidene)hydrazino]phenyl}methanesulfonamide	389	389 e-108
IKE7	A Chain A, Cyclin-Dependent Kinase 2 (Cdk2) Complexed With 3-{[(2,2-Dioxido-1, 3-Dihydro-2-Benzothien-5-Yl)amino]methylene}-5-(1,3-Oxazol-5-Yl)-1,3-Dihydro-2h-Indol-2-One	688	3§9 e-108
IKE8	A Chain A, Cyclin-Dependent Kinase 2 (Cdk2) Complexed With 4-{[(2-Oxo-1,2-Dihydro-3h-Indol-3-Ylidene)methyl]amino}-N-(1,3-Thiazol-2-Yl)benzenesulfonamide	389	389 e-108
1KE9	A Chain A, Cyclin-Dependent Kinase 2 (Cdk2) Complexed With 3-{[4- ({amino(Imino)methyl]aminosulfonyl)anilino]methylene}- 2- Oxo-2,3-Dihydro-1h-Indole	389	389 e-108
IFIN	A Chain A, Cyclin A - Cyclin-Dependent Kinase 2 Complex	389	389 e-108
IFIN	C Chain C, Cyclin A - Cyclin-Dependent Kinase 2 Complex	389	389 e-108

1FVV	C Chain C, The Structure Of Cdk2CYCLIN A IN COMPLEX WITH AN OXINDOLE Inhibitor	389	389 e-108
1FVV	A Chain A, The Structure Of Cdk2CYCLIN A IN COMPLEX WITH AN OXINDOLE Inhibitor	389	389 e-108
1HCL	Human Cyclin-Dependent Kinase 2	389	389 e-108
1HCK	Human Cyclin-Dependent Kinase 2	389	389 e-108
1F5Q	A Chain A, Crystal Structure Of Murine Gamma Herpesvirus Cyclin Complexed To Human Cyclin Dependent Kinase 2	389	389 e-108
1BUH	A Chain A, Crystal Structure Of The Human Cdk2 Kinase Complex With Cell Cycle-Regulatory Protein Ckshs1	389	e-108
IJSV	A Chain A, The Structure Of Cyclin-Dependent Kinase 2 (Cdk2) In Complex With 4- [(6-Amino-4-Pyrimidinyl) Amino]benzenesulfonamide	389	e-108
lJVP	P Chain P, Crystal Structure Of Human Cdk2 (Unphosphorylated) In Complex With Pkt049-365	389	389 e-108
1DI8	A Chain A, The Structure Of Cyclin-Dependent Kinase 2 (Cdk2) In Complex With 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline	389	389 e-108
IFVT	A Chain A, The Structure Of Cyclin-Dependent Kinase 2 (Cdk2) In Complex With An Oxindole Inhibitor	389	389 e-108
ICKP	A Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor Purvalanol B	389	389 e-108
14Q1	Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor Staurosporine	389	e-108
1GIH	A Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Cdk4 Inhibitor	389	e-108
1G5S	A Chain A, Crystal Structure Of Human Cyclin Dependent Kinase 2 (Cdk2) In Complex With The Inhibitor H717	389	389 e-108
1DM2	A Chain A, Human Cyclin-Dependent Kinase 2 Complexed With The Inhibitor Hymenialdisine	389	389 e-108
1F5Q	C Chain C, Crystal Structure Of Murine Gamma Herpesvirus Cyclin Complexed To Human Cyclin Dependent Kinase 2	389	389 e-108
AAA35667.1	cdc2-related protein kinase	389	389 e-108
AAH03065.1	cyclin-dependent kinase 2	389	389 e-108
AAM34794.1	AF512553_1 cyclin-dependent kinase 2	389	389 e-108
1717387A	cyclin A dependent p33 kinase:SUBUNIT=2	389	389 e-108

With The Inhibitor 389 e-108	With The Inhibitor 389 e-108	389 e-108	ed On Thr 160 389 e-108	3 Complex With The 387 e-107	3 Complex With The 387 e-107	LIN A COMPLEXED 387 e-107	LIN A COMPLEXED 387 e-107	LIN A COMPLEXED 387 e-107	LIN A COMPLEXED 387 e-107	LIN A COMPLEXED 387 e-107	LIN A COMPLEXED 387 e-107	LIN A COMPLEXED 387 e-107	LIN A COMPLEXED 387 e-107	P, NITRATE AND 387 e-107	P, NITRATE AND 387 e-107	le Complex 387 e-107	le Complex 387 e-107	387 e-107	
A Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor Nu6027	A Chain A, Human Cyclin Dependent Kinase 2 Complexed With The Inhibitor Nu2058	A Chain A, Human Cyclin-Dependent Kinase 2	A Chain A, Human Cyclin-Dependent Kinase 2 Phosphorylated On Thr 160	C Chain C, Thr 160 Phosphorylated Cdk2 - Human Cyclin A3 Complex With The Inhibitor Indirubin-5-Sulphonate Bound	A Chain A, Thr 160 Phosphorylated Cdk2 - Human Cyclin A3 Complex With The Inhibitor Indirubin-5-Sulphonate Bound	A Chain A, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu2058	C Chain C, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu2058	A Chain A, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu6094	C Chain C, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu6094	A Chain A, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu6086	C Chain C, Structure Of Human Thr 160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nuc086	A Chain A, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu6102	C Chain C, Structure Of Human Thr160-Phospho Cdk2CYCLIN A COMPLEXED With The Inhibitor Nu6102	A Chain A, Pedk2CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE Substrate	C Chain C, Pedk2CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE Substrate	A Chain A, Phosphorylated Cdk2-Cyclyin A-Substrate Peptide Complex	C Chain C, Phosphorylated Cdk2-Cyclyin A-Substrate Peptide Complex	cdk2	The second secon
1E1X	1E1V	1B38	1B39	1E9H	1E9H	1H1P	ІНІР	1Н1Q	1H1Q	IHIR	IHIR	1H1S	IHIS	1GY3	1GY3	1QMZ	1QMZ	CAA43985.1	
:																			
																			00000

		0 989	634 0	634 0	601 e-171	601 e-171	601 e-171	601 e-171	385 e-106	385 e-106	384 e-106	384 e-106	384 e-106	384 e-106	384 e-106	384 e-106	382 e-105	381 e-105	358 2E-98	e 355 2E-97	355 2E-97	258 4E-68	258 4E-68	258 4E-68	764 0			764 0
271		AF280399_1 alpha 2C adrenergic receptor	alpha2CII-adrenergic receptor	AF280400 1 alpha 2C adrenergic receptor variant		alpha-2C-adrenergic receptor	kidney alpha-2-adrenergic receptor	alpha2-C4-adrenergic receptor	alpha-2A-adrenergic receptor		alpha-2A-adrenergic receptor; platelet type adrenoceptor, alpha-2A; alpha-2A adrenoceptor; alpha-2AAR subtype C10	A2AA_HUMAN Alpha-2A adrenergic receptor (Alpha-2A adrenoceptor) (Alpha-2AAR subtype C10)	AF281308_1 alpha 2A adrenergic receptor	adrenergic receptor alpha-2A	alpha-2A adrenergic receptor	alpha-2A adrenergic receptor	AF316894 1 alpha 2A adrenergic receptor	alpha-2-adrenergic receptor old gene name 'ADRA2R'	AF316895_1 alpha 2B adrenergic receptor	A2AB_HUMAN Alpha-2B adrenergic receptor (Alpha-2B adrenoceptor) (Subtype C2)	alpha2B-adrenergic receptor	alpha-2B-adrenergic receptor; alpha-2-adrenergic receptor-like 1	alpha-2B-adrenergic receptor	alpha-2-adrenergic receptor (alpha-2 C2) old gene name 'ADRA2RL1'	actin, alpha, cardiac muscle precursor			similar to actin, alpha, cardiac
		AAG28076.1	BAA02737.1	AAG28077.1	NP 000674.1	A31237	AAA35513.1	AAC78723.1	A34169	AAA51665.1	NP_000672.2	P08913	AAF91441.1	AAG00447.2	AAK26743.1	AAK51162.1	AAK01634.1	AAA51664.1	AAK01635.1	P18089	AAB62558.1	NP 000673.1	A37223	AAA51666.1	NP_005150.1			XP 012405.3
	F:(IR-D) -2.1																								U:(C-IR)	F:(C-D) -	2.42 F:(IR-D) -5.6	
	_																								Mm.686			
	NP_031444.1																								809600 MN	NP_033738.1		

D04270	ACTC HIMAN Actin aluba cardiac	764	0
ATHUC	actin, cardiac muscle	764	0
AAB59619.1	alpha-cardiac actin	764 0	0
AAH09978.1	AAH09978 actin, alpha, cardiac muscle	764 0	0
NP 001091.1	alpha 1 actin precursor; alpha skeletal muscle actin	759 0	0
XP_001869.1	similar to Chain B, The X-Ray Crystal Structure Of The Complex Between Rabbit Skeletal Muscle Actin And Latrunculin A At 2.85 A Resolution	0 652	0
P02568	ACTS HUMAN Actin, alpha skeletal muscle (Alpha-actin 1)	759	0
ATHU	actin alpha 1, skeletal muscle	759	0
AAB59376.1	alpha-actin	759	0
AAA60296.1	alpha-skeletal actin precursor	759 0	0
AAF02694.1	AF182035 1 skeletal muscle alpha-actin precursor	759 0	0
AAH12597.1	Similar to actin, alpha 1, skeletal muscle	759 0	0
NP 001604.1	alpha 2 actin; alpha-cardiac actin	755	0
P03996	ACTA HUMAN Actin, aortic smooth muscle (Alpha-actin 2)	755	0
CAA32064.1	alpha-actin (AA 1-377)	755	0
AAH17554.1	AAH17554 actin, alpha 2, smooth muscle, aorta	755	0
ATHUSM	actin alpha 2, aortic smooth muscle	752 0	0
AAA51577.1	alpha-actin	752 0	0
NP 001606.1	actin, gamma 2 propeptide; actin, alpha-3	750	0
P12718	ACTH HUMAN Actin, gamma-enteric smooth muscle (Alpha-actin 3)	750	0
A40261	actin gamma, enteric smooth muscle	750 0	0
CAA34814.1	gamma-actin (AA 1-376)	750 0	0
BAA00546.1	enteric smooth muscle gamma-actin	750 0	0
AAH12617.1	Similar to actin, gamma 2, smooth muscle, enteric	750 0	0
JC5818	gamma-actin :	723	0
NP_001605.1	actin, gamma 1 propeptide; cytoskeletal gamma-actin; actin, cytoplasmic 2	723	0
P02571	ACTG_HUMAN Actin, cytoplasmic 2 (Gamma-actin)	723	0
ATHUG	actin gamna 1	723 0	0
CAA27723.1	gamna-actin	723 0	0
AAA51579.1	gamma-actin	723	0
AAH00292.1	actin, gamma 1	723	0
AAH01920.1	actin, gamma 1	723 0	0
AAH07442.1	actin, gamma 1	723 0	0

			A A H 09848.1	actin. gamma 1	723	0
			AAH10999.1	Similar to actin, gamma 1	723	0
			AAH12050.1	Similar to actin, gamma 1	723	0
			AAH15005.1	actin, gamma 1	723	0
			AAH15695.1	actin, gamma 1	723 0	0
			AAH15779.1	actin, gamma 1	723 0	o
			AAH18774.1	actin, gamma 1	723	0
			NP_001092.1	beta actin; beta cytoskeletal actin	722	0
			P02570	ACTB_HUMAN Actin, cytoplasmic 1 (Beta-actin)	722	0
			ATHUB	actin beta	722	0
			CAA25099.1	beta-actin	722	0
			AAA51567.1	cytoplasmic beta actin	722	0
			AAH01301.1	actin, beta	722	0
			AAH02409.1	actin, beta	722	0
			AAH04251.1	actin, beta	722	0
			AAH09275.1	actin, beta	722 0	0
			AAH13380.1	actin, beta	722 0	0
			AAH14861.1	actin, beta	722	0
			AAH16045	actin, beta	720 0	0
			CAA45026.1	mutant beta-actin (beta'-actin)	718 0	0
AA510875	Mm.28984 U:(C-IR) 2.21		NP_004640.1	chromosome 21 open reading frame 33; human HES1 protein, homolog to E.coli and zebrafish ES1 protein	243	243 9E-65
NP_613067.1	,	F:(IR-D) -2.64				
			P30042	ES1_HUMAN ES1 protein homolog, mitochondrial precursor (Protein KNP-I) (GT335 protein)	243	243 9E-65
			JC4913	anti-sigma cross-reacting protein homolog I alpha precursor	243	243 9E-65
			BAA12984.1	KNP-Ia	243	243 9E-65
			AAC50938.1	GT335	243	9E-65
			AAC50937.1	similar to E. coli SCRP27A and to zebrafish ES1	243	243 9E-65
			AAH02370.1	ES1 (zebrafish) protein, human homolog of	243	243 9E-65
			AAH03587.1	ES1 (zebrafish) protein, human homolog of	243	243 9E-65
			CAA68857.1	HES1	243	243 9E-65
			BAA95554.1	HES1 protein	243	243 9E-65

			BAA21138.1	KNP-I alpha protein	243	243 9E-65
						į
NM_009349 NP_033375.1	Mm.299	F:(C-IR) -2.85 U:(IR-D) 3.02	AAD04723.1	thioether S-methyltransferase-like; similar to P40936 (PID:g731019)	271	271 9E-73
			092050	INMT_HUMAN Indolethylamine N-methyltransferase (Aromatic alkylamine N-methyltransferase) (Indolamine N-methyltransferase) (Arylamine N-methyltransferase) (Amine N-methyltransferase)	267	267 2E-71
			AAF18304.1	AF128846 1 indolethylamine N-methyltransferase	267	267 2E-71
			AAF18306.1	AF128848 1 indolethylamine N-methyltransferase	267	2E-71
			NP 006765.3	indolethylamine N-methyltransferase; thioester S-methyltransferase-like	566	266 5E-71
			AAF18305.1	AF128847 1 indolethylamine N-methyltransferase	266	266 5E-71
			AAH33813.	Unknown (protein for IMAGE:5209218)	266	266 5E-71
			NP 006160.1	nicotinamide N-methyltransferase	239	239 6Е-63
			P40261	NNMT HUMAN Nicotinamide N-methyltransferase	239	239 6E-63
			A54060	nicotinamide N-methyltransferase (EC 2.1.1.1)	239	239 6E-63
			AAA19904.1	nicotinamide N-methyltransferase	239	239 6E-63
			AAA93158.1	nicotinamide N-methyltransferase	239	239 6E-63
			AAH00234.1	AAH00234 nicotinamide N-methyltransferase	239	239 6E-63
NM_019813 NP_062787.1	Mm.19016 F:(C-IR) -2.71 U:(IR-D) 2.42	F:(C-IR) -2.71 U:(IR-D) 2.42	Q16643	DREB_HUMAN Drebrin (Developmentally regulated brain protein)	760 0	0
			JN0809	drebrin E (clone gDbh13)	09/	0
			AAA16256.1	drebrin E2	760 0	0
			BAA04480.1	drebrin E	760 0	0
			AAH00283.1	AAH00283 drebrin 1	760	0
			AAH07281.1	AAH07281 drebrin 1	760	0
			AAH07567.1	AAH07567 drebrin 1	760 0	0
			NP 004386.2	drebrin 1 isoform a; drebrin E; drebrin-1; drebrin E2	759 0	0
			T14763	hypothetical protein DKFZp434D064.1	704 0	0
			CAB53683.1	hypothetical protein	704 0	0
			NP 543157.1	drebrin 1 isoform b; drebrin E; drebrin-1; drebrin E2	703	0

0		0	0	0	0	630 e-180		628 e-179	628 e-179		628 e-179	628 e-179	623 e-178	623 e-178	499 e-140	499 e-140	498 e-140	498 e-140
1749 0		1749 0	1749 0	1749 0	741 0	020		628	929		628	628	623	623	564	495	864	498
003026.1 TAL1 (SCL) interrupting locus; SCL interrupting locus		SIL protein	SIT	SIL protein	d118D14.1 (TAL1 (SCL) interrupting locus)	S-adenosylmethionine decarboxylase 1		S-adenosylmethionine decarboxylase 1 precursor	DCAM_HUMAN S-adenosylmethionine decarboxylase proenzyme (AdoMetDC) (SamDC) [Contains: S-adenosylmethionine decarboxylase alpha chain; S-	adenosylmethionine decarboxylase beta chain]	adenosylmethionine decarboxylase (EC 4.1.1.50) precursor	S-adenosylmethionine decarboxylase proenzyme (EC 4.1.1.50) old gene name 'AMD'	B Chain B, Structure Of A Human S-Adenosylmethionine Decarboxylase Self- Processing Ester Intermediate And Mechanism Of Putrescine Stimulation Of Processing As Revealed By The H243a Mutant	A Chain A, Structure Of A Human S-Adenosylmethionine Decarboxylase Self- Processing Ester Intermediate And Mechanism Of Putrescine Stimulation Of Processing As Revealed By The H243a Mutant	A Chain A, Human S-Adenosylmethionine Decarboxylase	C Chain C, Human S-Adenosylmethionine Decarboxylase	A Chain A, Human S-Adenosylmethionine Decarboxylase With Covalently Bound Pyruvoyl Group And Complexed With Methylglyoxal Bis- (Guanylhydrazone)	A Chain A, Human S-Adenosylmethionine Decarboxylase With Covalently Bound Pyruvoyl Group And Covalently Bound 5'-Deoxy-5'-[n- Methyl-N-(2-Aminooxyethyl) Amino]adenosine
NP_003026.1		A41685	AAA60550.1	AAK51418.1	CAB72102.1	AAH00171.1		NP 001625.1	P17707		DCHUDM	AAA51716.1	1,110	111.0	1JEN	1 JEN	117C	1172
F:(C-IR) -2.64	U:(IR-D) 2.51					-IR)	-2.0 U:(IR-D) 3.96											
Mm.3988						Mm.7880												
NM_009185 Mm.3988	NP_033211.1					99600 MN	NP_033795,1											

A Chain A, Human S-Adenosylmethionine Decarboxylase With Covalently Bound Pyruvoyl Group And Covalently Bound S-Adenosylmethionine Methyl Ester A Chain A, Human S-Adenosylmethionine Decarboxylase With Covalently One-2'-Amidinohydrazone C Chain C, Human S-Adenosylmethionine Decarboxylase With Covalently Bound Pyruvoyl Group And Complexed With 4-Amidinoindan-1-One-2'-Amidinohydrazone KIAA1749 protein hypothetical protein FLJ14957 unnamed protein product wingless-type MMTV integration site family, member 11 precursor
in A, Human S-Adenosylmethionine Decarboxylase With Covalently One-2 nohydrazone in C, Human S-Adenosylmethionine Decarboxylase With Covalently Bouncyl Group And Complexed With 4-Amidinoindan-1-One-2'-Amidinohydraz 1749 protein retical protein FLJ14957 ed protein product ed protein product ss-type MMTV integration site family, member 11 precursor
in C, Human S-Adenosylmethionine Decarboxylase With Covalently Bounc byl Group And Complexed With 4-Amidinoindan-1-One-2'-Amidinohydraz 1749 protein retical protein FLJ14957 retical protein product res-type MMTV integration site family, member 11 precursor
1749 protein letical protein FLJ14957 led protein product ss-type MMTV integration site family, member 11 precursor
ed protein product ed protein product ss-type MMTV integration site family, member 11 precursor
ed protein product ss-type MMTV integration site family, member 11 precursor
iss-type MMTV integration site family, member 11 precursor
ss-type MMTV integration site family, member 11 precursor
WN11 HUMAN WNT-11 protein precursor
WNT11
WNT11
HWNT1
unnamed protein product
WNT4
wingless-type MMTV integration site family, member 4 precursor; signaling protein WNT-4; WNT-4 protein precursor
WNT4 HUMAN WNT-4 protein precursor
AF316543 1 signaling protein WNT-4
WNT4 precursor

			526011	d1224A6.2 (similar to Mouse Wnt-4 protein)	295	295 1E-79
				wingless-type MMTV integration site family, member 5B precursor; WNT-5B protein precursur	262	262 1E-69
			NP_110402.2	wingless-type MMTV integration site family, member 5B precursor; WNT-5B protein precursor	792	262 1E-69
			Q9H1J7	WN5B HUMAN WNT-5B protein precursor	262	1E-69
			AAH01749.1	AAH01749 Similar to wingless-related MMTV integration site 5B	262	1E-69
			BAB62039.1	WNT5B 31	262	262 1E-69
			NP_003383.1	wingless-type MMTV integration site family, member 5A precursor; proto-oncogene	192	261 3E-69
				Wnt-5A precursor; WNT-5A protein precursor		
			P41221	WN5A_HUMAN WNT-5A protein precursor	261	3E-69
			A48914	proto-oncogene Wnt-5A precursor	261	261 3E-69
			AAA16842.1	hwnts	261	261 3E-69
			AAG38659.1	WNT5b precursor	255	1E-67
AF294617	Mm.19669 F:(C-IR)	F:(C-IR)	NP_004557.1	NP_004557.1 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	1030 0	0
AAG02118.1		U:(IR-D) 2.05				
			XP_096349.2	similar to 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (6PF-2-K/Fru-2,6-P2ASE brain/placenta-type isozyme) (iPFK-2)	1030 0	0
			Q16875	F263_HUMAN 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (6PF-2-K/Fru-2,6-P2ASE brain/placenta-type isozyme) (iPFK-2) [Includes: 6-phosphofructo-2-kinase; Fructose-2,6-bisphosphatase]	1030 0	0
			BAA08624.1	6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase	1030	0
			AAD08818.1	ubiquitous 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase	1030	0
				L77662 1 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase	1030 0	0
			AAH40482.1	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	1030 0	0
			2208342A	fructose 6-phosphate 2-kinase/fructose 2,6-bisphosphatase	1030	0
			AAB99795.1	6-phosphofracto-2-kinase/fractose-2,6-bisphosphatase	1028 0	0
			JC4626	6-phosphofructo-2-kinase (EC 2.7.1.105) / fructose-2, 6-bisphosphate 2-phosphatase (EC 3.1.3.46)	1028 0	0
			AAC62000.1	inducible 6-phosphofracto-2-kinase/fractose 2,6-bisphosphatase	1005	0
			CAA06605.1	CAA06605.1 6-phosphofructo-2-kinase	0 669	0

														73	73	73	73	73	73
0	0	0	0	0	0 (0	0	0	0	0	0	0	0	609 e-173	e-173	e-173	609 e-173	609 e-173	609 e-173
0 269	889	889	0 089	0 089	0 0/9	0 029	0/9	670	0 0/9	0 699	910 0	910	773	609	609	609	609	609	609
F262_HUMAN 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 (6PF-2-KFPru-2,6-P2ASE heart-type isozyme) (PFK-2/FBPase-2) [Includes: 6-phosphofructo-2-kinase; Fructose-2,6-bisphosphatase]	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2; Fructose-2,6-bisphosphatase, cardiac isozyme.	6-phosphofructo-2-kinase	6-phosphofructo-2-kinase heart isoform	AF470623 1 PFK2/F26DPase	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4	F264_HUMAN 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 (6PF-2-K/Fru-2,6-P2ASE testis-type isozyme) [Includes: 6-phosphofructo-2-kinase; Fructose-2,6-bisphosphatase]	6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase	\mathbf{T}		6-phosphofructo-2-kinase (EC 2.7.1.105) / fructose-2, 6-bisphosphate 2-phosphatase (EC 3.1.3.46	cyclic nucleotide gated channel beta 3; cyclic nucleotide-gated chanel, beta 3	AF272900_1 cone photoreceptor cyclic nucleotide-gated channel beta subunit	AF228520 1 cone photoreceptor cGMP-gated cation channel beta-subunit	1	cyclic nucleotide-gated cation channel		cGMP-gated cation channel subunit 2, cGMP-gated cation channel, subunit beta, hRCNC2 [human, retinal rod cells, Peptide, 909 aa]	cyclic nucleotide-gated cation channel	cGMP-gated cation channel beta subunit
O60825	NP_006203.1	CAA06606.1	BAB19681.1	AAL99386.1	NP 004558.1	Q16877	BAA18921.1	AAD09427.1	AAH10269.1	JC5871	NP_061971.2	AAF86274.1	AAF80179.1	Q14028	AAA65620.1	S32538	AAB32607.1	1912307A	AAB63387.1
											F:(C-IR) -2.33 U:(C-D) 3.63 U:(R-D) 2.84								
											Mm. 10357 F:(C-IR) 5 -2.33 U:(C-D) 3.63 U:(IR-D) 2.84								
											NM_013927 NP_038955.1								

		XP 047672.4	similar to RIKEN cDNA 4930447D24	207	207 KE 53
		1	Dillimit to the same of the sa		0.5-730
			KIAA1673 protein	207	6E-53
	_		Unknown (protein for MGC:46609)	207	6E-53
NM_008422 Mm. NP_032448.1			Similar to KIAA0940 protein	203	9E-52
P_032448.1	Mm.39092 F:(C-IR)		Shaw-related voltage-gated potassium channel protein 3; Kv3.3; voltage-gated potassium channel protein KV3.3	778	0
	U:(C-D) 2.07 U:(IR-D) 2.33				
		Q14003	KNC3_HUMAN Potassium voltage-gated channel subfamily C member 3 (Potassium channel Kv3.3) (KSHIIID)	778	0
		AAC24118.1	Shaw type potassium channel Kv3.3	778 0	0
			Shaw-related voltage-gated potassium channel protein 1; voltage-gated potassium channel protein KV3.1; potassium voltage-gated channel subfamily C member 1	612	612 e-175
		P48547	KNC1 HUMAN Potassium voltage-gated channel subfamily C member 1 (Potassium channel Kv3.1) (Kv4) (NGK2)	612	e-175
		A46020	potassium channel KCNC1	612	e-175
		AAB25764.1	voltage-gated potassium channel; NGK2	612	612 e-175
		NP_004969.2	Shaw-related voltage-gated potassium channel protein 4 isoform a; voltage-gated potassium channel protein KV3.4	571	571 e-162
		CAC19684.1	dJ1003J2.3.2 (potassium voltage-gated channel, Shaw-related subfamily, member 4)	571	e-162
		Q03721	CIKG HUMAN Potassium voltage-gated channel subfamily C member 4 (Potassium channel Kv3.4) (KSHIIIC)	571	571 e-162
		AAA57263.1	potassium channel protein	571	e-162
			Shaw-related voltage-gated potassium channel protein 4 isoform b; voltage-gated potassium channel protein KV3.4	571	571 e-162
		CAC19683.1	dJ1003J2.3.1 (potassium voltage-gated channel, Shaw-related subfamily, member 4)	571	571 e-162
		NP 715624.1	Shaw-related voltage-gated potassium channel protein 2 isoform KV3.2c	556	556 e-158
			unnamed protein product	556	556 e-158
		NP 631875.1	Shaw-related voltage-gated potassium channel protein 2 isoform KV3.2b	556	556 e-158

			AAL27272.1	AF268896 1 voltage gated potassium channel Kv3.2b	556	556 e-158
			AAM81577.1	potassium voltage-gated potassium channel subfamily C member 2	556	556 e-158
			NP 631874.1	Shaw-related voltage-gated potassium channel protein 2 isoform KV3.2a	556	556 e-158
			AAL27273.1	AF268897 1 voltage gated potassium channel Kv3.2a	556	556 e-158
NM_011749 NP_035879.1	Mm.417	F:(C-IR) -2.05	Q9UQR1	Z148_HUMAN Zinc finger protein 148 (Zinc finger DNA binding protein 89) (Transcription factor ZBP-89)	1460 0	0
		U:(IR-D) 2.34				
			AAC39926.1	zinc finger DNA binding protein 89 kDa	1460	0
			AAL99917.1	AF432210_1 CLL-associated antigen KW-10	1458 0	0
				zinc finger protein 148 (pHZ-52); zinc finger protein 148 (pHZ-52), BERF-1, ZBP-89	1455 0	0
			CAA15422.1	ZBP-89 protein	1455	0
			A54693	CACCC box-binding protein ht-beta	744	0
			AAA36664.1	CACCC box-binding protein	743 0	0
			AAH35591.1	Similar to zinc finger protein 148 (pHZ-52)	714 0	0
			AAB57692.1	zinc finger binding protein homolog	695 0	. 0
			CAB70967.1	zinc finger protein	371	e-102
			NP 036614.1		371	e-102
			Q9Y2X9	Z281_HUMAN Zinc finger protein 281 (Zinc finger DNA binding protein 99) (Transcription factor ZBP-99) (GC-box-binding zinc finger protein 1)	371	371 e-102
			JC7089	zinc finger binding protein-99	371	e-102
			AAD21084.1	zinc finger DNA binding protein 99	371	371 e-102
			CAB70968.1	zinc finger protein	371	371 e-102
NM_030566	Mm.35467 F:(C-IR)	F:(C-IR)	NP_079092.1	079092.1 Fos-related antigen	621	621 e-177
NP_085043.1		-2.05 U:(C-D)				
		2.62				
		U:(IR-D)				
		i	BAB15594.1	unnamed protein product	621	e-177
NM 026334	Mm.46408 F:(C-IR)	F:(C-IR)	NP 004181.1	lipase, gastric	0 699 0	0

NP 080610.1	-2.04				
1	U:(C-D) 2.14				
	U:(IR-D) 2.27				
		P07098	LIPG_HUMAN Triacylglycerol lipase, gastric precursor (Gastric lipase) (GL)	0 699	0
		S07145	triacylglycerol lipase (EC 3.1.1.3) precursor, gastric	693	0
		CAA29413.1	gastric lipase precursor	693	0
		CAA29414.1	gastric lipase precursor	657 0	0
		1HLG	A Chain A, Crystal Structure Of Human Gastric Lipase	635	0
		1HLG	B Chain B, Crystal Structure Of Human Gastric Lipase	635	0
		G01416	lysosomal acid lipase	474	474 e-133
		AAB60328.1	lysosomal acid lipase	474	e-133
		CAA83495.1	lysosomal acid lipase	474	474 e-133
		AAH12287.1	AAH12287 Similar to lipase A, lysosomal acid, cholesterol esterase (Wolman disease)	474	474 e-133
		S41408	lysosomal acid lipase (EC 3.1.1) / sterol esterase (EC 3.1.1.13) precursor	474	474 e-133
		CAA54026.1	lysosomal acid lipase; sterol esterase	474	474 e-133
		AAB60327.1	lysosomal acid lipase/cholesteryl ester hydrolase	474	474 e-133
		NP_000226.1	lipase A precursor; Lipase A, lysosomal acid, cholesterol esterase	474	474 e-133
		P38571	LICH_HUMAN Lysosomal acid lipase/cholesteryl ester hydrolase precursor (LAL) (Acid cholesteryl ester hydrolase) (Sterol esterase) (Lipase A) (Cholesteryl esterase)	474	474 e-133
			lysosomal acid lipase/cholesteryl esterase	474	474 e-133
:		XP_089555.2	089555.2 similar to bA30415.1 (novel lipase)	433	433 e-121
			similar to Triacylglycerol lipase, gastric precursor (Gastric lipase) (GL)	431	e-121
			bA30415.1 (novel lipase)	428	428 e-119

References

- 1. Unger, R.H., Foster, D.W. (1998) Diabetes mellitus. In Williams Textbook of Endocrinology, J.D. Wilson, D.W. Foster, H.M. Kronenberg, and P.R. Larsen, eds.
- 5 (Philadelphia, W.B. Saunders Company), pp. 973-1059.
 - 2. Polonsky, K.S. (1995) The beta-cell in diabetes: from molecular genetics to clinical research. Diabetes 44:705-717
- 3. Velho, G., Froguel, P. (1997) Genetic determinants of non-insulin-dependent diabetes mellitus: strategies and recent results. Diabete et Metabolisme 23:7-17
- 4. Groop, L.C., Tuomi, T. (1997) Non-insulin-dependent diabetes mellitus-a collision between thrifty genes and an affluent society. Ann. Med. 29:37-53.
- 5. Reaven, G.M. (1988) Role of insulin resistance in human disease. Diabetes 37:1595-1607.
 - 6. Clark, M.G., Rattigan, S., Clark, D.G. (1983) Obesity with insulin resistance: experimental insights. Lancet (ii) 1236-1240.
- 7. Kissebah, A.H., Vydelingum, N., Murray, R., Evans, D.J., Hartz, A.J., Kakloff, R.K., Adams, P.W. (1982)
 Relation of body fat distribution to metabolic complications of obesity. J Clin. Endo and Metab 54(2):254-260.
- 8. Kissebah, A.H. (1996) Intra-abdominal fat: is it a major factor in developing diabetes and coronary artery disease? Diabetes Res Clin Pract 30 (Suppl):25-30.
- 9. Friedman, J.M., Leibel, R. (1992) Tackling a weighty problem. Cell 69:217-220
 - 10. Bjorntorp, P. (1991) Metabolic implications of body fat distribution. Diabetes Care 14:1132-1143.

10

25

11. Emery, E.M., Schmid, T.L., Kahn, H.S., Filozof, P.P. (1993) A review of the association between abdominal fat distribution, health outcome measures, and modifiable risk factors. Am J Health Promot 7:342-353.

- 12. Wickelgren, I. (1998) Obesity: how big a problem? Science 280:1365.
- 13. Surwit, R.S., Kuhn, C.M., Cochrane, C., McCubbin, J.A.,
 10 Feinglos, M.N. (1988) Diet-induced type-II diabetes in
 C57BL/6J mice. Diabetes 37:1163-1167.
- Surwit, R.S., Feinglos, M.N., Rodin, J., Sutherland, A., Petro, A.E., Opara, E.C., Kuhn, C.M., Rebuffe-Scrive, M. (1995) Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism 44(5):645-651.
- 15. Ahren, B.E., Simonson, E., Scheurink, A.J.W., Mulder,
 20 H., Myerson, U., Sundler, F. (1997) Dissociated
 insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice.
 Metabolism 46(1):97-106.
- 16. Page, R., Morris, C., Williams, J., von Ruhland, C., Malik, A.N. (1997) Isolation of diabetes-associated kidney genes using differential display. Biochem Biophys Res Commun 232(1):49-53
- 17. Condorelli, G., Vigliotta, G., Iavarone, C., Caruso, M., Tocchetti, C.G., Andreozzi, F., Cafieri, A., Tecce, M.F., Formisano, P., Beguinot, L., Beguinot, F. (1998) PED/PEA-15 gene controls glucose transport and is overexpressed in type 2 diabetes mellitus. Embo J
- 35 17(14):3858-66
 - 18. Peraldi, M.N., Berrou, J., Hagege, J., Rondeau, E., Sraer, J.D. (1998) Subtractive hybridization cloning: an

efficient technique to detect overexpressed mRNAs in diabetic nephropathy. Kidney Int 53(4):926-31

- 19. Song, Y., Ailenberg, M., Silverman, M. (1998) Cloning
 5 of a novel gene in the human kidney homologous to rat
 munc13s: its potential role in diabetic nephropathy. Kidney
 Int 53(6):1689-95
- 20. Imagawa, M., Tsughiya, T., and Nishihara, T. (1999)

 10 Identification of inducible genes at the early stage of adipocyte differentiation of 3T3-L1 cells. Biochem.

 Biophys. Res. Comm. 254:299-305.
- Nadler, S.T., Stoehr, J.P., Schueler, K.L., Tanimoto,
 G., Yandell, B.S., Attie, A.D. (2000) The expression of adipogenic genes is decreased in obesity and diabetes mellitus. Proc Natl Acad Sci U S A 97:11371-11376
- 22. Lan H, Rabaglia ME, Stoehr JP, Nadler ST, Schueler KL,
 20 Zou F, Yandell BS, Attie AD. (2003) Gene expression
 profiles of nondiabetic and diabetic obese mice suggest a
 role of hepatic lipogenic capacity in diabetes
 susceptibility. Diabetes 52:688-700.
- 23. Petersen KF, Shulman GI (2002) Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am J Cardiol 90, 11G-18G.

Citation of documents herein is not intended as an admission that any of the documents cited herein is pertinent prior art, or an admission that the cited documents is considered material to the patentability of any of the claims of the present application. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicant and does not constitute any admission as to the correctness of the dates or contents of these documents.

5

10

15

20

25

30

35

The appended claims are to be treated as a non-limiting recitation of preferred embodiments.

In addition to those set forth elsewhere, the following references are hereby incorporated by reference, in their most recent editions as of the time of filing of this application: Kay, Phage Display of Peptides and Proteins: A Laboratory Manual; the John Wiley and Sons Current Protocols series, including Ausubel, Current Protocols in Molecular Biology; Coligan, Current Protocols in Protein Science; Coligan, Current Protocols in Immunology; Current Protocols in Human Genetics; Current Protocols in Cytometry; Current Protocols in Pharmacology; Current Protocols in Neuroscience; Current Protocols in Cell Biology; Current Protocols in Toxicology; Current Protocols in Field Analytical Chemistry; Current Protocols in Nucleic Acid Chemistry; and Current Protocols in Human Genetics; and the following Cold Spring Harbor Laboratory publications: Sambrook, Molecular Cloning: A Laboratory Manual; Harlow, Antibodies: A Laboratory Manual; Manipulating the Mouse Embryo: A Laboratory Manual; Methods in Yeast Genetics: A Cold Spring Harbor Laboratory Course Manual; Drosophila Protocols; Imaging Neurons: A Laboratory Manual; Development of Xenopus laevis: A Laboratory Manual; Antibodies: A Laboratory Manual; At the Bench: A Laboratory Navigator; Cells: A Laboratory Manual; Methods in Yeast Genetics: A Laboratory Course Manual; Discovering Neurons: The Expérimental Basis of Neuroscience; Genome Analysis: A Laboratory Manual Series ; Laboratory DNA Science; Strategies for Protein Purification and Characterization: A Laboratory Course Manual; Genetic Analysis of Pathogenic

287

Bacteria: A Laboratory Manual; PCR Primer: A Laboratory
Manual; Methods in Plant Molecular Biology: A Laboratory
Course Manual; Manipulating the Mouse Embryo: A Laboratory
Manual; Molecular Probes of the Nervous System; Experiments
with Fission Yeast: A Laboratory Course Manual; A Short
Course in Bacterial Genetics: A Laboratory Manual and
Handbook for Escherichia coli and Related Bacteria; DNA
Science: A First Course in Recombinant DNA Technology;
Methods in Yeast Genetics: A Laboratory Course Manual;
Molecular Biology of Plants: A Laboratory Course Manual.

All references cited herein, including journal articles or abstracts, published, corresponding, prior or otherwise related U.S. or foreign patent applications, issued U.S. or foreign patents, or any other references, are entirely incorporated by reference herein, including all data, tables, figures, and text presented in the cited references. Additionally, the entire contents of the references cited within the references cited herein are also entirely incorporated by reference.

Reference to known method steps, conventional methods steps, known methods or conventional methods is not in any way an admission that any aspect, description or embodiment of the present invention is disclosed, taught or suggested in the relevant art.

The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying knowledge within the skill of the art (including the contents of the references cited herein), readily modify and/or adapt for various applications such specific embodiments, without undue experimentation, without departing from the general concept Therefore, such adaptations and of the present invention. modifications are intended to be within the meaning and range of equivalents of the disclosed embodiments, based on the teaching and guidance presented herein. It is to be understood that the phraseology or terminology herein is for the purpose of description and not of limitation, such that the terminology or phraseology of the present specification is to be interpreted by the skilled artisan in light of the

20

5

10

15

25

30

288

teachings and guidance presented herein, in combination with the knowledge of one of ordinary skill in the art.

Any description of a class or range as being useful or preferred in the practice of the invention shall be deemed a description of any subclass (e.g., a disclosed class with one or more disclosed members omitted) or subrange contained therein, as well as a separate description of each individual member or value in said class or range.

The description of preferred embodiments individually shall be deemed a description of any possible combination of such preferred embodiments, except for combinations which are impossible (e.g, mutually exclusive choices for an element of the invention) or which are expressly excluded by this specification.

If an embodiment of this invention is disclosed in the prior art, the description of the invention shall be deemed to include the invention as herein disclosed with such embodiment excised.

15

5

CLAIMS

- 1. A method of protecting a human subject from progression from a normoinsulinemic state to a hyperinsulinemic state, or from either to a type II diabetic state, which comprises administering to the subject a protective amount of an agent which is
- (1) a polypeptide which is substantially structurally identical or conservatively identical in sequence to a reference protein which is selected from the group consisting of mouse and human proteins set forth in master table 1, subtables 1A and 1C,

15 or

5

(2) an expression vector encoding the polypeptide of (1) above and expressible in a human cell, under conditions conducive to expression of the polypeptide of (1);

20

where said agent protects said subject from progression from a normoinsulinemic state to a hyperinsulinemic state, or from either to a type II diabetic state.

25 2. A method of protecting a human subject from progression from a normoinsulinemic state to a hyperinsulinemic state, or from either to a type II diabetic state which comprises administering to the subject a protective amount of an agent which is

30

- (1) an antagonist of a polypeptide, occurring in said subject, which is substantially structurally identical or conservatively identical in sequence to a reference protein which is selected from the group consisting of mouse and human proteins set forth in master table 1, subtable 1B and 1C, or
- (2) an anti-sense vector which inhibits expression of said polypeptide in said subject,

where said agent protects said subject from progression from a normoinsulinemic state to a hyperinsulinemic state, or from either to a type II diabetic state.

3. A method of screening for human subjects who are prone to progression from a normoinsulinemic state to a hyperinsulinemic state, or from either to a type II diabetic state, which comprises assaying tissue or body fluid samples

prone to progression from a normoinsulinemic state to a hyperinsulinemic state, or from either to a type II diabetic state, which comprises assaying tissue or body fluid samples from said subjects to determine the level of expression of a "favorable" human marker gene, said human marker gene encoding a human protein which is substantially structurally identical or conservatively identical in sequence to a reference protein which is selected from the group consisting of mouse and human proteins set forth in master table 1, subtables 1A and 1C,

and directly correlating the level of expression of said marker gene with the propensity to progression in said patient.

20

25

30

15

5

10

4. A method of screening for human subjects who have a propensity for progression from a normoinsulinemic state to a hyperinsulinemic state, or from either to a type II diabetic state, which comprises assaying tissue or body fluid samples from said subjects to determine the level of expression of an "unfavorable" human marker gene, said human marker gene encoding a human protein which is substantially structurally identical or conservatively identical in sequence to a reference protein which is selected from the group consisting of mouse and human proteins set forth in master table 1, subtable 1B and 1C, and inversely correlating the level of expression of said marker gene with the propensity to progression in said patient.

- 5. The method of claims 1 or 3 in which the reference protein is of subtable 1A.
- 6. The method of claims 1 or 3 in which the reference

291 protein is of subtable 1B.

- 7. The method of claim 3 or 4 in which the sample is a muscle tissue sample.
- 8. The method of any one of claims 1-7 in which the reference protein is a human protein.
- 9. The method of any one of claims 1-7 in which the reference protein is a mouse protein.
 - 10. The method of any one of claims 3 or 4 in which the level of expression of the marker protein is ascertained by measuring the level of the corresponding messenger RNA.
 - 11. The method of any one of claims 3 or 4in which the level of expression is ascertained by measuring the level of a protein encoded by said marker gene.
- 12. The method of any one of claims 1-9 in which said polypeptide is at least 80% identical or at least highly conservatively identical to said reference protein.

 13. The method of any one of claims 1-10 in which said polypeptide is at least 90% identical to said reference protein.
 - 14. The method of any one of claims 1-11 in which said polypeptide is identical to said reference protein.
- 15. The method of any one of claims 1-14 in which the E-value cited for the reference protein in Master Table 1 is not more than e-6.
- 16. The method of claim 15 in which the E-value cited for the reference protein in Master Table 1 is less than e-10.
 - 17. The method of claim 17 in which the E value calculated by BLASTN or BLASTX would be less than e-15, more preferably less than e-20, still more preferably less than e-40, even

5

more preferably less than e-60, considerably more preferably less than e-80, and most preferably less than e-100.

- 18. The method of any of claims 2-17 in which the antagonist is an antibody, or an antigen-specific binding fragment of an antibody.
- 19. The method of any of claims 2-17 in which the antagonist is a peptide, peptoid, nucleic acid, or peptide nucleic acid oligomer.
 - 20. The method of any of claims 2-17 in which the antagonist is an organic molecule with a molecular weight of less than 500 daltons.
 - 21. The method of claim 20 in which said organic molecule is identifiable as a molecule which binds said polypeptide by screening a combinatorial library.
- 20 22. The method of claim 1 or 2 in which the agent is delivered systemically.
 - 23. The method of claim 1 or 2 in which the agent is selectively delivered to muscle tissue.

25

ABSTRACT OF THE DISCLOSURE

Mouse genes differentially expressed in comparisons of normal vs. hyperinsulinemic, hyperinsulinemic vs. type 2 diabetic, and normal vs. type 2 diabetic muscle by gene chip analysis have been identified, as have corresponding human genes and proteins. The human molecules, or antagonists thereof, may be used for protection against hyperinsulinemia or type 2 diabetes, or their sequelae.

10

 $^{{\}tt G:\line(d-f)Edis\Kopchick15.1\kopchick15.1.appl.masterdoc.wpd)}$




Figure 1(a)




Figure 1(b)




Figure 1(c)



